
@article{crenshaw823,
	title = {Extracorporeal gastric stapling reduces the incidence of gastric conduit failure after minimally invasive esophagectomy},
	volume = {76},
	issn = {0003-1348 (Print) 0003-1348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20726411},
	number = {8},
	journal = {Am Surg},
	author = {Crenshaw, G. D. and Shankar, S. S. and Brown, R. E. and Abbas, A. E. and Bolton, J. S.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {823--8},
}

@article{craig1381,
	title = {International physical activity questionnaire: 12-country reliability and validity},
	volume = {35},
	issn = {0195-9131 (Print) 0195-9131 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12900694},
	doi = {10.1249/01.MSS.0000078924.61453.FB},
	number = {8},
	journal = {Med Sci Sports Exerc},
	author = {Craig, C. L. and Marshall, A. L. and Sjostrom, M. and Bauman, A. E. and Booth, M. L. and Ainsworth, B. E. and Pratt, M. and Ekelund, U. and Yngve, A. and Sallis, J. F. and Oja, P.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {1381--95},
}

@article{christensen947,
	title = {Muscle dysfunction in cancer patients},
	volume = {25},
	issn = {1569-8041 (Electronic) 0923-7534 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24401927},
	doi = {10.1093/annonc/mdt551},
	number = {5},
	journal = {Ann Oncol},
	author = {Christensen, J. F. and Jones, L. W. and Andersen, J. L. and Daugaard, G. and Rorth, M. and Hojman, P.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {947--58},
}

@article{coughlin,
	title = {Use of consumer wearable devices to promote physical activity among breast, prostate, and colorectal cancer survivors: a review of health intervention studies},
	issn = {1932-2267 (Electronic) 1932-2259 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31933148},
	doi = {10.1007/s11764-020-00855-1},
	journal = {J Cancer Surviv},
	author = {Coughlin, S. S. and Caplan, L. S. and Stone, R.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{correa-de-araujo591,
	title = {Skeletal muscle function deficit: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction},
	volume = {69},
	issn = {1758-535X (Electronic) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24737562},
	doi = {10.1093/gerona/glt208},
	number = {5},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Correa-de-Araujo, R. and Hadley, E.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {591--4},
}

@article{chen5246,
	title = {Post-discharge complications after esophagectomy account for high readmission rates},
	volume = {22},
	issn = {2219-2840 (Electronic) 1007-9327 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27298567},
	doi = {10.3748/wjg.v22.i22.5246},
	number = {22},
	journal = {World J Gastroenterol},
	author = {Chen, S. Y. and Molena, D. and Stem, M. and Mungo, B. and Lidor, A. O.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {5246--53},
}

@article{chen927,
	title = {Pre-surgical {Geriatric} {Syndromes}, {Frailty}, and {Risks} for {Postoperative} {Delirium} in {Older} {Patients} {Undergoing} {Gastrointestinal} {Surgery}: {Prevalence} and {Red} {Flags}},
	volume = {19},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25650167},
	doi = {10.1007/s11605-015-2760-0},
	number = {5},
	journal = {J Gastrointest Surg},
	author = {Chen, C. C. and Lin, M. T. and Liang, J. T. and Chen, C. M. and Yen, C. J. and Huang, G. H.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {927--34},
}

@article{chen106,
	title = {The effect of ultrasound-guided intercostal nerve block, single-injection erector spinae plane block and multiple-injection paravertebral block on postoperative analgesia in thoracoscopic surgery: {A} randomized, double-blinded, clinical trial},
	volume = {59},
	issn = {1873-4529 (Electronic) 0952-8180 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31330457},
	doi = {10.1016/j.jclinane.2019.07.002},
	journal = {J Clin Anesth},
	author = {Chen, N. and Qiao, Q. and Chen, R. and Xu, Q. and Zhang, Y. and Tian, Y.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {106--111},
}

@article{chen98,
	title = {Hand-grip strength is a simple and effective outcome predictor in esophageal cancer following esophagectomy with reconstruction: a prospective study},
	volume = {6},
	issn = {1749-8090 (Electronic) 1749-8090 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21843340},
	doi = {10.1186/1749-8090-6-98},
	journal = {J Cardiothorac Surg},
	author = {Chen, C. H. and Ho, Chang and Huang, Y. Z. and Hung, T. T.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {98},
}

@article{cerfolio1187,
	title = {Fast tracking after {Ivor} {Lewis} esophagogastrectomy},
	volume = {126},
	issn = {0012-3692 (Print) 0012-3692 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15486381},
	doi = {10.1378/chest.126.4.1187},
	number = {4},
	journal = {Chest},
	author = {Cerfolio, R. J. and Bryant, A. S. and Bass, C. S. and Alexander, J. R. and Bartolucci, A. A.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {1187--94},
}

@article{charlote128,
	title = {Patient {Activation} {Mediates} {Health} {Literacy} {Associated} with {Hospital} {Utilization} among {Whites}},
	volume = {1},
	issn = {2474-8307 (Print)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29806046},
	doi = {10.3928/24748307-20170621-01},
	number = {3},
	journal = {Health Lit Res Pract},
	author = {Charlot, M. and Winter, M. R. and Cabral, H. and Wolf, M. S. and Curtis, L. M. and Hanchate, A. and Paasche-Orlow, M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {e128--e135},
}

@article{cella1179,
	title = {The {Patient}-{Reported} {Outcomes} {Measurement} {Information} {System} ({PROMIS}) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008},
	volume = {63},
	issn = {1878-5921 (Electronic) 0895-4356 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20685078},
	doi = {10.1016/j.jclinepi.2010.04.011},
	number = {11},
	journal = {J Clin Epidemiol},
	author = {Cella, D. and Riley, W. and Stone, A. and Rothrock, N. and Reeve, B. and Yount, S. and Amtmann, D. and Bode, R. and Buysse, D. and Choi, S. and Cook, K. and Devellis, R. and DeWalt, D. and Fries, J. F. and Gershon, R. and Hahn, E. A. and Lai, J. S. and Pilkonis, P. and Revicki, D. and Rose, M. and Weinfurt, K. and Hays, R. and Group, Promis Cooperative},
	year = {2010},
	note = {Type: Journal Article},
	pages = {1179--94},
}

@article{cella570,
	title = {The {Functional} {Assessment} of {Cancer} {Therapy} scale: development and validation of the general measure},
	volume = {11},
	issn = {0732-183X (Print) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8445433},
	doi = {10.1200/JCO.1993.11.3.570},
	number = {3},
	journal = {J Clin Oncol},
	author = {Cella, D. F. and Tulsky, D. S. and Gray, G. and Sarafian, B. and Linn, E. and Bonomi, A. and Silberman, M. and Yellen, S. B. and Winicour, P. and Brannon, J. and al, et},
	year = {1993},
	note = {Type: Journal Article},
	pages = {570--9},
}

@article{casson205,
	title = {What is the optimal distal resection margin for esophageal carcinoma?},
	volume = {69},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10654514},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Casson, A. G. and Darnton, S. J. and Subramanian, S. and Hiller, L.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {205--9},
}

@article{campbell806,
	title = {Conduit {Vascular} {Evaluation} is {Associated} with {Reduction} in {Anastomotic} {Leak} {After} {Esophagectomy}},
	volume = {19},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25791907},
	doi = {10.1007/s11605-015-2794-3},
	number = {5},
	journal = {J Gastrointest Surg},
	author = {Campbell, C. and Reames, M. K. and Robinson, M. and Symanowski, J. and Salo, J. C.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {806--12},
}

@article{brooke821,
	title = {Early primary care provider follow-up and readmission after high-risk surgery},
	volume = {149},
	issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25074237},
	doi = {10.1001/jamasurg.2014.157},
	number = {8},
	journal = {JAMA Surg},
	author = {Brooke, B. S. and Stone, D. H. and Cronenwett, J. L. and Nolan, B. and DeMartino, R. R. and MacKenzie, T. A. and Goodman, D. C. and Goodney, P. P.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {821--8},
}

@article{bray394,
	title = {Global cancer statistics 2018: {GLOBOCAN} estimates of incidence and mortality worldwide for 36 cancers in 185 countries},
	volume = {68},
	issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30207593},
	doi = {10.3322/caac.21492},
	number = {6},
	journal = {CA Cancer J Clin},
	author = {Bray, F. and Ferlay, J. and Soerjomataram, I. and Siegel, R. L. and Torre, L. A. and Jemal, A.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {394--424},
}

@article{botsen955,
	title = {Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients},
	volume = {18},
	issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30286724},
	doi = {10.1186/s12885-018-4860-1},
	number = {1},
	journal = {BMC Cancer},
	author = {Botsen, D. and Ordan, M. A. and Barbe, C. and Mazza, C. and Perrier, M. and Moreau, J. and Brasseur, M. and Renard, Y. and Tailliere, B. and Slimano, F. and Bertin, E. and Bouche, O.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {955},
}

@article{bonilha77,
	title = {Radiation exposure time during {MBSS}: influence of swallowing impairment severity, medical diagnosis, clinician experience, and standardized protocol use},
	volume = {28},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22692431},
	doi = {10.1007/s00455-012-9415-z},
	number = {1},
	journal = {Dysphagia},
	author = {Bonilha, H. S. and Humphries, K. and Blair, J. and Hill, E. G. and McGrattan, K. and Carnes, B. and Huda, W. and Martin-Harris, B.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {77--85},
}

@article{bonilha922,
	title = {Radiation {Risks} to {Adult} {Patients} {Undergoing} {Modified} {Barium} {Swallow} {Studies}},
	volume = {34},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30830303},
	doi = {10.1007/s00455-019-09993-w},
	number = {6},
	journal = {Dysphagia},
	author = {Bonilha, H. S. and Huda, W. and Wilmskoetter, J. and Martin-Harris, B. and Tipnis, S. V.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {922--929},
}

@article{blumenthal2451,
	title = {The {Affordable} {Care} {Act} at 5 {Years}},
	volume = {372},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25946142},
	doi = {10.1056/NEJMhpr1503614},
	number = {25},
	journal = {N Engl J Med},
	author = {Blumenthal, D. and Abrams, M. and Nuzum, R.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {2451--8},
}

@article{blencowe658,
	title = {Reporting of short-term clinical outcomes after esophagectomy: a systematic review},
	volume = {255},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22395090},
	doi = {10.1097/SLA.0b013e3182480a6a},
	number = {4},
	journal = {Ann Surg},
	author = {Blencowe, N. S. and Strong, S. and McNair, A. G. and Brookes, S. T. and Crosby, T. and Griffin, S. M. and Blazeby, J. M.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {658--66},
}

@article{blazeby1912,
	title = {Development of an {EORTC} questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. {The} {EORTC} {Quality} of {Life} {Study} {Group}},
	volume = {32A},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8943674},
	number = {11},
	journal = {Eur J Cancer},
	author = {Blazeby, J. M. and Alderson, D. and Winstone, K. and Steyn, R. and Hammerlid, E. and Arraras, J. and Farndon, J. R.},
	year = {1996},
	note = {Type: Journal Article},
	pages = {1912--7},
}

@article{bizekis402,
	title = {Initial experience with minimally invasive {Ivor} {Lewis} esophagectomy},
	volume = {82},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16863737},
	doi = {10.1016/j.athoracsur.2006.02.052},
	number = {2},
	journal = {Ann Thorac Surg},
	author = {Bizekis, C. and Kent, M. S. and Luketich, J. D. and Buenaventura, P. O. and Landreneau, R. J. and Schuchert, M. J. and Alvelo-Rivera, M.},
	year = {2006},
	note = {Type: Journal Article},
	pages = {402--6; discussion 406--7},
}

@article{blazeby1384,
	title = {Clinical and psychometric validation of an {EORTC} questionnaire module, the {EORTC} {QLQ}-{OES18}, to assess quality of life in patients with oesophageal cancer},
	volume = {39},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12826041},
	number = {10},
	journal = {Eur J Cancer},
	author = {Blazeby, J. M. and Conroy, T. and Hammerlid, E. and Fayers, P. and Sezer, O. and Koller, M. and Arraras, J. and Bottomley, A. and Vickery, C. W. and Etienne, P. L. and Alderson, D. and European Organisation for, Research and Treatement of Cancer, Gastrointestinal and Quality of Life, Groups},
	year = {2003},
	note = {Type: Journal Article},
	pages = {1384--94},
}

@article{birkmeyer1128,
	title = {Hospital volume and surgical mortality in the {United} {States}},
	volume = {346},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11948273},
	doi = {10.1056/NEJMsa012337},
	number = {15},
	journal = {N Engl J Med},
	author = {Birkmeyer, J. D. and Siewers, A. E. and Finlayson, E. V. and Stukel, T. A. and Lucas, F. L. and Batista, I. and Welch, H. G. and Wennberg, D. E.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {1128--37},
}

@article{biere1887,
	title = {Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial},
	volume = {379},
	issn = {1474-547X (Electronic) 0140-6736 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22552194},
	doi = {10.1016/S0140-6736(12)60516-9},
	number = {9829},
	journal = {Lancet},
	author = {Biere, S. S. and van Berge Henegouwen, M. I. and Maas, K. W. and Bonavina, L. and Rosman, C. and Garcia, J. R. and Gisbertz, S. S. and Klinkenbijl, J. H. and Hollmann, M. W. and de Lange, E. S. and Bonjer, H. J. and van der Peet, D. L. and Cuesta, M. A.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {1887--92},
}

@article{berry1266,
	title = {A comprehensive evaluation for aspiration after esophagectomy reduces the incidence of postoperative pneumonia},
	volume = {140},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20884018},
	doi = {10.1016/j.jtcvs.2010.08.038},
	number = {6},
	journal = {J Thorac Cardiovasc Surg},
	author = {Berry, M. F. and Atkins, B. Z. and Tong, B. C. and Harpole, D. H. and D'Amico, T. A. and Onaitis, M. W.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {1266--71},
}

@article{bergman635,
	title = {The {EORTC} {QLQ}-{LC13}: a modular supplement to the {EORTC} {Core} {Quality} of {Life} {Questionnaire} ({QLQ}-{C30}) for use in lung cancer clinical trials. {EORTC} {Study} {Group} on {Quality} of {Life}},
	volume = {30A},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8080679},
	number = {5},
	journal = {Eur J Cancer},
	author = {Bergman, B. and Aaronson, N. K. and Ahmedzai, S. and Kaasa, S. and Sullivan, M.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {635--42},
}

@article{bergese107,
	title = {Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia},
	volume = {5},
	issn = {1178-7090 (Electronic) 1178-7090 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22570563},
	doi = {10.2147/JPR.S30861},
	journal = {J Pain Res},
	author = {Bergese, S. D. and Ramamoorthy, S. and Patou, G. and Bramlett, K. and Gorfine, S. R. and Candiotti, K. A.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {107--16},
}

@article{ben-david1748,
	title = {Prospective {Comprehensive} {Swallowing} {Evaluation} of {Minimally} {Invasive} {Esophagectomies} with {Cervical} {Anastomosis}: {Silent} {Versus} {Vocal} {Aspiration}},
	volume = {19},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26202151},
	doi = {10.1007/s11605-015-2889-x},
	number = {10},
	journal = {J Gastrointest Surg},
	author = {Ben-David, K. and Fullerton, A. and Rossidis, G. and Michel, M. and Thomas, R. and Sarosi, G. and White, J. and Giordano, C. and Hochwald, S.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1748--52},
}

@article{baracos527,
	title = {Psoas as a sentinel muscle for sarcopenia: a flawed premise},
	volume = {8},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28675689},
	doi = {10.1002/jcsm.12221},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Baracos, V. E.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {527--528},
}

@article{basch557,
	title = {Symptom {Monitoring} {With} {Patient}-{Reported} {Outcomes} {During} {Routine} {Cancer} {Treatment}: {A} {Randomized} {Controlled} {Trial}},
	volume = {34},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26644527},
	doi = {10.1200/JCO.2015.63.0830},
	number = {6},
	journal = {J Clin Oncol},
	author = {Basch, E. and Deal, A. M. and Kris, M. G. and Scher, H. I. and Hudis, C. A. and Sabbatini, P. and Rogak, L. and Bennett, A. V. and Dueck, A. C. and Atkinson, T. M. and Chou, J. F. and Dulko, D. and Sit, L. and Barz, A. and Novotny, P. and Fruscione, M. and Sloan, J. A. and Schrag, D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {557--65},
}

@article{ajani855,
	title = {Esophageal and {Esophagogastric} {Junction} {Cancers}, {Version} 2.2019, {NCCN} {Clinical} {Practice} {Guidelines} in {Oncology}},
	volume = {17},
	issn = {1540-1413 (Electronic) 1540-1405 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31319389},
	doi = {10.6004/jnccn.2019.0033},
	number = {7},
	journal = {J Natl Compr Canc Netw},
	author = {Ajani, J. A. and D'Amico, T. A. and Bentrem, D. J. and Chao, J. and Corvera, C. and Das, P. and Denlinger, C. S. and Enzinger, P. C. and Fanta, P. and Farjah, F. and Gerdes, H. and Gibson, M. and Glasgow, R. E. and Hayman, J. A. and Hochwald, S. and Hofstetter, W. L. and Ilson, D. H. and Jaroszewski, D. and Johung, K. L. and Keswani, R. N. and Kleinberg, L. R. and Leong, S. and Ly, Q. P. and Matkowskyj, K. A. and McNamara, M. and Mulcahy, M. F. and Paluri, R. K. and Park, H. and Perry, K. A. and Pimiento, J. and Poultsides, G. A. and Roses, R. and Strong, V. E. and Wiesner, G. and Willett, C. G. and Wright, C. D. and McMillian, N. R. and Pluchino, L. A.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {855--883},
}

@article{baker181,
	title = {Drain amylase aids detection of anastomotic leak after esophagectomy},
	volume = {7},
	issn = {2078-6891 (Print) 2078-6891 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27034784},
	doi = {10.3978/j.issn.2078-6891.2015.074},
	number = {2},
	journal = {J Gastrointest Oncol},
	author = {Baker, E. H. and Hill, J. S. and Reames, M. K. and Symanowski, J. and Hurley, S. C. and Salo, J. C.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {181--8},
}

@article{azab,
	title = {Impact of {Chemoradiation}-to-{Surgery} {Interval} on {Pathological} {Complete} {Response} and {Short}- and {Long}-{Term} {Overall} {Survival} in {Esophageal} {Cancer} {Patients}},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30311162},
	doi = {10.1245/s10434-018-6897-4},
	journal = {Ann Surg Oncol},
	author = {Azab, B. and Amundson, J. R. and Picado, O. and Ripat, C. and Macedo, F. I. and Franceschi, D. and Livingstone, A. S. and Yakoub, D.},
	year = {2018},
	note = {Type: Journal Article},
}

@article{aviv1000,
	title = {Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia},
	volume = {109},
	issn = {0003-4894 (Print) 0003-4894 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11089989},
	doi = {10.1177/000348940010901103},
	number = {11},
	journal = {Ann Otol Rhinol Laryngol},
	author = {Aviv, J. E. and Liu, H. and Parides, M. and Kaplan, S. T. and Close, L. G.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {1000--6},
}

@book{zotero-38,
	url = {https://www.cancer.org/cancer/esophagus-cancer/about/key-statistics.html#: :text=The%20American%20Cancer%20Society's%20estimates,men%20and%203%2C070%20in%20women)},
	month = jun,
	year = {2020},
	note = {Type: Web Page},
}

@incollection{zotero-39,
	address = {Silver Spring (MD)},
	title = {{BEST} ({Biomarkers}, {EndpointS}, and other {Tools}) {Resource} {Glossary}},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27010052},
	booktitle = {{BEST} ({Biomarkers}, {EndpointS}, and other {Tools}) {Resource}},
	year = {2016},
	note = {Type: Book Section},
}

@article{aaronson365,
	title = {The {European} {Organization} for {Research} and {Treatment} of {Cancer} {QLQ}-{C30}: a quality-of-life instrument for use in international clinical trials in oncology},
	volume = {85},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8433390},
	number = {5},
	journal = {J Natl Cancer Inst},
	author = {Aaronson, N. K. and Ahmedzai, S. and Bergman, B. and Bullinger, M. and Cull, A. and Duez, N. J. and Filiberti, A. and Flechtner, H. and Fleishman, S. B. and de Haes, J. C. and al, et},
	year = {1993},
	note = {Type: Journal Article},
	pages = {365--76},
}

@book{zotero-41,
	title = {Guidelines for data processing and analysis of the {International} {Physical} {Activity} {Questionnaire} ({IPAQ})},
	url = {https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4OjE0NDgxMDk3NDU1YWRlZTM},
	year = {2005},
	note = {Type: Web Page},
}

@article{gomes196,
	title = {Opioid {Dose} and {Risk} of {Road} {Trauma} in {Canada}: {A} {Population}-{Based} {Study}},
	volume = {173},
	issn = {2168-6106},
	shorttitle = {Opioid {Dose} and {Risk} of {Road} {Trauma} in {Canada}},
	url = {https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1556791},
	doi = {10.1001/2013.jamainternmed.733},
	abstract = {{\textless}h3{\textgreater}Background{\textless}/h3{\textgreater}Use of opioids may predispose drivers to road trauma, yet the effect of opioid dose on this association is unknown.{\textless}h3{\textgreater}Methods{\textless}/h3{\textgreater}We conducted a population-based nested case-control study of patients aged 18 to 64 years who received at least 1 publicly funded prescription for an opioid from April 1, 2003, through March 31, 2011. Cases were defined as having an emergency department visit related to road trauma. Patients without road trauma served as a control group matched to cases by age, sex, index year, prior road trauma, and a disease risk index. We compared the risk of road trauma among patients treated with doses of opioids ranging from very low to very high (\&lt;20 to ≥200 morphine equivalents daily). In a subgroup analysis, we stratified our analysis by driver status.{\textless}h3{\textgreater}Results{\textless}/h3{\textgreater}Among 549 878 eligible adults, we identified 5300 cases with road trauma and matched an equal number of controls. Multivariate adjustment yielded no significant association between escalating opioid dose and odds of road trauma (adjusted odds ratio ranged between 1.00 and 1.09). However, a significant association between opioid dose and road trauma was observed among drivers. Compared with very low opioid doses, drivers prescribed low doses had a 21\% increased odds of road trauma (adjusted odds ratio, 1.21 [95\% CI, 1.02-1.42]); those prescribed moderate doses, 29\% increased odds (1.29 [1.06-1.57]); those prescribed high doses, 42\% increased odds (1.42 [1.15-1.76]); and those prescribed very high doses, 23\% increased odds (1.23 [1.02-1.49]).{\textless}h3{\textgreater}Conclusions{\textless}/h3{\textgreater}Among drivers prescribed opioids, a significant relationship exists between drug dose and risk of road trauma. This association is distinct and does not appear with passengers, pedestrians, and others injured in road trauma.},
	language = {en},
	number = {3},
	urldate = {2019-08-03},
	journal = {JAMA Intern Med},
	author = {Gomes, Tara and Redelmeier, Donald A. and Juurlink, David N. and Dhalla, Irfan A. and Camacho, Ximena and Mamdani, Muhammad M.},
	month = feb,
	year = {2013},
	pages = {196--201},
	file = {Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\A4WLJP2V\\1556791.html:text/html;Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\LBYMQ584\\Gomes et al. - 2013 - Opioid Dose and Risk of Road Trauma in Canada A P.pdf:application/pdf},
}

@article{macdonald342,
	title = {The advantages and limitations of cross-sectional body composition analysis},
	volume = {5},
	issn = {1751-4266},
	doi = {10.1097/SPC.0b013e32834c49eb},
	abstract = {PURPOSE OF REVIEW: Cross-sectional (C-S) imaging is now commonly used to measure body composition in clinical studies. This review highlights the advantages, limitations and suggested future directions for this technique.
RECENT FINDINGS: Current understanding of C-S imaging reproducibility, tissue identification and segmentation methods, comparison between imaging techniques and estimates of whole body composition using a single image are described.
SUMMARY: C-S imaging can reliably measure muscle and fat distribution and uniquely discriminate between intra-abdominal organ and muscle component of fat-free mass. It precisely tracks changes within an individual, but is less able to distinguish true differences in whole body estimates between individuals.},
	language = {eng},
	number = {4},
	journal = {Curr Opin Support Palliat Care},
	author = {MacDonald, Alisdair J. and Greig, Carolyn A. and Baracos, Vickie},
	month = dec,
	year = {2011},
	pmid = {21986910},
	keywords = {Abdomen, Adipose Tissue, Adiposity, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed},
	pages = {342--349},
}

@article{awad74,
	title = {Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer},
	volume = {31},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2011.08.008},
	abstract = {BACKGROUND \& AIMS: Patients with sarcopenia [reduced fat free mass (FFM)] have a higher incidence of chemotherapy-related toxicity and decreased survival. As there are no such data in patients with oesophagogastric cancer (OGC), this study investigated changes in body composition in OGC patients receiving neoadjuvant chemotherapy (NAC).
METHODS: OGC patients who had CT scans before and after NAC were studied. CT images at the L3 vertebral level were analysed using SliceOmatic(®) software to derive estimates of FFM and fat mass (FM). Comparisons were made between pre- and post-NAC CT images. Data are reported as mean ± SD.
RESULTS: Forty-seven patients (34 male) aged 63 ± 12 years were studied and 79\% completed their course of NAC. The interval between CT scans was 107 ± 27 days. The proportion of patients with sarcopenia increased from 57\% pre-NAC to 79\% post-NAC (p = 0.046). During NAC there were significant reductions in estimated FFM and FM (2.9 ± 4.7 kg, p {\textless} 0.0001 and 1.3 ± 3.2 kg, p = 0.007, respectively). No association was demonstrated between loss of FFM and non-completion of NAC, increased hospital stay or mortality.
CONCLUSIONS: In patients with OGC commencing NAC, sarcopenia was present in 57\%. NAC was associated with further reductions in FFM and an increase in the proportion of patients becoming sarcopenic.},
	language = {eng},
	number = {1},
	journal = {Clin Nutr},
	author = {Awad, Sherif and Tan, Benjamin H. and Cui, Helen and Bhalla, Ashish and Fearon, Kenneth C. H. and Parsons, Simon L. and Catton, James A. and Lobo, Dileep N.},
	month = feb,
	year = {2012},
	pmid = {21875767},
	keywords = {Body Composition, Humans, Aged, Female, Gastrointestinal Neoplasms, Hospitalization, Length of Stay, Male, Middle Aged, Neoadjuvant Therapy, Obesity, Pilot Projects, Postoperative Care, Prevalence, Sarcopenia, Treatment Outcome},
	pages = {74--77},
}

@article{caan1008,
	title = {Explaining the {Obesity} {Paradox}: {The} {Association} between {Body} {Composition} and {Colorectal} {Cancer} {Survival} ({C}-{SCANS} {Study})},
	volume = {26},
	issn = {1538-7755},
	shorttitle = {Explaining the {Obesity} {Paradox}},
	doi = {10.1158/1055-9965.EPI-17-0200},
	abstract = {Background: Body composition may partially explain the U-shaped association between body mass index (BMI) and colorectal cancer survival.Methods: Muscle and adiposity at colorectal cancer diagnosis and survival were examined in a retrospective cohort using Kaplan-Meier curves, multivariable Cox regression, and restricted cubic splines in 3,262 early-stage (I-III) male (50\%) and female (50\%) patients. Sarcopenia was defined using optimal stratification and sex- and BMI-specific cut points. High adiposity was defined as the highest tertile of sex-specific total adipose tissue (TAT). Primary outcomes were overall mortality and colorectal cancer-specific mortality (CRCsM).Results: Slightly over 42\% patients were sarcopenic. During 5.8 years of follow-up, 788 deaths occurred, including 433 from colorectal cancer. Sarcopenic patients had a 27\% [HR, 1.27; 95\% confidence interval (CI), 1.09-1.48] higher risk of overall mortality than those who were not sarcopenic. Females with both low muscle and high adiposity had a 64\% higher risk of overall mortality (HR, 1.64; 95\% CI, 1.05-2.57) than females with adequate muscle and lower adiposity. The lowest risk of overall mortality was seen in patients with a BMI between 25 and {\textless}30 kg/m2, a range associated with the greatest number of patients (58.6\%) who were not at increased risk of overall mortality due to either low muscle or high adiposity.Conclusions: Sarcopenia is prevalent among patients with non-metastatic colorectal cancer, and should, along with adiposity be a standard oncological marker.Impact: Our findings suggest a biologic explanation for the obesity paradox in colorectal cancer and refute the notion that the association between overweight and lower mortality is due solely to methodologic biases. Cancer Epidemiol Biomarkers Prev; 26(7); 1008-15. ©2017 AACR.},
	language = {eng},
	number = {7},
	journal = {Cancer Epidemiol Biomarkers Prev},
	author = {Caan, Bette J. and Meyerhardt, Jeffrey A. and Kroenke, Candyce H. and Alexeeff, Stacey and Xiao, Jingjie and Weltzien, Erin and Feliciano, Elizabeth Cespedes and Castillo, Adrienne L. and Quesenberry, Charles P. and Kwan, Marilyn L. and Prado, Carla M.},
	month = jul,
	year = {2017},
	pmid = {28506965},
	pmcid = {PMC5647152},
	keywords = {Adiposity, Humans, Aged, Female, Male, Middle Aged, Obesity, Prevalence, Sarcopenia, Body Mass Index, Cause of Death, Colorectal Neoplasms, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Risk Factors, Sex Factors},
	pages = {1008--1015},
}

@misc{zotero-46,
	title = {Explaining the {Obesity} {Paradox}: {The} {Association} between {Body} {Composition} and {Colorectal} {Cancer} {Survival} ({C}-{SCANS} {Study}) - {PubMed}},
	url = {https://pubmed-ncbi-nlm-nih-gov.libproxy.lib.unc.edu/28506965/},
	urldate = {2021-10-18},
	file = {Explaining the Obesity Paradox\: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study) - PubMed:C\:\\Users\\jcsal\\Zotero\\storage\\I4VEQG3J\\28506965.html:text/html},
}

@article{blauwhoff-buskermolen1339,
	title = {Loss of {Muscle} {Mass} {During} {Chemotherapy} {Is} {Predictive} for {Poor} {Survival} of {Patients} {With} {Metastatic} {Colorectal} {Cancer}},
	volume = {34},
	issn = {1527-7755},
	doi = {10.1200/JCO.2015.63.6043},
	abstract = {PURPOSE: Low muscle mass is present in approximately 40\% of patients with metastatic colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in skeletal muscle during palliative chemotherapy in patients with mCRC and its association with treatment modifications and overall survival.
PATIENTS AND METHODS: In 67 patients with mCRC (mean age ± standard deviation, 66.4 ± 10.6 years; 63\% male), muscle area (square centimeters) was assessed using computed tomography scans of the third lumbar vertebra before and during palliative chemotherapy. Treatment modifications resulting from toxicity were evaluated, including delay, dose reduction, or termination of chemotherapy. Multiple regression analyses were performed for the association between change in muscle area and treatment modification and secondly overall survival.
RESULTS: Muscle area of patients with mCRC decreased significantly during 3 months of chemotherapy by 6.1\% (95\% CI, -8.4 to -3.8; P {\textless} .001). Change in muscle area was not associated with treatment modifications. However, patients with muscle loss during treatment of 9\% or more (lowest tertile) had significantly lower survival rates than patients with muscle loss of less than 9\% (at 6 months, 33\% v 69\% of patients alive; at 1 year, 17\% v 49\% of patients alive; log-rank P = .001). Muscle loss of 9\% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95\% CI, 2.21 to 9.05; P {\textless} .001).
CONCLUSION: Muscle area decreased significantly during chemotherapy and was independently associated with survival in patients with mCRC. Further clinical evaluation is required to determine whether nutritional interventions and exercise training may preserve muscle area and thereby improve outcome.},
	language = {eng},
	number = {12},
	journal = {J Clin Oncol},
	author = {Blauwhoff-Buskermolen, Susanne and Versteeg, Kathelijn S. and de van der Schueren, Marian A. E. and den Braver, Nicole R. and Berkhof, Johannes and Langius, Jacqueline A. E. and Verheul, Henk M. W.},
	month = apr,
	year = {2016},
	pmid = {26903572},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Kaplan-Meier Estimate, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Body Weight, Cachexia, Disease Progression, Health Status, Muscular Atrophy, Neoplasm Metastasis, Palliative Care, Proportional Hazards Models, Prospective Studies, Radiography, Risk Assessment, Time Factors},
	pages = {1339--1344},
}

@article{prado1012,
	title = {Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?},
	volume = {98},
	issn = {1938-3207},
	shorttitle = {Central tenet of cancer cachexia therapy},
	doi = {10.3945/ajcn.113.060228},
	abstract = {BACKGROUND: Skeletal muscle wasting is considered the central feature of cachexia, but the potential for skeletal muscle anabolism in patients with advanced cancer is unproven.
OBJECTIVE: We investigated the clinical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabolism.
DESIGN: We conducted a quantitative analysis of computed tomography (CT) images for the loss and gain of muscle in population-based cohorts of advanced cancer patients (lung, colorectal, and pancreas cancer and cholangiocarcinoma) in a longitudinal observational study.
RESULTS: Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39\% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4\%, and muscle was stable in 45.6\% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with {\textgreater}90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95\% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95\% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain.
CONCLUSIONS: A window of anabolic potential exists at defined early phases of the disease trajectory ({\textgreater}90 d survival), creating an opportunity for nutritional intervention to stop or reverse cachexia. Cancer patients within 90 d of death have a low likelihood of anabolic potential.},
	language = {eng},
	number = {4},
	journal = {Am J Clin Nutr},
	author = {Prado, Carla M. and Sawyer, Michael B. and Ghosh, Sunita and Lieffers, Jessica R. and Esfandiari, Nina and Antoun, Sami and Baracos, Vickie E.},
	month = oct,
	year = {2013},
	pmid = {23966429},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Neoplasm Staging, Cachexia, Muscular Atrophy, Cholangiocarcinoma, Longitudinal Studies, Lung Neoplasms, Metabolism, Neoplasms, Pancreatic Neoplasms, Survival Rate},
	pages = {1012--1019},
}

@article{prado269,
	title = {The emerging role of computerized tomography in assessing cancer cachexia},
	volume = {3},
	issn = {1751-4266},
	doi = {10.1097/SPC.0b013e328331124a},
	abstract = {PURPOSE OF REVIEW: The present review represents an overview of the potential opportunistic use of computerized tomography (CT) to enhance our understanding of abnormal body composition, specifically lean and adipose tissue changes in cancer cachexia.
RECENT FINDINGS: One of the characteristics of cancer cachexia is the depletion of muscle with or without adipose tissue loss. Therefore, a body composition tool that specifically distinguishes between these tissues is essential in assessing this syndrome. Cancer patients are routinely evaluated by high resolution imaging such as CT for the purpose of diagnosis and follow-up. Recent work exploiting CT images for body composition analysis has revealed the natural history of cancer cachexia, including progressive alterations in skeletal muscle, adipose tissue, organs, and tumor mass. CT-based quantification of skeletal muscle has permitted identification of individuals with sarcopenia, and links between sarcopenia and functional status, chemotherapy toxicity, time to tumor progression, and mortality.
SUMMARY: CT images routinely acquired from health records of cancer patients can be used to quantify specific lean and adipose tissues, to interpret body composition in population-based studies, and to evaluate individual patients in a clinical and therapeutic decision-making setting.},
	language = {eng},
	number = {4},
	journal = {Curr Opin Support Palliat Care},
	author = {Prado, Carla M. M. and Birdsell, Laura A. and Baracos, Vickie E.},
	month = dec,
	year = {2009},
	pmid = {19667996},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Cachexia, Disease Progression, Neoplasms, Thinness},
	pages = {269--275},
}

@article{fogelman307,
	title = {Does {IGFR1} inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?},
	volume = {5},
	issn = {2190-5991},
	doi = {10.1007/s13539-014-0145-y},
	abstract = {BACKGROUND: IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.
METHODS: We evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK-0646 (M), a monoclonal antibody directed against the IGF-1 protein, in patients with metastatic pancreatic cancer (MPC). Two different doses of M were tested, 5 and 10 mg/kg. We used the Slice-o-matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm(2)) at baseline and after 2 and 4 months of treatment. Patients received either gemcitabine with erlotinib (G + E), G + E + M, or G + M. Differences between the groups were compared using t tests.
RESULTS: Fifty-three patients had both baseline and 2-month imaging available for analysis. Of these, 42 received M with their chemo, and 11 had G + E only. After 2 months of treatment, both groups demonstrated decrease in muscle mass. G + E patients lost 5.6 \% of muscle mass; M patients lost 9.1 and 8.6 \% after treatment with 5 and 10 mg/kg, respectively (p = 0.53). Patients demonstrating a response lost less muscle (median 4.6 \%) than those with stable disease (9.6 \%) and progressive disease (8.9 \%, p = 0.14). Muscle retention from baseline to 2-month imaging, defined as loss of {\textless}6 cm(2) of muscle, correlated with better survival than those patients demonstrating a muscle loss (HR 0.51, p = 0.03).
CONCLUSIONS: MPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop-out and death. There was a non-significant trend toward greater muscle mass loss in patients on anti-IGF-1R therapy. However, it is unclear if this loss translates into functional differences between patients.},
	language = {eng},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Fogelman, David R. and Holmes, Holly and Mohammed, Khalil and Katz, Matthew H. G. and Prado, Carla M. and Lieffers, Jessica and Garg, Naveen and Varadhachary, Gauri R. and Shroff, Rachna and Overman, Michael J. and Garrett, Christopher and Wolff, Robert A. and Javle, Milind},
	month = dec,
	year = {2014},
	pmid = {24740741},
	pmcid = {PMC4248412},
	pages = {307--313},
}

@article{baracos1133S,
	title = {Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis},
	volume = {91},
	issn = {1938-3207},
	shorttitle = {Body composition in patients with non-small cell lung cancer},
	doi = {10.3945/ajcn.2010.28608C},
	abstract = {BACKGROUND: The prominent clinical feature of cachexia has traditionally been understood to be weight loss; however, in recognition of the potential for divergent behavior of muscle and adipose tissue, cachexia was recently defined as loss of muscle with or without loss of fat mass. Detailed assessments are required to verify body composition in patients with cancer cachexia.
DESIGN: We adopted a population-based approach to study body composition in patients with cancer, with the use of diagnostic computed tomography images acquired for cancer diagnosis and follow-up. A prospective cohort of 441 patients with non-small cell lung cancer, who were referred consecutively to a regional medical oncology service in Alberta, Canada, was evaluated.
RESULTS: At referral (median time to death: 265 d), mean body mass index (BMI; in kg/m(2)) was 24.9, with 47.4\% of patients being overweight or obese. Only 7.5\% overall were underweight as conventionally understood (BMI {\textless} 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8\% and was present in patients in all BMI categories. A much higher proportion of men (61\%) than women (31\%) met the criteria for sarcopenia.
CONCLUSIONS: Wasting of skeletal muscle is a prominent feature of patients with lung cancer, despite normal or heavy body weights. The significance of muscle wasting in normal-weight, overweight, and obese patients as a nutritional risk factor, as a prognostic factor, and as a predictor of cancer treatment toxicity is discussed in this article.},
	language = {eng},
	number = {4},
	journal = {Am J Clin Nutr},
	author = {Baracos, Vickie E. and Reiman, Tony and Mourtzakis, Marina and Gioulbasanis, Ioannis and Antoun, Sami},
	month = apr,
	year = {2010},
	pmid = {20164322},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Body Mass Index, Risk Factors, Sex Factors, Body Weight, Cachexia, Muscular Atrophy, Prospective Studies, Lung Neoplasms, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Prognosis},
	pages = {1133S--1137S},
}

@article{tan6973,
	title = {Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer},
	volume = {15},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-09-1525},
	abstract = {PURPOSE: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also evaluated.
EXPERIMENTAL DESIGN: A total of 111 patients entering a palliative therapy program, who had CT images and had undergone nutritional screening, were studied. In patients for whom follow-up scans were available (n = 44), longitudinal changes in body composition were studied at a mean of 230 +/- 62 and 95 +/- 60 days prior to demise.
RESULTS: Sixty-two patients (55.9\%) were sarcopenic, 44 (39.6\%) were overweight/obese, and 18 (16.2\%) were both. Age {\textgreater} or =59 years (hazard ratio, 1.71; 95\% confidence interval, 1.10-2.66; P = 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95\% confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass index decreased from 15.5 +/- 2.5 kg/m(2) to 14.5 +/- 2.0 kg/m2 (P = 0.002), and total fat mass index decreased from 7.5 +/- 2.0kg/m2 to 6.0 +/- 1.5kg/m2 (P {\textless} 0.0001) over 135 days.
CONCLUSIONS: Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult condition but can be identified using CT scans. This condition is an independent adverse prognostic indicator that should be considered for stratification of patients' entering clinical trials, systemic therapy, or support care programs.},
	language = {eng},
	number = {22},
	journal = {Clin Cancer Res},
	author = {Tan, Benjamin H. L. and Birdsell, Laura A. and Martin, Lisa and Baracos, Vickie E. and Fearon, Kenneth C. H.},
	month = nov,
	year = {2009},
	pmid = {19887488},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Obesity, Sarcopenia, Treatment Outcome, Body Weight, Pancreatic Neoplasms, Prognosis, Overweight, Risk},
	pages = {6973--6979},
}

@article{lieffers1173,
	title = {A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands},
	volume = {89},
	issn = {1938-3207},
	shorttitle = {A viscerally driven cachexia syndrome in patients with advanced colorectal cancer},
	doi = {10.3945/ajcn.2008.27273},
	abstract = {BACKGROUND: Cancer cachexia-associated weight loss is poorly understood; energetically demanding tissues (eg, organ and tumor mass) and resting energy expenditure (REE) are reported to increase with advanced cancer.
OBJECTIVE: The objective was to quantify the potential contribution of increasing masses of energetically demanding tissues to REE with colorectal cancer cachexia progression.
DESIGN: A longitudinal computed tomography (CT) image review was performed to quantify organ size (liver, including metastases, and spleen) and peripheral tissues (skeletal muscle and adipose tissue) during colorectal cancer cachexia progression (n = 34). Body composition was prospectively evaluated by CT and dual-energy X-ray absorptiometry, and REE was determined by indirect calorimetry in advanced colorectal cancer patients (n = 18).
RESULTS: Eleven months from death, the liver (2.3 +/- 0.7 kg) and spleen (0.32 +/- 0.2 kg) were larger than reference values. One month from death, liver weight increased to 3.0 +/- 1.5 kg (P = 0.010), spleen showed a trend to increase (P = 0.077), and concurrent losses of muscle (4.2 kg) and fat (3.5 kg) (P {\textless} 0.05) were observed. The estimated percentage of fat-free mass (FFM) occupied by the liver increased from 4.5\% to 7.0\% (P {\textless} 0.001). The most rapid loss of peripheral tissues and liver and metastases gain occurred within 3 mo of death. A positive linear relation existed between liver mass and measured whole-body REE (r(2) = 0.35, P = 0.010); because liver accounted for a larger percentage of FFM, measured REE . kg FFM(-1) . d(-1) increased (r(2) = 0.35, P = 0.010).
CONCLUSIONS: Increases in mass and in the proportion of high metabolic rate tissues, including liver and tumor, represented a cumulative incremental REE of approximately 17,700 kcal during the last 3 mo of life and may contribute substantially to cachexia-associated weight loss.},
	language = {eng},
	number = {4},
	journal = {Am J Clin Nutr},
	author = {Lieffers, Jessica R. and Mourtzakis, Marina and Hall, Kevin D. and McCargar, Linda J. and Prado, Carla M. M. and Baracos, Vickie E.},
	month = apr,
	year = {2009},
	pmid = {19244378},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, Cachexia, Disease Progression, Neoplasm Metastasis, Prospective Studies, Longitudinal Studies, Absorptiometry, Photon, Basal Metabolism, Calorimetry, Indirect, Cohort Studies, CRC, Liver, Organ Size, Spleen, Weight Loss},
	pages = {1173--1179},
}

@article{frontera1038,
	title = {Strength conditioning in older men: skeletal muscle hypertrophy and improved function},
	volume = {64},
	issn = {8750-7587},
	shorttitle = {Strength conditioning in older men},
	doi = {10.1152/jappl.1988.64.3.1038},
	abstract = {The effects of strength conditioning on skeletal muscle function and mass were determined in older men. Twelve healthy untrained volunteers (age range 60-72 yr) participated in a 12-wk strength training program (8 repetitions/set; 3 sets/day; 3 days/wk) at 80\% of the one repetition maximum (1 RM) for extensors and flexors of both knee joints. They were evaluated before the program and after 6 and 12 wk of training. Weekly measurements of 1 RM showed a progressive increase in strength in extensors and flexors. By 12 wk extensor and flexor strength had increased 107.4 (P less than 0.0001) and 226.7\% (P less than 0.0001), respectively. Isokinetic peak torque of extensors and flexors measured on a Cybex II dynamometer increased 10.0 and 18.5\% (P less than 0.05) at 60 degrees/s and 16.7 and 14.7\% (P less than 0.05) at 240 degrees/s. The torque-velocity relationship showed an upward displacement of the curve at the end of training, mainly in the slow-velocity high-torque region. Midthigh composition from computerized tomographic scans showed an increase (P less than 0.01) in total thigh area (4.8\%), total muscle area (11.4\%), and quadriceps area (9.3\%). Biopsies of the vastus lateralis muscle revealed similar increases (P less than 0.001) in type I fiber area (33.5\%) and type II fiber area (27.6\%). Daily excretion of urinary 3-methyl-L-histidine increased with training (P less than 0.05) by an average 40.8\%. Strength gains in older men were associated with significant muscle hypertrophy and an increase in myofibrillar protein turnover.},
	language = {eng},
	number = {3},
	journal = {J Appl Physiol (1985)},
	author = {Frontera, W. R. and Meredith, C. N. and O'Reilly, K. P. and Knuttgen, H. G. and Evans, W. J.},
	month = mar,
	year = {1988},
	pmid = {3366726},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Male, Middle Aged, Body Weight, Organ Size, Creatinine, Exercise Therapy, Hypertrophy, Methylhistidines, Muscles},
	pages = {1038--1044},
}

@article{mitsiopoulos115,
	title = {Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography},
	volume = {85},
	issn = {8750-7587},
	doi = {10.1152/jappl.1998.85.1.115},
	abstract = {Magnetic resonance imaging (MRI) and computerized tomography (CT) are promising reference methods for quantifying whole body and regional skeletal muscle mass. Earlier MRI and CT validation studies used data-acquisition techniques and data-analysis procedures now outdated, evaluated anatomic rather than adipose tissue-free skeletal muscle (ATFSM), studied only the relatively large thigh, or found unduly large estimation errors. The aim of the present study was to compare arm and leg ATFSM cross-sectional area estimates (cm2) by using standard MRI and CT acquisition and image-analysis methods with corresponding cadaver estimates. A second objective was to validate MRI and CT measurements of adipose tissue embedded within muscle (interstitial adipose tissue) and surrounding muscle (subcutaneous adipose tissue). ATFSM area (n = 119) by MRI [38.9 +/- 22.3 (SD) cm2], CT (39.7 +/- 22.8 cm2), and cadaver (39.5 +/- 23.0 cm2) were not different (P {\textgreater} 0.001), and both MRI and CT estimates of ATFSM were highly correlated with corresponding cadaver values [MRI: r = 0.99, SE of estimate (SEE) 3.9 cm2, P {\textless} 0.001; and CT: r = 0.99, SEE = 3.8 cm2, P {\textless} 0.001]. Similarly good results were observed between MRI- and CT-measured vs. cadaver-measured interstitial and subcutaneous adipose tissue. For MRI-ATFSM the intraobserver correlation for duplicate measurements in vivo was 0. 99 [SEE = 8.7 cm2 (2.9\%), P {\textless} 0.001]. These findings strongly support the use of MRI and CT as reference methods for appendicular skeletal muscle, interstitial and subcutaneous adipose tissue measurement in vivo.},
	language = {eng},
	number = {1},
	journal = {J Appl Physiol (1985)},
	author = {Mitsiopoulos, N. and Baumgartner, R. N. and Heymsfield, S. B. and Lyons, W. and Gallagher, D. and Ross, R.},
	month = jul,
	year = {1998},
	pmid = {9655763},
	keywords = {Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Middle Aged, Obesity, Image Processing, Computer-Assisted, L3, Aged, 80 and over, Cadaver, Leg, Reproducibility of Results},
	pages = {115--122},
}

@article{shen2333,
	title = {Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image},
	volume = {97},
	issn = {8750-7587},
	shorttitle = {Total body skeletal muscle and adipose tissue volumes},
	doi = {10.1152/japplphysiol.00744.2004},
	abstract = {A single abdominal cross-sectional computerized axial tomography and magnetic resonance image is often obtained in studies examining adipose tissue (AT) distribution. An abdominal image might also provide additional useful information on total body skeletal muscle (SM) and AT volumes with related physiological insights. We therefore investigated the relationships between abdominal SM and AT areas from single images and total body component volumes in a large and diverse sample of healthy adult subjects. Total body SM and AT volumes were derived by whole body multislice magnetic resonance imaging in 123 men [age (mean +/- SD) of 41.6 +/- 15.8 yr; body mass index of 25.9 +/- 3.4 kg/m(2)] and 205 women (age of 47.8 +/- 18.7 yr; body mass index of 26.7 +/- 5.6 kg/m(2)). Single abdominal SM and AT slice areas were highly correlated with total body SM (r = 0.71-0.92; r = 0.90 at L(4)-L(5) intervertebral space) and AT (r = 0.84-0.96; r = 0.94 at L(4)-L(5) intervertebral space) volumes, respectively. R(2) increased by only 5.7-6.1\% for SM and 2.7-4.4\% for AT with the inclusion of subject sex, age, ethnicity, scanning position, body mass index, and waist circumference in the model. The developed SM and AT models were validated in an additional 49 subjects. To achieve equivalent power to a study measuring total body SM or AT volumes, a study using a single abdominal image would require 17-24\% more subjects for SM and 6-12\% more subjects for AT. Measurement of a single abdominal image can thus provide estimates of total body SM and AT for group studies of healthy adults.},
	language = {eng},
	number = {6},
	journal = {J Appl Physiol (1985)},
	author = {Shen, Wei and Punyanitya, Mark and Wang, ZiMian and Gallagher, Dympna and St-Onge, Marie-Pierre and Albu, Jeanine and Heymsfield, Steven B. and Heshka, Stanley},
	month = dec,
	year = {2004},
	pmid = {15310748},
	keywords = {Abdomen, Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Reproducibility of Results, Adult, Predictive Value of Tests},
	pages = {2333--2338},
}

@article{bayar311,
	title = {Statistical approaches for evaluating body composition markers in clinical cancer research},
	volume = {17},
	issn = {1744-8328},
	doi = {10.1080/14737140.2017.1298446},
	abstract = {INTRODUCTION: The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review statistical approaches used to evaluate these markers and suggest practical statistical recommendations. Area covered: We identified statistical methods used recently to take into account properties of morphomics measurements. We also reviewed adjustment methods on major confounding factors such as gender and approaches to model morphomic data, especially mixed models for repeated measures. Finally, we focused on methods for determining a cut-off for a morphomic marker that could be used in clinical practice and how to assess its robustness. Expert commentary: From our review, we proposed 13 key points to strengthen analyses and reporting of clinical research assessing associations between morphomics and outcome or toxicity.},
	language = {eng},
	number = {4},
	journal = {Expert Rev Anticancer Ther},
	author = {Bayar, Mohamed Amine and Antoun, Sami and Lanoy, Emilie},
	month = apr,
	year = {2017},
	pmid = {28277100},
	keywords = {Body Composition, Humans, Neoplasms, Biomarkers, Tumor, Biomedical Research, body composition biomarkers, Confounding Factors, Epidemiologic, Models, Statistical, Morphomics, Outcome Assessment, Health Care, recommendations, sarcopenia, statistical analysis, statistics},
	pages = {311--318},
}

@article{kurk1033,
	title = {Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: {Secondary} analysis of the phase 3 {CAIRO3} trial},
	volume = {9},
	issn = {2045-7634},
	shorttitle = {Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer},
	doi = {10.1002/cam4.2787},
	abstract = {BACKGROUND: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown.
METHODS: This is a retrospective analysis of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine + bevacizumab (CAP-B) or observation, after six cycles capecitabine + oxaliplatin + bevacizumab (CAPOX-B). Upon first disease progression (PD1), CAPOX-B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time-periods; p1: during initial CAPOX-B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1-p3, with PD1, PD2, and survival was studied by Cox regression models.
RESULTS: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean -0.6 SMI units [95\% CI -1.07;-0.26] and p3: -2.2 units [-2.7;-1.8], whereas during p2, SMI increased + 1.2 units [0.8-1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09-1.35]; 1.54 [1.31-1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10-1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14-1.63]).
CONCLUSIONS: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines.},
	language = {eng},
	number = {3},
	journal = {Cancer Med},
	author = {Kurk, Sophie A. and Peeters, Petra H. M. and Dorresteijn, Bram and de Jong, Pim A. and Jourdan, Marion and Creemers, Geert-Jan M. and Erdkamp, Frans L. G. and de Jongh, Felix E. and Kint, Peter A. M. and Poppema, Boelo J. and Radema, Sandra A. and Simkens, Lieke H. J. and Tanis, Bea C. and Tjin-A-Ton, Manuel L. R. and Van Der Velden, Ankie and Punt, Cornelis J. A. and Koopman, Miriam and May, Anne M.},
	month = feb,
	year = {2020},
	pmid = {31850687},
	pmcid = {PMC6997070},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Colorectal Neoplasms, Retrospective Studies, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Palliative Care, Time Factors, Longitudinal Studies, Prognosis, sarcopenia, Body composition, body mass index, chemo, chemotherapy, Clinical Trials, Phase III as Topic, crc, Maintenance Chemotherapy, metastatic colorectal cancer, Progression-Free Survival, Randomized Controlled Trials as Topic, skeletal muscle mass, survival},
	pages = {1033--1043},
}

@article{bozzetti2107,
	title = {Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy},
	volume = {28},
	issn = {1569-8041},
	shorttitle = {Forcing the vicious circle},
	doi = {10.1093/annonc/mdx271},
	abstract = {Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials. The examination of the computed tomography scan at the level of the third lumbar vertebra-a common procedure for staging many tumours-has allowed the oncologist to evaluate the muscle mass and to collect many retrospective data on the prevalence of sarcopenia and its clinical consequences. Sarcopenia is a condition affecting a high percentage of patients with a range depending on type of primary tumour and stage of disease. It is noteworthy that patients may be sarcopenic even if their nutritional status is apparently maintained or they are obese. Sarcopenic patients exhibited higher chemotherapy toxicity and poorer compliance with oncological treatments. Furthermore, several antineoplastic drugs appeared to worsen the sarcopenic status. Therapeutic approaches are several and this review will focus on those validated by randomized controlled trials. They include the use of ω-3-enriched oral nutritional supplements and orexigenic agents, the administration of adequate high-protein regimens delivered enterally or parenterally, and programmes of physical exercise. Better results are expected combining different procedures in a multimodal approach. In conclusion, there are several premises to prevent/treat sarcopenia. The oncologist should coordinate this multimodal approach by selecting priorities and sequences of treatments and then involving a nutrition health care professional or a physical therapist depending on the condition of the single patient.},
	language = {eng},
	number = {9},
	journal = {Ann Oncol},
	author = {Bozzetti, F.},
	month = sep,
	year = {2017},
	pmid = {28911059},
	keywords = {Humans, Tomography, X-Ray Computed, Prevalence, Sarcopenia, Neoplasms, Antineoplastic Agents, Prognosis, sarcopenia, chemo, Randomized Controlled Trials as Topic, cancer and sarcopenia, sarcopenia and chemotherapy, sarcopenia and prognosis, sarcopenia and toxicity, sarcopenia therapy},
	pages = {2107--2118},
}

@article{kurk803,
	title = {Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients},
	volume = {10},
	issn = {2190-6009},
	doi = {10.1002/jcsm.12436},
	abstract = {BACKGROUND: Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation and during more intensive capecitabine + oxaliplatin + bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B.
METHODS: Sarcopenia status and SMI loss were assessed by using consecutive computed tomography scans. DLTs were defined as any dose delay/reduction/discontinuation of systemic treatment because of reported CTCAE (version 3.0) toxicities at the start or during treatment. Poisson regression models were used to study whether sarcopenia and body mass index (BMI) at the start of treatment and SMI and BMI loss during treatment were associated with DLTs.
RESULTS: One hundred eighty-two patients (mean age 63.0 ± 8.8 years, 37\% female) received CAP-B, and 232 patients (mean age 63.0 ± 9.0 years, 34\% female) received CAPOX-B. At the start of CAP-B and CAPOX-B, 54\% and 46\% of patients were sarcopenic, respectively. Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic at the start of CAP-B 25.0 ± 3.9 vs. 26.7 ± 4.1 and CAPOX-B 25.8 ± 3.8 vs. 27.1 ± 3.8 kg/m2 ). Sarcopenia at the start of CAP-B was not associated with DLTs [relative risk 0.87 (95\% confidence interval 0.64-1.19)], whereas patients with {\textgreater}2\% SMI loss had a significantly higher risk of DLTs [1.29 (1.01-1.66)]. At the start of subsequent CAPOX-B, 25\% of patients received a dose reduction, and the risk of dose reduction was significantly higher for patients with preceding SMI loss [1.78 (1.06-3.01)] or sarcopenia [1.75 (1.08-2.86)]. After the received dose reductions, sarcopenia or SMI loss was not significantly associated with a higher risk of DLTs during CAPOX-B [sarcopenia vs. non-sarcopenic: 0.86 (0.69-1.08) and SMI loss vs. stable/gain: 0.83 (0.65-1.07)]. In contrast, BMI (loss) at the start or during either treatment was not associated with an increased risk of DLTs.
CONCLUSIONS: In this large longitudinal study in metastatic colorectal cancer patients during palliative systemic treatment, sarcopenia and/or muscle loss was associated with an increased risk of DLTs. BMI was not associated with DLTs and could not detect sarcopenia or SMI loss. Prospective (randomized) studies should reveal whether normalizing chemotherapeutic doses to muscle mass or muscle mass preservation (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.},
	language = {eng},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Kurk, Sophie and Peeters, Petra and Stellato, Rebecca and Dorresteijn, B. and de Jong, Pim and Jourdan, Marion and Creemers, Geert-Jan and Erdkamp, Frans and de Jongh, Felix and Kint, Peter and Simkens, Lieke and Tanis, Bea and Tjin-A-Ton, Manuel and Van Der Velden, Ankie and Punt, Cornelis and Koopman, Miriam and May, Anne},
	month = aug,
	year = {2019},
	pmid = {31094083},
	pmcid = {PMC6711417},
	keywords = {Humans, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Longitudinal Studies, Body composition, chemo, crc, Chemotherapy, Dose-limiting toxicity, Dose-Response Relationship, Drug, Metastatic colorectal cancer, Skeletal muscle mass},
	pages = {803--813},
}

@article{cespedesfeliciano4868,
	title = {Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant {FOLFOX}: {The} {C}-{SCANS} study},
	volume = {123},
	issn = {1097-0142},
	shorttitle = {Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant {FOLFOX}},
	doi = {10.1002/cncr.30950},
	abstract = {BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer.
METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients). Patients' muscle mass was quantified using clinically acquired computed tomography scans. The authors quantified chemotherapy doses, treatment dates, and related toxicities using the electronic medical record. In logistic regression models adjusting for age, sex, and American Joint Committee on Cancer stage of disease, the authors examined associations of muscle tertiles with early treatment discontinuation ({\textless}6 cycles), treatment delay ({\textgreater}3 days off schedule for ≥3 times), and/or dose reduction (relative dose intensity ≤ 0.70, based on planned treatment).
RESULTS: The average age of the patients at the time of diagnosis was 58.7 years; BSA was 1.9 m2 and body mass index was 28.7 kg/m2 . Compared with the highest sex-specific tertile of muscle mass, patients in the lowest tertile were more likely to experience toxicities and had twice the risk of adverse outcomes while receiving FOLFOX; for early discontinuation, the odds ratio (OR) was 2.34 (95\% confidence interval [95\% CI], 1.04-5.24; P for trend = .03), whereas the ORs were 2.24 (95\% CI, 1.37-3.66; P for trend = .002) for treatment delay and 2.28 (95\% CI, 1.19-4.36; P for trend = .01) for dose reduction.
CONCLUSIONS: Lower muscle mass is associated with greater toxicity and poor chemotherapy adherence among patients receiving FOLFOX. Many chemotherapy drugs are dosed based on BSA, but treatment may be better individualized if muscle mass is considered. Cancer 2017;123:4868-77. © 2017 American Cancer Society.},
	language = {eng},
	number = {24},
	journal = {Cancer},
	author = {Cespedes Feliciano, Elizabeth M. and Lee, Valerie S. and Prado, Carla M. and Meyerhardt, Jeffrey A. and Alexeeff, Stacey and Kroenke, Candyce H. and Xiao, Jingjie and Castillo, Adrienne L. and Caan, Bette J.},
	month = dec,
	year = {2017},
	pmid = {28881381},
	pmcid = {PMC5716836},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Body Mass Index, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Risk Assessment, Prognosis, Organ Size, Adult, chemotherapy, skeletal muscle mass, Dose-Response Relationship, Drug, Analysis of Variance, body composition, body surface area, Chemotherapy, Adjuvant, Chi-Square Distribution, Colectomy, colon cancer, Colonic Neoplasms, Databases, Factual, dose-limiting toxicity, Drug Administration Schedule, Fluorouracil, Leucovorin, Neoplasm Invasiveness, Organoplatinum Compounds, relative dose intensity, Statistics, Nonparametric, Survival Analysis, United States, Withholding Treatment},
	pages = {4868--4877},
}

@article{ali607,
	title = {Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with {FOLFOX} regimens},
	volume = {5},
	issn = {2045-7634},
	doi = {10.1002/cam4.621},
	abstract = {Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose-limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue was measured by computerized tomography (CT) and used to evaluate the LBM compartment of the whole body. In prospective randomized clinical trials conducted in France (n = 58), for patients given FOLFOX-based regimens according to body surface area, values of oxaliplatin/kg LBM were highly variable, ranging from 2.55 to 6.6 mg/kg LBM. A cut point of 3.09 mg oxaliplatin/kg LBM for developing toxicity was determined by Receiver Operating Characteristic (ROC) analysis, below this value 0/17 (0.0\%) of patients experienced DLT; in contrast above this value 18/41 (44.0\%) of patients were dose reduced or had treatment terminated owing to toxicity (≥Grade 3 or neuropathy ≥Grade 2); for 9/41 the DLT was sensory neuropathy. These findings were validated in an independent cohort of colon cancer patients (n = 80) receiving FOLFOX regimens as part of standard care, in Canada. Low LBM is a significant predictor of toxicity and neuropathy in patients administered FOLFOX-based regimens using conventional body surface area (BSA) dosing.},
	language = {eng},
	number = {4},
	journal = {Cancer Med},
	author = {Ali, Raafi and Baracos, Vickie E. and Sawyer, Michael B. and Bianchi, Laurent and Roberts, Sarah and Assenat, Eric and Mollevi, Caroline and Senesse, Pierre},
	month = apr,
	year = {2016},
	pmid = {26814378},
	pmcid = {PMC4831278},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Body composition, chemo, crc, Canada, colon cancer, Colonic Neoplasms, Fluorouracil, Leucovorin, Organoplatinum Compounds, Body Surface Area, chemotherapy toxicity, Drug-Related Side Effects and Adverse Reactions, France, irinotecan, lean body mass, Nervous System Diseases, neuropathy, oxaliplatin, Population Surveillance},
	pages = {607--616},
}

@article{prado3264,
	title = {Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity},
	volume = {13},
	issn = {1078-0432},
	doi = {10.1158/1078-0432.CCR-06-3067},
	abstract = {PURPOSE: Evidence suggests that lean body mass (LBM) may be useful to normalize doses of chemotherapy. Data from a prospective study were used to determine if the highest doses of 5-fluorouracil (5-FU) per kilogram LBM would be associated with dose-limiting toxicity in stage II/III colon cancer patients treated with 5-FU and leucovorin.
EXPERIMENTAL DESIGN: Toxicity after cycle 1 was graded according to National Cancer Institute Common Toxicity Criteria, version 2.0. Muscle tissue was measured by computerized tomography. An extrapolation to the LBM compartment of the whole body was employed.
RESULTS: Mean values of 5-FU/LBM of the entire population were different in terms of presence or absence of toxicity (P = 0.036). A cut point of 20 mg 5-FU/kg LBM seemed to be a threshold for developing toxicity (P = 0.005). This observation was pertinent to women (odds ratio, 16.73; P = 0.021). Women in this study had a relatively low proportion of LBM relative to their body surface area.
CONCLUSION: Our study shows that low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area. We conclude that variation in toxicity between females and males may be partially explained by this feature of body composition.},
	language = {eng},
	number = {11},
	journal = {Clin Cancer Res},
	author = {Prado, Carla M. M. and Baracos, Vickie E. and McCargar, Linda J. and Mourtzakis, Marina and Mulder, Karen E. and Reiman, Tony and Butts, Charles A. and Scarfe, Andrew G. and Sawyer, Michael B.},
	month = jun,
	year = {2007},
	pmid = {17545532},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Sex Factors, Prospective Studies, Antineoplastic Agents, Adult, chemo, crc, Dose-Response Relationship, Drug, Fluorouracil, Leucovorin, Body Surface Area},
	pages = {3264--3268},
}

@article{barret583,
	title = {Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer},
	volume = {66},
	issn = {1532-7914},
	doi = {10.1080/01635581.2014.894103},
	abstract = {Chemotherapy toxicity could be linked to decreased skeletal muscle (sarcopenia). We evaluated the effect of sarcopenia on chemotherapy toxicity among metastatic colorectal cancer (mCRC) patients. All consecutive mCRC patients in 3 hospitals were enrolled in this prospective, cross-sectional, multicenter study. Several nutritional indexes and scores were generated. Computed tomography (CT) images were analyzed to evaluate cross-sectional areas of muscle tissue (MT), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT). Toxicities were evaluated in the 2 mo following clinical evaluation. Fifty-one mCRC patients were included in the study. Sarcopenia was observed in 71\% of patients (39\% of women and 82\% of men) whereas only 4\% and 18\% were considered as underweight using body mass index (BMI) or severely malnourished using the Nutritional Risk Index (NRI), respectively. Grade 3-4 toxicities were observed in 28\% of patients. In multivariate analysis including age, sex, BMI, sarcopenia, SAT, and VAT, the only factor associated with Grade 3-4 toxicities was sarcopenia (odds ratio = 13.55; 95\% confidence interval [1.08; 169.31], P = 0.043). In mCRC patients undergoing chemotherapy, sarcopenia was much more frequently observed than visible malnutrition. Despite the small number of patients included in our study, we found sarcopenia to be significantly associated with severe chemotherapy toxicity.},
	language = {eng},
	number = {4},
	journal = {Nutr Cancer},
	author = {Barret, Maximilien and Antoun, Sami and Dalban, Cécile and Malka, David and Mansourbakht, Touraj and Zaanan, Aziz and Latko, Ewa and Taieb, Julien},
	year = {2014},
	pmid = {24707897},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Colorectal Neoplasms, Neoplasm Metastasis, Prospective Studies, Antineoplastic Agents, Aged, 80 and over, Adult, chemo, crc, Antibodies, Monoclonal, Humanized, Camptothecin, Cetuximab, Cross-Sectional Studies, Intra-Abdominal Fat, Irinotecan, Nutrition Assessment, Young Adult},
	pages = {583--589},
}

@article{park17683,
	title = {Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer},
	volume = {10},
	issn = {2045-2322},
	doi = {10.1038/s41598-020-74765-8},
	abstract = {Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively reviewed 111 consecutive AGC patients who underwent first-line palliative chemotherapy. Skeletal muscle area was measured before and after chemotherapy at the third lumbar vertebra level using computed tomography scans. We compared skeletal muscle index (SMI), body mass index (BMI), and body weight changes to chemotherapy response and survival. The 80 male and 31 female patients' median age was 65 (range 31-87) years, and 46.8\% had sarcopenia at baseline. Median pre-chemotherapy to post-chemotherapy SMI, BMI, and body weight decreases were - 4.5 cm2/m2 (- 11.3\%) (P {\textless} 0.001); - 0.7 kg/m2 (- 3.2\%) (P {\textless} 0.001); and - 2.0 kg (- 3.5\%) (P {\textless} 0.001), respectively. Median SMI decreases for patients with objective response, stable disease, and disease progression were - 4.0 cm2/m2 (range - 20.1 {\textasciitilde} 9.5); - 4.5 cm2/m2 (range - 19.8 {\textasciitilde} 0.8); and - 3.8 cm2/m2 (range: - 17.6 {\textasciitilde} 0.1), respectively. Response to chemotherapy was not associated with SMI decrease (P = 0.463). In multivariable analysis, sarcopenia at baseline (HR 1.681; 95\% CI 1.083-2.609, P = 0.021), decreased SMI (HR 1.620; 95\% CI 1.041-2.520; P = 0.032) were significant poor prognostic factors for survival. Skeletal muscle mass decreased significantly during chemotherapy in AGC patients, but was not associated with chemotherapy response. Decreased SMI was a poor prognostic factor in AGC patients during first-line palliative chemotherapy.},
	language = {eng},
	number = {1},
	journal = {Sci Rep},
	author = {Park, Song Ee and Choi, Jin Hwa and Park, Jae Yong and Kim, Beom Jin and Kim, Jae Gyu and Kim, Jong Won and Park, Joong-Min and Chi, Kyong-Choun and Hwang, In Gyu},
	month = oct,
	year = {2020},
	pmid = {33077864},
	pmcid = {PMC7573603},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Palliative Care, Antineoplastic Agents, Prognosis, Organ Size, Aged, 80 and over, Adult, chemo, gastric, Stomach Neoplasms},
	pages = {17683},
}

@article{wang751,
	title = {Muscle {Density}, but {Not} {Size}, {Correlates} {Well} {With} {Muscle} {Strength} and {Physical} {Performance}},
	volume = {22},
	issn = {1525-8610},
	url = {https://www.sciencedirect.com/science/article/pii/S1525861020305740},
	doi = {10.1016/j.jamda.2020.06.052},
	abstract = {Objectives
There is increasing evidence that muscle volume and mass are poor predictors of muscle strength and physical performance. Other assessments of muscle quality such as skeletal muscle density measured by computed tomography (CT) may be more important. The aim of this study was to explore associations of muscle size and density with handgrip strength (HGS) and the Timed Up and Go test (TUG). We also hypothesized that the strength of these associations would depend on the specific muscle of muscle group, namely trunk, hip, and mid-thigh muscles.
Design
Cross-sectional study.
Setting and Participants
University hospital; 316 volunteers aged 59 to 85 years.
Methods
HGS, TUG, and quantitative CT imaging of the lumber, hip, and mid-thigh were performed in volunteers. From the CT images, cross-sectional area and attenuation were determined for the gluteus muscle, trunk muscle at vertebrae L2 level, and mid-thigh muscle.
Results
In men and women, associations of muscle area with TUG were insignificant after adjustment for age, height, and weight. Associations with HGS were only significant in men for the gluteus maximus and the mid-thigh but slopes were rather low (β {\textless} 0.20). Associations between muscle density and TUG/HGS were more pronounced, in particular for HGS. After adjustment, associations with TUG were significant in women for the gluteus maximus and trunk muscle even (β −0.06, P .001 and β −0.07, P .031, respectively).
Conclusions and Implications
Muscle density is more strongly associated with muscle strength than muscle size andin women muscle density was also more strongly associated than muscle size with physical performance. Therefore, muscle density may represent a more clinically meaningful surrogate of muscle performance than muscle size. Muscle density measurements of trunk and gluteus muscles can be easily obtained from routine CT scan and, therefore, may become an important measurement to diagnose and screen for sarcopenia.},
	language = {en},
	number = {4},
	urldate = {2021-06-17},
	journal = {Journal of the American Medical Directors Association},
	author = {Wang, Ling and Yin, Lu and Zhao, Yue and Su, Yongbin and Sun, Wei and Chen, Shuo and Liu, Yandong and Yang, Minghui and Yu, Aihong and Guglielmi, Giuseppe and Blake, Glen M. and Cheng, Xiaoguang and Wu, Xinbao and Veldhuis-Vlug, Annegreet G. and Engelke, Klaus},
	month = apr,
	year = {2021},
	keywords = {sarcopenia, computed tomography, grip strength, Muscle density, muscle size, Myosteatosis, Timed Up and Go test},
	pages = {751--759.e2},
	file = {ScienceDirect Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\7PKCKLE7\\S1525861020305740.html:text/html},
}

@article{rinninella2045,
	title = {Muscle mass, assessed at diagnosis by {L3}-{CT} scan as a prognostic marker of clinical outcomes in patients with gastric cancer: {A} systematic review and meta-analysis},
	volume = {39},
	issn = {0261-5614},
	shorttitle = {Muscle mass, assessed at diagnosis by {L3}-{CT} scan as a prognostic marker of clinical outcomes in patients with gastric cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S0261561419331085},
	doi = {10.1016/j.clnu.2019.10.021},
	abstract = {Background \& aims
Computed tomographic (CT) imaging at third lumbar vertebra (L3), routinely used by oncologists, represents a reliable tool to quantify muscle mass. A systematic review and meta-analysis was performed to assess the efficacy of CT scan to define muscle mass as a prognostic marker in gastric cancer (GC) patients undergoing gastrectomy and/or chemotherapy. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS) and the secondary outcomes included postoperative length of hospital stay (P-LOS), total and severe complications in GC patients undergoing gastrectomy.
Methods
Three electronic bibliographic databases — MEDLINE, Web of Science and Cochrane Central Register of Controlled Trials - were used to conduct a systematic literature search based on fixed inclusion and exclusion criteria, until April 2019. The adjusted and unadjusted hazard ratio (HR), odds ratio (OR) and mean difference (MD) with 95\% confidence interval (CI) were used to analyse the dichotomous variables (OS, RFS, total and severe complications) and continuous variables (P-LOS). Random- and fixed effects models were used according to the heterogeneity.
Results
A total of 5610 GC patients from 20 studies were identified. Low muscle mass at diagnosis was found in 32.7\% of GC patients and was significantly associated with poorer OS (HR 2.02, 95\% CI 1.71–2.38, p {\textless} 0.00001, I2 = 47\%) and worse RFS (HR 1.97, 95\% CI 1.71–2.26, p {\textless} 0.00001, I2 = 0\%). Meta-analysis of adjusted HR from multivariable analyses confirmed the association between OS and low muscle mass (HR 1.89, 95\% CI 1.68–2.12, p {\textless} 0.00001, I2 = 36\%). Furthermore, low muscle mass and poorer OS were significantly associated in metastatic GC patients exclusively undergoing chemotherapy (HR 1.61, 95\% CI 1.23–2.11, p {\textless} 0.0006, I2 = 18\%). Moreover, preoperative low muscle mass was significantly associated with longer P-LOS (MD 1.19, 95\% CI 0.68–1.71, p {\textless} 0.00001, I2 = 0\%), higher risk of postoperative complications (OR 1.76, 95\% CI 1.17–2.66, p = 0.007, I2 = 77\%) and severe complications (OR 1.54, 95\% CI 1.03–2.29, p = 0.04, I2 = 49\%) in GC patients undergoing gastrectomy.
Conclusions
Low muscle mass, assessed by L3 CT-scan, affects almost 1/3 of GC patients at diagnosis and acts as a negative prognostic marker on many clinical outcomes. Therefore, identifying GC patients with low muscle mass at diagnosis or at follow-up visit should be recommendable. Clinical nutritionists should be part of tumor boards meetings to screen low muscle mass in order to prompt personalized nutritional support.},
	language = {en},
	number = {7},
	urldate = {2021-06-17},
	journal = {Clinical Nutrition},
	author = {Rinninella, Emanuele and Cintoni, Marco and Raoul, Pauline and Pozzo, Carmelo and Strippoli, Antonia and Bria, Emilio and Tortora, Giampaolo and Gasbarrini, Antonio and Mele, Maria Cristina},
	month = jul,
	year = {2020},
	keywords = {Sarcopenia, Disease-related malnutrition, Gastric cancer, Muscle mass, Personalised medicine, Tumor boards},
	pages = {2045--2054},
	file = {ScienceDirect Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\IUBJ3T6B\\S0261561419331085.html:text/html},
}

@article{sugiyama5859a,
	title = {Baseline {Sarcopenia} and {Skeletal} {Muscle} {Loss} {During} {Chemotherapy} {Affect} {Survival} {Outcomes} in {Metastatic} {Gastric} {Cancer}},
	volume = {38},
	copyright = {Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved},
	issn = {0250-7005, 1791-7530},
	url = {https://ar.iiarjournals.org/content/38/10/5859},
	doi = {10.21873/anticanres.12928},
	abstract = {{\textless}p{\textgreater}Aim: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. Patients and Methods: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10\% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). Results: Of 118 patients, 89\% had baseline sarcopenia and 31\% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. Conclusion: Muscle loss during chemotherapy negatively affected survival among patients with mGC.{\textless}/p{\textgreater}},
	language = {en},
	number = {10},
	urldate = {2021-06-17},
	journal = {Anticancer Research},
	author = {Sugiyama, Keiji and Narita, Yukiya and Mitani, Seiichiro and Honda, Kazunori and Masuishi, Toshiki and Taniguchi, Hiroya and Kadowaki, Shigenori and Ura, Takashi and Ando, Masashi and Tajika, Masahiro and Muro, Kei},
	month = oct,
	year = {2018},
	pmid = {30275211},
	note = {Publisher: International Institute of Anticancer Research
Section: Clinical Studies},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Follow-Up Studies, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Prognosis, Aged, 80 and over, Adult, sarcopenia, chemo, Chemotherapy, gastric, Stomach Neoplasms, Adenocarcinoma, Case-Control Studies, gastric cancer, Liver Neoplasms, Peritoneal Neoplasms, prognostic factor, skeletal muscle loss, Stage4},
	pages = {5859--5866},
	file = {Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\3KU4EEAZ\\5859.html:text/html;Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\DFP429QJ\\Sugiyama et al. - 2018 - Baseline Sarcopenia and Skeletal Muscle Loss Durin.pdf:application/pdf},
}

@article{narita52,
	title = {Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients},
	volume = {9},
	issn = {2078-6891},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848026/},
	doi = {10.21037/jgo.2017.11.08},
	abstract = {Background
It remains unclear whether human epidermal growth factor receptor 2 (HER2) status is an outcome-associated biomarker independent of known prognostic factors for metastatic gastric cancer. Moreover, there are few reports about nomograms in inoperable locally advanced or metastatic gastric cancer (AGC), although several studies have been reported regarding other cancer types. This retrospective study aimed to develop nomograms that combine HER2 status and other prognostic factors to predict the survival outcomes of AGC patients starting first-line treatment.

Methods
In this study, 838 consecutive AGC patients starting first-line chemotherapy at the Aichi Cancer Center Hospital (ACC) were included to establish the nomograms that calculated the predicted probability of survival at different time points, 6 months and 1 and 2 years for overall survival (OS) and 3 and 6 months, and 1 year for progression free survival (PFS). Nomograms were independently validated with 269 consecutive AGC patients at the Cancer Center Hospital (SCC) who underwent first-line chemotherapy. The discriminatory ability and accuracy of the models were assessed using Harrell’s c-index. IHC3+ or IHC2+/ISH+ tumors were defined as HER2 positive.

Results
At a median follow-up of 12.3 (ACC) and 11.6 (SCC) months, the median OS was 12.5 and 12.4 months (P=1.00), and the median PFS was 4.8 and 5.8 months (P=0.03), respectively. The nomograms showed good C-index values: OS was respectively 0.688 and 0.576 and PFS was respectively for 0.643 and 0.544.

Conclusions
The nomograms including HER2 status as covariate are crucial determinants of clinical care.},
	number = {1},
	urldate = {2021-06-17},
	journal = {J Gastrointest Oncol},
	author = {Narita, Yukiya and Kadowaki, Shigenori and Oze, Isao and Kito, Yosuke and Kawakami, Takeshi and Machida, Nozomu and Taniguchi, Hiroya and Ura, Takashi and Ando, Masashi and Ito, Seiji and Tajika, Masahiro and Yatabe, Yasushi and Yasui, Hirofumi and Muro, Kei},
	month = feb,
	year = {2018},
	pmid = {29564171},
	pmcid = {PMC5848026},
	keywords = {Stage4},
	pages = {52--63},
	file = {PubMed Central Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\4HMEJ8Y2\\Narita et al. - 2018 - Establishment and validation of prognostic nomogra.pdf:application/pdf},
}

@article{custodio1526,
	title = {Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab},
	volume = {116},
	copyright = {2017 The Author(s)},
	issn = {1532-1827},
	shorttitle = {Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy},
	url = {https://www.nature.com/articles/bjc2017122},
	doi = {10.1038/bjc.2017.122},
	abstract = {To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy.},
	language = {en},
	number = {12},
	urldate = {2021-06-17},
	journal = {Br J Cancer},
	author = {Custodio, A. and Carmona-Bayonas, A. and Jiménez-Fonseca, P. and Sánchez, M. L. and Viudez, A. and Hernández, R. and Cano, J. M. and Echavarria, I. and Pericay, C. and Mangas, M. and Visa, L. and Buxo, E. and García, T. and Rodríguez Palomo, A. and Álvarez Manceñido, F. and Lacalle, A. and Macias, I. and Azkarate, A. and Ramchandani, A. and Fernández Montes, A. and López, C. and Longo, F. and Sánchez Bayona, R. and Limón, M. L. and Díaz-Serrano, A. and Hurtado, A. and Madero, R. and Gómez, C. and Gallego, J.},
	month = jun,
	year = {2017},
	note = {Number: 12
Publisher: Nature Publishing Group},
	keywords = {Stage4},
	pages = {1526--1535},
	file = {Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\I9RXBV8K\\bjc2017122.html:text/html;Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\KZAXNPF9\\Custodio et al. - 2017 - Nomogram-based prediction of survival in patients .pdf:application/pdf},
}

@article{takahari358,
	title = {Determination of {Prognostic} {Factors} in {Japanese} {Patients} {With} {Advanced} {Gastric} {Cancer} {Using} the {Data} {From} a {Randomized} {Controlled} {Trial}, {Japan} {Clinical} {Oncology} {Group} 9912},
	volume = {19},
	issn = {1083-7159},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983816/},
	doi = {10.1634/theoncologist.2013-0306},
	abstract = {In this study, the authors explored baseline prognostic factors in Japanese advanced gastric cancer (AGC) patients. They propose a new prognostic index for patients with AGC. This can be used for more appropriate patient stratification in future clinical trials.},
	number = {4},
	urldate = {2021-06-17},
	journal = {Oncologist},
	author = {Takahari, Daisuke and Boku, Narikazu and Mizusawa, Junki and Takashima, Atsuo and Yamada, Yasuhide and Yoshino, Takayuki and Yamazaki, Kentaro and Koizumi, Wasaburo and Fukase, Kazutoshi and Yamaguchi, Kensei and Goto, Masahiro and Nishina, Tomohiro and Tamura, Takao and Tsuji, Akihito and Ohtsu, Atsushi},
	month = apr,
	year = {2014},
	pmid = {24668328},
	pmcid = {PMC3983816},
	keywords = {Stage4},
	pages = {358--366},
	file = {PubMed Central Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\GF4USAIG\\Takahari et al. - 2014 - Determination of Prognostic Factors in Japanese Pa.pdf:application/pdf},
}

@article{1565,
	title = {Role of chemotherapy for advanced/recurrent gastric cancer: {An} individual-patient-data meta-analysis},
	volume = {49},
	issn = {0959-8049},
	shorttitle = {Role of chemotherapy for advanced/recurrent gastric cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S0959804912009860},
	doi = {10.1016/j.ejca.2012.12.016},
	abstract = {We conducted an individual-patient-data meta-analysis of the efficacy of chemotherapy on overall survival (OS) and progression-free survival (PFS) in advanced/recurrent gastric cancer (AGC). Our primary research question was whether the experimental arms of the trials included in the meta-analysis showed a benefit as compared with their corresponding control arms. MEDLINE (up to 2010), Cochrane Central Register of Controlled Trials, National Institutes of Health (NIH) trial registry and proceedings of major oncologic and gastrointestinal cancer meetings were searched. Randomised controlled trials for AGC closed to patient accrual before the end of 2006 were eligible. As of December 2010, individual patient data were available from 22 trials (4245 patients, representing 47\% of the targeted data) of 55 eligible trials. The overall comparison of experimental arms with the corresponding control arms showed statistically significant differences in terms of both OS and PFS. Hazard ratio was 0.88 (95\% confidence interval 0.82–0.94, P{\textless}0.0001) for OS and 0.81 (0.76–0.88, P{\textless}0.0001) for PFS. The results of the sub-analysis of adding a given chemotherapeutic agent to any chemotherapy confirm the results of the overall analysis, with a hazard reduction of 11\% for OS (P{\textless}0.01) and 26\% for PFS (P{\textless}0.0001). This meta-analysis of individual patient data shows that the additions of experimental chemotherapeutic agents to pre-existing control or standard regimens have produced a modest improvement in OS and PFS. Median survival remained below 1year for all investigated chemotherapy regimens and none emerged as a clear standard.},
	language = {en},
	number = {7},
	urldate = {2021-06-17},
	journal = {European Journal of Cancer},
	month = may,
	year = {2013},
	keywords = {Chemotherapy, Stage4, Advanced gastric cancer, Individual patient data, Meta-analysis, Randomised trial, Recurrent gastric cancer},
	pages = {1565--1577},
	file = {ScienceDirect Snapshot:C\:\\Users\\jcsal\\Zotero\\storage\\NAZXD5V4\\S0959804912009860.html:text/html},
}

@article{koo913,
	title = {A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models},
	volume = {68},
	issn = {1432-0843},
	shorttitle = {A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer},
	url = {https://doi.org/10.1007/s00280-011-1561-8},
	doi = {10.1007/s00280-011-1561-8},
	abstract = {To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models.},
	language = {en},
	number = {4},
	urldate = {2021-06-17},
	journal = {Cancer Chemother Pharmacol},
	author = {Koo, Dong Hoe and Ryoo, Baek-Yeol and Kim, Hwa Jung and Ryu, Min-Hee and Lee, Sung-Sook and Moon, Jung-Hwa and Chang, Heung-Moon and Lee, Jae-Lyun and Kim, Tae Won and Kang, Yoon-Koo},
	month = oct,
	year = {2011},
	keywords = {Stage4},
	pages = {913--921},
}

@article{yagi71,
	title = {Prognostic factors in stage {IV} gastric cancer: univariate and multivariate analyses},
	volume = {3},
	issn = {1436-3291},
	shorttitle = {Prognostic factors in stage {IV} gastric cancer},
	url = {https://doi.org/10.1007/PL00011699},
	doi = {10.1007/PL00011699},
	language = {en},
	number = {2},
	urldate = {2021-06-16},
	journal = {Gastric Cancer},
	author = {Yagi, Yoshinori and Seshimo, Akiyoshi and Kameoka, Shingo},
	month = sep,
	year = {2000},
	keywords = {Stage4},
	pages = {71--80},
	file = {Springer Full Text PDF:C\:\\Users\\jcsal\\Zotero\\storage\\8LNHURYR\\Yagi et al. - 2000 - Prognostic factors in stage IV gastric cancer uni.pdf:application/pdf},
}

@article{castoro1375,
	title = {Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?},
	volume = {17},
	issn = {1873-4626},
	shorttitle = {Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus},
	doi = {10.1007/s11605-013-2269-3},
	abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (CT-RT) before oesophagectomy is standard management for squamous cell carcinoma(SCC) of the thoracic oesophagus. The aim of this study was to compare the outcome of patients who had clinical complete response(CR) with neoadjuvant CT-RT + oesophagectomy with the survival of patients who had clinical CR and were not operated on.
PATIENTS AND METHODS: Seventy-seven consecutive patients with SCC of the thoracic oesophagus with CR with neoadjuvant CT-RT presenting at the Regional Center of Esophageal Diseases from 1992 to 2008 were included in this retrospective study on a prospectively collected database. Thirty-nine patients underwent oesophagectomy (CT-RT + oesophagectomy), while 38(CT-RT) were not operated on because they were considered unfit for surgery or refused the operation. Patients’ outcome and survival were compared.
RESULTS: In the CT-RT + oesophagectomy group, clinical CR was confirmed after histological examination of the surgical specimen in 27/39 (69.2 \%) patients. Five-year overall survival rates were 50.0 \% in the CT-RT + oesophagectomy group and 57.0 \% in the CT-RT group (p=0.99); 5-year disease-free survival rates were 55.5\%in the CT-RT + oesophagectomy group and 34.6\%in the CTRT group (p=0.15). Even after adjusting for propensity score, age, ASA and clinical stage, the treatment regimen did not show a statistically significant effect on overall survival (adjusted p=0.65) nor on disease-free survival (adjusted p=0.15).
CONCLUSION: In our group of patients with clinical CR after neoadjuvant CT-RT for SCC of the thoracic oesophagus, waiting for recurrence and then using salvage surgery did not negatively impact their survival compared to patients treated with surgery. More accurate restaging protocols are warranted to improve decision making after CR with neoadjuvant CT-RT.},
	language = {eng},
	number = {8},
	journal = {J Gastrointest Surg},
	author = {Castoro, Carlo and Scarpa, Marco and Cagol, Matteo and Alfieri, Rita and Ruol, Alberto and Cavallin, Francesco and Michieletto, Silvia and Zanchettin, Giampietro and Chiarion-Sileni, Vanna and Corti, Luigi and Ancona, Ermanno},
	month = aug,
	year = {2013},
	pmid = {23797888},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Fluorouracil, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Dose Fractionation, Radiation, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local},
	pages = {1375--1381},
}

@article{noordman142,
	title = {Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial},
	volume = {18},
	issn = {1471-2407},
	shorttitle = {Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer},
	doi = {10.1186/s12885-018-4034-1},
	abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced oesophageal cancer. With this treatment, 29\% of patients have a pathologically complete response in the resection specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer.
METHODS: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15\%, intra-correlation coefficient 0.02, power 80\%, 2-sided α 0.05, 12\% drop-out). Patients will undergo a first clinical response evaluation (CRE-I) 4-6 weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second CRE (CRE-II), 6-8 weeks after CRE-I. CRE-II will include 18F-FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance (second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life, clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy.
DISCUSSION: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.},
	language = {eng},
	number = {1},
	journal = {BMC Cancer},
	author = {Noordman, Bo Jan and Wijnhoven, Bas P. L. and Lagarde, Sjoerd M. and Boonstra, Jurjen J. and Coene, Peter Paul L. O. and Dekker, Jan Willem T. and Doukas, Michael and van der Gaast, Ate and Heisterkamp, Joos and Kouwenhoven, Ewout A. and Nieuwenhuijzen, Grard A. P. and Pierie, Jean-Pierre E. N. and Rosman, Camiel and van Sandick, Johanna W. and van der Sangen, Maurice J. C. and Sosef, Meindert N. and Spaander, Manon C. W. and Valkema, Roelf and van der Zaag, Edwin S. and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {SANO-study group}},
	month = feb,
	year = {2018},
	pmid = {29409469},
	pmcid = {PMC5801846},
	keywords = {Humans, Neoadjuvant Therapy, Outcome Assessment, Health Care, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Active surveillance, Chemoradiotherapy, Cost-Benefit Analysis, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Multicenter Studies as Topic, Neoadjuvant chemoradiotherapy, Oesophageal cancer, Positron Emission Tomography Computed Tomography, Research Design, Standard oesophagectomy},
	pages = {142},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\JPM8RE68\\Noordman et al. - 2018 - Neoadjuvant chemoradiotherapy plus surgery versus .pdf:application/pdf},
}

@article{vanderwilk462,
	title = {Towards an {Organ}-{Sparing} {Approach} for {Locally} {Advanced} {Esophageal} {Cancer}},
	volume = {36},
	issn = {1421-9883},
	doi = {10.1159/000493435},
	abstract = {BACKGROUND: Active surveillance after neoadjuvant therapies has emerged among several malignancies. During active surveillance, frequent assessments are performed to detect residual disease and surgery is only reserved for those patients in whom residual disease is proven or highly suspected without distant metastases. After neoadjuvant chemoradiotherapy (nCRT), nearly one-third of esophageal cancer patients achieve a pathologically complete response (pCR). Both patients that achieve a pCR and patients that harbor subclinical disseminated disease after nCRT could benefit from an active surveillance strategy.
SUMMARY: Esophagectomy is still the cornerstone of treatment in patients with esophageal cancer. Non-surgical treatment via definitive chemoradiotherapy (dCRT) is currently reserved only for patients not eligible for esophagectomy. Since salvage esophagectomy after dCRT (50-60 Gy) results in increased complications, morbidity and mortality compared to surgery after nCRT (41.4 Gy), the latter seems preferable in the setting of active surveillance. Clinical response evaluations can detect substantial (i.e., tumor regression grade [TRG] 3-4) tumors after nCRT with a sensitivity of 90\%, minimizing the risk of development of non-resectable recurrences. Current scarce and retrospective literature suggests that active surveillance following nCRT might not jeopardize overall survival and postponed surgery could be performed safely. Key Message: Before an active surveillance approach could be considered standard treatment, results of phase III randomized trials should be awaited.},
	language = {eng},
	number = {6},
	journal = {Dig Surg},
	author = {van der Wilk, Berend Jan and Eyck, Ben M. and Spaander, Manon C. W. and Valkema, Roelf and Lagarde, Sjoerd M. and Wijnhoven, Bas P. L. and van Lanschot, J. Jan B.},
	year = {2019},
	pmid = {30227434},
	pmcid = {PMC6878756},
	keywords = {Humans, Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Active surveillance, Chemoradiotherapy, Neoadjuvant chemoradiotherapy, Esophageal cancer, Organ Sparing Treatments, Organ-sparing treatment, Watchful Waiting},
	pages = {462--469},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\VNUPTADR\\van der Wilk et al. - 2019 - Towards an Organ-Sparing Approach for Locally Adva.pdf:application/pdf},
}

@article{domachevskye13412,
	title = {Baseline {18F}-{FDG} {PET}/{CT} as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: {A} retrospective study},
	volume = {97},
	issn = {1536-5964},
	shorttitle = {Baseline {18F}-{FDG} {PET}/{CT} as predictor of the pathological response to neoadjuvant therapy in esophageal cancer},
	doi = {10.1097/MD.0000000000013412},
	abstract = {The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42\%, 50\% and 60\% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.},
	language = {eng},
	number = {49},
	journal = {Medicine (Baltimore)},
	author = {Domachevsky, Liran and Kashtan, Hanoch and Brenner, Baruch and Nidam, Meital and Morgenstern, Sara and Kundel, Yulia and Groshar, David and Bernstine, Hanna},
	month = dec,
	year = {2018},
	pmid = {30544419},
	pmcid = {PMC6310504},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Prognosis, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals},
	pages = {e13412},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\QFQQS3RT\\Domachevsky et al. - 2018 - Baseline 18F-FDG PETCT as predictor of the pathol.pdf:application/pdf},
}

@article{huange0210055,
	title = {Post-chemoradiotherapy {FDG} {PET} with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma},
	volume = {14},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0210055},
	abstract = {OBJECTIVES: Post-chemoradiotherapy (CRT) FDG PET is a useful prognosticator of esophageal cancer. However, debate on the diverse criteria of previous publications preclude worldwide multicenter comparisons, and even a universal practice guide. We aimed to validate a simple qualitative interpretation criterion of post-CRT FDG PET for outcome stratification and compare it with other criteria.
METHODS: The post-CRT FDG PET of 114 patients with esophageal squamous cell carcinoma (ESCC) were independently interpreted using a qualitative 4-point scale (Qual4PS) that identified focal esophageal FDG uptake greater than liver uptake as residual tumor. Cohen's κ coefficient (κ) was used to measure interobserver agreement of Qual4PS. The Kaplan-Meier method and Cox proportional hazards regression analyses were used for survival analysis. Other criteria included a different qualitative approach (QualBK), maximal standardized uptake values (SUVmax3.4, SUVmax2.5), relative change of SUVmax between pre- and post-CRT FDG PET (ΔSUVmax), mean standardized uptake values (SUVmean), metabolic volume (MV) and total lesion glycolysis (TLG).
RESULTS: Overall interobserver agreement on the Qual4PS criterion was excellent (κ: 0.95). Except the QualBK, SUVmax2.5, and TLG, all the other criteria were significant predictors for overall survival (OS). Multivariable analysis showed only Qual4PS (HR: 15.41; P = 0.005) and AJCC stage (HR: 2.47; P = 0.007) were significant independent variables. The 2-year OS rates of Qual4PS(‒) patients undergoing CRT alone (68.4\%) and patients undergoing trimodality therapy (62.5\%) were not significant different, but the 2-year OS rates of Qual4PS(+) patients undergoing CRT alone (10.0\%) were significantly lower than in patients undergoing trimodality therapy (42.1\%).
CONCLUSIONS: The Qual4PS criterion is reproducible for assessing the response of ESCC to CRT, and valuable for predicting survival. It may add value to response-adapted treatment for ESCC patients, and help to decide whether surgery is warranted after CRT.},
	language = {eng},
	number = {1},
	journal = {PLoS One},
	author = {Huang, Yung-Cheng and Li, Shau-Hsuan and Lu, Hung-I. and Hsu, Chien-Chin and Wang, Yu-Ming and Lin, Wei-Che and Chen, Chao-Jung and Ho, Kuo-Wei and Chiu, Nan-Tsing},
	year = {2019},
	pmid = {30615636},
	pmcid = {PMC6322736},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Retrospective Studies, Proportional Hazards Models, Aged, 80 and over, Adult, Outcome Assessment, Health Care, Carcinoma, Squamous Cell, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18},
	pages = {e0210055},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\6CMDDZQS\\Huang et al. - 2019 - Post-chemoradiotherapy FDG PET with qualitative in.pdf:application/pdf},
}

@article{faiz986,
	title = {Impact of {Age} and {Comorbidity} on {Choice} and {Outcome} of {Two} {Different} {Treatment} {Options} for {Patients} with {Potentially} {Curable} {Esophageal} {Cancer}},
	volume = {26},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07181-6},
	abstract = {PURPOSE: This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery.
METHODS: In this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan-Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS).
RESULTS: A total of 702 patients was included. Age ≥ 75 years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95\% confidence interval [CI] 4.72-15.58; and OR 3.09; 95\% CI 1.93-4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95\% CI 1.97-7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95\% CI 1.57-6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95\% CI 0.78-2.97; and HR 0.73; 95\% CI 0.13-4.14).
CONCLUSIONS: Histological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, dCRT may be the preferred strategy.},
	language = {eng},
	number = {4},
	journal = {Ann Surg Oncol},
	author = {Faiz, Z. and van Putten, M. and Verhoeven, R. H. A. and van Sandick, J. W. and Nieuwenhuijzen, G. a. P. and van der Sangen, M. J. C. and Lemmens, V. E. P. P. and Wijnhoven, B. P. L. and Plukker, J. T. M.},
	month = apr,
	year = {2019},
	pmid = {30719634},
	pmcid = {PMC6399439},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Age Factors, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Comorbidity, Netherlands},
	pages = {986--995},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\MPJFEZPR\\Faiz et al. - 2019 - Impact of Age and Comorbidity on Choice and Outcom.pdf:application/pdf},
}

@article{stahl183,
	title = {Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction ({POET}): {Long}-term results of a controlled randomised trial},
	volume = {81},
	issn = {1879-0852},
	shorttitle = {Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction ({POET})},
	doi = {10.1016/j.ejca.2017.04.027},
	abstract = {BACKGROUND: Results of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study.
PATIENTS AND METHODS: Patients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery.
RESULTS: The primary end-point of the study was overall survival at 3 years. The study was closed early after 119 patients having been randomised and were eligible. Local progression-free survival after tumour resection was significantly improved by CRT (hazard ratio [HR] 0.37; 0.16-0.85, p = value 0.01) and 20 versus 12 patients were free of local tumour progression at 5 years (p = 0.03). Although the rate of postoperative in-hospital mortality was somewhat higher with CRT (10.2\% versus 3.8\%, p = 0.26), more patients were alive at 3 and 5 years after CRT (46.7\% and 39.5\%) compared with chemotherapy (26.1\% and 24.4\%). Thus, overall survival showed a trend in favour of preoperative CRT (HR 0.65, 95\% confidence interval [CI] 0.42-1.01, p = 0.055).
CONCLUSION: Although the primary end-point overall survival of the study was not met, our long-term follow-up data suggest a benefit in local progression-free survival when radiotherapy was added to preoperative chemotherapy in patients with locally advanced adenocarcinoma of the oesophagogastric junction.},
	language = {eng},
	journal = {Eur J Cancer},
	author = {Stahl, Michael and Walz, Martin K. and Riera-Knorrenschild, Jorge and Stuschke, Martin and Sandermann, Andreas and Bitzer, Michael and Wilke, Hansjochen and Budach, Wilfried},
	month = aug,
	year = {2017},
	pmid = {28628843},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Chemoradiotherapy, Esophagogastric Junction, Germany, Oesophagogastric adenocarcinoma, Phase III trial, Preoperative chemoradiotherapy, Preoperative chemotherapy},
	pages = {183--190},
}

@article{degraaf988,
	title = {The role of staging laparoscopy in oesophagogastric cancers},
	volume = {33},
	issn = {0748-7983},
	doi = {10.1016/j.ejso.2007.01.007},
	abstract = {AIMS: Selection of patients for treatment of oesophagogastric cancers rests on accurate staging. Laparoscopy has become a safe and effective staging tool in upper gastrointestinal cancers because of its ability to detect small peritoneal and liver metastases missed by imaging techniques. The aim of this study was to evaluate the role of staging laparoscopy (SL) in determining resectability of oesophagogastric cancers.
METHODS: A review of 511 patients with oesophagogastric cancers referred to our centre during a 7-year period was performed. Four hundred and sixteen of them assessed to have resectable tumours after preoperative staging with CT and/or ultrasound underwent SL. The main outcome measure was the number of patients in whom laparoscopy changed treatment decision.
RESULTS: Staging laparoscopy changed treatment decision in 84 cases (20.2\%): locally advanced disease in 17, extensive lymph node disease in four and distant metastases (liver and peritoneum) in 63 cases. The sensitivity of laparoscopy for resectability was 88\%. Eighty-one percent of patients who had combined CT scan and EUS were resectable at surgery compared with 65\% of those who had CT scan alone (statistically significant with P-value{\textless}0.05). Of those patients deemed resectable by SL 8.1\% were found to be unresectable at laparotomy, 16 with locally advanced disease and 11 with metastases.
CONCLUSION: Staging laparoscopy avoided unnecessary laparotomy in 20.2\% of our patients and was most useful in adenocarcinoma, distal oesophageal, GOJ and gastric cancers and probably not necessary in lesions of the upper two-third of the oesophagus.},
	language = {eng},
	number = {8},
	journal = {Eur J Surg Oncol},
	author = {de Graaf, G. W. and Ayantunde, A. A. and Parsons, S. L. and Duffy, J. P. and Welch, N. T.},
	month = oct,
	year = {2007},
	pmid = {17344017},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Adult, Predictive Value of Tests, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Evaluation Studies as Topic, Laparoscopy, Sensitivity and Specificity, Ultrasonography},
	pages = {988--992},
}

@article{messager318,
	title = {Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid ({FOLFOX}) for resectable esophageal and junctional cancer: the {PROTECT}-1402, randomized phase 2 trial},
	volume = {16},
	issn = {1471-2407},
	shorttitle = {Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid ({FOLFOX}) for resectable esophageal and junctional cancer},
	doi = {10.1186/s12885-016-2335-9},
	abstract = {BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemotherapeutic regimens (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid) when each is combined with the radiation regime utilized in the CROSS trial.
METHODS/DESIGN: PROTECT is a prospective, randomized, multicenter, open arms, phase II trial. Eligible patients will have a histologically confirmed adenocarcinoma or squamous cell carcinoma and be treated with neoadjuvant radiochemotherapy followed by surgery for stage IIB or stage III resectable esophageal cancer. A total of 106 patients will be randomized to receive either 3 cycles of FOLFOX combined to concurrent radiotherapy (41.4 Grays) or carboplatin and paclitaxel with the same radiation regimen, using a 1:1 allocation ratio.
DISCUSSION: This ongoing trial offers the unique opportunity to compare two standards of chemotherapy delivered with a common regimen of preoperative radiation, in the setting of operable locally advanced esophageal or gastro-esophageal junctional tumors.
TRIAL REGISTRATION: NCT02359968 (ClinicalTrials.gov) (registration date: 9 FEB 2015), EudraCT: 2014-000649-62 (registration date: 10 FEB 2014).},
	language = {eng},
	journal = {BMC Cancer},
	author = {Messager, Mathieu and Mirabel, Xavier and Tresch, Emmanuelle and Paumier, Amaury and Vendrely, Véronique and Dahan, Laetitia and Glehen, Olivier and Vasseur, Frederique and Lacornerie, Thomas and Piessen, Guillaume and El Hajbi, Farid and Robb, William B. and Clisant, Stéphanie and Kramar, Andrew and Mariette, Christophe and Adenis, Antoine},
	month = may,
	year = {2016},
	pmid = {27194176},
	pmcid = {PMC4872363},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Fluorouracil, Leucovorin, Organoplatinum Compounds, Survival Analysis, Young Adult, Carcinoma, Squamous Cell, Cisplatin, Dose Fractionation, Radiation, Esophageal Neoplasms, Chemoradiotherapy, Esophageal cancer, FOLFOX, Paclitaxel, Paclitaxel-carboplatin, Randomized trial},
	pages = {318},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\2H5DG8SX\\Messager et al. - 2016 - Preoperative chemoradiation with paclitaxel-carbop.pdf:application/pdf},
}

@article{zhaoe0202185,
	title = {Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: {A} meta-analysis based on clinical trials},
	volume = {13},
	issn = {1932-6203},
	shorttitle = {Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction},
	doi = {10.1371/journal.pone.0202185},
	abstract = {BACKGROUND: The benefit of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for treating cancer of the esophagus or the gastroesophageal junction remains controversial. In the present study, we conducted a comprehensive meta-analysis to examine the efficacy of these two management strategies.
METHODS: The MEDLINE (PubMed), SinoMed, Embase, and Cochrane Library databases were searched for eligible studies. We searched for the most relevant studies published until the end of September 2017. Data were extracted independently and were analyzed using RevMan statistical software version 5.3 (Cochrane Collaboration, http://tech.cochrane.org/revman/download). Weighted mean differences, risk ratios (RRs), and 95\% confidence intervals (CIs) were calculated. Cochrane Collaboration's risk of bias tool was used to assess the risk of bias. In this comprehensive meta-analysis, we examined the efficiency of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for the treatment of cancer of the esophagus or the gastroesophageal junction as reported in qualified clinical trials.
RESULTS: Six qualified articles that included a total of 866 patients were identified. The meta-analysis showed that for 3-year and 5-year survival rates in primary outcomes, the results favored neoadjuvant chemoradiotherapy strategies compared with neoadjuvant chemotherapy (RR = 0.78, 95\% CI = 0.62-0.98, P = 0.03; RR = 0.69, 95\% CI = 0.50-0.96, P = 0.03, respectively). In terms of secondary outcomes, neoadjuvant chemoradiotherapy significantly increased the rate of R0 resection and pathological complete response as well (RR = 0.87, 95\% CI = 0.81-0.92, P {\textless} 0.0001; RR = 0.16, 95\% CI = 0.09-0.28, P {\textless} 0.00001, respectively). However, there were no significant differences in postoperative mortality between the two groups (RR = 1.85, 95\% CI = 0.93-3.65, P = 0.08). For the results of postoperative complications, revealed that there was a statistically significant difference between the two groups in the incidence of postoperative complications such as pulmonary, anastomotic leak and cardiovascular complications. The subgroup analysis of patients with esophageal adenocarcinoma or squamous cell carcinoma showed that both esophageal adenocarcinoma and squamous cell carcinoma patients achieved a high rate of R0 resection (RR = 0.85, 95\% CI = 0.77-0.93, P = 0.0006; RR = 0.88, 95\% CI = 0.81-0.96, P = 0.005, respectively) and pathological complete response benefit of neoadjuvant chemoradiotherapy (RR = 0.23, 95\% CI = 0.09-0.57, P = 0.001; RR = 0.18, 95\% CI = 0.03-0.96, P = 0.05, respectively).
CONCLUSION: Our findings suggested that compared with neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy should be recommended with a significant long-term survival benefit in patients with cancer of the esophagus or the gastroesophageal junction. In view of the clinical heterogeneity, whether these conclusions are broadly applicable should be further determined.},
	language = {eng},
	number = {8},
	journal = {PLoS One},
	author = {Zhao, Xin and Ren, Yiming and Hu, Yong and Cui, Naiqiang and Wang, Ximo and Cui, Yunfeng},
	year = {2018},
	pmid = {30138325},
	pmcid = {PMC6107145},
	keywords = {Humans, Neoadjuvant Therapy, Randomized Controlled Trials as Topic, Stomach Neoplasms, Esophageal Neoplasms, Chemoradiotherapy, Esophagogastric Junction},
	pages = {e0202185},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\AITR5E6P\\Zhao et al. - 2018 - Neoadjuvant chemotherapy versus neoadjuvant chemor.pdf:application/pdf},
}

@article{yang2796,
	title = {Neoadjuvant {Chemoradiotherapy} {Followed} by {Surgery} {Versus} {Surgery} {Alone} for {Locally} {Advanced} {Squamous} {Cell} {Carcinoma} of the {Esophagus} ({NEOCRTEC5010}): {A} {Phase} {III} {Multicenter}, {Randomized}, {Open}-{Label} {Clinical} {Trial}},
	volume = {36},
	issn = {1527-7755},
	shorttitle = {Neoadjuvant {Chemoradiotherapy} {Followed} by {Surgery} {Versus} {Surgery} {Alone} for {Locally} {Advanced} {Squamous} {Cell} {Carcinoma} of the {Esophagus} ({NEOCRTEC5010})},
	doi = {10.1200/JCO.2018.79.1483},
	abstract = {Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients and Methods From June 2007 to December 2014, 451 patients with potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated to NCRT plus surgery (group CRT; n = 224) and surgery alone (group S; n = 227). In group CRT, patients received vinorelbine 25 mg/m2 intravenously (IV) on days 1 and 8 and cisplatin 75 mg/m2 IV day 1, or 25 mg/m2 IV on days 1 to 4 every 3 weeks for two cycles, with a total concurrent radiation dose of 40.0 Gy administered in 20 fractions of 2.0 Gy on 5 days per week. In both groups, patients underwent McKeown or Ivor Lewis esophagectomy. The primary end point was overall survival. Results The pathologic complete response rate was 43.2\% in group CRT. Compared with group S, group CRT had a higher R0 resection rate (98.4\% v 91.2\%; P = .002), a better median overall survival (100.1 months v 66.5 months; hazard ratio, 0.71; 95\% CI, 0.53 to 0.96; P = .025), and a prolonged disease-free survival (100.1 months v 41.7 months; hazard ratio, 0.58; 95\% CI, 0.43 to 0.78; P {\textless} .001). Leukopenia (48.9\%) and neutropenia (45.7\%) were the most common grade 3 or 4 adverse events during chemoradiotherapy. Incidences of postoperative complications were similar between groups, with the exception of arrhythmia (group CRT: 13\% v group S: 4.0\%; P = .001). Peritreatment mortality was 2.2\% in group CRT versus 0.4\% in group S ( P = .212). Conclusion This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.},
	language = {eng},
	number = {27},
	journal = {J Clin Oncol},
	author = {Yang, Hong and Liu, Hui and Chen, Yuping and Zhu, Chengchu and Fang, Wentao and Yu, Zhentao and Mao, Weimin and Xiang, Jiaqing and Han, Yongtao and Chen, Zhijian and Yang, Haihua and Wang, Jiaming and Pang, Qingsong and Zheng, Xiao and Yang, Huanjun and Li, Tao and Lordick, Florian and D'Journo, Xavier Benoit and Cerfolio, Robert J. and Korst, Robert J. and Novoa, Nuria M. and Swanson, Scott J. and Brunelli, Alessandro and Ismail, Mahmoud and Fernando, Hiran C. and Zhang, Xu and Li, Qun and Wang, Geng and Chen, Baofu and Mao, Teng and Kong, Min and Guo, Xufeng and Lin, Ting and Liu, Mengzhong and Fu, Jianhua and {AME Thoracic Surgery Collaborative Group}},
	month = sep,
	year = {2018},
	pmid = {30089078},
	pmcid = {PMC6145832},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma, Incidence, Postoperative Complications, Vinorelbine},
	pages = {2796--2803},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\6NCLMHG8\\Yang et al. - 2018 - Neoadjuvant Chemoradiotherapy Followed by Surgery .pdf:application/pdf},
}

@article{soetikno4490,
	title = {Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract},
	volume = {23},
	issn = {0732-183X},
	doi = {10.1200/JCO.2005.19.935},
	abstract = {The purpose of this literature review is to examine recent advances in technique and technology of endoscopic mucosal resection of superficial early cancers of the upper gastrointestinal tract. Endoscopic mucosal resection (EMR) of superficial early cancers of the upper gastrointestinal tract is standard technique in Japan and is increasingly used in Western countries. Newer techniques of EMR allow removal of larger lesions en-bloc. These minimally invasive techniques, when applied correctly, allow safe and efficacious treatment in situations that would otherwise require major surgery. Through the establishment of long-term outcomes data, standardization of endoscopic and pathologic reporting, and newer EMR technology and techniques, the future treatment of early cancers in the upper gastrointestinal tract may be achieved primarily through the endoscope.},
	language = {eng},
	number = {20},
	journal = {J Clin Oncol},
	author = {Soetikno, Roy and Kaltenbach, Tonya and Yeh, Ronald and Gotoda, Takuji},
	month = jul,
	year = {2005},
	pmid = {16002839},
	keywords = {Humans, Stomach Neoplasms, Esophageal Neoplasms, Endoscopy, Gastrointestinal, Intestinal Mucosa, Lymphatic Metastasis},
	pages = {4490--4498},
}

@article{rusch444,
	title = {Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?},
	volume = {31},
	issn = {0093-7754},
	doi = {10.1053/j.seminoncol.2004.04.023},
	abstract = {Recent epidemiological shifts have led to controversy about the etiology and treatment of gastroesophageal (GE) junction adenocarcinomas. The Siewert classification conveniently describes the anatomical location of these tumors relative to the GE junction. However, available data suggest that there may be epidemiological, clinical, and molecular differences among GE junction adenocarcinomas, depending on whether they are predominantly esophageal or gastric in location. Much more investigation is required to confirm or refute these apparent differences, which can affect clinical treatment.},
	language = {eng},
	number = {4},
	journal = {Semin Oncol},
	author = {Rusch, Valerie W.},
	month = aug,
	year = {2004},
	pmid = {15297937},
	keywords = {Humans, Neoplasm Staging, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Cardia, Terminology as Topic},
	pages = {444--449},
}

@article{repici715,
	title = {Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective {Western} series},
	volume = {71},
	issn = {1097-6779},
	shorttitle = {Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma},
	doi = {10.1016/j.gie.2009.11.020},
	abstract = {BACKGROUND: Although endoscopic submucosal dissection (ESD) is becoming accepted as an established treatment for superficial esophageal squamous cell neoplasia, the majority of data on this endoscopic modality has been provided by Japanese series.
OBJECTIVE: To assess the efficacy and safety of ESD for esophageal squamous cell neoplasia in a consecutive series of patients treated in a Western setting.
DESIGN AND SETTING: Single-center, prospective observational study.
PATIENTS AND INTERVENTION: From January 2005 to July 2008, 20 patients with superficial esophageal squamous cell neoplasia were treated by ESD.
MAIN OUTCOME MEASUREMENTS: Rates of en bloc resection, complete resection, and complications were evaluated as short-term outcomes. Overall survival, local or distant recurrence, and postoperative stricture rates were evaluated as long-term outcomes.
RESULTS: ESD was performed in 20 patients (mean age 64 years, range 46-81 years; 16 men). The mean size of the lesion was 32 mm (range 15-60 mm); it was 30 mm or larger in 14 patients (70\%). The mean time of ESD was 89 minutes (range 58-180 minutes). En bloc resection with resection-free margins was achieved in 18 patients (90\%), whereas 2 patients presented with incomplete or indeterminate resection. Two cases (10\%) of mediastinal emphysema without overt perforation and 1 case (5\%) of post-ESD symptomatic stricture were reported. No local or distant post-ESD recurrence occurred in those with resection-free margins at a median follow-up of 18 months.
LIMITATIONS: Small number of patients and limited follow-up.
CONCLUSION: This Western series study confirms that ESD is a potentially curative treatment for superficial esophageal squamous cell neoplasia. Early and late complication rates were comparable to those of Japanese series. ESD should be probably considered as the treatment of choice in all large lesions amenable to endoscopic treatment.},
	language = {eng},
	number = {4},
	journal = {Gastrointest Endosc},
	author = {Repici, Alessandro and Hassan, Cesare and Carlino, Alessandra and Pagano, Nico and Zullo, Angelo and Rando, Giacomo and Strangio, Giuseppe and Romeo, Fabio and Nicita, Rinaldo and Rosati, Riccardo and Malesci, Alberto},
	month = apr,
	year = {2010},
	pmid = {20363414},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Aged, 80 and over, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Postoperative Complications, Animals, Esophagoscopy, Esophagus},
	pages = {715--721},
}

@article{orringer363,
	title = {Two thousand transhiatal esophagectomies: changing trends, lessons learned},
	volume = {246},
	issn = {0003-4932},
	shorttitle = {Two thousand transhiatal esophagectomies},
	doi = {10.1097/SLA.0b013e31814697f2},
	abstract = {OBJECTIVE: "Rediscovered" in 1976, transhiatal esophagectomy (THE) has been applicable in most situations requiring esophageal resection and reconstruction. The objective of this study was to review the authors' 30-year experience with THE and changing trends in its use.
METHODS: Using the authors' prospective Esophagectomy Database, this single institution experience with THE was analyzed retrospectively.
RESULTS: Two thousand and seven THEs were performed-1063 (previously reported) between 1976 and 1998 (group I) and 944 from 1998 to 2006 (group II), 24\% for benign disease, 76\%, cancer. THE was possible in 98\%. Stomach was the esophageal substitute in 97\%. Comparing outcomes between group I and group II, statistically significant differences (P {\textless} 0.001) were observed in hospital mortality (4\% vs. 1\%); adenocarcinoma histology (69\% vs. 86\%); use of neoadjuvant chemoradiation (28\% vs. 52\%); mean blood loss (677 vs. 368 mL); anastomotic leak (14\% vs. 9\%); and discharge within 10 days (52\% vs. 78\%). Major complications remain infrequent: wound infection/dehiscence, 3\%, atelectasis/pneumonia, 2\%, intrathoracic hemorrhage, recurrent laryngeal nerve paralysis, chylothorax, and tracheal laceration, {\textless}1\% each. Late functional results have been good or excellent in 73\%. Aggressive preoperative conditioning, avoiding the ICU, improved pain management, and early ambulation reduce length of stay, with 50\% in group II discharged within 1 week.
CONCLUSION: THE refinements have reduced the historic morbidity and mortality of esophageal resection. This largest reported THE experience reinforces the value of consistent technique and a clinical pathway in managing these high acuity esophageal patients.},
	language = {eng},
	number = {3},
	journal = {Ann Surg},
	author = {Orringer, Mark B. and Marshall, Becky and Chang, Andrew C. and Lee, Julia and Pickens, Allan and Lau, Christine L.},
	month = sep,
	year = {2007},
	pmid = {17717440},
	pmcid = {PMC1959358},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Proportional Hazards Models, Survival Rate, Chi-Square Distribution, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Early Ambulation, Esophageal Diseases, Logistic Models, Stomach},
	pages = {363--372; discussion 372--374},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\6NS7F4WJ\\Orringer et al. - 2007 - Two thousand transhiatal esophagectomies changing.pdf:application/pdf},
}

@article{noh1389,
	title = {Adjuvant capecitabine plus oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC}): 5-year follow-up of an open-label, randomised phase 3 trial},
	volume = {15},
	issn = {1474-5488},
	shorttitle = {Adjuvant capecitabine plus oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC})},
	doi = {10.1016/S1470-2045(14)70473-5},
	abstract = {BACKGROUND: The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The planned interim analysis of CLASSIC (median follow-up 34 months) showed that adjuvant capecitabine plus oxaliplatin significantly improved disease-free survival, the primary endpoint, compared with observation after D2 gastrectomy. We report the 5-year follow-up data from the trial.
METHODS: CLASSIC was a phase 3, randomised, open-label study done at 35 cancer centres, medical centres, and hospitals in China, South Korea, and Taiwan. Patients with stage II-IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m(2) twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m(2) on day 1) for 6 months or observation alone. Randomisation was stratified by country and disease stage with a permuted block (size four) design. Neither patients nor investigators were masked to treatment assignment. The primary outcome was 3-year disease-free survival in the intention-to-treat population. This analysis presents the final preplanned assessment of outcomes after 5 years. The study is registered with ClinicalTrials.gov, NCT00411229.
FINDINGS: We enrolled 1035 patients: 520 were randomly assigned to adjuvant capecitabine and oxaliplatin, and 515 to observation. Median follow-up for this analysis in the intention-to-treat population was 62·4 months (IQR 54-70). 139 (27\%) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus 203 (39\%) patients in the observation group (stratified hazard ratio [HR] 0·58, 95\% CI 0·47-0·72; p{\textless}0·0001). Estimated 5-year disease-free survival was 68\% (95\% CI 63-73) in the adjuvant capecitabine and oxaliplatin group versus 53\% (47-58) in the observation alone group. By the clinical cutoff date, 103 patients (20\%) had died in the adjuvant capecitabine and oxaliplatin group versus 141 patients (27\%) in the observation group (stratified HR 0·66, 95\% CI 0·51-0·85; p=0·0015). Estimated 5-year overall survival was 78\% (95\% CI 74-82) in the adjuvant capecitabine and oxaliplatin group versus 69\% (64-73) in the observation group. Adverse event data were not collected after the primary analysis.
INTERPRETATION: Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer.
FUNDING: F Hoffmann La-Roche and Sanofi.},
	language = {eng},
	number = {12},
	journal = {Lancet Oncol},
	author = {Noh, Sung Hoon and Park, Sook Ryun and Yang, Han-Kwang and Chung, Hyun Cheol and Chung, Ik-Joo and Kim, Sang-Woon and Kim, Hyung-Ho and Choi, Jin-Hyuk and Kim, Hoon-Kyo and Yu, Wansik and Lee, Jong Inn and Shin, Dong Bok and Ji, Jiafu and Chen, Jen-Shi and Lim, Yunni and Ha, Stella and Bang, Yung-Jue and {CLASSIC trial investigators}},
	month = nov,
	year = {2014},
	pmid = {25439693},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Fluorouracil, Organoplatinum Compounds, Drug-Related Side Effects and Adverse Reactions, Stomach Neoplasms, Disease-Free Survival, Capecitabine, Deoxycytidine, Gastrectomy, Oxaliplatin},
	pages = {1389--1396},
}

@article{maish1777,
	title = {Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma},
	volume = {78},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2004.04.064},
	abstract = {BACKGROUND: Endoscopic ablation and vagal-sparing esophagectomy offer the potential for reduced morbidity in patients with high-grade dysplasia or early esophageal adenocarcinoma, but neither includes a lymphadenectomy. Although adequate for intramucosal tumors, both are potentially inadequate for patients with submucosal tumor invasion given the high prevalence of nodal metastases with these lesions. Currently there is no test including endoscopic ultrasound that can accurately determine whether a small tumor is confined to the mucosa or has penetrated into the submucosa. The aim of this study was to compare the pathologic depth of invasion by endoscopic mucosal resection with findings and outcome after surgical resection to assess the accuracy and reliability of endoscopic mucosal resection for staging early esophageal adenocarcinoma.
METHODS: From 2001 to 2003, 7 patients presented with small, endoscopically visible adenocarcinomas. All underwent endoscopic mucosal resection followed by surgical resection.
RESULTS: Analysis of the resected specimens confirmed that the endoscopic mucosal resection had accurately determined the depth of tumor invasion in all patients, and had completely excised the lesion in all but 1 patient (86\%). Lymph node dissection was included as part of the resection in 2 patients with submucosal invasion by endoscopic mucosal resection, and a vagal-sparing esophagectomy was used in the 5 patients with only intramucosal tumors. All patients are alive and disease-free at a median follow-up of 7 months.
CONCLUSIONS: Endoscopic mucosal resection accurately determines the depth of tumor invasion, and should be used as a staging procedure in patients with early esophageal cancer when therapies that do not include a lymphadenectomy are considered.},
	language = {eng},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {Maish, Mary S. and DeMeester, Steven R.},
	month = nov,
	year = {2004},
	pmid = {15511474},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Neoplasm Invasiveness, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagoscopy, Gastrectomy, Lymph Node Excision, Mucous Membrane, Remission Induction, Vagus Nerve},
	pages = {1777--1782},
}

@article{leichman4555,
	title = {S0356: a phase {II} clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma},
	volume = {29},
	issn = {1527-7755},
	shorttitle = {S0356},
	doi = {10.1200/JCO.2011.36.7490},
	abstract = {PURPOSE: Pathologic complete response (pCR) after neoadjuvant therapy for locally advanced esophageal adenocarcinoma is associated with improved survival. The Southwest Oncology Group designed a trimodality, phase II, single-arm trial with objectives of achieving a pCR rate of 40\% with prospective exploratory analyses of intratumoral molecular markers postulated to affect response and survival.
PATIENTS AND METHODS: Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions; surgery was performed 28 to 42 days after neoadjuvant therapy. Chemotherapy was planned after surgery. Tumors were analyzed for mRNA expression and polymorphisms in genes involved in drug metabolism and DNA repair.
RESULTS: Ninety-three patients were evaluable. Two deaths (2.2\%) were attributable to preoperative therapy, and two deaths (2.2\%) were attributable to surgery. Grade 3 and 4 toxicities were recorded for 47.3\% and 19.4\% of patients, respectively. Seventy-nine patients (84.9\%) underwent surgery; 67.7\% of patients had R0 resections. Twenty-six patients (28.0\%) had confirmed pCR (95\% CI, 19.1\% to 38.2\%). At a median follow-up of 39.2 months, estimates of median and 3-year overall survival (OS) were 28.3 months and 45.1\%, respectively. Intratumoral ERCC-1 gene expression was inversely related to progression-free survival and OS.
CONCLUSION: Neoadjuvant oxaliplatin, PI-FU, and EBRT for esophageal adenocarcinoma is active and tolerable. Because the regimen failed to meet the primary end point, it does not define a new standard. However, future trials can be built on this platform to validate the role of ERCC-1 in determining the best systemic regimen for individual patients.},
	language = {eng},
	number = {34},
	journal = {J Clin Oncol},
	author = {Leichman, Lawrence P. and Goldman, Bryan H. and Bohanes, Pierre O. and Lenz, Heinz J. and Thomas, Charles R. and Billingsley, Kevin G. and Corless, Christopher L. and Iqbal, Syma and Gold, Philip J. and Benedetti, Jacqueline K. and Danenberg, Kathleen D. and Blanke, Charles D.},
	month = dec,
	year = {2011},
	pmid = {22025151},
	pmcid = {PMC3236655},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Drug Administration Schedule, Fluorouracil, Organoplatinum Compounds, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Oxaliplatin, Radiotherapy, Adjuvant},
	pages = {4555--4560},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\UZJAFIUX\\Leichman et al. - 2011 - S0356 a phase II clinical and prospective molecul.pdf:application/pdf},
}

@article{kofoed26,
	title = {Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction},
	volume = {101},
	issn = {1799-7267},
	doi = {10.1177/145749691210100106},
	abstract = {BACKGROUND AND AIMS: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18\% and 50\%. In the pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adeno-carcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradio-therapy.
METHODS: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 pa-tients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol.
RESULTS: Patients with positive node status in the resected specimen, the 3-year disease-free survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24\% and 37\%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival.
CONCLUSION: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.},
	language = {eng},
	number = {1},
	journal = {Scand J Surg},
	author = {Kofoed, S. C. and Muhic, A. and Baeksgaard, L. and Jendresen, M. and Gustafsen, J. and Holm, J. and Bardram, L. and Brandt, B. and Brenø, J. and Svendsen, L. B.},
	year = {2012},
	pmid = {22414465},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophagogastric Junction, Lymphatic Metastasis, Radiotherapy Dosage},
	pages = {26--31},
}

@article{ganz35,
	title = {Circumferential ablation of {Barrett}'s esophagus that contains high-grade dysplasia: a {U}.{S}. {Multicenter} {Registry}},
	volume = {68},
	issn = {1097-6779},
	shorttitle = {Circumferential ablation of {Barrett}'s esophagus that contains high-grade dysplasia},
	doi = {10.1016/j.gie.2007.12.015},
	abstract = {BACKGROUND: The management strategies for Barrett's esophagus (BE) that contains high-grade dysplasia (HGD) include intensive endoscopic surveillance, photodynamic therapy, thermal ablation, EMR, and esophagectomy.
OBJECTIVE: To assess the safety and effectiveness of endoscopic circumferential balloon-based ablation by using radiofrequency energy for treating BE HGD.
DESIGN: Multicenter U.S. registry.
SETTING: Sixteen academic and community centers; treatment period from September 2004 to March 2007.
PATIENTS: Patients with histologic evidence of intestinal metaplasia (IM) that contained HGD confirmed by at least 2 expert pathologists. A prior EMR was permitted, provided that residual HGD remained in the BE region for ablation.
INTERVENTION: Endoscopic circumferential ablation with follow-up esophageal biopsies to assess the histologic response to treatment.
OUTCOMES: Histologic complete response (CR) end points: (1) all biopsy specimen fragments obtained at the last biopsy session were negative for HGD (CR-HGD), (2) all biopsy specimens were negative for any dysplasia (CR-D), and (3) all biopsy specimens were negative for IM (CR-IM).
RESULTS: A total of 142 patients (median age 66 years, interquartile range [IQR] 59-75 years) who had BE HGD (median length 6 cm, IQR 3-8 cm) underwent circumferential ablation (median 1 session, IQR 1-2). No serious adverse events were reported. There was 1 asymptomatic stricture and no buried glands. Ninety-two patients had at least 1 follow-up biopsy session (median follow-up 12 months, IQR 8-15 months). A CR-HGD was achieved in 90.2\% of patients, CR-D in 80.4\%, and CR-IM in 54.3\%.
LIMITATIONS: A nonrandomized study design, without a control arm, a lack of centralized pathology review, ablation and biopsy technique not standardized, and a relatively short-term follow-up.
CONCLUSIONS: Endoscopic circumferential ablation is a promising modality for the treatment of BE that contains HGD. In this multicenter registry, the intervention safely achieved a CR for HGD in 90.2\% of patients at a median of 12 months of follow-up.},
	language = {eng},
	number = {1},
	journal = {Gastrointest Endosc},
	author = {Ganz, Robert A. and Overholt, Bergein F. and Sharma, Virender K. and Fleischer, David E. and Shaheen, Nicholas J. and Lightdale, Charles J. and Freeman, Stephen R. and Pruitt, Ronald E. and Urayama, Shiro M. and Gress, Frank and Pavey, Darren A. and Branch, M. Stanley and Savides, Thomas J. and Chang, Kenneth J. and Muthusamy, V. Raman and Bohorfoush, Anthony G. and Pace, Samuel C. and DeMeester, Steven R. and Eysselein, Viktor E. and Panjehpour, Masoud and Triadafilopoulos, George and {U.S. Multicenter Registry}},
	month = jul,
	year = {2008},
	pmid = {18355819},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Risk Assessment, United States, Esophageal Neoplasms, Sensitivity and Specificity, Esophagoscopy, Barrett Esophagus, Biopsy, Needle, Catheter Ablation, Education, Medical, Continuing, Immunohistochemistry, Precancerous Conditions, Registries},
	pages = {35--40},
}

@article{swisher175,
	title = {Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy},
	volume = {123},
	issn = {0022-5223},
	doi = {10.1067/mtc.2002.119070},
	abstract = {OBJECTIVES: Some patients and oncologists choose to treat localized esophageal cancer with definitive chemotherapy and radiation therapy rather than surgery. A subset of these patients have local relapse without distant metastases and therefore have no other curative intent treatment option but salvage esophagectomy.
METHODS: We reviewed our experience with salvage esophagectomy from 1987 to 2000 at M.D. Anderson Cancer Center (n = 13, salvage after chemotherapy and radiotherapy group) and compared the data with those of patients receiving esophagectomy in a planned fashion 4 to 6 weeks after preoperative chemotherapy and radiation therapy (n = 99, preoperative chemotherapy and radiotherapy group).
RESULTS: Increases in morbidity were seen after resection in the salvage after chemotherapy and radiotherapy group relative to the preoperative chemotherapy and radiotherapy group: mechanical ventilation (9.0 days vs 3.3 days, P =.08), intensive care unit stay (11.2 days vs 5.1 days, P =.07), hospital stay (29.4 days vs 18.4 days, P =.03), and anastomotic leak rates (5/13 [39\%] vs 7/99 [7\%], P =.005). Operative mortality (within 30 days) also tended to be increased statistically nonsignificantly (2/13 [15\%] vs 6/99 [6\%], P =.2). Salvage esophagectomy resulted in long-term survival (25\% 5-year survival) in a subset of patients. Improved survival after salvage esophagectomy was associated with early pathologic stage (T1 N0, T2 N0), prolonged time to relapse, and R0 surgical resection.
CONCLUSION: Patients who undergo salvage esophagectomy for relapse of tumor after definitive chemoradiation therapy have increased morbidity, mortality, and hospital use relative to patients undergoing planned esophagectomy after preoperative chemoradiation. Nevertheless, long-term survival can be achieved in this group, and such treatment should be considered for carefully selected patients at an experienced center.},
	language = {eng},
	number = {1},
	journal = {J Thorac Cardiovasc Surg},
	author = {Swisher, Stephen G. and Wynn, Paula and Putnam, Joe B. and Mosheim, Melinda B. and Correa, Arlene M. and Komaki, Ritsuko R. and Ajani, Jaffer A. and Smythe, W. Roy and Vaporciyan, Ara A. and Roth, Jack A. and Walsh, Garrett L.},
	month = jan,
	year = {2002},
	pmid = {11782772},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Survival Rate, Aged, 80 and over, Adult, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Combined Modality Therapy, Salvage Therapy},
	pages = {175--183},
}

@article{ouattara1088,
	title = {Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer},
	volume = {41},
	issn = {1873-734X},
	doi = {10.1093/ejcts/ezr182},
	abstract = {OBJECTIVE: Malnutrition is common after oesophageal cancer surgery. This study aims to investigate body mass index (BMI) kinetics and the risk factors of malnutrition among 1-year disease-free survivors after radical transthoracic oesophagectomy for cancer.
METHODS: From a prospective single-institution database, 118 1-year disease-free survivors having undergone a R0 transthoracic oesophagectomy with gastric tubulization between 2000 and 2008 were identified retrospectively. BMI values were collected at the onset of the disease (pre-treatment BMI), at the time of surgery (preoperative BMI), at postoperative 6 months and 1 year after oesophagectomy (1-year BMI). Logistic regression was performed with adjustment for confounders to estimate odds ratios of the factors associated with a 1-year weight loss (WL) of at least 15\% of the pre-treatment body weight (BW).
RESULTS: At the onset of the disease, 5 patients (4\%) were underweighted (BMI {\textless} 8.5 kg/m\&sup2;), 65 (55\%) were normal (BMI = 18.5-24.9 kg/m\&sup2;), 36 (31\%) were overweighted (BMI {\textgreater} 25 kg/m\&sup2;) and 12 (10\%) were obese (BMI {\textgreater} 30 kg/m\&sup2;). Mean pre-treatment, preoperative, postoperative 6-month and 1-year BMI values were 24.64 ± 4 kg/m\&sup2;, 23.55 ± 3.8 kg/m\&sup2;, 21.7 ± 3 kg/m\&sup2; and 21.97 ± 4 kg/m\&sup2;, respectively. One-year WL ≥ 15\% of the pre-treatment BW was present in 29 patients (25\%): 18 among the 48 patients (37\%) with a pre-treatment BMI ≥ 25 and 11 among the 70 patients (15\%) with pre-treatment BMI {\textless} 25 (P = 0.006). On logistic regression, initial overweighting was the sole independent prognosticator of 1-year postoperative WL of at least 15\% of the pre-treatment BW (P = 0.039; OR: 2.96, [1.06-8.32]).
CONCLUSIONS: Postoperative malnutrition remains a severe problem after oesophageal cancer resection, even in long-term disease-free survivors. Overweight and obese patients are the segment population most exposed to this postoperative malnutrition, suggesting that such surgery could have substantial bariatric effect. A special vigilance programme on the nutritional status of this sub-group of patients should be the rule.},
	language = {eng},
	number = {5},
	journal = {Eur J Cardiothorac Surg},
	author = {Ouattara, Moussa and D'Journo, Xavier Benoit and Loundou, Anderson and Trousse, Delphine and Dahan, Laetitia and Doddoli, Christophe and Seitz, Jean Francois and Thomas, Pascal-Alexandre},
	month = may,
	year = {2012},
	pmid = {22334635},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Body Mass Index, Neoplasm Staging, Retrospective Studies, Risk Factors, Sex Factors, Overweight, Weight Loss, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Malnutrition},
	pages = {1088--1093},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\T8SMT8EF\\Ouattara et al. - 2012 - Body mass index kinetics and risk factors of malnu.pdf:application/pdf},
}

@article{worrell484,
	title = {Accuracy of {Clinical} {Staging} and {Outcome} {With} {Primary} {Resection} for {Local}-{Regionally} {Limited} {Esophageal} {Adenocarcinoma}},
	volume = {267},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000002139},
	abstract = {OBJECTIVE: The aim of this study was to determine the accuracy of clinical staging, to assess survival with surgical resection alone, and to determine factors associated with understaging in patients with esophageal adenocarcinoma thought to have limited local-regional disease.
BACKGROUND: Primary surgical resection is the preferred treatment in patients with esophageal adenocarcinoma clinically staged to have limited nodal disease. This approach requires reliable clinical staging.
METHODS: A retrospective chart review was performed of all patients who had primary esophagectomy for clinical stage T1-3 N0-1 adenocarcinoma (seventh edition AJCC) from January 2002 to May 2013. Clinical and pathologic stages were compared and overall survival was analyzed.
RESULTS: There were 88 patients who met inclusion criteria. Final pathology confirmed appropriate clinical staging (≤T3N1) in 76\% of patients (67/88). There were 21 patients who were understaged ({\textgreater}T3N1), and in all cases, understaging was based on the presence of advanced nodal (N2 or N3) disease. Factors independently associated with understaging were the presence of dysphagia, tumor length {\textgreater}3 cm, and poor differentiation. At a median follow-up of 35 months, 63\% of all patients (55/88) remain alive. The 5-year survival in correctly staged patients was 67\%, compared with 33\% for those who were understaged (P {\textless} 0.0001).
CONCLUSIONS: Modern clinical staging will accurately identify the majority of patients with esophageal adenocarcinoma and limited local-regional disease (≤pT3N1). Survival with surgery alone in correctly staged patients was excellent and unlikely to be improved with neoadjuvant therapy. A combination of dysphagia, poor differentiation, and tumor length {\textgreater}3 cm was associated with understaging in 92\% of patients. Patients with these factors are likely to have more advanced disease than clinically suspected and may benefit from neoadjuvant therapy before resection.},
	language = {eng},
	number = {3},
	journal = {Ann Surg},
	author = {Worrell, Stephanie G. and Alicuben, Evan T. and Oh, Daniel S. and Hagen, Jeffrey A. and DeMeester, Steven R.},
	month = mar,
	year = {2018},
	pmid = {28151801},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Risk Factors, Survival Rate, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Lymphatic Metastasis},
	pages = {484--488},
}

@article{taketa1139,
	title = {Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma},
	volume = {12},
	issn = {1540-1413},
	doi = {10.6004/jnccn.2014.0111},
	abstract = {Current algorithms for surveillance of patients with esophageal adenocarcinoma (EAC) after chemoradiation and surgery (trimodality therapy [TMT]) remain empiric. The authors hypothesized that the frequency, type, and timing of relapses after TMT would be highly associated with surgical pathology stage (SPS), and therefore SPS could be used to individualize the surveillance strategy. Between 2000 and 2010, 518 patients with EAC were identified who underwent TMT at The University of Texas MD Anderson Cancer Center and were frequently surveyed. Frequency, type, and timing of the first relapse (locoregional and/or distant) were tabulated according to SPS. Standard statistical approaches were used. The median follow-up time after esophageal surgery was 55.4 months (range, 1.0-149.2 months). Disease relapse occurred in 215 patients (41.5\%). Higher SPS was associated with a higher rate of relapse (0/I vs II/III, P≤.001; 0/I vs II, P=.002; SPS 0/I vs III, P≤.001; and SPS II vs III, P=.005) and with shorter time to relapse (P{\textless}.001). Irrespective of the SPS, approximately 95\% of all relapses occurred within 36 months of surgery. The 3- and 5-year overall survival rates were shorter for patients with a higher SPS than those with a lower SPS (0/I vs II/III, P≤.001; 0/I vs II, P≤.001; 0/I vs III, P≤.001; and II vs III, P=.014). The compelling data show an excellent association between SPS and frequency/type/timing of relapses after TMT in patients with EAC. Thus, the surveillance strategy can potentially be customized based on SPS. These data can inform a future evidence-based surveillance strategy that can be efficient and cost-effective.},
	language = {eng},
	number = {8},
	journal = {J Natl Compr Canc Netw},
	author = {Taketa, Takashi and Sudo, Kazuki and Correa, Arlene M. and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Campagna, Maria-Claudia and Blum, Mariela A. and Skinner, Heath D. and Komaki, Ritsuko U. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian R. and Rice, David C. and Swisher, Stephen G. and Maru, Dipen M. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	month = aug,
	year = {2014},
	pmid = {25099446},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Adult, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Combined Modality Therapy},
	pages = {1139--1144},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\GQA733Q2\\Taketa et al. - 2014 - Post-chemoradiation surgical pathology stage can c.pdf:application/pdf},
}

@article{sudo4306,
	title = {Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies},
	volume = {31},
	issn = {1527-7755},
	doi = {10.1200/JCO.2013.51.7250},
	abstract = {PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort.
PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used.
RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36\%), and LRF only occurred in 27 patients (5\%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89\%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37\%) survived more than 2 years. Thus, only 2\% of all 518 patients benefited from surveillance/salvage strategies.
CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.},
	language = {eng},
	number = {34},
	journal = {J Clin Oncol},
	author = {Sudo, Kazuki and Taketa, Takashi and Correa, Arlene M. and Campagna, Maria-Claudia and Wadhwa, Roopma and Blum, Mariela A. and Komaki, Ritsuko and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Skinner, Heath D. and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	month = dec,
	year = {2013},
	pmid = {24145339},
	pmcid = {PMC3837091},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Retrospective Studies, Risk Factors, Proportional Hazards Models, Time Factors, Adult, Young Adult, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Salvage Therapy, Multivariate Analysis, Reoperation, Treatment Failure},
	pages = {4306--4310},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\7CNQWK75\\Sudo et al. - 2013 - Locoregional failure rate after preoperative chemo.pdf:application/pdf},
}

@article{terheggen783,
	title = {A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early {Barrett}'s neoplasia},
	volume = {66},
	issn = {1468-3288},
	doi = {10.1136/gutjnl-2015-310126},
	abstract = {BACKGROUND: For endoscopic resection of early GI neoplasia, endoscopic submucosal dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal resection (EMR). However, ESD is technically more difficult and evidence from randomised trial is missing.
OBJECTIVE: We compared the efficacy and safety of ESD and EMR in patients with neoplastic Barrett's oesophagus (BO).
DESIGN: BO patients with a focal lesion of high-grade intraepithelial neoplasia (HGIN) or early adenocarcinoma (EAC) ≤3 cm were randomised to either ESD or EMR. Primary outcome was R0 resection; secondary outcomes were complete remission from neoplasia, recurrences and adverse events (AEs).
RESULTS: There were no significant differences in patient and lesion characteristics between the groups randomised to ESD (n=20) or EMR (n=20). Histology of the resected specimen showed HGIN or EAC in all but six cases. Although R0 resection defined as margins free of HGIN/EAC was achieved more frequently with ESD (10/17 vs 2/17, p=0.01), there was no difference in complete remission from neoplasia at 3 months (ESD 15/16 vs EMR 16/17, p=1.0). During a mean follow-up period of 23.1±6.4 months, recurrent EAC was observed in one case in the ESD group. Elective surgery was performed in four and three cases after ESD and EMR, respectively (p=1.0). Two severe AEs were recorded for ESD and none for EMR (p=0.49).
CONCLUSIONS: In terms of need for surgery, neoplasia remission and recurrence, ESD and EMR are both highly effective for endoscopic resection of early BO neoplasia. ESD achieves a higher R0 resection rate, but for most BO patients this bears little clinical relevance. ESD is, however, more time consuming and may cause severe AE.
TRIAL REGISTRATION NUMBER: NCT1871636.},
	language = {eng},
	number = {5},
	journal = {Gut},
	author = {Terheggen, Grischa and Horn, Eva Maria and Vieth, Michael and Gabbert, Helmut and Enderle, Markus and Neugebauer, Alexander and Schumacher, Brigitte and Neuhaus, Horst},
	month = may,
	year = {2017},
	pmid = {26801885},
	pmcid = {PMC5531224},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Barrett Esophagus, Carcinoma in Situ, Reoperation, BARRETT’S OESOPHAGUS, Endoscopic Mucosal Resection, ENDOSCOPIC PROCEDURES, ENDOSCOPY, Margins of Excision, Neoplasm, Residual},
	pages = {783--793},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\M5KNJB2X\\Terheggen et al. - 2017 - A randomised trial of endoscopic submucosal dissec.pdf:application/pdf},
}

@article{vakil1791,
	title = {A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction},
	volume = {96},
	issn = {0002-9270},
	doi = {10.1111/j.1572-0241.2001.03923.x},
	abstract = {OBJECTIVE: Palliation of malignant esophageal obstruction is an important clinical problem. Expandable metal stents are a major advance in therapy, but many stents become obstructed because of tumor ingrowth. The aim of this study was to compare a new, membrane-covered expandable metal stent to conventional prostheses in a randomized controlled trial.
METHODS: Sixty-two patients with malignant inoperable esophageal obstruction at the gastroesophageal junction participated in the study. Patients were randomly assigned to covered or uncovered stents. The principal outcome measure was the need for reintervention because of recurrent dysphagia or migration. Secondary endpoints were relief of dysphagia measured by a dysphagia score (grade 0 = no dysphagia, grade 1 = able to eat solid food, grade 2 = semisolids only, grade 3 = liquids only, grade 4 = complete dysphagia) and the rate of complications and functional status. All patients were observed at monthly intervals until death or for 6 months.
RESULTS: One week after stenting the dysphagia score improved significantly in both the uncovered (n = 32, 3 +/- 0.1 to 1 +/- 0.1 [means +/- SEMs], p {\textless} 0.001) and covered (n = 30, 3 +/- 0.1 to 1 +/- 0.2 [means +/- SEMs], p {\textless} 0.001) stents. Obstructing tumor ingrowth was significantly more likely in the uncovered stent group (9/30) than in the covered group (1/32) (p = 0.005). Significant stent migration occurred in 2/30 patients with uncovered stents, as compared with 4/32 patients in the covered group (p = 0.44). Reinterventions for tumor ingrowth were significantly greater in the uncovered stent group (27\%), as compared with 0\% in the covered group (p = 0.002). Life table analysis showed similar survival in both groups.
CONCLUSION: Membrane-covered stents have significantly better palliation than conventional bare metal stents because of decreased rates of tumor ingrowth that necessitate endoscopic reintervention for dysphagia.},
	language = {eng},
	number = {6},
	journal = {Am J Gastroenterol},
	author = {Vakil, N. and Morris, A. I. and Marcon, N. and Segalin, A. and Peracchia, A. and Bethge, N. and Zuccaro, G. and Bosco, J. J. and Jones, W. F.},
	month = jun,
	year = {2001},
	pmid = {11419831},
	keywords = {Humans, Aged, Treatment Outcome, Palliative Care, Survival Rate, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Deglutition Disorders, Intestinal Obstruction, Karnofsky Performance Status, Stents},
	pages = {1791--1796},
}

@article{beukema85,
	title = {Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?},
	volume = {114},
	issn = {1879-0887},
	doi = {10.1016/j.radonc.2014.11.037},
	abstract = {PURPOSE: In recent years several papers have been published on radiation-induced cardiac toxicity, especially in breast cancer patients. However, in esophageal cancer patients the radiation dose to the heart is usually markedly higher. To determine whether radiation-induced cardiac toxicity is also a relevant issue for this group, we conducted a review of the current literature.
METHODS: A literature search was performed in Medline for papers concerning cardiac toxicity in esophageal cancer patients treated with radiotherapy with or without chemotherapy.
RESULTS: The overall crude incidence of symptomatic cardiac toxicity was as high as 10.8\%. Toxicities corresponded with several dose-volume parameters of the heart. The most frequently reported complications were pericardial effusion, ischemic heart disease and heart failure.
CONCLUSION: Cardiac toxicity is a relevant issue in the treatment of esophageal cancer. However, valid Normal Tissue Complication Probability models for esophageal cancer are not available at present.},
	language = {eng},
	number = {1},
	journal = {Radiother Oncol},
	author = {Beukema, Jannet C. and van Luijk, Peter and Widder, Joachim and Langendijk, Johannes A. and Muijs, Christina T.},
	month = jan,
	year = {2015},
	pmid = {25554226},
	keywords = {Humans, Female, Male, Esophageal Neoplasms, Esophageal cancer, Incidence, Radiotherapy Dosage, Cardiac toxicity, Cardiotoxicity, Heart, Heart Diseases, Radiation Dosage, Radiation Injuries, Radiotherapy},
	pages = {85--90},
}

@article{sts1661,
	title = {The {Society} of {Thoracic} {Surgeons} {Composite} {Score} for {Evaluating} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {103},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28385375},
	doi = {10.1016/j.athoracsur.2016.10.027},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {STS, Force},
	year = {2017},
	note = {Type: Journal Article},
	pages = {1661--1667},
}

@article{sudo3400,
	title = {Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer},
	volume = {32},
	issn = {1527-7755},
	doi = {10.1200/JCO.2014.56.7156},
	abstract = {PURPOSE: Patients with esophageal carcinoma (EC) who are treated with definitive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses. In a large cohort, we assessed the timing, frequency, and types of relapses during an aggressive surveillance program and the value of the salvage strategies.
PATIENTS AND METHODS: Patients with EC (N = 276) who received BMT were analyzed. Patients who had surgery within 6 months of chemoradiotherapy were excluded to reduce bias. We focused on local relapse (LR) and distant metastases (DM) and the salvage treatment of patients with LR only. Standard statistical methods were applied.
RESULTS: The median follow-up time was 54.3 months (95\% CI, 48.4 to 62.4). First relapses included LR only in 23.2\% (n = 64), DM with or without LR in 43.5\% (n = 120), and no relapses in 33.3\% (n = 92) of patients. Final relapses included no relapses in 33.3\%, LR only in 14.5\%, DM only in 15.9\%, and DM plus LR in 36.2\% of patients. Ninety-one percent of LRs occurred within 2 years and 98\% occurred within 3 years of BMT. Twenty-three (36\%) of 64 patients with LR only underwent salvage surgery, and their median overall survival was 58.6 months (95\% CI, 28.8 to not reached) compared with those patients with LR only who were unable to undergo surgery (9.5 months; 95\% CI, 7.8 to 13.3).
CONCLUSION: Unlike in patients undergoing trimodality therapy, for whom surveillance/salvage treatment plays a lesser role,(1) in the BMT population, approximately 8\% of all patients (or 36\% of patients with LR only) with LRs occurring more than 6 months after chemoradiotherapy can undergo salvage treatment, and their survival is excellent. Our data support vigilant surveillance, at least in the first 24 months after chemotherapy, in these patients.},
	language = {eng},
	number = {30},
	journal = {J Clin Oncol},
	author = {Sudo, Kazuki and Xiao, Lianchun and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Taketa, Takashi and Blum, Mariela A. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Ross, William A. and Komaki, Ritsuko and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Maru, Dipen M. and Skinner, Heath D. and Ajani, Jaffer A.},
	month = oct,
	year = {2014},
	pmid = {25225435},
	pmcid = {PMC4195852},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Aged, 80 and over, Adult, Esophageal Neoplasms, Chemoradiotherapy, Salvage Therapy},
	pages = {3400--3405},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\IFSMZGKM\\Sudo et al. - 2014 - Importance of surveillance and success of salvage .pdf:application/pdf},
}

@article{smalley2327,
	title = {Updated analysis of {SWOG}-directed intergroup study 0116: a phase {III} trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection},
	volume = {30},
	issn = {1527-7755},
	shorttitle = {Updated analysis of {SWOG}-directed intergroup study 0116},
	doi = {10.1200/JCO.2011.36.7136},
	abstract = {PURPOSE: Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures. We performed a randomized phase III trial of postoperative radiochemotherapy in those at moderate risk of locoregional failure (LRF) following surgery. We originally reported results with 4-year median follow-up. This update, with a more than 10-year median follow-up, presents data on failure patterns and second malignancies and explores selected subset analyses.
PATIENTS AND METHODS: In all, 559 patients with primaries ≥ T3 and/or node-positive gastric cancer were randomly assigned to observation versus radiochemotherapy after R0 resection. Fluorouracil and leucovorin were administered before, during, and after radiotherapy. Radiotherapy was given to all LRF sites to a dose of 45 Gy.
RESULTS: Overall survival (OS) and relapse-free survival (RFS) data demonstrate continued strong benefit from postoperative radiochemotherapy. The hazard ratio (HR) for OS is 1.32 (95\% CI, 1.10 to 1.60; P = .0046). The HR for RFS is 1.51 (95\% CI, 1.25 to 1.83; P {\textless} .001). Adjuvant radiochemotherapy produced substantial reduction in both overall relapse and locoregional relapse. Second malignancies were observed in 21 patients with radiotherapy versus eight with observation (P = .21). Subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology who exhibited minimal nonsignificant treatment effect.
CONCLUSION: Intergroup 0116 (INT-0116) demonstrates strong persistent benefit from adjuvant radiochemotherapy. Toxicities, including second malignancies, appear acceptable, given the magnitude of RFS and OS improvement. LRF reduction may account for the majority of overall relapse reduction. Adjuvant radiochemotherapy remains a rational standard therapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes.},
	language = {eng},
	number = {19},
	journal = {J Clin Oncol},
	author = {Smalley, Stephen R. and Benedetti, Jacqueline K. and Haller, Daniel G. and Hundahl, Scott A. and Estes, Norman C. and Ajani, Jaffer A. and Gunderson, Leonard L. and Goldman, Bryan and Martenson, James A. and Jessup, J. Milburn and Stemmermann, Grant N. and Blanke, Charles D. and Macdonald, John S.},
	month = jul,
	year = {2012},
	pmid = {22585691},
	pmcid = {PMC4517071},
	keywords = {Humans, Female, Male, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Leucovorin, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Gastrectomy},
	pages = {2327--2333},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\G4JPLSTN\\Smalley et al. - 2012 - Updated analysis of SWOG-directed intergroup study.pdf:application/pdf},
}

@article{shaheen30,
	title = {{ACG} {Clinical} {Guideline}: {Diagnosis} and {Management} of {Barrett}'s {Esophagus}},
	volume = {111},
	issn = {1572-0241},
	shorttitle = {{ACG} {Clinical} {Guideline}},
	doi = {10.1038/ajg.2015.322},
	abstract = {Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist. In this document, the American College of Gastroenterology updates its guidance for the best practices in caring for these patients. These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors. Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years. Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time. Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma. Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative. Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals. Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.},
	language = {eng},
	number = {1},
	journal = {Am J Gastroenterol},
	author = {Shaheen, Nicholas J. and Falk, Gary W. and Iyer, Prasad G. and Gerson, Lauren B. and {American College of Gastroenterology}},
	month = jan,
	year = {2016},
	pmid = {26526079},
	keywords = {Humans, Risk Factors, Barrett Esophagus, Decision Trees},
	pages = {30--50; quiz 51},
}

@article{cotton681,
	title = {Late {Recurrence} of {Barrett}'s {Esophagus} {After} {Complete} {Eradication} of {Intestinal} {Metaplasia} is {Rare}: {Final} {Report} {From} {Ablation} in {Intestinal} {Metaplasia} {Containing} {Dysplasia} {Trial}},
	volume = {153},
	issn = {1528-0012},
	shorttitle = {Late {Recurrence} of {Barrett}'s {Esophagus} {After} {Complete} {Eradication} of {Intestinal} {Metaplasia} is {Rare}},
	doi = {10.1053/j.gastro.2017.05.044},
	abstract = {BACKGROUND \& AIMS: The goal of treatment for Barrett's esophagus (BE) with dysplasia is complete eradication of intestinal metaplasia (CEIM). The long-term durability of CEIM has not been well characterized, so the frequency and duration of surveillance are unclear. We report results from a 5-year follow-up analysis of patients with BE and dysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal Metaplasia Containing Dysplasia (AIM) trial.
METHODS: Participants for the AIM Dysplasia trial (18-80 years old) were recruited from 19 sites in the United States and had endoscopic evidence of non-nodular dysplastic BE ≤8 cm in length. Subjects (n = 127) were randomly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a sham endoscopic procedure; patients in the sham group were offered RFA treatment 1 year later, and all patients were followed for 5 years. We collected data on BE recurrence (defined as intestinal metaplasia in the tubular esophagus) and dysplastic BE recurrence among patients who achieved CEIM. We constructed Kaplan-Meier estimates and applied parametric survival analysis to examine proportions of patients without any recurrence and without dysplastic recurrence.
RESULTS: Of 127 patients in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria. Of those 119, 110 (92\%) achieved CEIM. Over 401 person-years of follow-up (mean, 3.6 years per patient; range, 0.2-5.8 years), 35 of 110 (32\%) patients had recurrence of BE or dysplasia, and 19 (17\%) had dysplasia recurrence. The incidence rate of BE recurrence was 10.8 per 100 person-years overall (95\% CI, 7.8-15.0); 8.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI, 4.9-14.0), and 13.5 per 100 person-years among patients with baseline high-grade dysplasia (95\% CI 8.8-20.7). The incidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95\% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-grade dysplasia (95\% CI 4.2-12.5). Neither BE nor dysplasia recurred at a constant rate. There was a greater probability of recurrence in the first year following CEIM than in the following 4 years combined.
CONCLUSIONS: In this analysis of prospective cohort data from the AIM Dysplasia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dysplastic disease; most recurrences occurred during the first year after CEIM. However, patients who achieved CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence. Studies are needed to determine when surveillance can be decreased or discontinued; our study did not identify any BE or dysplasia recurrence after 4 years of surveillance.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Cotton, Cary C. and Wolf, W. Asher and Overholt, Bergein F. and Li, Nan and Lightdale, Charles J. and Wolfsen, Herbert C. and Pasricha, Sarina and Wang, Kenneth K. and Shaheen, Nicholas J. and {AIM Dysplasia Trial Group}},
	month = sep,
	year = {2017},
	pmid = {28579538},
	pmcid = {PMC5581683},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Kaplan-Meier Estimate, Disease Progression, Prospective Studies, Time Factors, Population Surveillance, Incidence, Esophagus, Mucous Membrane, Barrett Esophagus, Catheter Ablation, HGD, High Grade Dysplasia, LGD, Long-term Outcome, Low Grade Dysplasia, Metaplasia, Prognostic Factor, Recurrence},
	pages = {681--688.e2},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\AXWXYKRT\\Cotton et al. - 2017 - Late Recurrence of Barrett's Esophagus After Compl.pdf:application/pdf},
}

@article{sharma258,
	title = {Role of esophageal stents in benign and malignant diseases},
	volume = {105},
	issn = {1572-0241},
	doi = {10.1038/ajg.2009.684},
	abstract = {These recommendations provide an evidence-based approach to the role of esophageal stents in the management of benign and malignant diseases. These guidelines have been developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. The following guidelines are based on a critical review of the available scientific literature on the topic identified in Medline and PubMed (January 1992-December 2008) using search terms that included stents, self-expandable metal stents, self-expandable plastic stents, esophageal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, esophageal stricture, perforations, anastomotic leaks, tracheoesophageal fistula, and achalasia. These guidelines are intended for use by health-care providers and apply to adult, but not pediatric, patients. As with other practice guidelines, these guidelines are not intended to replace clinical judgment but rather to provide general guidelines applicable to the majority of patients. Clinicians need to integrate recommendations with their own clinical judgment, and with individual patient circumstances, values, and preferences. They are intended to be flexible, in contrast to standards of care, which are inflexible policies designed to be followed in every case. Specific recommendations are based on relevant published information. The quality of evidence and strength of recommendations have been assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, which is a system that has been adopted by multiple national and international societies. The GRADE system is based on a sequential assessment of quality of evidence, followed by assessment of the balance between benefits vs. downsides (harms, burden, and costs) and subsequent judgment regarding the strength of recommendation.},
	language = {eng},
	number = {2},
	journal = {Am J Gastroenterol},
	author = {Sharma, Prateek and Kozarek, Richard and {Practice Parameters Committee of American College of Gastroenterology}},
	month = feb,
	year = {2010},
	pmid = {20029413},
	keywords = {Humans, Treatment Outcome, Adult, United States, Esophageal Diseases, Stents, Endoscopy, Equipment Design, Equipment Failure, Severity of Illness Index},
	pages = {258--273; quiz 274},
}

@article{sarkaria764,
	title = {Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer},
	volume = {249},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e3181a38e9e},
	abstract = {PURPOSE: Endoscopic biopsy after chemoradiation therapy (CRT) for esophageal cancer has been used to determine response to treatment. We wanted to determine if endoscopic biopsy can accurately establish evidence of local pathologic complete response (pCR) in patients undergoing CRT.
METHODS: We queried a prospectively maintained database for patients seen at Memorial Sloan-Kettering Cancer Center from 1996 to the present who underwent, (1) CRT for local-regionally advanced esophageal cancer, (2) post-CRT endoscopic biopsy, and (3) esophagectomy. Data points included pathology of post-CRT endoscopy and surgical specimens, tumor histology, and survival. Correlations were analyzed by the chi2 test and one-way analysis of variance. Survival comparisons were assessed using the Kaplan-Meier method and log-rank analysis.
RESULTS: One hundred fifty-six patients were identified. Over 80\% of patients received cisplatin-based chemotherapy and 5040 cGy of radiation. One hundred eighteen patients had no tumor identified on endoscopic biopsy. A negative biopsy at endoscopy was a poor predictor of pCR (negative predictive value: 31\%), with 69\% having local disease at esophagectomy. A positive biopsy was predictive of residual disease (positive predictive value: 95\%). Negative endoscopic biopsy better predicted a pCR for squamous cell carcinomas versus adenocarcinomas (P[r] {\textless} 0.001). Nodal status of surgical specimens was not correlated with post-treatment endoscopic findings. Survival was equivalent after surgery in patients with a negative endoscopic biopsy versus patients with positive pathology.
CONCLUSION: A negative endoscopic biopsy is not a useful predictor of a pCR after CRT, final nodal status, or overall survival.},
	language = {eng},
	number = {5},
	journal = {Ann Surg},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P. and Bains, Manjit S. and Tang, Laura H. and Ilson, David H. and Minsky, Bruce I. and Rusch, Valerie W.},
	month = may,
	year = {2009},
	pmid = {19387328},
	keywords = {Humans, Female, Male, Middle Aged, Retrospective Studies, Predictive Value of Tests, Chemotherapy, Adjuvant, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Esophagus, Radiotherapy, Adjuvant, Endoscopy, Lymph Nodes},
	pages = {764--767},
}

@article{thomas1609,
	title = {Trimodal imaging-assisted endoscopic mucosal resection of early {Barrett}'s neoplasia},
	volume = {23},
	issn = {1432-2218},
	doi = {10.1007/s00464-009-0429-z},
	abstract = {BACKGROUND: Chromoendoscopy is traditionally used to identify inconspicuous Barrett's neoplasia and mark the boundaries before endoscopic mucosal resection (EMR). Trimodal imaging endoscopy is useful in identifying early neoplasia in Barrett's esophagus. The purpose of this study was to determine the efficacy (lateral and deep margin clearance) of trimodal imaging endoscopy-assisted EMR in early Barrett's neoplasia in a tertiary referral setting.
METHODS: The entire Barrett's segment was visualized by high-resolution endoscopy followed by autofluorescence imaging, and suspicious areas were identified. Narrow band imaging and magnification was used to confirm the suspicious areas. The outer boundary of the lesion was then marked using the tip of a snare diathermy and EMR was performed using multiband mucosectomy technique by a single operator (KR).
RESULTS: Sixteen patients were included: 13 patients had high-grade intraepithelial neoplasia (HGIN); 3 patients had intramucosal carcinoma (IMC); (8 males, median age, 69.5 (range, 50-77) years with Barrett's esophagus (interquartile range (IQR), 2-5 cm; median length, 3 cm). All lesions were successfully identified, using trimodal imaging endoscopy. Overall EMR was complete in 14 of 16 (81.2\%) patients with early Barrett's neoplasia. Four of 16 patients (18\%; all with pre-EMR HGIN) were considered to have incomplete EMR (deep margins involved), but operative histology showed only Barrett's metaplasia in 2 (histological false positive) and IMC in 1. Thus, overall 14 of 16 (87.5\%) patients had complete EMR of the original lesions. In patients who did not undergo esophagectomy, there was no disease recurrence on endoscopic biopsies at a mean follow-up of 8 (IQR, 6-12) months. Three of the 16 patients (18.75\%) with post-EMR bleeding were successfully treated with APC/hemoclips.
CONCLUSIONS: Trimodal imaging endoscopy is a feasible alternative to chromoendoscopy to identify inconspicuous neoplasia and assist EMR of early neoplasia in Barrett's esophagus.},
	language = {eng},
	number = {7},
	journal = {Surg Endosc},
	author = {Thomas, T. and Singh, R. and Ragunath, K.},
	month = jul,
	year = {2009},
	pmid = {19296171},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Disease Progression, Aged, 80 and over, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Carcinoma in Situ, Diathermy, Fluorometry, Gastroscopes, Hemostasis, Surgical, Postoperative Hemorrhage, Video-Assisted Surgery},
	pages = {1609--1613},
}

@article{nurkin1090,
	title = {Outcomes of endoscopic resection for high-grade dysplasia  and esophageal cancer},
	volume = {28},
	issn = {1432-2218},
	doi = {10.1007/s00464-013-3270-3},
	abstract = {BACKGROUND: Endoscopic resection (ER) is an important advance in the management of esophageal tumors. It has been used successfully for superficial esophageal cancer and high-grade dysplasia (HGD) arising out of Barrett epithelium.
METHODS: From a single institution within the Department of Surgery, patients who underwent ER for esophageal tumors between December 2001 and January 2012 were evaluated. Demographic, clinical, and pathologic variables were collected and reviewed.
RESULTS: We identified 81 patients who underwent ER for esophageal lesions. Median patient age was 69 years, and the median follow-up was 3.25 years. In patients with HGD, at the time of last endoscopy, the complete eradication rate of HGD was 84 \% and cancer-specific survival was 100 \%. During surveillance, one patient developed an invasive carcinoma that required endoscopic therapy. Patients with T1a and negative deep margins on ER had a recurrence-free and cancer-specific survival of 100 \%. There were seven patients with T1b and negative margins on ER. Three patients underwent esophagectomy; final pathology revealed no residual malignancy or lymph node metastasis. Two patients had definitive chemoradiation, and two patients were observed. To date, there has been no cancer recurrence. In all patients who underwent ER, there was one episode of bleeding that required endoscopic treatment and admission for observation.
CONCLUSIONS: ER can be performed safely and can adequately stage and often treat patients with HGD and superficial cancers. Patients with HGD and T1a disease with negative margins are cured with ER alone. Observation and surveillance may be an option for select patients with low-risk, early submucosal disease (T1b) and negative margins.},
	language = {eng},
	number = {4},
	journal = {Surg Endosc},
	author = {Nurkin, Steven J. and Nava, Hector R. and Yendamuri, Sai and LeVea, Charles M. and Nwogu, Chumy E. and Groman, Adrienne and Wilding, Gregory and Bain, Andrew J. and Hochwald, Steven N. and Khushalani, Nikhil I.},
	month = apr,
	year = {2014},
	pmid = {24232046},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Assessment, Time Factors, Survival Rate, Aged, 80 and over, Adult, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Incidence, Endoscopy, Gastrointestinal, Lymphatic Metastasis, Barrett Esophagus, New York},
	pages = {1090--1095},
}

@article{martin1308,
	title = {Long-term weight change after oesophageal cancer surgery},
	volume = {96},
	issn = {1365-2168},
	doi = {10.1002/bjs.6723},
	abstract = {BACKGROUND: Malnutrition is common after oesophageal cancer surgery. This study investigated weight changes and the risk of malnutrition among long-term survivors.
METHODS: A nationwide cohort study was conducted in Sweden in 2001-2004, with follow-up to 2008. Weight was assessed before oesophagectomy, after 6 months and at 3 years. Logistic regression was performed with adjustment for confounders. Odds ratios (ORs) for postoperative weight loss of at least 15 per cent were estimated.
RESULTS: Some 203 patients survived at least 3 years after oesophagectomy. Continuous weight loss occurred for up to 3 years. Women and men had a similar risk of malnutrition after 3 years (OR 0.85 (95 per cent confidence interval 0.24 to 2.98)). In overweight patients (preoperative body mass index at least 25 kg/m(2)) the risk of malnutrition was increased almost fivefold at 6 months (OR 4.90 (2.27 to 10.59)) and 3 years (OR 4.60 (1.80 to 11.78)). There was no difference in weight loss at 6 months between survivors and those who died between 6 months and 3 years after surgery (OR 1.11 (0.64 to 1.94)).
CONCLUSION: Weight loss can be long lasting after oesophagectomy; overweight patients are at particularly increased risk of malnutrition.},
	language = {eng},
	number = {11},
	journal = {Br J Surg},
	author = {Martin, L. and Lagergren, P.},
	month = nov,
	year = {2009},
	pmid = {19847871},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Weight Loss, Adult, Stomach Neoplasms, Esophageal Neoplasms, Postoperative Complications, Malnutrition, Epidemiologic Methods, Survivors, Survivorship},
	pages = {1308--1314},
}

@article{lee268,
	title = {Phase {III} trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with {D2} lymph node dissection: the {ARTIST} trial},
	volume = {30},
	issn = {1527-7755},
	shorttitle = {Phase {III} trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with {D2} lymph node dissection},
	doi = {10.1200/JCO.2011.39.1953},
	abstract = {PURPOSE: The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge to investigate the role of postoperative chemoradiotherapy therapy in patients with curatively resected gastric cancer with D2 lymph node dissection. This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP).
PATIENTS AND METHODS: The XP arm received six cycles of XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy. The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and two cycles of XP.
RESULTS: Of 458 patients, 228 were randomly assigned to the XP arm and 230 to the XP/XRT/XP arm. Treatment was completed as planned by 75.4\% of patients (172 of 228) in the XP arm and 81.7\% (188 of 230) in the XP/XRT/XP arm. Overall, the addition of XRT to XP chemotherapy did not significantly prolong disease-free survival (DFS; P = .0862). However, in the subgroup of patients with pathologic lymph node metastasis at the time of surgery (n = 396), patients randomly assigned to the XP/XRT/XP arm experienced superior DFS when compared with those who received XP alone (P = .0365), and the statistical significance was retained at multivariate analysis (estimated hazard ratio, 0.6865; 95\% CI, 0.4735 to 0.9952; P = .0471). CONCLUSION The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in gastric cancer. A subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.},
	language = {eng},
	number = {3},
	journal = {J Clin Oncol},
	author = {Lee, Jeeyun and Lim, Do Hoon and Kim, Sung and Park, Se Hoon and Park, Joon Oh and Park, Young Suk and Lim, Ho Yeong and Choi, Min Gew and Sohn, Tae Sung and Noh, Jae Hyung and Bae, Jae Moon and Ahn, Yong Chan and Sohn, Insuk and Jung, Sin Ho and Park, Cheol Keun and Kim, Kyoung-Mee and Kang, Won Ki},
	month = jan,
	year = {2012},
	pmid = {22184384},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Young Adult, Stomach Neoplasms, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Neoplasm Recurrence, Local, Capecitabine, Deoxycytidine, Lymph Node Excision},
	pages = {268--273},
}

@article{gharzaie0158916,
	title = {Radiation {Therapy} and {Cardiac} {Death} in {Long}-{Term} {Survivors} of {Esophageal} {Cancer}: {An} {Analysis} of the {Surveillance}, {Epidemiology}, and {End} {Result} {Database}},
	volume = {11},
	issn = {1932-6203},
	shorttitle = {Radiation {Therapy} and {Cardiac} {Death} in {Long}-{Term} {Survivors} of {Esophageal} {Cancer}},
	doi = {10.1371/journal.pone.0158916},
	abstract = {OBJECTIVE: Radiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined late cardiac death in survivors of esophageal cancer that had or had not received RT.
METHODS: 5,630 patients were identified that were diagnosed with esophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) from 1973-2012, who were followed for at least 5 years after therapy. Examined risk factors for cardiac death included age (≤55/56-65/66-75/{\textgreater}75), gender, race (white/non-white), stage (local/regional/distant), histology (SCC/AC), esophageal location ({\textless}18cm/18-24cm/25-32cm/33-40cm from incisors), diagnosis year (1973-1992/1993-2002/2003-2012), and receipt of surgery and/or RT. Time to cardiac death was evaluated using the Kaplan-Meier method. A Cox model was used to evaluate risk factors for cardiac death in propensity score matched data.
RESULTS: Patients who received RT were younger, diagnosed more recently, had more advanced disease, SCC histology, and no surgery. The RT group had higher risk of cardiac death than the no-RT group (log-rank p{\textless}0.0001). The median time to cardiac death in the RT group was 289 months (95\% CI, 255-367) and was not reached in the no-RT group. The probability of cardiac death increased with age and decreased with diagnosis year, and this trend was more pronounced in the RT group. Multivariate analysis found RT to be associated with higher probability of cardiac death (OR 1.23, 95\% CI 1.03-1.47, HR 1.961, 95\% CI 1.466-2.624). Lower esophageal subsite (33-40 cm) was also associated with a higher risk of cardiac death. Other variables were not associated with cardiac death.
CONCLUSIONS: Recognizing the limitations of a SEER analysis including lack of comorbidity accountability, these data should prompt more definitive study as to whether a possible associative effect of RT on cardiac death could potentially be a causative effect.},
	language = {eng},
	number = {7},
	journal = {PLoS One},
	author = {Gharzai, Laila and Verma, Vivek and Denniston, Kyle A. and Bhirud, Abhijeet R. and Bennion, Nathan R. and Lin, Chi},
	year = {2016},
	pmid = {27428362},
	pmcid = {PMC4948887},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Kaplan-Meier Estimate, Proportional Hazards Models, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Esophagus, Survivors, Death},
	pages = {e0158916},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\FCIURAFT\\Gharzai et al. - 2016 - Radiation Therapy and Cardiac Death in Long-Term S.pdf:application/pdf},
}

@article{frandsen516,
	title = {Increased risk of death due to heart disease after radiotherapy for esophageal cancer},
	volume = {6},
	issn = {2078-6891},
	doi = {10.3978/j.issn.2078-6891.2015.040},
	abstract = {OBJECTIVE: To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC).
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses.
RESULTS: We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P{\textless}0.05), with an absolute risk of HDRD of 2.8\%, 5.3\% and 9.4\% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P{\textless}0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P{\textless}0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P{\textless}0.0001) and multivariate (HR 1.62, P{\textless}0.0001) analyses.
CONCLUSIONS: The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.},
	language = {eng},
	number = {5},
	journal = {J Gastrointest Oncol},
	author = {Frandsen, Jonathan and Boothe, Dustin and Gaffney, David K. and Wilson, Brent D. and Lloyd, Shane},
	month = oct,
	year = {2015},
	pmid = {26487946},
	pmcid = {PMC4570919},
	keywords = {Esophageal cancer (EC), heart disease, radiation therapy (RT)},
	pages = {516--523},
}

@article{dunbar850,
	title = {The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in {Barrett}'s esophagus: a systematic review},
	volume = {107},
	issn = {1572-0241},
	shorttitle = {The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in {Barrett}'s esophagus},
	doi = {10.1038/ajg.2012.78},
	abstract = {OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus.
METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens.
RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39 \% , 95 \% CI 0.86 – 1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93 \% , 95 \% CI 1.19 – 2.66 \%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes.
CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1 – 2 \%. Esophagectomy has a mortality rate that often exceeds 2 \%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.},
	language = {eng},
	number = {6},
	journal = {Am J Gastroenterol},
	author = {Dunbar, Kerry B. and Spechler, Stuart Jon},
	month = jun,
	year = {2012},
	pmid = {22488081},
	pmcid = {PMC3578695},
	keywords = {Humans, Risk Factors, Risk Assessment, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Incidence, Lymphatic Metastasis, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Lymph Nodes, Carcinoma, Neoplasm Grading},
	pages = {850--862; quiz 863},
	file = {Accepted Version:C\:\\Users\\jcsal\\Zotero\\storage\\LL3AHQRI\\Dunbar and Spechler - 2012 - The risk of lymph-node metastases in patients with.pdf:application/pdf},
}

@article{dorth2099,
	title = {Patterns of recurrence after trimodality therapy for esophageal cancer},
	volume = {120},
	issn = {1097-0142},
	doi = {10.1002/cncr.28703},
	abstract = {BACKGROUND: Patterns of failure after neoadjuvant chemoradiotherapy and surgery for esophageal cancer are poorly defined.
METHODS: All patients in the current study were treated with trimodality therapy for nonmetastatic esophageal cancer from 1995 to 2009. Locoregional failure included lymph node failure (NF), anastomotic failure, or both. Abdominal paraaortic failure (PAF) was defined as disease recurrence at or below the superior mesenteric artery.
RESULTS: Among 155 patients, the primary tumor location was the upper/middle esophagus in 18\%, the lower esophagus in 32\%, and the gastroesophageal junction in 50\% (adenocarcinoma in 79\% and squamous cell carcinoma in 21\%) of patients. Staging methods included endoscopic ultrasound (73\%), computed tomography (46\%), and positron emission tomography/computed tomography (54\%). Approximately 40\% of patients had American Joint Committee on Cancer stage II disease and 60\% had stage III disease. The median follow-up was 1.3 years. The 2-year locoregional control, event-free survival, and overall survival rates were 86\%, 36\%, and 48\%, respectively. The 2-year NF rate was 14\%, the isolated NF rate was 3\%, and the anastomotic failure rate was 6\%. The 2-year PAF rate was 9\% and the isolated PAF rate was 5\%. PAF was found to be increased among patients with gastroesophageal junction tumors (12\% vs 6\%), especially for the subset with ≥ 2 clinically involved lymph nodes at the time of diagnosis (19\% vs 4\%).
CONCLUSIONS: Few patients experience isolated NF or PAF as their first disease recurrence. Therefore, it is unlikely that targeting additional regional lymph node basins with radiotherapy would significantly improve clinical outcomes.},
	language = {eng},
	number = {14},
	journal = {Cancer},
	author = {Dorth, Jennifer A. and Pura, John A. and Palta, Manisha and Willett, Christopher G. and Uronis, Hope E. and D'Amico, Thomas A. and Czito, Brian G.},
	month = jul,
	year = {2014},
	pmid = {24711267},
	pmcid = {PMC4519032},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Adult, Fluorouracil, United States, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Lymphatic Metastasis, Radiotherapy Dosage, Treatment Failure, Anastomotic Leak, esophageal cancer, esophagectomy, lymphatic irradiation, lymphatic metastasis, Platinum Compounds, Positron-Emission Tomography, Taxoids},
	pages = {2099--2105},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\99SP9W84\\Dorth et al. - 2014 - Patterns of recurrence after trimodality therapy f.pdf:application/pdf},
}

@article{bergeron765,
	title = {Endoscopic ultrasound is inadequate to determine which {T1}/{T2} esophageal tumors are candidates for endoluminal therapies},
	volume = {147},
	issn = {1097-685X},
	doi = {10.1016/j.jtcvs.2013.10.003},
	abstract = {OBJECTIVES: Esophageal endoscopic ultrasound is now regarded as essential in the staging of esophageal carcinoma. There is an increasing trend toward endoluminal therapies (ie, endoscopic mucosal resection and radiofrequency ablation) for pre-cancer or early-stage cancers because of concerns of high morbidity associated with esophagectomy. This study reviews our institutional experience with preoperative endoscopic ultrasound staging of early esophageal cancers in patients who underwent an esophagectomy to evaluate the accuracy of staging by endoscopic ultrasound and how this affects treatment recommendations.
METHODS: A prospective esophagectomy database of all patients undergoing an esophagectomy for esophageal cancer at a single high-volume institution was retrospectively reviewed for patients with early-stage esophageal cancer. This study analyzed patients with clinical Tis to T1 disease, as predicted by preoperative endoscopic ultrasound, and correlated this with the pathologic stages after esophagectomy. The surgical outcomes were evaluated to assess the safety of esophagectomy as a treatment modality.
RESULTS: From 2005 to 2011, 107 patients (93 male, 14 female) with a mean age of 66 years (range, 39-91 years) were staged by preoperative endoscopic ultrasound to have esophageal high-grade dysplasia, carcinoma in situ, or T1 cancer and underwent an esophagectomy. Tumor depth was correctly staged by endoscopic ultrasound in only 39\% (23/59) of pT1a tumors (invading into the lamina propria or muscularis mucosa) and 51\% (18/35) of pT1b tumors (submucosal). Of the endoscopic ultrasound-staged cT1a-lpN0 lesions, there were positive lymph nodes in 15\% of pathologic specimens (2/13). Patients with pT1a-mm lesions had a 9\% rate of pathologic lymph node involvement (1/11), and those with pT1b tumors had a 17\% rate of lymph node spread (6/35). Esophagectomy was performed in all 107 patients with a 30-day mortality rate of less than 1\% (1/107).
CONCLUSIONS: The sensitivity and specificity of endoscopic ultrasound for determining true pathologic staging are poor for early-stage esophageal cancers. Lesions thought to be cT1a-lpN0 by endoscopic ultrasound have at least pN1 disease in 15\% of cases. Endoluminal therapy of these lesions based on endoscopic ultrasound undertreats a significant number of patients. Esophagectomy is still the standard therapy for early-stage esophageal cancers in the majority of patients.},
	language = {eng},
	number = {2},
	journal = {J Thorac Cardiovasc Surg},
	author = {Bergeron, Edward J. and Lin, Jules and Chang, Andrew C. and Orringer, Mark B. and Reddy, Rishindra M.},
	month = feb,
	year = {2014},
	pmid = {24314788},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Risk Factors, Time Factors, Aged, 80 and over, Adult, Predictive Value of Tests, Neoplasm Invasiveness, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Lymphatic Metastasis, Catheter Ablation, Carcinoma, 7, 8.1, 8.4, 8.7, Barrett’s esophagus, BE, Decision Support Techniques, EAC, EMR, endomucosal resection, endoscopic ultrasound, Endosonography, esophageal adenocarcinoma, EUS, Hospital Mortality, Hospitals, High-Volume, Michigan, negative predictive value, NPV, Patient Selection, PDT, PET, photodynamic therapy, positive predictive value, positron emission tomography, PPV, radiofrequency ablation, RFA, THE, transhiatal esophagectomy},
	pages = {765--771: Discussion 771--773},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\ZK6NMRZU\\Bergeron et al. - 2014 - Endoscopic ultrasound is inadequate to determine w.pdf:application/pdf},
}

@article{baker987,
	title = {A systematic review of the nutritional consequences of esophagectomy},
	volume = {35},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2015.08.010},
	abstract = {BACKGROUND \& AIMS: As improved outcomes after esophagectomy have been observed over the last two decades, the focus on care has shifted to survivorship and quality of life. The aim of this review was to determine changes in nutrition after esophagectomy and to assess the evidence for extended nutrition support.
METHODS: A search strategy was developed to identify primary research reporting change in nutritional status a minimum of one month after esophagectomy.
RESULTS: Changes in nutritional parameters reported by 18 studies indicated a weight loss of 5-12\% at six months postoperatively. More than half of patients lost {\textgreater}10\% of body weight at 12 months. One study reported a persistent weight loss of 14\% from baseline three years after surgery. Three studies reporting on longer term follow up noted that 27\%-95\% of patients failed to regain their baseline weight. Changes in dietary intake (three studies) indicated inadequate energy and protein intake up to three years after surgery. Global quality of life scores reported in one study correlated with better weight preservation. There were a high frequency of gastrointestinal symptoms reported in six studies, most notably in the first year after surgery, but persisting up to 19 years. Extended enteral nutrition on a selective basis has been reported in several studies.
CONCLUSIONS: Nutritional status is compromised in the months/years following oesophagectomy and may never return to baseline levels. The causes/consequences of weight loss/impaired nutritional intake require further investigation. The role of extended nutritional support in this population remains unclear.},
	language = {eng},
	number = {5},
	journal = {Clin Nutr},
	author = {Baker, Melanie and Halliday, Vanessa and Williams, Robert N. and Bowrey, David J.},
	month = oct,
	year = {2016},
	pmid = {26411750},
	pmcid = {PMC5410167},
	keywords = {Humans, Body Weight, Esophagectomy, Diet, Enteral nutrition, Enteral Nutrition, Non-Randomized Controlled Trials as Topic, Nutrition, Nutritional status, Nutritional Status, Quality of Life, Weight},
	pages = {987--994},
	file = {Accepted Version:C\:\\Users\\jcsal\\Zotero\\storage\\DZHTUY7A\\Baker et al. - 2016 - A systematic review of the nutritional consequence.pdf:application/pdf},
}

@article{siewert260,
	title = {Adenocarcinoma of the esophago-gastric junction},
	volume = {95},
	issn = {1457-4969},
	doi = {10.1177/145749690609500409},
	abstract = {BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction. We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification.
METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors. Demographic data, morphologic and histopathologic tumor characteristics, and long-term survival rates were compared among the three tumor subclassifiations.
RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities. The degree of resection and lymph node status were the dominating independent prognostic factors by multivariate analysis. The data show no significant differences of long-term survival after abdomino-thoracic esophagectomy and extended total gastrectomy in these patients.
CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach. Complete tumor resection and adequate lymphadenectomy are associated with good long-term prognosis. Better surgical management and standardized procedures will improve the outcome also of patients who need to undergo more radical surgery, i.e. abdomino-thoracic esophagectomy.},
	language = {eng},
	number = {4},
	journal = {Scand J Surg},
	author = {Siewert, J. R. and Stein, H. J. and Feith, M.},
	year = {2006},
	pmid = {17249275},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Prognosis, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Lymphatic Metastasis, Sex Distribution},
	pages = {260--269},
}

@article{haidry87,
	title = {Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the {UK} {National} {Halo} {RFA} {Registry}},
	volume = {145},
	issn = {1528-0012},
	shorttitle = {Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma},
	doi = {10.1053/j.gastro.2013.03.045},
	abstract = {BACKGROUND \& AIMS: Patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) or early neoplasia increasingly receive endoscopic mucosal resection and radiofrequency ablation (RFA) therapy. We analyzed data from a UK registry that follows the outcomes of patients with BE who have undergone RFA for neoplasia.
METHODS: We collected data on 335 patients with BE and neoplasia (72\% with HGD, 24\% with intramucosal cancer, 4\% with low-grade dysplasia [mean age, 69 years; 81\% male]), treated at 19 centers in the United Kingdom from July 2008 through August 2012. Mean length of BE segments was 5.8 cm (range, 1-20 cm). Patients' nodules were removed by endoscopic mucosal resection, and the patients then underwent RFA every 3 months until all areas of BE were ablated or cancer developed. Biopsies were collected 12 months after the first RFA; clearance of HGD, dysplasia, and BE were assessed.
RESULTS: HGD was cleared from 86\% of patients, all dysplasia from 81\%, and BE from 62\% at the 12-month time point, after a mean of 2.5 (range, 2-6) RFA procedures. Complete reversal dysplasia was 15\% less likely for every 1-cm increment in BE length (odds ratio = 1.156; SE = 0.048; 95\% confidence interval: 1.07-1.26; P {\textless} .001). Endoscopic mucosal resection before RFA did not provide any benefit. Invasive cancer developed in 10 patients (3\%) by the 12-month time point and disease had progressed in 17 patients (5.1\%) after a median follow-up time of 19 months. Symptomatic strictures developed in 9\% of patients and were treated by endoscopic dilatation. Nineteen months after therapy began, 94\% of patients remained clear of dysplasia.
CONCLUSIONS: We analyzed data from a large series of patients in the United Kingdom who underwent RFA for BE-related neoplasia and found that by 12 months after treatment, dysplasia was cleared from 81\%. Shorter segments of BE respond better to RFA; http://www.controlled-trials.com, number ISRCTN93069556.},
	language = {eng},
	number = {1},
	journal = {Gastroenterology},
	author = {Haidry, Rehan J. and Dunn, Jason M. and Butt, Mohammed A. and Burnell, Matthew G. and Gupta, Abhinav and Green, Sarah and Miah, Haroon and Smart, Howard L. and Bhandari, Pradeep and Smith, Lesley Ann and Willert, Robert and Fullarton, Grant and Morris, John and Di Pietro, Massimo and Gordon, Charles and Penman, Ian and Barr, Hugh and Patel, Praful and Boger, Philip and Kapoor, Neel and Mahon, Brinder and Hoare, Jonathon and Narayanasamy, Ravi and O'Toole, Dermot and Cheong, Edward and Direkze, Natalie C. and Ang, Yeng and Novelli, Marco and Banks, Matthew R. and Lovat, Laurence Bruce},
	month = jul,
	year = {2013},
	pmid = {23542069},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Disease Progression, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Catheter Ablation, Registries},
	pages = {87--95},
}

@article{kato921,
	title = {Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma},
	volume = {94},
	issn = {0008-543X},
	abstract = {BACKGROUND: The role and potential value of positron emission tomography (PET) scanning in certain tumors has been widely investigated in recent years. The authors retrospectively assessed the performance of 18-F-fluorodeoxyglucose (FDG)-PET in the assessment of esophageal squamous cell carcinoma (SCC).
METHODS: The results using PET were compared with those using computed tomography (CT), and these were correlated with the pathologic findings. The authors studied 32 patients with thoracic esophageal SCC who had undergone radical esophagectomy.
RESULTS: Uptake of FDG in the primary tumor was found in 25 of the 32 (78.1\%) cases. Comparison of the FDG uptake and the clinicopathologic findings showed that there was a significant association between the FDG uptake and each of the depth of tumor invasion (P {\textless} 0.05), occurrence of lymph node metastasis (P {\textless} 0.01), and lymphatic invasion (P {\textless} 0.01). The survival rate in cases with high FDG uptake (standardized uptake value [SUV], {\textgreater}3) was significantly lower than that in cases with low FDG uptake (SUV, {\textless} 3; P {\textless} 0.05). In the evaluation of lymph node staging by the detection of lymph node metastasis, FDG-PET showed 77.8\% sensitivity, 92.9\% specificity, and 84.4\% accuracy, and CT scanning showed 61.1\% sensitivity, 71.4\% specificity, and 65.6\% accuracy. Positron emission tomography scanning showed a high degree of accuracy in the neck, upper thoracic, and abdominal regions. However, in the mid- and lower thoracic regions, the sensitivity was very low. The smallest lymph node metastasis that was detected by FDG-PET imaging was 6 mm. The average size of lymph node metastasis that was undetected by FDG-PET scanning was 7.3 mm (range, 1-17 mm).
CONCLUSIONS: In conclusion, FDG-PET may be used as a noninvasive diagnostic technique in assessing the aggressiveness of the tumor and the prognosis in patients with esophageal SCC. During the preoperative diagnostic procedures, the sensitivity, specificity, and accuracy of lymph node staging is higher with FDG-PET than with CT imaging. In view of the high specificity of FDG-PET, it also gives useful information to guide the choice of treatment of esophageal carcinoma.},
	language = {eng},
	number = {4},
	journal = {Cancer},
	author = {Kato, Hiroyuki and Kuwano, Hiroyuki and Nakajima, Masanobu and Miyazaki, Tatsuya and Yoshikawa, Minako and Ojima, Hitoshi and Tsukada, Katsuhiko and Oriuchi, Noboru and Inoue, Tomio and Endo, Keigo},
	month = feb,
	year = {2002},
	pmid = {11920459},
	note = {tex.ids: kato921a},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Prognosis, Reproducibility of Results, Adult, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Sensitivity and Specificity, Lymphatic Metastasis, Carcinoma, Tomography, Emission-Computed},
	pages = {921--928},
}

@article{henneman4068,
	title = {Centralization of esophagectomy: how far should we go?},
	volume = {21},
	issn = {1534-4681},
	shorttitle = {Centralization of esophagectomy},
	doi = {10.1245/s10434-014-3873-5},
	abstract = {BACKGROUND: This study was designed to define a statistically sound and clinically meaningful cutoff point for annual hospital volume for esophagectomy. Higher hospital volumes are associated with improved outcomes after esophagectomy. However, reported optimal volumes in literature vary, and minimal volume standards in different countries show considerable variation. So far, there has been no research on the noncategorical, nonlinear, volume-outcome relationship in esophagectomy.
METHODS: Data were derived from the Netherlands Cancer Registry. Restricted cubic splines were used to investigate the nonlinear effects of annual hospital volume on 6 month and 2 year mortality rates. Outcomes were adjusted for year of diagnosis, case-mix, and (neo)adjuvant treatment.
RESULTS: Between 1989 and 2009, 10,025 patients underwent esophagectomy for cancer in the Netherlands. Annual hospital volumes varied between 1 and 83 year, increasing over time. Increasing annual hospital volume showed a continuous, nonlinear decrease in hazard ratio (HR) for mortality along the curve. Increasing hospital volume from 20 year (baseline, HR = 1.00) to 40 and 60 year was associated with decreasing 6 month mortality, with a HR of 0.73 (95 \% confidence interval (0.65-0.83) and 0.67 (0.58-0.77) respectively. Beyond 60 year, no further decrease was detected. Higher hospital volume also was associated with decreasing 2 year mortality until 50 esophagectomies year with a HR of 0.86 (0.79-0.93).
CONCLUSIONS: Centralization of esophagectomy to a minimum of 20 resections/year has been effectively introduced in the Netherlands. Increasing annual hospital volume was associated with a nonlinear decrease in mortality up to 40-60 esophagectomies/year, after which a plateau was reached. This finding may guide quality improvement efforts worldwide.},
	language = {eng},
	number = {13},
	journal = {Ann Surg Oncol},
	author = {Henneman, Daniel and Dikken, Johan L. and Putter, Hein and Lemmens, Valery E. P. P. and Van der Geest, Lydia G. M. and van Hillegersberg, Richard and Verheij, Marcel and van de Velde, Cornelis J. H. and Wouters, Michel W. J. M.},
	month = dec,
	year = {2014},
	pmid = {25005073},
	note = {tex.ids: henneman4068a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Factors, Databases, Factual, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Netherlands, Hospitals, High-Volume, Learning Curve, Mortality, Surgery},
	pages = {4068--4074},
}

@article{minsky1167,
	title = {{INT} 0123 ({Radiation} {Therapy} {Oncology} {Group} 94-05) phase {III} trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy},
	volume = {20},
	issn = {0732-183X},
	shorttitle = {{INT} 0123 ({Radiation} {Therapy} {Oncology} {Group} 94-05) phase {III} trial of combined-modality therapy for esophageal cancer},
	doi = {10.1200/JCO.2002.20.5.1167},
	abstract = {PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer.
PATIENTS AND METHODS: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m(2)/24 hours for 4 days) and cisplatin (75 mg/m(2) bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive.
RESULTS: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31\% v 40\%), or local/regional failure and local/regional persistence of disease (56\% v 52\%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less.
CONCLUSION: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.},
	language = {eng},
	number = {5},
	journal = {J Clin Oncol},
	author = {Minsky, Bruce D. and Pajak, Thomas F. and Ginsberg, Robert J. and Pisansky, Thomas M. and Martenson, James and Komaki, Ritsuko and Okawara, Gordon and Rosenthal, Seth A. and Kelsen, David P.},
	month = mar,
	year = {2002},
	pmid = {11870157},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Recurrence, Local, Combined Modality Therapy, Radiotherapy Dosage, Radiotherapy},
	pages = {1167--1174},
}

@article{ajani3953,
	title = {Phase {II} trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma ({RTOG} 9904): quality of combined modality therapy and pathologic response},
	volume = {24},
	issn = {1527-7755},
	shorttitle = {Phase {II} trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma ({RTOG} 9904)},
	doi = {10.1200/JCO.2006.06.4840},
	abstract = {PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal. We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20\% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points.
PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible. A negative laparoscopic evaluation was required. Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after chemoradiotherapy was completed. Quality of therapy was assessed with other end points.
RESULTS: Twenty institutions participated. Forty-nine patients were entered and 43 were assessable (12\% stage IB; 37\% stage II; and 52\% stage III). The pathCR and R0 resection rates were 26\% and 77\%, respectively. At 1 year, more patients with pathCR (82\%) are living than those with less than pathCR (69\%). Grade 4 toxicity occurred in 21\% of patients. Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98\%, 44\%, and 63\% of patients, respectively. A D2 dissection was performed in 50\% of patients. Of 18 major radiotherapy variations, 17 were due to the lack of inclusion of the L3-4 vertebral interphase as prespecified.
CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20\% in a cooperative group setting. The quality of surgery improved (50\% with D2 dissection) possibly because surgery was part of this trial. With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.},
	language = {eng},
	number = {24},
	journal = {J Clin Oncol},
	author = {Ajani, Jaffer A. and Winter, Kathryn and Okawara, Gordon S. and Donohue, John H. and Pisters, Peter W. T. and Crane, Christopher H. and Greskovich, John F. and Anne, P. Rani and Bradley, Jeffrey D. and Willett, Christopher and Rich, Tyvin A.},
	month = aug,
	year = {2006},
	pmid = {16921048},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Gastrectomy, Radiotherapy, Adjuvant},
	pages = {3953--3958},
}

@article{hoeppner503,
	title = {{ESOPEC}: prospective randomized controlled multicenter phase {III} trial comparing perioperative chemotherapy ({FLOT} protocol) to neoadjuvant chemoradiation ({CROSS} protocol) in patients with adenocarcinoma of the esophagus ({NCT02509286})},
	volume = {16},
	issn = {1471-2407},
	shorttitle = {{ESOPEC}},
	doi = {10.1186/s12885-016-2564-y},
	abstract = {BACKGROUND: Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of neoadjuvant chemoradiation and perioperative chemotherapy applying contemporary treatment protocols are lacking. The present trial was initiated to obtain valid information whether neoadjuvant chemoradiation or perioperative chemotherapy yields better survival in the treatment of localized esophageal adenocarcinoma.
METHODS/DESIGN: The ESOPEC trial is an investigator-initiated multicenter prospective randomized controlled two-arm trial, comparing the efficacy of neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery versus perioperative chemotherapy and surgery (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) for the curative treatment of localized esophageal adenocarcinoma. Patients with cT1cN + cM0 and cT2-4acNxcM0 esophageal and junctional adenocarcinoma are eligible. The trial aims to include 438 participants who are centrally randomized to one of the two treatment groups in a 1:1 ratio stratified by N-stage and study site. The primary endpoint of the trial is overall survival assessed with a minimum follow-up of 36 months. Secondary objectives are progression-free survival, recurrence-free survival, site of failure, postoperative morbidity and mortality, duration of hospitalization as well as quality of life.
DISCUSSION: The ESOPEC trial compares perioperative chemotherapy according to the FLOT protocol to neoadjuvant chemoradiation according to the CROSS protocol in multimodal treatment of non-metastasized recectable adenocarcinoma of the esophagus and the gastroesophageal junction. The goal of the trial is identify the superior protocol with regard to patient survival, treatment morbidity and quality of life.
TRIAL REGISTRATION: NCT02509286 (July 22, 2015).},
	language = {eng},
	journal = {BMC Cancer},
	author = {Hoeppner, Jens and Lordick, Florian and Brunner, Thomas and Glatz, Torben and Bronsert, Peter and Röthling, Nadine and Schmoor, Claudia and Lorenz, Dietmar and Ell, Christian and Hopt, Ulrich T. and Siewert, J. Rüdiger},
	month = jul,
	year = {2016},
	pmid = {27435280},
	pmcid = {PMC4952147},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Neoplasm Recurrence, Local, Chemoradiotherapy, Esophageal cancer, Esophagus, Radiotherapy, Quality of Life, Drug Therapy, Neoadjuvant chemoradiation, Perioperative chemotherapy},
	pages = {503},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\WEA45JGV\\Hoeppner et al. - 2016 - ESOPEC prospective randomized controlled multicen.pdf:application/pdf},
}

@article{al-batran1948,
	title = {Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma ({FLOT4}): a randomised, phase 2/3 trial},
	volume = {393},
	issn = {1474-547X},
	shorttitle = {Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma ({FLOT4})},
	doi = {10.1016/S0140-6736(18)32557-1},
	abstract = {BACKGROUND: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours.
METHODS: In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 plus either 200 mg/m2 fluorouracil as continuous intravenous infusion or 1250 mg/m2 capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin and 2600 mg/m2 fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01216644.
FINDINGS: Between Aug 8, 2010, and Feb 10, 2015, 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists. 360 patients were assigned to ECF/ECX and 356 patients to FLOT. Overall survival was increased in the FLOT group compared with the ECF/ECX group (hazard ratio [HR] 0·77; 95\% confidence interval [CI; 0.63 to 0·94]; median overall survival, 50 months [38·33 to not reached] vs 35 months [27·35 to 46·26]). The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was similar in the two groups (96 [27\%] in the ECF/ECX group vs 97 [27\%] in the FLOT group), as was the number of toxic deaths (two [{\textless}1\%] in both groups). Hospitalisation for toxicity occurred in 94 patients (26\%) in the ECF/ECX group and 89 patients (25\%) in the FLOT group.
INTERPRETATION: In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX.
FUNDING: The German Cancer Aid (Deutsche Krebshilfe), Sanofi-Aventis, Chugai, and Stiftung Leben mit Krebs Foundation.},
	language = {eng},
	number = {10184},
	journal = {Lancet},
	author = {Al-Batran, Salah-Eddin and Homann, Nils and Pauligk, Claudia and Goetze, Thorsten O. and Meiler, Johannes and Kasper, Stefan and Kopp, Hans-Georg and Mayer, Frank and Haag, Georg Martin and Luley, Kim and Lindig, Udo and Schmiegel, Wolff and Pohl, Michael and Stoehlmacher, Jan and Folprecht, Gunnar and Probst, Stephan and Prasnikar, Nicole and Fischbach, Wolfgang and Mahlberg, Rolf and Trojan, Jörg and Koenigsmann, Michael and Martens, Uwe M. and Thuss-Patience, Peter and Egger, Matthias and Block, Andreas and Heinemann, Volker and Illerhaus, Gerald and Moehler, Markus and Schenk, Michael and Kullmann, Frank and Behringer, Dirk M. and Heike, Michael and Pink, Daniel and Teschendorf, Christian and Löhr, Carmen and Bernhard, Helga and Schuch, Gunter and Rethwisch, Volker and von Weikersthal, Ludwig Fischer and Hartmann, Jörg T. and Kneba, Michael and Daum, Severin and Schulmann, Karsten and Weniger, Jörg and Belle, Sebastian and Gaiser, Timo and Oduncu, Fuat S. and Güntner, Martina and Hozaeel, Wael and Reichart, Alexander and Jäger, Elke and Kraus, Thomas and Mönig, Stefan and Bechstein, Wolf O. and Schuler, Martin and Schmalenberg, Harald and Hofheinz, Ralf D. and {FLOT4-AIO Investigators}},
	month = may,
	year = {2019},
	pmid = {30982686},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Fluorouracil, Leucovorin, Stomach Neoplasms, Adenocarcinoma, Cisplatin, Disease-Free Survival, Esophagogastric Junction, Capecitabine, Oxaliplatin, Administration, Oral, Digestive System Surgical Procedures, Docetaxel},
	pages = {1948--1957},
}

@article{macdonald725,
	title = {Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction},
	volume = {345},
	issn = {0028-4793},
	doi = {10.1056/NEJMoa010187},
	abstract = {BACKGROUND: Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
METHODS: A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart.
RESULTS: The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P{\textless}0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent.
CONCLUSIONS: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.},
	language = {eng},
	number = {10},
	journal = {N Engl J Med},
	author = {Macdonald, J. S. and Smalley, S. R. and Benedetti, J. and Hundahl, S. A. and Estes, N. C. and Stemmermann, G. N. and Haller, D. G. and Ajani, J. A. and Gunderson, L. L. and Jessup, J. M. and Martenson, J. A.},
	month = sep,
	year = {2001},
	pmid = {11547741},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Survival Rate, Aged, 80 and over, Adult, Fluorouracil, Leucovorin, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Combined Modality Therapy, Esophagogastric Junction, Gastrectomy, Lymph Node Excision, Radiation Dosage, Antimetabolites, Antineoplastic},
	pages = {725--730},
}

@article{stahl2310,
	title = {Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus},
	volume = {23},
	issn = {0732-183X},
	doi = {10.1200/JCO.2005.00.034},
	abstract = {PURPOSE: Combined chemoradiotherapy with and without surgery are widely accepted alternatives for the curative treatment of patients with locally advanced esophageal cancer. The value of adding surgery to chemotherapy and radiotherapy is unknown.
PATIENTS AND METHODS: Patients with locally advanced squamous cell carcinoma (SCC) of the esophagus were randomly allocated to either induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B). Primary outcome was overall survival time.
RESULTS: The median observation time was 6 years. The analysis of 172 eligible, randomized patients (86 patients per arm) showed overall survival to be equivalent between the two treatment groups (log-rank test for equivalence, P {\textless} .05). Local progression-free survival was better in the surgery group (2-year progression-free survival, 64.3\%; 95\% CI, 52.1\% to 76.5\%) than in the chemoradiotherapy group (2-year progression-free survival, 40.7\%; 95\% CI, 28.9\% to 52.5\%; hazard ratio [HR] for arm B v arm A, 2.1; 95\% CI, 1.3 to 3.5; P = .003). Treatment-related mortality was significantly increased in the surgery group than in the chemoradiotherapy group (12.8\% v 3.5\%, respectively; P = .03). Cox regression analysis revealed clinical tumor response to induction chemotherapy to be the single independent prognostic factor for overall survival (HR, 0.30; 95\% CI, 0.19 to 0.47; P {\textless} .0001).
CONCLUSION: Adding surgery to chemoradiotherapy improves local tumor control but does not increase survival of patients with locally advanced esophageal SCC. Tumor response to induction chemotherapy identifies a favorable prognostic group within these high-risk patients, regardless of the treatment group.},
	language = {eng},
	number = {10},
	journal = {J Clin Oncol},
	author = {Stahl, Michael and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and Walz, Martin K. and Seeber, Siegfried and Klump, Bodo and Budach, Wilfried and Teichmann, Reinhard and Schmitt, Marcus and Schmitt, Gerd and Franke, Claus and Wilke, Hansjochen},
	month = apr,
	year = {2005},
	pmid = {15800321},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Leucovorin, Survival Analysis, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Combined Modality Therapy, ChemoRT\_Surgery, Etoposide},
	pages = {2310--2317},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\A89BCRRC\\Stahl et al. - 2005 - Chemoradiation with and without surgery in patient.pdf:application/pdf},
}

@article{birkmeyer2117,
	title = {Surgeon volume and operative mortality in the {United} {States}},
	volume = {349},
	issn = {1533-4406},
	doi = {10.1056/NEJMsa035205},
	abstract = {BACKGROUND: Although the relation between hospital volume and surgical mortality is well established, for most procedures, the relative importance of the experience of the operating surgeon is uncertain.
METHODS: Using information from the national Medicare claims data base for 1998 through 1999, we examined mortality among all 474,108 patients who underwent one of eight cardiovascular procedures or cancer resections. Using nested regression models, we examined the relations between operative mortality and surgeon volume and hospital volume (each in terms of total procedures performed per year), with adjustment for characteristics of the patients and other characteristics of the providers.
RESULTS: Surgeon volume was inversely related to operative mortality for all eight procedures (P=0.003 for lung resection, P{\textless}0.001 for all other procedures). The adjusted odds ratio for operative death (for patients with a low-volume surgeon vs. those with a high-volume surgeon) varied widely according to the procedure--from 1.24 for lung resection to 3.61 for pancreatic resection. Surgeon volume accounted for a large proportion of the apparent effect of the hospital volume, to an extent that varied according to the procedure: it accounted for 100 percent of the effect for aortic-valve replacement, 57 percent for elective repair of an abdominal aortic aneurysm, 55 percent for pancreatic resection, 49 percent for coronary-artery bypass grafting, 46 percent for esophagectomy, 39 percent for cystectomy, and 24 percent for lung resection. For most procedures, the mortality rate was higher among patients of low-volume surgeons than among those of high-volume surgeons, regardless of the surgical volume of the hospital in which they practiced.
CONCLUSIONS: For many procedures, the observed associations between hospital volume and operative mortality are largely mediated by surgeon volume. Patients can often improve their chances of survival substantially, even at high-volume hospitals, by selecting surgeons who perform the operations frequently.},
	language = {eng},
	number = {22},
	journal = {N Engl J Med},
	author = {Birkmeyer, John D. and Stukel, Therese A. and Siewers, Andrea E. and Goodney, Philip P. and Wennberg, David E. and Lucas, F. Lee},
	month = nov,
	year = {2003},
	pmid = {14645640},
	keywords = {Humans, Aged, Female, Male, Neoplasms, Outcome Assessment, Health Care, Databases, Factual, United States, Logistic Models, Cardiovascular Surgical Procedures, General Surgery, Hospitals, Medicare, Surgical Procedures, Operative},
	pages = {2117--2127},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\6CFPE35V\\Birkmeyer et al. - 2003 - Surgeon volume and operative mortality in the Unit.pdf:application/pdf},
}

@article{wouters1789,
	title = {Centralization of esophageal cancer surgery: does it improve clinical outcome?},
	volume = {16},
	issn = {1534-4681},
	shorttitle = {Centralization of esophageal cancer surgery},
	doi = {10.1245/s10434-009-0458-9},
	abstract = {BACKGROUND: The volume-outcome relationship for complex surgical procedures has been extensively studied. Most studies are based on administrative data and use in-hospital mortality as the sole outcome measure. It is still unknown if concentration of these procedures leads to improvement of clinical outcome. The aim of our study was to audit the process and effect of centralizing oesophageal resections for cancer by using detailed clinical data.
METHODS: From January 1990 until December 2004, 555 esophagectomies for cancer were performed in 11 hospitals in the region of the Comprehensive Cancer Center West (CCCW); 342 patients were operated on before and 213 patients after the introduction of a centralization project. In this project patients were referred to the hospitals which showed superior outcomes in a regional audit. In this audit patient, tumor, and operative details as well as clinical outcome were compared between hospitals. The outcome of both cohorts, patients operated on before and after the start of the project, were evaluated.
RESULTS: Despite the more severe comorbidity of the patient group, outcome improved after centralizing esophageal resections. Along with a reduction in postoperative morbidity and length of stay, mortality fell from 12\% to 4\% and survival improved significantly (P = 0.001). The hospitals with the highest procedural volume showed the biggest improvement in outcome.
CONCLUSION: Volume is an important determinant of quality of care in esophageal cancer surgery. Referral of patients with esophageal cancer to surgical units with adequate experience and superior outcomes (outcome-based referral) improves quality of care.},
	language = {eng},
	number = {7},
	journal = {Ann Surg Oncol},
	author = {Wouters, M. W. J. M. and Karim-Kos, H. E. and le Cessie, S. and Wijnhoven, B. P. L. and Stassen, L. P. S. and Steup, W. H. and Tilanus, H. W. and Tollenaar, R. a. E. M.},
	month = jul,
	year = {2009},
	pmid = {19370377},
	pmcid = {PMC2695873},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Aged, 80 and over, Adult, Outcome Assessment, Health Care, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Netherlands, Barrett Esophagus, Quality of Health Care},
	pages = {1789--1798},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\4A4G43T9\\Wouters et al. - 2009 - Centralization of esophageal cancer surgery does .pdf:application/pdf},
}

@article{markar922,
	title = {Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis},
	volume = {21},
	issn = {1534-4681},
	shorttitle = {Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy},
	doi = {10.1245/s10434-013-3364-0},
	abstract = {BACKGROUND: Combined chemoradiotherapy is increasingly being used as definitive treatment for locoregional esophageal malignancy. Patients with residual or recurrent localized cancer are often selectively considered for salvage esophagectomy (SALV). The aim of this pooled analysis was to compare short-term clinical outcomes from SALV following definitive chemoradiotherapy with those from planned esophagectomy following neoadjuvant chemoradiotherapy (NCRS).
METHODS: MEDLINE, EMBASE, Cochrane, trial registries, conference proceedings and reference lists were searched for relevant comparative studies. Primary outcome measures were in-hospital mortality, anastomotic leak and pulmonary complications. Secondary outcomes were length of hospital stay, negative (R0) resection margin, and estimated blood loss.
RESULTS: Eight studies comprising 954 patients; 242 (SALV) and 712 (NCRS) were included. SALV was associated with a significantly increased incidence of post-operative mortality (9.50 vs. 4.07 \%; pooled odds ratio [POR] = 3.02; p {\textless} 0.001), anastomotic leak (23.97 vs. 14.47 \%; POR = 1.99; p = 0.005), pulmonary complications (29.75 vs. 16.99 \%; POR = 2.12; p {\textless} 0.001), and an increased length of hospital stay (weighted mean difference = 8.29 days; 95 \% CI 7.08-9.5; p {\textless} 0.001). There were no significant differences between the groups in the incidence of negative resection margins or estimated blood loss.
CONCLUSIONS: SALV has poorer short-term outcomes when compared with planned esophagectomy following neoadjuvant chemoradiotherapy. Patients and multidisciplinary tumor boards should be made aware of these differences in outcomes and SALV should be reserved for practice in high-volume institutions.},
	language = {eng},
	number = {3},
	journal = {Ann Surg Oncol},
	author = {Markar, Sheraz R. and Karthikesalingam, Alan and Penna, Marta and Low, Donald E.},
	month = mar,
	year = {2014},
	pmid = {24212722},
	keywords = {Humans, Survival Rate, Prognosis, Esophageal Neoplasms, Esophagectomy, Salvage Therapy},
	pages = {922--931},
}

@article{orringer282,
	title = {Transhiatal esophagectomy without thoracotomy for carcinoma of the thoracic esophagus},
	volume = {200},
	issn = {0003-4932},
	doi = {10.1097/00000658-198409000-00005},
	abstract = {Transhiatal esophagectomy (THE) without thoracotomy was performed in 100 patients with carcinoma of the thoracic esophagus (7 upper, 45 mid, and 48 lower third). The esophagus was replaced with stomach (96) or colon (4). Intraoperative complications included pneumothorax requiring a chest tube(s) (63) and membranous tracheal tear (2). Blood loss averaged 880 ml. Postoperative complications included transient recurrent laryngeal nerve paresis (31), anastomotic leak (5), and chylothorax (2). There were no intraoperative deaths or re-explorations for postoperative bleeding. Six hospital deaths resulted from aspiration pneumonia (2), retroperitoneal or mediastinal abscess (2), pulmonary embolus (1), and respiratory insufficiency (1). Postoperative hospitalization averaged 14 days. Actuarial survival among the 94 operative survivors is 82\% at 6 months, 52\% at 12 months, 32\% at 24 months, 22\% at 36 months, and 17\% at 48 months. Of the operative survivors, 15\% have lived 2 years or more and 10\% are clinically disease free. THE is safe, associated with a low morbidity, and achieves excellent palliation and survival at least as good as that reported in many series of transthoracic esophagectomies for esophageal carcinoma.},
	language = {eng},
	number = {3},
	journal = {Ann Surg},
	author = {Orringer, M. B.},
	month = sep,
	year = {1984},
	pmid = {6465981},
	pmcid = {PMC1250471},
	keywords = {Humans, Follow-Up Studies, Prognosis, Esophageal Neoplasms, Postoperative Complications, Chylothorax, Intraoperative Complications, Ligation, Methods, Thoracic Duct, Trachea, Vocal Cord Paralysis},
	pages = {282--288},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\J4R2GSJ3\\Orringer - 1984 - Transhiatal esophagectomy without thoracotomy for .pdf:application/pdf},
}

@article{zhang429,
	title = {Neoadjuvant chemoradiation therapy is beneficial for clinical stage {T2} {N0} esophageal cancer patients due to inaccurate preoperative staging},
	volume = {93},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22269708},
	doi = {10.1016/j.athoracsur.2011.10.061},
	number = {2},
	journal = {Ann Thorac Surg},
	author = {Zhang, J. Q. and Hooker, C. M. and Brock, M. V. and Shin, J. and Lee, S. and How, R. and Franco, N. and Prevas, H. and Hulbert, A. and Yang, S. C.},
	year = {2012},
	pmcid = {PMC4365971},
	pmid = {22269708},
	note = {tex.ids: zhang429a
type: Journal Article},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Proportional Hazards Models, Fluorouracil, Neoplasm Invasiveness, Organoplatinum Compounds, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Postoperative Complications, Lymphatic Metastasis, Radiotherapy Dosage, Diagnostic Errors, Induction Chemotherapy, Preoperative Care},
	pages = {429--35; discussion 436--7},
	file = {Accepted Version:C\:\\Users\\jcsal\\Zotero\\storage\\SJIWBSXX\\Zhang et al. - 2012 - Neoadjuvant chemoradiation therapy is beneficial f.pdf:application/pdf},
}

@article{vanhagen2074,
	title = {Preoperative chemoradiotherapy for esophageal or junctional cancer},
	volume = {366},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22646630},
	doi = {10.1056/NEJMoa1112088},
	number = {22},
	journal = {N Engl J Med},
	author = {van Hagen, P. and Hulshof, M. C. and van Lanschot, J. J. and Steyerberg, E. W. and van Berge Henegouwen, M. I. and Wijnhoven, B. P. and Richel, D. J. and Nieuwenhuijzen, G. A. and Hospers, G. A. and Bonenkamp, J. J. and Cuesta, M. A. and Blaisse, R. J. and Busch, O. R. and ten Kate, F. J. and Creemers, G. J. and Punt, C. J. and Plukker, J. T. and Verheul, H. M. and Spillenaar Bilgen, E. J. and van Dekken, H. and van der Sangen, M. J. and Rozema, T. and Biermann, K. and Beukema, J. C. and Piet, A. H. and van Rij, C. M. and Reinders, J. G. and Tilanus, H. W. and van der Gaast, A. and Group, Cross},
	year = {2012},
	note = {Type: Journal Article},
	pages = {2074--84},
}

@article{speicher1195,
	title = {Induction therapy does not improve survival for clinical stage {T2N0} esophageal cancer},
	volume = {9},
	issn = {1556-1380},
	doi = {10.1097/JTO.0000000000000228},
	abstract = {INTRODUCTION: This study compared survival after initial treatment with esophagectomy as primary therapy to induction therapy followed by esophagectomy for patients with clinical T2N0 (cT2N0) esophageal cancer in the National Cancer Database (NCDB).
METHODS: Predictors of therapy selection for patients with cT2N0 esophageal cancer in the NCDB from 1998 to 2011 were identified with multivariable logistic regression. Survival was evaluated using Kaplan-Meier and Cox proportional hazards methods.
RESULTS: Surgery was used in 42.9\% (2057 of 4799) of cT2N0 patients. Of 1599 esophagectomy patients for whom treatment timing was recorded, induction therapy was used in 44.1\% (688). Pretreatment staging was proven accurate in only 26.7\% of patients (210 of 786) who underwent initial surgery without induction treatment and had complete pathologic data available: 41.6\% (n = 327) were upstaged and 31.7\% (n = 249) were downstaged. Adjuvant therapy (chemotherapy or radiation therapy) was given to 50.2\% of patients treated initially with surgery who were found after resection to have nodal disease. There was no significant difference in long-term survival between strategies of primary surgery and induction therapy followed by surgery (median 41.1 versus 41.9 months, p = 0.51). In multivariable analysis, induction therapy was not independently associated with risk of death (hazard ratio [HR], 1.16, p = 0.32).
CONCLUSIONS: Current clinical staging for early-stage esophageal cancer is highly inaccurate, with only a quarter of surgically resected cT2N0 patients found to have had accurate pretreatment staging. Induction therapy for patients with cT2N0 esophageal cancer in the NCDB is not associated with improved survival.},
	language = {eng},
	number = {8},
	journal = {J Thorac Oncol},
	author = {Speicher, Paul J. and Ganapathi, Asvin M. and Englum, Brian R. and Hartwig, Matthew G. and Onaitis, Mark W. and D'Amico, Thomas A. and Berry, Mark F.},
	month = aug,
	year = {2014},
	pmcid = {PMC4145610},
	pmid = {25157773},
	note = {tex.ids: speicher1195a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Retrospective Studies, Survival Rate, Chemotherapy, Adjuvant, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Radiotherapy, Adjuvant},
	pages = {1195--1201},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\QJQEDGSE\\Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf:application/pdf;Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\S53GQMPN\\Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf:application/pdf},
}

@article{shapiro1090,
	title = {Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer ({CROSS}): long-term results of a randomised controlled trial},
	volume = {16},
	issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26254683},
	doi = {10.1016/S1470-2045(15)00040-6},
	number = {9},
	journal = {Lancet Oncol},
	author = {Shapiro, J. and van Lanschot, J. J. B. and Hulshof, Mccm and van Hagen, P. and van Berge Henegouwen, M. I. and Wijnhoven, B. P. L. and van Laarhoven, H. W. M. and Nieuwenhuijzen, G. A. P. and Hospers, G. A. P. and Bonenkamp, J. J. and Cuesta, M. A. and Blaisse, R. J. B. and Busch, O. R. C. and Ten Kate, F. J. W. and Creemers, G. M. and Punt, C. J. A. and Plukker, J. T. M. and Verheul, H. M. W. and Bilgen, E. J. S. and van Dekken, H. and van der Sangen, M. J. C. and Rozema, T. and Biermann, K. and Beukema, J. C. and Piet, A. H. M. and van Rij, C. M. and Reinders, J. G. and Tilanus, H. W. and Steyerberg, E. W. and van der Gaast, A. and group, Cross study},
	year = {2015},
	pmid = {26254683},
	note = {tex.ids: shapiroNeoadjuvantChemoradiotherapySurgery2015
type: Journal Article},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Disease-Free Survival, Esophageal Neoplasms, Chemoradiotherapy, Esophagogastric Junction, Paclitaxel, Carboplatin},
	pages = {1090--1098},
}

@article{shaheen2277,
	title = {Radiofrequency ablation in {Barrett}'s esophagus with dysplasia},
	volume = {360},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa0808145},
	abstract = {BACKGROUND: Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression.
METHODS: In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group) or a sham procedure (control group). Randomization was stratified according to the grade of dysplasia and the length of Barrett's esophagus. Primary outcomes at 12 months included the complete eradication of dysplasia and intestinal metaplasia.
RESULTS: In the intention-to-treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia occurred in 90.5\% of those in the ablation group, as compared with 22.7\% of those in the control group (P{\textless}0.001). Among patients with high-grade dysplasia, complete eradication occurred in 81.0\% of those in the ablation group, as compared with 19.0\% of those in the control group (P{\textless}0.001). Overall, 77.4\% of patients in the ablation group had complete eradication of intestinal metaplasia, as compared with 2.3\% of those in the control group (P{\textless}0.001). Patients in the ablation group had less disease progression (3.6\% vs. 16.3\%, P=0.03) and fewer cancers (1.2\% vs. 9.3\%, P=0.045). Patients reported having more chest pain after the ablation procedure than after the sham procedure. In the ablation group, one patient had upper gastrointestinal hemorrhage, and five patients (6.0\%) had esophageal stricture.
CONCLUSIONS: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression. (ClinicalTrials.gov number, NCT00282672.)},
	language = {eng},
	number = {22},
	journal = {N Engl J Med},
	author = {Shaheen, Nicholas J. and Sharma, Prateek and Overholt, Bergein F. and Wolfsen, Herbert C. and Sampliner, Richard E. and Wang, Kenneth K. and Galanko, Joseph A. and Bronner, Mary P. and Goldblum, John R. and Bennett, Ana E. and Jobe, Blair A. and Eisen, Glenn M. and Fennerty, M. Brian and Hunter, John G. and Fleischer, David E. and Sharma, Virender K. and Hawes, Robert H. and Hoffman, Brenda J. and Rothstein, Richard I. and Gordon, Stuart R. and Mashimo, Hiroshi and Chang, Kenneth J. and Muthusamy, V. Raman and Edmundowicz, Steven A. and Spechler, Stuart J. and Siddiqui, Ali A. and Souza, Rhonda F. and Infantolino, Anthony and Falk, Gary W. and Kimmey, Michael B. and Madanick, Ryan D. and Chak, Amitabh and Lightdale, Charles J.},
	month = may,
	year = {2009},
	pmid = {19474425},
	note = {tex.ids: shaheen2277a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Disease Progression, Aged, 80 and over, Esophagus, Logistic Models, Barrett Esophagus, Catheter Ablation, Metaplasia},
	pages = {2277--2288},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\XSBVNK7Y\\Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf:application/pdf;Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\K5YB5ZII\\Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf:application/pdf},
}

@article{phoa1209,
	title = {Radiofrequency ablation vs endoscopic surveillance for patients with {Barrett} esophagus and low-grade dysplasia: a randomized clinical trial},
	volume = {311},
	issn = {1538-3598},
	shorttitle = {Radiofrequency ablation vs endoscopic surveillance for patients with {Barrett} esophagus and low-grade dysplasia},
	doi = {10.1001/jama.2014.2511},
	abstract = {IMPORTANCE: Barrett esophagus containing low-grade dysplasia is associated with an increased risk of developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the western world.
OBJECTIVE: To investigate whether endoscopic radiofrequency ablation could decrease the rate of neoplastic progression.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial that enrolled 136 patients with a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia at 9 European sites between June 2007 and June 2011. Patient follow-up ended May 2013.
INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to either endoscopic treatment with radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with the balloon device for circumferential ablation of the esophagus or the focal device for targeted ablation, with a maximum of 5 sessions allowed.
MAIN OUTCOMES AND MEASURES: The primary outcome was neoplastic progression to high-grade dysplasia or adenocarcinoma during a 3-year follow-up since randomization. Secondary outcomes were complete eradication of dysplasia and intestinal metaplasia and adverse events.
RESULTS: Sixty-eight patients were randomized to receive ablation and 68 to receive control. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0\% (1.5\% for ablation vs 26.5\% for control; 95\% CI, 14.1\%-35.9\%; P {\textless} .001) and the risk of progression to adenocarcinoma by 7.4\% (1.5\% for ablation vs 8.8\% for control; 95\% CI, 0\%-14.7\%; P = .03). Among patients in the ablation group, complete eradication occurred in 92.6\% for dysplasia and 88.2\% for intestinal metaplasia compared with 27.9\% for dysplasia and 0.0\% for intestinal metaplasia among patients in the control group (P {\textless} .001). Treatment-related adverse events occurred in 19.1\% of patients receiving ablation (P {\textless} .001). The most common adverse event was stricture, occurring in 8 patients receiving ablation (11.8\%), all resolved by endoscopic dilation (median, 1 session). The data and safety monitoring board recommended early termination of the trial due to superiority of ablation for the primary outcome and the potential for patient safety issues if the trial continued.
CONCLUSIONS AND RELEVANCE: In this randomized trial of patients with Barrett esophagus and a confirmed diagnosis of low-grade dysplasia, radiofrequency ablation resulted in a reduced risk of neoplastic progression over 3 years of follow-up.
TRIAL REGISTRATION: trialregister.nl Identifier: NTR1198.},
	language = {eng},
	number = {12},
	journal = {JAMA},
	author = {Phoa, K. Nadine and van Vilsteren, Frederike G. I. and Weusten, Bas L. A. M. and Bisschops, Raf and Schoon, Erik J. and Ragunath, Krish and Fullarton, Grant and Di Pietro, Massimiliano and Ravi, Narayanasamy and Visser, Mike and Offerhaus, G. Johan and Seldenrijk, Cees A. and Meijer, Sybren L. and ten Kate, Fiebo J. W. and Tijssen, Jan G. P. and Bergman, Jacques J. G. H. M.},
	month = mar,
	year = {2014},
	pmid = {24668102},
	note = {tex.ids: phoa1209a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Disease Progression, Adenocarcinoma, Esophageal Neoplasms, Watchful Waiting, Esophagoscopy, Esophagus, Barrett Esophagus, Catheter Ablation},
	pages = {1209--1217},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\2MJ8Z3LW\\Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf:application/pdf;Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\XK5ED99S\\Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf:application/pdf},
}

@article{pech652,
	title = {Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus},
	volume = {146},
	issn = {1528-0012},
	doi = {10.1053/j.gastro.2013.11.006},
	abstract = {BACKGROUND \& AIMS: Barrett's esophagus-associated high-grade dysplasia is commonly treated by endoscopy. However, most guidelines offer no recommendations for endoscopic treatment of mucosal adenocarcinoma of the esophagus (mAC). We investigated the efficacy and safety of endoscopic resection in a large series of patients with mAC.
METHODS: We collected data from 1000 consecutive patients (mean age, 69.1 ± 10.7 years; 861 men) with mAC (481 with short-segment and 519 with long-segment Barrett's esophagus) who presented at a tertiary care center from October 1996 to September 2010. Patients with low-grade and high-grade dysplasia and submucosal or more advanced cancer were excluded. All patients underwent endoscopic resection of mACs. Patients found to have submucosal cancer at their first endoscopy examination were excluded from the analysis.
RESULTS: After a mean follow-up period of 56.6 ± 33.4 months, 963 patients (96.3\%) had achieved a complete response; surgery was necessary in 12 patients (3.7\%) after endoscopic therapy failed. Metachronous lesions or recurrence of cancer developed during the follow-up period in 140 patients (14.5\%) but endoscopic re-treatment was successful in 115, resulting in a long-term complete remission rate of 93.8\%; 111 died of concomitant disease and 2 of Barrett's esophagus-associated cancer. The calculated 10-year survival rate of patients who underwent endoscopic resection of mACs was 75\%. Major complications developed in 15 patients (1.5\%) but could be managed conservatively.
CONCLUSIONS: Endoscopic therapy is highly effective and safe for patients with mAC, with excellent long-term results. In an almost 5-year follow-up of 1000 patients treated with endoscopic resection, there was no mortality and less than 2\% had major complications. Endoscopic therapy should become the standard of care for patients with mAC.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Pech, Oliver and May, Andrea and Manner, Hendrik and Behrens, Angelika and Pohl, Jürgen and Weferling, Maren and Hartmann, Urs and Manner, Nicola and Huijsmans, Josephus and Gossner, Liebwin and Rabenstein, Thomas and Vieth, Michael and Stolte, Manfred and Ell, Christian},
	month = mar,
	year = {2014},
	pmid = {24269290},
	note = {tex.ids: pechLongtermEfficacySafety2014},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Retrospective Studies, Prospective Studies, Survival Rate, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Incidence, Esophagus, Mucous Membrane, Endoscopic Mucosal Resection, Endoscopy, Barrett’s Esophagus, Esophageal Cancer, Local, Neoplasm Recurrence, T1},
	pages = {652--660.e1},
}

@article{penniment114,
	title = {Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial ({TROG} 03.01)},
	volume = {3},
	issn = {2468-1253},
	shorttitle = {Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer},
	doi = {10.1016/S2468-1253(17)30363-1},
	abstract = {BACKGROUND: A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. We compared chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.
METHODS: This multicentre randomised controlled trial included patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) through a computer-generated adaptive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zealand, and the UK. Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological and renal function. Patients were stratified by hospital, dysphagia score (Mellow scale 1-4), and presence of metastases. The radiotherapy dose was 35 Gy in 15 fractions over 3 weeks for patients in Australia and New Zealand and 30 Gy in ten fractions over 2 weeks for patients in Canada and the UK. Chemotherapy consisted of one cycle of intravenous cisplatin (either 80 mg/m2 on day 1 or 20 mg/m2 per day on days 1-4 of radiotherapy at clinician's discretion) and intravenous fluorouracil 800 mg/m2 per day on days 1-4 of radiotherapy in week 1. Patients were assessed weekly during treatment. The primary endpoint was dysphagia relief (defined as ≥1 point reduction on the Mellow scale at 9 weeks and maintained 4 weeks later), and key secondary endpoints were dysphagia progression-free survival (defined as a worsening of at least 1 point on the Mellow scale from baseline or best response) and overall survival. These endpoints were analysed in the intention-to-treat population. This study is registered at ClinicalTrials.gov, number NCT00193882. This trial is closed.
FINDINGS: Between July 7, 2003, and March 21, 2012, 111 patients were randomly assigned to chemoradiotherapy and 109 patients to radiotherapy. One patient in the chemoradiotherapy group was omitted from analysis because of ineligibility. 50 (45\%, 95\% CI 36-55) patients in the chemoradiotherapy group and 38 (35\%, 26-44) in the radiotherapy group obtained dysphagia relief (difference 10·6\%, 95\% CI -2 to 23; p=0·13). Median dysphagia progression-free survival was 4·1 months (95\% CI 3·5-4·8) versus 3·4 months (3·1-4·3) in the chemoradiotherapy and radiotherapy groups, respectively (p=0·58), and median overall survival was 6·9 months (95\% CI 5·1-8·3) versus 6·7 months (4·9-8·0), respectively (p=0·88). Of the 211 patients who commenced radiotherapy, grade 3-4 acute toxicity occurred in 38 (36\%) patients in the chemoradiotherapy group and in 17 (16\%) patients in the radiotherapy group (p=0·0017). Anaemia, thrombocytopenia, neutropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in patients who had chemoradiotherapy than in patients who had radiotherapy.
INTERPRETATION: Palliative chemoradiotherapy showed a modest, but not statistically significant, increase in dysphagia relief compared with radiotherapy alone, with minimal improvement in dysphagia progression-free survival and overall survival with chemoradiotherapy but at a cost of increased toxicity. A short course of radiotherapy alone should be considered a safe and well tolerated treatment for malignant dysphagia in the palliative setting.
FUNDING: National Health and Medical Research Council, Canadian Cancer Society Research Institute, Canadian Cancer Trials Group, Trans Tasman Radiation Oncology Group, and Cancer Australia.},
	language = {eng},
	number = {2},
	journal = {Lancet Gastroenterol Hepatol},
	author = {Penniment, Michael G. and De Ieso, Paolo B. and Harvey, Jennifer A. and Stephens, Sonya and Au, Heather-Jane and O'Callaghan, Christopher J. and Kneebone, Andrew and Ngan, Samuel Y. and Ward, Iain G. and Roy, Rajarshi and Smith, Jennifer G. and Nijjar, Tirath and Biagi, James J. and Mulroy, Liam A. and Wong, Rebecca and {TROG 03.01/CCTG ES.2 group}},
	month = feb,
	year = {2018},
	pmid = {29248399},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Metastasis, Palliative Care, Antineoplastic Agents, Aged, 80 and over, Fluorouracil, Survival Analysis, Cisplatin, Esophageal Neoplasms, Chemoradiotherapy, Deglutition Disorders, Radiotherapy, Intention to Treat Analysis},
	pages = {114--124},
}

@article{zhoue0132889,
	title = {Superiority of {Minimally} {Invasive} {Oesophagectomy} in {Reducing} {In}-{Hospital} {Mortality} of {Patients} with {Resectable} {Oesophageal} {Cancer}: {A} {Meta}-{Analysis}},
	volume = {10},
	issn = {1932-6203},
	shorttitle = {Superiority of {Minimally} {Invasive} {Oesophagectomy} in {Reducing} {In}-{Hospital} {Mortality} of {Patients} with {Resectable} {Oesophageal} {Cancer}},
	doi = {10.1371/journal.pone.0132889},
	abstract = {BACKGROUND: Compared with open oesophagectomy (OE), minimally invasive oesophagectomy (MIO) proves to have benefits in reducing the risk of pulmonary complications for patients with resectable oesophageal cancer. However, it is unknown whether MIO has superiority in reducing the occurrence of in-hospital mortality (IHM).
OBJECTIVE: The objective of this meta-analysis was to explore the effect of MIO vs. OE on the occurrence of in-hospital mortality (IHM).
DATA SOURCES: Sources such as Medline (through December 31, 2014), Embase (through December 31, 2014), Wiley Online Library (through December 31, 2014), and the Cochrane Library (through December 31, 2014) were searched.
STUDY SELECTION: Data of randomized and non-randomized clinical trials related to MIO versus OE were included.
INTERVENTIONS: Eligible studies were those that reported patients who underwent MIO procedure. The control group included patients undergoing conventional OE.
STUDY APPRAISAL AND SYNTHESIS METHODS: Fixed or random -effects models were used to calculate summary odds ratios (ORs) or relative risks (RRs) for quantification of associations. Heterogeneity among studies was evaluated by using Cochran's Q and I2 statistics.
RESULTS: A total of 48 studies involving 14,311 cases of resectable oesophageal cancer were included in the meta-analysis. Compared to patients undergoing OE, patients undergoing MIO had statistically reduced occurrence of IHM (OR=0.69, 95\%CI =0.55 -0.86). Patients undergoing MIO also had significantly reduced incidence of pulmonary complications (PCs) (RR=0.73, 95\%CI = 0.63-0.86), pulmonary embolism (PE) (OR=0.71, 95\%CI= 0.51-0.99) and arrhythmia (OR=0.79, 95\%CI = 0.68-0.92). Non-significant reductions were observed among the included studies in the occurrence of anastomotic leak (AL) (OR=0.93, 95\%CI =0.78-1.11), or Gastric Tip Necrosis (GTN) (OR=0.89, 95\%CI =0.54-1.49).
LIMITATION: Most of the included studies were non-randomized case-control studies, with a diversity of study designs, demographics of participants and surgical intervention.
CONCLUSIONS: Minimally invasive oesophagectomy (MIO) has superiority over open oesophagectomy (OE) in terms of the occurrence of in-hospital mortality (IHM) and should be the first-choice surgical procedure in esophageal surgery.},
	language = {eng},
	number = {7},
	journal = {PLoS One},
	author = {Zhou, Can and Zhang, Li and Wang, Hua and Ma, Xiaoxia and Shi, Bohui and Chen, Wuke and He, Jianjun and Wang, Ke and Liu, Peijun and Ren, Yu},
	year = {2015},
	pmid = {26196135},
	pmcid = {PMC4509855},
	keywords = {Humans, Treatment Outcome, Risk, Esophageal Neoplasms, Esophagectomy, Esophagus, Anastomotic Leak, Hospital Mortality, Arrhythmias, Cardiac, Clinical Trials as Topic, Minimally Invasive Surgical Procedures, Necrosis, Odds Ratio},
	pages = {e0132889},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\NN3TAP3B\\Zhou et al. - 2015 - Superiority of Minimally Invasive Oesophagectomy i.pdf:application/pdf},
}

@article{ychou1715,
	title = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an {FNCLCC} and {FFCD} multicenter phase {III} trial},
	volume = {29},
	issn = {1527-7755},
	shorttitle = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma},
	doi = {10.1200/JCO.2010.33.0597},
	abstract = {PURPOSE: After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma.
PATIENTS AND METHODS: Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS.
RESULTS: Compared with the S group, the CS group had a better OS (5-year rate 38\% v 24\%; hazard ratio [HR] for death: 0.69; 95\% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34\% v 19\%; HR, 0.65; 95\% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P {\textless} .01). Perioperative chemotherapy significantly improved the curative resection rate (84\% v 73\%; P = .04). Grade 3 to 4 toxicity occurred in 38\% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups.
CONCLUSION: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.},
	language = {eng},
	number = {13},
	journal = {J Clin Oncol},
	author = {Ychou, Marc and Boige, Valérie and Pignon, Jean-Pierre and Conroy, Thierry and Bouché, Olivier and Lebreton, Gilles and Ducourtieux, Muriel and Bedenne, Laurent and Fabre, Jean-Michel and Saint-Aubert, Bernard and Genève, Jean and Lasser, Philippe and Rougier, Philippe},
	month = may,
	year = {2011},
	pmid = {21444866},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Drug Administration Schedule, Fluorouracil, Stomach Neoplasms, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Combined Modality Therapy, Esophagogastric Junction, Perioperative Period},
	pages = {1715--1721},
}

@article{visbal1803,
	title = {Ivor {Lewis} esophagogastrectomy for esophageal cancer},
	volume = {71},
	issn = {0003-4975},
	doi = {10.1016/s0003-4975(01)02601-7},
	abstract = {BACKGROUND: To examine the efficacy of the Ivor Lewis esophagogastrectomy for esophageal carcinoma prior to the widespread use of preoperative chemotherapy and irradiation, we reviewed our experience.
METHODS: We reexamined the cases of 220 consecutive patients who underwent an Ivor Lewis esophagogastrectomy for esophageal cancer from January 1992 through December 1995.
RESULTS: There were 196 men (89.1\%) and 24 women. Median age was 65 years (range, 29 to 85 years). The results of pathological study showed adenocarcinoma in 188 patients (85.5\%), squamous cell carcinoma in 31 (14.1\%), and leiomyosarcoma in 1 patient (0.5\%). Postsurgical staging was as follows: stage 0 in 10 patients, stage I in 19, stage IIa in 38, stage IIb in 28, stage III in 111, and stage IV in 14. The operative mortality rate was 1.4\% (3 patients), and complications occurred in 83 patients (37.7\%). Follow-up was 98.6\% complete. Median survival for operative survivors was 1.9 years (range, 32 days to 8.7 years). The overall 5-year survival rate was 25.2\%; it was 80\% for patients in stage 0, 94.4\% for those in stage I, 36.0\% for those in stage IIa, 14.3\% for patients in stage IIb, 10\% for those in stage III and 0\% for patients in stage IV.
CONCLUSIONS: Ivor Lewis esophagogastrectomy for esophageal cancer is a safe operation. Long-term survival is stage dependent. The low survival associated with advanced cancers should stimulate the search for effective neoadjuvant therapy.},
	language = {eng},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Visbal, A. L. and Allen, M. S. and Miller, D. L. and Deschamps, C. and Trastek, V. F. and Pairolero, P. C.},
	month = jun,
	year = {2001},
	pmid = {11426751},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Survival Rate, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Gastrectomy},
	pages = {1803--1808},
}

@article{sjoquist681,
	title = {Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis},
	volume = {12},
	issn = {1474-5488},
	shorttitle = {Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma},
	doi = {10.1016/S1470-2045(11)70142-5},
	abstract = {BACKGROUND: In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy.
METHODS: To identify additional studies and published abstracts from major scientific meetings, we searched Medline, Embase, and Central (Cochrane clinical trials database) for studies published since January, 2006, and also manually searched for abstracts from major conferences from the same period. Only randomised studies analysed by intention to treat were included, and searches were restricted to those databases citing articles in English. We used published hazard ratios (HRs) if available or estimates from other survival data. We also investigated treatment effects by tumour histology and relations between risk (survival after surgery alone) and effect size.
FINDINGS: We included all 17 trials from the previous meta-analysis and seven further studies. 12 were randomised comparisons of neoadjuvant chemoradiotherapy versus surgery alone (n=1854), nine were randomised comparisons of neoadjuvant chemotherapy versus surgery alone (n=1981), and two compared neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy (n=194) in patients with resectable oesophageal carcinoma; one factorial trial included two comparisons and was included in analyses of both neoadjuvant chemoradiotherapy (n=78) and neoadjuvant chemotherapy (n=81). The updated analysis contained 4188 patients whereas the previous publication included 2933 patients. This updated meta-analysis contains about 3500 events compared with about 2230 in the previous meta-analysis (estimated 57\% increase). The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95\% CI 0.70-0.88; p{\textless}0.0001); the HR for squamous-cell carcinoma only was 0.80 (0.68-0.93; p=0.004) and for adenocarcinoma only was 0.75 (0.59-0.95; p=0.02). The HR for all-cause mortality for neoadjuvant chemotherapy was 0.87 (0.79-0.96; p=0.005); the HR for squamous-cell carcinoma only was 0.92 (0.81-1.04; p=0.18) and for adenocarcinoma only was 0.83 (0.71-0.95; p=0.01). The HR for the overall indirect comparison of all-cause mortality for neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy was 0.88 (0.76-1.01; p=0.07).
INTERPRETATION: This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemoradiotherapy or chemotherapy over surgery alone in patients with oesophageal carcinoma. A clear advantage of neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy has not been established. These results should help inform decisions about patient management and design of future trials.
FUNDING: Cancer Australia and the NSW Cancer Institute.},
	language = {eng},
	number = {7},
	journal = {Lancet Oncol},
	author = {Sjoquist, Katrin M. and Burmeister, Bryan H. and Smithers, B. Mark and Zalcberg, John R. and Simes, R. John and Barbour, Andrew and Gebski, Val and {Australasian Gastro-Intestinal Trials Group}},
	month = jul,
	year = {2011},
	pmid = {21684205},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Follow-Up Studies, Antineoplastic Agents, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Radiotherapy, Adjuvant, Australia, Databases as Topic},
	pages = {681--692},
}

@article{pasquali481,
	title = {Survival {After} {Neoadjuvant} and {Adjuvant} {Treatments} {Compared} to {Surgery} {Alone} for {Resectable} {Esophageal} {Carcinoma}: {A} {Network} {Meta}-analysis},
	volume = {265},
	issn = {1528-1140},
	shorttitle = {Survival {After} {Neoadjuvant} and {Adjuvant} {Treatments} {Compared} to {Surgery} {Alone} for {Resectable} {Esophageal} {Carcinoma}},
	doi = {10.1097/SLA.0000000000001905},
	abstract = {OBJECTIVE: This network meta-analysis compared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the most effective approach.
SUMMARY BACKGROUND DATA: The optimal treatment for resectable esophageal cancer is unknown.
METHODS: A search for randomized controlled trials reporting on neoadjuvant and adjuvant therapies was conducted. Using a network meta-analysis, treatments were ranked based on their effectiveness for improving survival.
RESULTS: In 33 eligible randomized controlled trials, 6072 patients were randomized to receive either surgery alone (N = 2459) or neoadjuvant CT (N = 1332), RT (N = 58), and CRT (N = 1196) followed by surgery or surgery followed by adjuvant CT (N = 542), RT (N = 383), and CRT (N = 102). Twenty-one comparisons were generated. Neoadjuvant CRT followed by surgery compared with surgery alone was the only treatment to significantly improve survival [hazard ratio (HR) = 0.77, 95\% confidence interval (CI): 0.68-0.87]. When trials were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared with surgery alone showed a survival advantage (HR = 0.83, 95\% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advantage (HR = 0.87, 95\% CI 0.67-1.14). A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR = 0.77, 95\% CI 0.68-0.87).
CONCLUSIONS: This network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effective strategy in improving survival of resectable esophageal cancer. Resources should be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.},
	language = {eng},
	number = {3},
	journal = {Ann Surg},
	author = {Pasquali, Sandro and Yim, Guang and Vohra, Ravinder S. and Mocellin, Simone and Nyanhongo, Donald and Marriott, Paul and Geh, Ju Ian and Griffiths, Ewen A.},
	month = mar,
	year = {2017},
	pmid = {27429017},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Risk Assessment, Prognosis, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant, Survival Analysis, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Radiotherapy, Adjuvant, Network Meta-Analysis},
	pages = {481--491},
}

@article{orringer643,
	title = {Esophagectomy without thoracotomy},
	volume = {76},
	issn = {0022-5223},
	abstract = {Blunt esophagectomy without thoracotomy has been performed in 26 patients: four with benign disease and 22 with carcinomas involving various levels of the esophagus (10 cervicothoracic, one upper third, five middle third, and six distal third). Continuity of the alimentary tract was restored by anastomosing the pharynx or cervical esophagus either to stomach (19 patients) or to a colonic graft (seven patients). Esophageal resection and reconstruction were performed in a single stage in 25 patients, and the esophageal substitute was positioned in the posterior mediastinum in the original esophageal bed in 24 patients. There were no deaths directly related to the technique of blunt esophagectomy. Average intraoperative blood loss was 1,350 ml. for the entire group, 1,650 ml. for those requiring concomitant laryngectomy and 1,050 ml. for those undergoing esophagectomy without laryngectomy. Complications in these patients included pneumothorax (eight), transient hoarseness (five), pleural effusion (five), anastomotic leak (four), subphrenic abscess (one), and cerebrovascular accident (one). The five deaths were due to pheumonia (two), innominate artery rupture (two), and pulmonary embolus (one). Blunt esophagectomy without thoracotomy is safe and is far better tolerated physiologically than the combined transthoracic and abdominal operations more traditionally used for exophageal resection and reconstruction.},
	language = {eng},
	number = {5},
	journal = {J Thorac Cardiovasc Surg},
	author = {Orringer, M. B. and Sloan, H.},
	month = nov,
	year = {1978},
	pmid = {703369},
	keywords = {Humans, Follow-Up Studies, Adenocarcinoma, Esophageal Neoplasms, Postoperative Complications, Esophagus, Esophageal Diseases, Methods, Esophagoplasty},
	pages = {643--654},
}

@article{oppedijk385,
	title = {Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the {CROSS} trials},
	volume = {32},
	issn = {1527-7755},
	doi = {10.1200/JCO.2013.51.2186},
	abstract = {PURPOSE: To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone.
PATIENTS AND METHODS: Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin.
RESULTS: Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75\%). Of the 374 patients who underwent resection, 86\% were allocated to surgery and 92\% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58\% versus 35\% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34\% to 14\% (P {\textless} .001) and peritoneal carcinomatosis from 14\% to 4\% (P {\textless} .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35\% v 29\%; P = .025). LRR occurred in 5\% within the target volume, in 2\% in the margins, and in 6\% outside the radiation target volume. In 1\%, the exact site in relation to the target volume was unclear. Only 1\% had an isolated infield recurrence after CRT plus surgery.
CONCLUSION: Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5\%, mostly combined with outfield failures.},
	language = {eng},
	number = {5},
	journal = {J Clin Oncol},
	author = {Oppedijk, Vera and van der Gaast, Ate and van Lanschot, Jan J. B. and van Hagen, Pieter and van Os, Rob and van Rij, Caroline M. and van der Sangen, Maurice J. and Beukema, Jannet C. and Rütten, Heidi and Spruit, Patty H. and Reinders, Janny G. and Richel, Dick J. and van Berge Henegouwen, Mark I. and Hulshof, Maarten C. C. M.},
	month = feb,
	year = {2014},
	pmid = {24419108},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Time Factors, Adult, Chemotherapy, Adjuvant, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Dose Fractionation, Radiation, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Esophagogastric Junction, Paclitaxel, Gastrectomy, Multivariate Analysis, Carboplatin},
	pages = {385--391},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\M4JZC4RT\\Oppedijk et al. - 2014 - Patterns of recurrence after surgery alone versus .pdf:application/pdf},
}

@article{omloo992,
	title = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial},
	volume = {246},
	issn = {0003-4932},
	shorttitle = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus},
	doi = {10.1097/SLA.0b013e31815c4037},
	abstract = {OBJECTIVE: To determine whether extended transthoracic esophagectomy for adenocarcinoma of the mid/distal esophagus improves long-term survival.
BACKGROUND: A randomized trial was performed to compare surgical techniques. Complete 5-year survival data are now available.
METHODS: A total of 220 patients with adenocarcinoma of the distal esophagus (type I) or gastric cardia involving the distal esophagus (type II) were randomly assigned to limited transhiatal esophagectomy or to extended transthoracic esophagectomy with en bloc lymphadenectomy. Patients with peroperatively irresectable/incurable cancer were excluded from this analysis (n = 15). A total of 95 patients underwent transhiatal esophagectomy and 110 patients underwent transthoracic esophagectomy.
RESULTS: After transhiatal and transthoracic resection, 5-year survival was 34\% and 36\%, respectively (P = 0.71, per protocol analysis). In a subgroup analysis, based on the location of the primary tumor according to the resection specimen, no overall survival benefit for either surgical approach was seen in 115 patients with a type II tumor (P = 0.81). In 90 patients with a type I tumor, a survival benefit of 14\% was seen with the transthoracic approach (51\% vs. 37\%, P = 0.33). There was evidence that the treatment effect differed depending on the number of positive lymph nodes in the resection specimen (test for interaction P = 0.06). In patients (n = 55) without positive nodes locoregional disease-free survival after transhiatal esophagectomy was comparable to that after transthoracic esophagectomy (86\% and 89\%, respectively). The same was true for patients (n = 46) with more than 8 positive nodes (0\% in both groups). Patients (n = 104) with 1 to 8 positive lymph nodes in the resection specimen showed a 5-year locoregional disease-free survival advantage if operated via the transthoracic route (23\% vs. 64\%, P = 0.02).
CONCLUSION: There is no significant overall survival benefit for either approach. However, compared with limited transhiatal resection extended transthoracic esophagectomy for type I esophageal adenocarcinoma shows an ongoing trend towards better 5-year survival. Moreover, patients with a limited number of positive lymph nodes in the resection specimen seem to benefit from an extended transthoracic esophagectomy.},
	language = {eng},
	number = {6},
	journal = {Ann Surg},
	author = {Omloo, Jikke M. T. and Lagarde, Sjoerd M. and Hulscher, Jan B. F. and Reitsma, Johannes B. and Fockens, Paul and van Dekken, Herman and Ten Kate, Fiebo J. W. and Obertop, Huug and Tilanus, Hugo W. and van Lanschot, J. Jan B.},
	month = dec,
	year = {2007},
	pmid = {18043101},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Time Factors, Survival Rate, Adult, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Laparotomy, Thoracotomy},
	pages = {992--1000; discussion 1000--1001},
}

@article{mckeown259,
	title = {Total three-stage oesophagectomy for cancer of the oesophagus},
	volume = {63},
	issn = {0007-1323},
	doi = {10.1002/bjs.1800630403},
	abstract = {The technique of total three-stage oesophagectomy is described fully. Points of detail in the procedure of the abdominal, thoracic and cervical phases are emphasized. A brief note is made regarding the management of the respiratory situation at the end of the operation.},
	language = {eng},
	number = {4},
	journal = {Br J Surg},
	author = {McKeown, K. C.},
	month = apr,
	year = {1976},
	pmid = {1276657},
	keywords = {Humans, Esophageal Neoplasms, Esophagus, Stomach, Methods},
	pages = {259--262},
}

@article{mackenzie88,
	title = {National proficiency-gain curves for minimally invasive gastrointestinal cancer surgery},
	volume = {103},
	issn = {1365-2168},
	doi = {10.1002/bjs.9963},
	abstract = {BACKGROUND: Minimal access surgery for gastrointestinal cancer has short-term benefits but is associated with a proficiency-gain curve. The aim of this study was to define national proficiency-gain curves for minimal access colorectal and oesophagogastric surgery, and to determine the impact on clinical outcomes.
METHODS: All adult patients undergoing minimal access oesophageal, colonic and rectal surgery between 2002 and 2012 were identified from the Hospital Episode Statistics database. Proficiency-gain curves were created using risk-adjusted cumulative sum analysis. Change points were identified, and bootstrapping was performed with 1000 iterations to identify a confidence level. The primary outcome was 30-day mortality; secondary outcomes were 90-day mortality, reintervention, conversion and length of hospital stay.
RESULTS: Some 1696, 15 008 and 16 701 minimal access oesophageal, rectal and colonic cancer resections were performed during the study period. The change point in the proficiency-gain curve for 30-day mortality for oesophageal, rectal and colonic surgery was 19 (confidence level 98·4 per cent), 20 (99·2 per cent) and three (99·5 per cent) procedures; the mortality rate fell from 4·0 to 2·0 per cent (relative risk reduction (RRR) 0·50, P = 0·033), from 2·1 to 1·2 per cent (RRR 0·43, P {\textless} 0·001) and from 2·4 to 1·8 per cent (RRR 0·25, P = 0·058) respectively. The change point in the proficiency-gain curve for reintervention in oesophageal, rectal and colonic resection was 19 (98·1 per cent), 32 (99·5 per cent) and 26 (99·2 per cent) procedures respectively. There were also significant proficiency-gain curves for 90-day mortality, conversion and length of stay.
CONCLUSION: The introduction of minimal access gastrointestinal cancer surgery has been associated with a proficiency-gain curve for mortality and major morbidity at a national level. Unnecessary patient harm should be avoided by appropriate training and monitoring of new surgical techniques.},
	language = {eng},
	number = {1},
	journal = {Br J Surg},
	author = {Mackenzie, H. and Markar, S. R. and Askari, A. and Ni, M. and Faiz, O. and Hanna, G. B.},
	month = jan,
	year = {2016},
	pmid = {26578089},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Adult, Colectomy, Esophagectomy, Gastrectomy, Learning Curve, Digestive System Surgical Procedures, Minimally Invasive Surgical Procedures, Clinical Competence, Conversion to Open Surgery, Rectum, United Kingdom},
	pages = {88--96},
}

@article{hollis1114,
	title = {Prognostic significance of tumor length in patients receiving esophagectomy for esophageal cancer},
	volume = {116},
	issn = {1096-9098},
	doi = {10.1002/jso.24789},
	abstract = {AIMS: We investigated the prognostic value of tumor length measurements acquired both from pre-operative imaging and post-operative pathology in esophageal cancer.
METHODS: Tumor lengths were examined retrospectively for 389 esophagectomy patients with respect to Endoscopy, EUS (Endoscopic Ultrasound), CT and PET-CT, and pathology. Correlations between the measurements on the different approaches were assessed, and associations between tumor length and survival were analyzed.
RESULTS: Only the tumor lengths assessed on pathology were found to be significantly associated with overall (P = 0.001) and recurrence free (P {\textless} 0.001) survival on univariable analysis. The median overall survival was 47.1 months in those patients with tumor lengths {\textless}3.0 cm, falling to 19.6 and 18.0 months in those with 3.0-4.4 and 4.5+ cm tumors, respectively, demonstrating a reduction in patient survival at a tumor length of around 3 cm. Tumor length on pathology was significantly correlated with tumor differentiation and both T- and N-categories. After accounting for these factors, tumor length on pathology was a significant independent predictor of recurrence-free (P = 0.016), but not overall (P = 0.128) survival.
CONCLUSIONS: Tumor lengths on pathology were found to be the most predictive of patient outcome. However, after accounting for other tumor-related factors, tumor length only resulted in a marginal improvement in predictive accuracy.},
	language = {eng},
	number = {8},
	journal = {J Surg Oncol},
	author = {Hollis, Alexander C. and Quinn, Lauren M. and Hodson, James and Evans, Emily and Plowright, James and Begum, Ruksana and Mitchell, Harriet and Hallissey, Mike T. and Whiting, John L. and Griffiths, Ewen A.},
	month = dec,
	year = {2017},
	pmid = {28767142},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Prognosis, survival, Esophageal Neoplasms, Esophagectomy, esophageal cancer, esophagectomy, Endosonography, recurrence, tumor length},
	pages = {1114--1122},
}

@article{cunningham11,
	title = {Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer},
	volume = {355},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa055531},
	abstract = {BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer.
METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival.
RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P{\textless}0.001).
CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).},
	language = {eng},
	number = {1},
	journal = {N Engl J Med},
	author = {Cunningham, David and Allum, William H. and Stenning, Sally P. and Thompson, Jeremy N. and Van de Velde, Cornelis J. H. and Nicolson, Marianne and Scarffe, J. Howard and Lofts, Fiona J. and Falk, Stephen J. and Iveson, Timothy J. and Smith, David B. and Langley, Ruth E. and Verma, Monica and Weeden, Simon and Chua, Yu Jo and MAGIC Trial Participants, null},
	month = jul,
	year = {2006},
	pmid = {16822992},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Fluorouracil, Stomach Neoplasms, Adenocarcinoma, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Gastrectomy, Epirubicin, Perioperative Care},
	pages = {11--20},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\QRE45YL7\\Cunningham et al. - 2006 - Perioperative chemotherapy versus surgery alone fo.pdf:application/pdf},
}

@article{hulscher1662,
	title = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus},
	volume = {347},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa022343},
	abstract = {BACKGROUND: Controversy exists about the best surgical treatment for esophageal carcinoma.
METHODS: We randomly assigned 220 patients with adenocarcinoma of the mid-to-distal esophagus or adenocarcinoma of the gastric cardia involving the distal esophagus either to transhiatal esophagectomy or to transthoracic esophagectomy with extended en bloc lymphadenectomy. Principal end points were overall survival and disease-free survival. Early morbidity and mortality, the number of quality-adjusted life-years gained, and cost effectiveness were also determined.
RESULTS: A total of 106 patients were assigned to undergo transhiatal esophagectomy, and 114 to undergo transthoracic esophagectomy. Demographic characteristics and characteristics of the tumor were similar in the two groups. Perioperative morbidity was higher after transthoracic esophagectomy, but there was no significant difference in in-hospital mortality (P=0.45). After a median follow-up of 4.7 years, 142 patients had died--74 (70 percent) after transhiatal resection and 68 (60 percent) after transthoracic resection (P=0.12). Although the difference in survival was not statistically significant, there was a trend toward a survival benefit with the extended approach at five years: disease-free survival was 27 percent in the transhiatal-esophagectomy group, as compared with 39 percent in the transthoracic-esophagectomy group (95 percent confidence interval for the difference, -1 to 24 percent [the negative value indicates better survival with transhiatal resection]), whereas overall survival was 29 percent as compared with 39 percent (95 percent confidence interval for the difference, -3 to 23 percent).
CONCLUSIONS: Transhiatal esophagectomy was associated with lower morbidity than transthoracic esophagectomy with extended en bloc lymphadenectomy. Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term survival at five years with the extended transthoracic approach.},
	language = {eng},
	number = {21},
	journal = {N Engl J Med},
	author = {Hulscher, Jan B. F. and van Sandick, Johanna W. and de Boer, Angela G. E. M. and Wijnhoven, Bas P. L. and Tijssen, Jan G. P. and Fockens, Paul and Stalmeier, Peep F. M. and ten Kate, Fiebo J. W. and van Dekken, Herman and Obertop, Huug and Tilanus, Hugo W. and van Lanschot, J. Jan B.},
	month = nov,
	year = {2002},
	pmid = {12444180},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Adult, Survival Analysis, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Cost-Benefit Analysis, Health Care Costs, Quality-Adjusted Life Years},
	pages = {1662--1669},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\MBHERUZX\\Hulscher et al. - 2002 - Extended transthoracic resection compared with lim.pdf:application/pdf},
}

@article{cao751,
	title = {Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract},
	volume = {41},
	issn = {1438-8812},
	doi = {10.1055/s-0029-1215053},
	abstract = {BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) has been developed to overcome the limitations of endoscopic mucosal resection (EMR). We aimed to compare the outcomes of these two methods.
METHODS: Databases, including Pubmed, EMBASE, and The Cochrane Library, were searched to identify studies comparing ESD with EMR for premalignant and malignant lesions of the gastrointestinal tract. In a meta-analysis, primary end points were the en bloc resection rate and the curative resection rate; secondary end points were operation time, and rates of bleeding, perforation, and local recurrence.
RESULTS: 15 nonrandomized studies (seven full-text and eight abstracts) were identified. Meta-analysis showed higher en bloc and curative resection rates (odds ratio [OR] 13.87, 95 \%CI 10.12 - 18.99; OR 3.53, 95 \%CI 2.57 - 4.84) irrespective of lesion size. Subgroup analysis showed higher en bloc and curative resection rates with ESD for esophageal, gastric, and colorectal neoplasms, and for lesions of size {\textless} 10 mm, 10 mm {\textless} 20 mm, and {\textgreater} 20 mm. Local recurrence was lower with ESD (OR 0.09, 95 \%CI 0.04 - 0.18). But ESD was more time-consuming than EMR (weighted mean difference [WMD] 1.76; 95 \%CI 0.60 - 2.92), and showed high procedure-related bleeding and perforation rates (OR 2.20, 95 \%CI 1.58 - 3.07; OR 4.09, 95 \%CI 2.47 - 6.80).
CONCLUSIONS: ESD showed better en bloc and curative resection rates and local recurrence compared with EMR, but was more time-consuming and had higher rates of bleeding and perforation complications. These results need to be confirmed by high quality trials and further studies in the west.},
	language = {eng},
	number = {9},
	journal = {Endoscopy},
	author = {Cao, Y. and Liao, C. and Tan, A. and Gao, Y. and Mo, Z. and Gao, F.},
	month = sep,
	year = {2009},
	pmid = {19693750},
	keywords = {Humans, Gastrointestinal Neoplasms, Treatment Outcome, Adenocarcinoma, Neoplasm Recurrence, Local, Endoscopy, Gastrointestinal, Dissection, Electrocoagulation, Gastric Mucosa},
	pages = {751--757},
}

@article{bedenne1160,
	title = {Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: {FFCD} 9102},
	volume = {25},
	issn = {1527-7755},
	shorttitle = {Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus},
	doi = {10.1200/JCO.2005.04.7118},
	abstract = {PURPOSE: Uncontrolled studies suggest that chemoradiation has similar efficacy as surgery for esophageal cancer. Therefore, a randomized trial was carried out to compare, in responders only, chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors.
PATIENTS AND METHODS: Eligible patients had operable T3N0-1M0 thoracic esophageal cancer. Patients received two cycles of fluorouracil (FU) and cisplatin (days 1 to 5 and 22 to 26) and either conventional (46 Gy in 4.5 weeks) or split-course (15 Gy, days 1 to 5 and 22 to 26) concomitant radiotherapy. Patients with response and no contraindication to either treatment were randomly assigned to surgery (arm A) or continuation of chemoradiation (arm B; three cycles of FU/cisplatin and either conventional [20 Gy] or split-course [15 Gy] radiotherapy). Chemoradiation was considered equivalent to surgery if the difference in 2-year survival rate was less than 10\%.
RESULTS: Of 444 eligible patients, 259 were randomly assigned; 230 patients (88.8\%) had epidermoid cancer, and 29 (11.2\%) had glandular carcinoma. Two-year survival rate was 34\% in arm A versus 40\% in arm B (hazard ratio for arm B v arm A = 0.90; adjusted P = .44). Median survival time was 17.7 months in arm A compared with 19.3 months in arm B. Two-year local control rate was 66.4\% in arm A compared with 57.0\% in arm B, and stents were less required in the surgery arm (5\% in arm A v 32\% in arm B; P {\textless} .001). The 3-month mortality rate was 9.3\% in arm A compared with 0.8\% in arm B (P = .002). Cumulative hospital stay was 68 days in arm A compared with 52 days in arm B (P = .02).
CONCLUSION: Our data suggest that, in patients with locally advanced thoracic esophageal cancers, especially epidermoid, who respond to chemoradiation, there is no benefit for the addition of surgery after chemoradiation compared with the continuation of additional chemoradiation.},
	language = {eng},
	number = {10},
	journal = {J Clin Oncol},
	author = {Bedenne, Laurent and Michel, Pierre and Bouché, Olivier and Milan, Chantal and Mariette, Christophe and Conroy, Thierry and Pezet, Denis and Roullet, Bernard and Seitz, Jean-François and Herr, Jean-Philippe and Paillot, Bernard and Arveux, Patrick and Bonnetain, Franck and Binquet, Christine},
	month = apr,
	year = {2007},
	pmid = {17401004},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Esophageal Neoplasms, Combined Modality Therapy, Radiotherapy Dosage, Radiotherapy, Positron-Emission Tomography, Quality of Life},
	pages = {1160--1168},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\4U2Z558T\\Bedenne et al. - 2007 - Chemoradiation followed by surgery compared with c.pdf:application/pdf},
}

@article{bang315,
	title = {Adjuvant capecitabine and oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC}): a phase 3 open-label, randomised controlled trial},
	volume = {379},
	issn = {1474-547X},
	shorttitle = {Adjuvant capecitabine and oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC})},
	doi = {10.1016/S0140-6736(11)61873-4},
	abstract = {BACKGROUND: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with stage II-IIIB gastric cancer.
METHODS: The capecitabine and oxaliplatin adjuvant study in stomach cancer (CLASSIC) study was an open-label, parallel-group, phase 3, randomised controlled trial undertaken in 37 centres in South Korea, China, and Taiwan. Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only. Block randomisation was done by a central interactive computerised system, stratified by country and disease stage. Patients, and investigators giving interventions, assessing outcomes, and analysing data were not masked. The primary endpoint was 3 year disease-free survival, analysed by intention to treat. This study reports a prespecified interim efficacy analysis, after which the trial was stopped after a recommendation by the data monitoring committee. The trial is registered at ClinicalTrials.gov (NCT00411229).
FINDINGS: 1035 patients were randomised (520 to receive chemotherapy and surgery, 515 surgery only). Median follow-up was 34·2 months (25·4-41·7) in the chemotherapy and surgery group and 34·3 months (25·6-41·9) in the surgery only group. 3 year disease-free survival was 74\% (95\% CI 69-79) in the chemotherapy and surgery group and 59\% (53-64) in the surgery only group (hazard ratio 0·56, 95\% CI 0·44-0·72; p{\textless}0·0001). Grade 3 or 4 adverse events were reported in 279 of 496 patients (56\%) in the chemotherapy and surgery group and in 30 of 478 patients (6\%) in the surgery only group. The most common adverse events in the intervention group were nausea (n=326), neutropenia (n=300), and decreased appetite (n=294).
INTERPRETATION: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer.
FUNDING: F Hoffmann-La Roche and Sanofi-Aventis.},
	language = {eng},
	number = {9813},
	journal = {Lancet},
	author = {Bang, Yung-Jue and Kim, Young-Woo and Yang, Han-Kwang and Chung, Hyun Cheol and Park, Young-Kyu and Lee, Kyung Hee and Lee, Keun-Wook and Kim, Yong Ho and Noh, Sang-Ik and Cho, Jae Yong and Mok, Young Jae and Kim, Yeul Hong and Ji, Jiafu and Yeh, Ta-Sen and Button, Peter and Sirzén, Florin and Noh, Sung Hoon and {CLASSIC trial investigators}},
	month = jan,
	year = {2012},
	pmid = {22226517},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Chemotherapy, Adjuvant, Fluorouracil, Organoplatinum Compounds, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Capecitabine, Deoxycytidine, Gastrectomy, Oxaliplatin},
	pages = {315--321},
}

@article{guttmann1131,
	title = {Improved {Overall} {Survival} with {Aggressive} {Primary} {Tumor} {Radiotherapy} for {Patients} with {Metastatic} {Esophageal} {Cancer}},
	volume = {12},
	issn = {1556-1380},
	doi = {10.1016/j.jtho.2017.03.026},
	abstract = {OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer.
METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy ({\textless}5040 cGy), chemotherapy plus definitive dose radiotherapy (≥5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score. Potential unmeasured confounding was assessed through sensitivity analyses.
RESULTS: The final cohort consisted of 12,683 patients: 57\% were treated with chemotherapy alone, 24\% were treated with chemotherapy plus palliative dose radiotherapy, and 19\% were treated with chemotherapy plus definitive dose radiotherapy. Compared with chemotherapy alone, chemotherapy plus definitive dose radiotherapy was associated with improved survival (median overall survival of 8.3 versus 11.3 months [hazard ratio = 0.72, 95\% confidence interval: 0.70-0.74, p ≤ 0.001]), whereas chemotherapy plus palliative dose radiotherapy was associated with slightly inferior outcomes (median overall survival of 8.3 months versus 7.5 months (hazard ratio = 1.10, 95\% confidence interval 1.07-1.13, p ≤ 0.001). These findings were robust to potential unmeasured confounding in sensitivity analyses. Additionally, landmark analyses confirmed these findings in patients surviving 12 months or longer.
CONCLUSIONS: Definitive dose, but not conventional palliative dose, PTDRT is associated with improved overall survival in metastatic esophageal cancer, suggesting that local control may be important to prognosis. These findings support integrating PTDRT into future clinical trials aimed at refining personalized treatment for patients with metastatic esophageal cancer.},
	language = {eng},
	number = {7},
	journal = {J Thorac Oncol},
	author = {Guttmann, David M. and Mitra, Nandita and Bekelman, Justin and Metz, James M. and Plastaras, John and Feng, Weiwei and Swisher-McClure, Samuel},
	month = jul,
	year = {2017},
	pmid = {28461255},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Metastasis, Cohort Studies, Aged, 80 and over, Survival Analysis, Esophageal Neoplasms, Radiotherapy, Esophageal neoplasms, Neoplasm metastasis, Palliative care, Radiation},
	pages = {1131--1142},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\GJ9E6HED\\Guttmann et al. - 2017 - Improved Overall Survival with Aggressive Primary .pdf:application/pdf},
}

@article{stahl851,
	title = {Phase {III} comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction},
	volume = {27},
	issn = {1527-7755},
	doi = {10.1200/JCO.2008.17.0506},
	abstract = {PURPOSE: Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown.
PATIENTS AND METHODS: Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B). Primary outcome was overall survival time. A total of 354 patients were needed to detect a 10\% increase in 3-year survival from 25\% to 35\% by addition of radiation therapy. The study was prematurely closed due to low accrual.
RESULTS: The median observation time was 46 months. A total of 126 patients were randomly assigned and 119 eligible patients were evaluated. The number of patients undergoing complete tumor resection was not different between treatment groups (69.5\% v 71.5\%). Patients in arm B had a significant higher probability of showing pathologic complete response (15.6\% v 2.0\%) or tumor-free lymph nodes (64.4\% v 37.7\%) at resection. Preoperative radiation therapy improved 3-year survival rate from 27.7\% to 47.4\% (log-rank P = .07, hazard ratio adjusted for randomization strata variables 0.67, 95\% CI, 0.41 to 1.07). Postoperative mortality was nonsignificantly increased in the chemoradiotherapy group (10.2\% v 3.8\%; P = .26).
CONCLUSION: Although the study was closed early and statistical significance was not achieved, results point to a survival advantage for preoperative chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas of the esophagogastric junction.},
	language = {eng},
	number = {6},
	journal = {J Clin Oncol},
	author = {Stahl, Michael and Walz, Martin K. and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and Riera-Knorrenschild, Jorge and Langer, Peter and Engenhart-Cabillic, Rita and Bitzer, Michael and Königsrainer, Alfred and Budach, Wilfried and Wilke, Hansjochen},
	month = feb,
	year = {2009},
	pmid = {19139439},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Antineoplastic Agents, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Combined Modality Therapy, Esophagogastric Junction, Radiotherapy},
	pages = {851--856},
	file = {Submitted Version:C\:\\Users\\jcsal\\Zotero\\storage\\LY6ZPTBQ\\Stahl et al. - 2009 - Phase III comparison of preoperative chemotherapy .pdf:application/pdf},
}

@article{kim403,
	title = {Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy},
	volume = {29},
	issn = {1527-1323},
	shorttitle = {Multimodality assessment of esophageal cancer},
	doi = {10.1148/rg.292085106},
	abstract = {Esophageal cancer is a leading cause of cancer mortality worldwide. Complete resection of esophageal cancer and adjacent malignant lymph nodes is the only potentially curative treatment. Accurate preoperative staging and assessment of therapeutic response after neoadjuvant therapy are crucial in determining the most suitable therapy and avoiding inappropriate attempts at curative surgery. Computed tomography (CT) is recommended for initial imaging following confirmation of malignancy at pathologic analysis, primarily to rule out unresectable or distant metastatic disease. With the advent of multidetector CT, use of thin sections and multiplanar reformation allows more accurate staging of esophageal cancer. Endoscopic ultrasonography (US) is the best modality for determining the depth of tumor invasion and presence of regional lymph node involvement. Combined use of fine-needle aspiration and endoscopic US can improve assessment of lymph node involvement. Positron emission tomography (PET) is useful for assessment of distant metastases but is not appropriate for detecting and staging primary tumors. PET may also be helpful in restaging after neoadjuvant therapy, since it allows identification of early response to treatment and detection of interval distant metastases. Each imaging modality has its advantages and disadvantages; therefore, CT, endoscopic US, and PET should be considered complementary modalities for preoperative staging and therapeutic monitoring of patients with esophageal cancer.},
	language = {eng},
	number = {2},
	journal = {Radiographics},
	author = {Kim, Tae Jung and Kim, Hyae Young and Lee, Kyung Won and Kim, Moon Soo},
	month = apr,
	year = {2009},
	pmid = {19325056},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Prognosis, Outcome Assessment, Health Care, Esophageal Neoplasms, Positron-Emission Tomography, Endosonography, Preoperative Care},
	pages = {403--421},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\BQSG8IXG\\Kim et al. - 2009 - Multimodality assessment of esophageal cancer pre.pdf:application/pdf},
}

@article{chatterton354,
	title = {Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study},
	volume = {36},
	issn = {1619-7089},
	shorttitle = {Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer},
	doi = {10.1007/s00259-008-0959-y},
	abstract = {OBJECTIVES: The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis.
METHODS: In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis.
RESULTS: A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41\%). Significant changes in management (high or medium impact) were observed in 38\% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p {\textless} 0.05), but was not related to SUV(max).
CONCLUSION: These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.},
	language = {eng},
	number = {3},
	journal = {Eur J Nucl Med Mol Imaging},
	author = {Chatterton, B. E. and Ho Shon, I. and Baldey, A. and Lenzo, N. and Patrikeos, A. and Kelley, B. and Wong, D. and Ramshaw, J. E. and Scott, A. M.},
	month = mar,
	year = {2009},
	pmid = {18931839},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Neoplasm Staging, Prospective Studies, Prognosis, Disease-Free Survival, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Positron-Emission Tomography, Fluorine Radioisotopes},
	pages = {354--361},
}

@article{vanvliet547,
	title = {Staging investigations for oesophageal cancer: a meta-analysis},
	volume = {98},
	issn = {0007-0920},
	shorttitle = {Staging investigations for oesophageal cancer},
	doi = {10.1038/sj.bjc.6604200},
	abstract = {The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT, and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT, and FDG-PET for regional lymph node metastases were 0.80 (95\% confidence interval 0.75-0.84), 0.50 (0.41-0.60), and 0.57 (0.43-0.70), respectively, and specificities were 0.70 (0.65-0.75), 0.83 (0.77-0.89), and 0.85 (0.76-0.95), respectively. Diagnostic performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and specificity were 0.85 (0.72-0.99) and 0.96 (0.92-1.00), respectively. For abdominal lymph node metastases by CT, these values were 0.42 (0.29-0.54) and 0.93 (0.86-1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62-0.79) and 0.93 (0.89-0.97) for FDG-PET and 0.52 (0.33-0.71) and 0.91 (0.86-0.96) for CT, respectively. Diagnostic performance of FDG-PET for distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients. For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining the location(s).},
	language = {eng},
	number = {3},
	journal = {Br J Cancer},
	author = {van Vliet, E. P. M. and Heijenbrok-Kal, M. H. and Hunink, M. G. M. and Kuipers, E. J. and Siersema, P. D.},
	month = feb,
	year = {2008},
	pmid = {18212745},
	pmcid = {PMC2243147},
	keywords = {Humans, Tomography, X-Ray Computed, Neoplasm Staging, Neoplasm Metastasis, Esophageal Neoplasms, Fluorodeoxyglucose F18, Sensitivity and Specificity, Lymphatic Metastasis, Positron-Emission Tomography, Endosonography},
	pages = {547--557},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\S2GH3SWG\\van Vliet et al. - 2008 - Staging investigations for oesophageal cancer a m.pdf:application/pdf},
}

@article{markar1528,
	title = {Surgical {Proficiency} {Gain} and {Survival} {After} {Esophagectomy} for {Cancer}},
	volume = {34},
	issn = {1527-7755},
	doi = {10.1200/JCO.2015.65.2875},
	abstract = {PURPOSE: We aimed to identify the presence and length of esophagectomy proficiency gain curves in terms of short- and long-term mortality for esophageal cancer.
PATIENTS AND METHODS: Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with follow-up until 2014 were identified from a well-established, population-based, nationwide Swedish cohort study. Proficiency gain curves were created by using risk-adjusted cumulative sum analysis for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-specific mortality measures. Similarly, the proficiency gain curves for lymph node harvest, resection margin status, and reoperation incidence were assessed as performance-contributing factors to the observed changes in long-term survival.
RESULTS: Esophagectomies in 1,821 patients with esophageal cancer were conducted by 139 surgeons. The change-point in proficiency gain curve for all-cause 30-day mortality was early, at 15 cases, when mortality decreased from 7.9\% to 3.1\% (P {\textless} .001). Later change-points, which ranged from 35 to 59 cases, were observed for 1-, 3- and 5-year mortality rates, for which all-cause mortality decreased from 34.9\% to 27.7\% (P = .011), from 47.4\% to 41.5\% (P = .049), and from 31.4\% to 19.1\% (P = .009), respectively. Similar change-points were observed in disease-specific mortality at 1 and 3 years. There was a continuous increase in lymph node harvest, which did not plateau. Also, change-points were observed for resection margin with tumor involvement at 17 cases, with a reduction from 20.9\% to 15.2\% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6\% to 5.0\% (P {\textless} .001).
CONCLUSION: The gain of proficiency in esophagectomy for cancer is associated with measurable changes in short- and long-term mortality results. These findings indicate a need for structured national training and mentorship programs for esophageal cancer surgery.},
	language = {eng},
	number = {13},
	journal = {J Clin Oncol},
	author = {Markar, Sheraz R. and Mackenzie, Hugh and Lagergren, Pernilla and Hanna, George B. and Lagergren, Jesper},
	month = may,
	year = {2016},
	pmid = {26951311},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Cohort Studies, Aged, 80 and over, Adult, Young Adult, Esophageal Neoplasms, Esophagectomy, Registries, Adolescent, Sweden},
	pages = {1528--1536},
	file = {Full Text:C\:\\Users\\jcsal\\Zotero\\storage\\8BPPVD93\\Markar et al. - 2016 - Surgical Proficiency Gain and Survival After Esoph.pdf:application/pdf},
}

@article{bennettCD007334,
	title = {Surgery versus radical endotherapies for early cancer and high-grade dysplasia in {Barrett}'s oesophagus},
	volume = {5},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD007334.pub5},
	abstract = {BACKGROUND: Barrett's oesophagus is one of the most common pre-malignant lesions in the world. Currently the mainstay of therapy is surgical management of advanced cancer but this has improved the five-year survival very little since the 1980s. As a consequence, improved survival relies on early detection through endoscopic surveillance programmes. Success of this strategy relies on the fact that late-stage pre-malignant lesions or very early cancers can be cured by intervention. Currently there is considerable controversy over which method is best: that is conventional open surgery or endotherapy (techniques involving endoscopy).
OBJECTIVES: We used data from randomised controlled trials (RCTs) to examine the effectiveness of endotherapies compared with surgery in people with Barrett's oesophagus, those with early neoplasias (defined as high-grade dysplasia (HGD) and those with early cancer (defined as carcinoma in-situ, superficially invasive, early cancer or superficial cancer T-1m (T1-a) and T-1sm (T1-b)).
SEARCH METHODS: We used the Cochrane highly sensitive search strategy to identify RCTs in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, EBMR, Controlled Trials mRCT and ISRCTN, and LILACS, in July and August 2008. The searches were updated in 2009 and again in April 2012.
SELECTION CRITERIA: Types of studies: RCTs comparing endotherapies with surgery in the treatment of high-grade dysplasia or early cancer. All cellular types of cancer were included (i.e. adenocarcinomas, squamous cell carcinomas and more unusual types) but will be discussed separately.
TYPES OF PARTICIPANTS: patients of any age and either gender with a histologically confirmed diagnosis of early neoplasia (HGD and early cancer) in Barrett's or squamous lined oesophagus. Types of interventions; endotherapies (the intervention) compared with surgery (the control), all with curative intent.
DATA COLLECTION AND ANALYSIS: Reports of studies that meet the inclusion criteria for this review would have been analysed using the methods detailed in Appendix 9.
MAIN RESULTS: We did not identify any studies that met the inclusion criteria. In total we excluded 13 studies that were not RCTs but that compared surgery and endotherapies.
AUTHORS' CONCLUSIONS: This Cochrane review has indicated that there are no RCTs to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. The problems with such randomised methods are standardising surgery and endotherapies in all sites, standardising histopathology in all centres, assessing which patients are fit or unfit for surgery and making sure there are relevant outcomes for the study (i.e. long-term survival (over five or more years)) and no progression of HGD.},
	language = {eng},
	journal = {Cochrane Database Syst Rev},
	author = {Bennett, Cathy and Green, Susi and DeCaestecker, John and Almond, Max and Barr, Hugh and Bhandari, Pradeep and Ragunath, Krish and Singh, Rajvinder and Jankowski, Janusz},
	month = may,
	year = {2020},
	pmid = {32442322},
	pmcid = {PMC7390331},
	keywords = {Humans, Esophageal Neoplasms, Esophagoscopy, Barrett Esophagus, Precancerous Conditions},
	pages = {CD007334},
}

@article{pech1200,
	title = {Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in {Barrett}'s oesophagus},
	volume = {57},
	issn = {1468-3288},
	doi = {10.1136/gut.2007.142539},
	abstract = {OBJECTIVE: Endoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus. This report provides 5 year follow-up data from a large prospective study investigating the efficacy and safety of endoscopic treatment in these patients and analysing risk factors for recurrence.
DESIGN: Prospective case series.
SETTING: Academic tertiary care centre.
PATIENTS: Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia. Patients with submucosal or more advanced cancer were excluded.
INTERVENTIONS: Endoscopic therapy.
MAIN OUTCOME MEASURES: Rate of complete remission and recurrence rate, tumour-associated death.
RESULTS: Endoscopic resection was performed in 279 patients, photodynamic therapy in 55, and both procedures in 13; two patients received argon plasma coagulation. The mean follow-up period was 63.6 (SD 23.1) months. Complete response (CR) was achieved in 337 patients (96.6\%); surgery was necessary in 13 (3.7\%) after endoscopic therapy failed. Metachronous lesions developed during the follow-up in 74 patients (21.5\%); 56 died of concomitant disease, but none died of BC. The calculated 5 year survival rate was 84\%. The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved {\textgreater}10 months and multifocal neoplasia.
CONCLUSIONS: This study showed that endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. The risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.},
	language = {eng},
	number = {9},
	journal = {Gut},
	author = {Pech, O. and Behrens, A. and May, A. and Nachbar, L. and Gossner, L. and Rabenstein, T. and Manner, H. and Guenter, E. and Huijsmans, J. and Vieth, M. and Stolte, M. and Ell, C.},
	month = sep,
	year = {2008},
	pmid = {18460553},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagoscopy, Barrett Esophagus, Precancerous Conditions, Carcinoma in Situ, Epidemiologic Methods},
	pages = {1200--1206},
}

@article{crabtree1509,
	title = {Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival},
	volume = {91},
	issn = {1552-6259},
	shorttitle = {Endoscopic ultrasound for early stage esophageal adenocarcinoma},
	doi = {10.1016/j.athoracsur.2011.01.063},
	abstract = {BACKGROUND: Patients often receive induction therapy based on endoscopic ultrasound (EUS)-identified nodal spread (N1) or deep tumor invasion (T3), although controversy exists regarding the role of induction therapy for early stage disease. We aim to evaluate the reliability of EUS in identifying early stage disease and the subsequent impact on treatment and outcomes.
METHODS: We retrospectively studied 149 patients who underwent EUS and esophagectomy for adenocarcinoma between January 2000 and December 2008. Computed tomography (CT) was performed in all patients, whereas positron emission tomography (PET) was performed in 91\%. Clinical stage (c), pathologic stage (p), operative mortality, and survival were recorded.
RESULTS: Unanticipated pathologic nodal disease was similar in patients with cT1N0 and cT2N0 tumors (6/25 [24\%] versus 7/18 [38.8\%]; p=0.6). Among the 18 cases of cT2N0 disease, 9 (50\%) were pathologically staged as T1N0, 8 (44\%) were upstaged to pT3N0-1, and 1 (6\%) was pT2N0. One case of cT1N0 tumor (4\%) was upstaged to pT3N0. Among patients with cT1-2N0 tumors, 5-year disease-free survival for the group that was appropriately staged was 89.8\% versus 39.9\% for the group that had a higher pathologic stage than their clinical stage (ie, {\textgreater}T2N0) (p{\textless}0.001). Operative mortality for patients with cT1-2N0 tumors was 0/43 (0\%), which was no different from that in the higher clinical stage groups with (1/37, 2.7\%) or without (2/68, 2.9\%) induction therapy (p=0.5). Multivariate analysis identified marked/intense uptake on staging PET (odds ratio, 5.76, 95\%; confidence interval, 1.25 to 26.52; p=0.021) to be a factor predictive of upstaging of cT1-2N0 tumors.
CONCLUSIONS: Current staging techniques are inadequate for predicting T1-2N0 disease in esophageal adenocarcinoma. Survival is excellent with operation alone in patients with tumors appropriately staged as T1-2N0, although patients with tumors upstaged to greater than T2N0 have significantly worse survival. Other preoperative factors such as PET uptake may help select patients with cT1-2N0 tumors that will be upstaged at resection.},
	language = {eng},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {Crabtree, Traves D. and Yacoub, Wael N. and Puri, Varun and Azar, Riad and Zoole, Jennifer Bell and Patterson, G. Alexander and Krupnick, A. Sasha and Kreisel, Daniel and Meyers, Bryan F.},
	month = may,
	year = {2011},
	pmid = {21435632},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Assessment, Cohort Studies, Neoplasm Invasiveness, Survival Analysis, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Biopsy, Needle, Immunohistochemistry, Multivariate Analysis, Positron-Emission Tomography, Endosonography, Hospital Mortality, Odds Ratio, Confidence Intervals, Diagnostic Imaging},
	pages = {1509--1515; discussion 1515--1516},
}

@article{hardacker3739,
	title = {Treatment of clinical {T2N0M0} esophageal cancer},
	volume = {21},
	issn = {1534-4681},
	doi = {10.1245/s10434-014-3929-6},
	abstract = {BACKGROUND: Management of clinical T2N0M0 (cT2N0M0) esophageal cancer remains controversial. We reviewed our institutional experience over 21 years (1990-2011) to determine clinical staging accuracy, optimal treatment approaches, and factors predictive of survival in this patient population.
METHODS: Patients with cT2N0M0 esophageal cancer determined by endoscopic ultrasound (EUS) were identified through a prospectively collected database. Demographics, perioperative data, and outcomes were examined. Cox regression model and Kaplan-Meier plots were used for statistical survival analysis.
RESULTS: A total of 731 patients underwent esophagectomy, of whom 68 cT2N0M0 patients (9 \%) were identified. Fifty-seven patients (84 \%) had adenocarcinoma. Thirty-three patients (48.5 \%) were treated with neoadjuvant chemoradiation followed by surgery, and 35 underwent surgical resection alone. All resections except one included a transthoracic approach with two-field lymph node dissection. Thirty-day operative mortality was 2.9 \%. Only 3 patients (8.5 \%) who underwent surgery alone had T2N0M0 disease identified by pathology: the disease of 15 (42.8 \%) was found to be overstaged and 17 (48.5 \%) understaged after surgery. Understaging was more common in poorly differentiated tumors (p = 0.03). Nine patients (27.2 \%) had complete pathologic response after chemoradiotherapy. Absence of lymph node metastases (pN0) was significantly more frequent in the neoadjuvant group (29 of 33 vs. 21 of 35, p = 0.01). Median follow-up was 44.2 months. Overall 5-year survival was 50.8 \%. On multivariate analysis, adenocarcinoma (p = 0.001) and pN0 after resection (p = 0.01) were significant predictors of survival.
CONCLUSIONS: EUS was inaccurate in staging cT2N0M0 esophageal cancer in this study. Poorly differentiated tumors were more frequently understaged. Adenocarcinoma and absence of lymph node metastases (pN0) were independently predictive of long-term survival. pN0 status was significantly more common in patients undergoing neoadjuvant therapy, but long-term survival was not affected by neoadjuvant therapy. A strategy of neoadjuvant therapy followed by resection may be optimal in this group, especially in patients with disease likely to be understaged.},
	language = {eng},
	number = {12},
	journal = {Ann Surg Oncol},
	author = {Hardacker, Thomas J. and Ceppa, DuyKhanh and Okereke, Ikenna and Rieger, Karen M. and Jalal, Shadia I. and LeBlanc, Julia K. and DeWitt, John M. and Kesler, Kenneth A. and Birdas, Thomas J.},
	month = nov,
	year = {2014},
	pmid = {25047477},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Survival Rate, Prognosis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Lymph Node Excision, Radiotherapy, Endosonography},
	pages = {3739--3743},
}

@article{dolan320,
	title = {Significant understaging is seen in clinically staged {T2N0} esophageal cancer patients undergoing esophagectomy},
	volume = {29},
	issn = {1442-2050},
	doi = {10.1111/dote.12334},
	abstract = {This study aimed to determine the impact of preoperative staging on the treatment of clinical T2N0 (cT2N0) esophageal cancer patients undergoing esophagectomy. We reviewed a retrospective cohort of 27 patients treated at a single institution between 1999 and 2011. Clinical staging was performed with computed tomography, positron emission tomography, and endoscopic ultrasound. Patients were separated into two groups: neoadjuvant therapy followed by surgery (NEOSURG) and surgery alone (SURG). There were 11 patients (41\%) in the NEOSURG group and 16 patients (59\%) in the SURG group. In the NEOSURG group, three of 11 patients (27\%) had a pathological complete response and eight (73\%) were partial or nonresponders after neoadjuvant therapy. In the SURG group, nine of 16 patients (56\%) were understaged, 6 (38\%) were overstaged, and 1 (6\%) was correctly staged. In the entire cohort, despite being clinically node negative, 14 of 27 patients (52\%) had node-positive disease (5/11 [45\%] in the NEOSURG group, and 9/16 [56\%] in the SURG group). Overall survival rate was not statistically significant between the two groups (P = 0.96). Many cT2N0 patients are clinically understaged and show no preoperative evidence of node-positive disease. Consequently, neoadjuvant therapy may have a beneficial role in treatment.},
	language = {eng},
	number = {4},
	journal = {Dis Esophagus},
	author = {Dolan, J. P. and Kaur, T. and Diggs, B. S. and Luna, R. A. and Sheppard, B. C. and Schipper, P. H. and Tieu, B. H. and Bakis, G. and Vaccaro, G. M. and Holland, J. M. and Gatter, K. M. and Conroy, M. A. and Thomas, C. A. and Hunter, J. G.},
	month = may,
	year = {2016},
	pmid = {25707341},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Survival Rate, Adult, chemotherapy, United States, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Lymphatic Metastasis, Esophagoscopy, esophageal cancer, esophagectomy, Positron-Emission Tomography, neoadjuvant therapy, oesophageal cancer, Outcome and Process Assessment, Health Care, Preoperative Period, radiation therapy},
	pages = {320--325},
}

@article{markar59,
	title = {Role of neoadjuvant treatment in clinical {T2N0M0} oesophageal cancer: results from a retrospective multi-center {European} study},
	volume = {56},
	issn = {1879-0852},
	shorttitle = {Role of neoadjuvant treatment in clinical {T2N0M0} oesophageal cancer},
	doi = {10.1016/j.ejca.2015.11.024},
	abstract = {AIMS: The aims of this study were to compare short- and long-term outcomes for clinical T2N0 oesophageal cancer with analysis of (i) primary surgery (S) versus neoadjuvant therapy plus surgery (NS), (ii) squamous cell carcinoma and adenocarcinoma subsets; and (iii) neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy.
METHODS: Data were collected from 30 European centres from 2000 to 2010. Among 2944 included patients, 355 patients (12.1\%) had cT2N0 disease; 285 (S) and 70 (NS), were compared in terms of short- and long-term outcomes. Propensity score matching analyses were used to compensate for differences in baseline characteristics.
RESULTS: No significant differences between the groups were shown in terms of in hospital morbidity and mortality. Nodal disease was observed in 50\% of S-group at the time of surgery, with 20\% pN2/N3. Utilisation of neoadjuvant therapy was associated with significant tumour downstaging as reflected by increases in pT0, pN0 and pTNM stage 0 disease, this effect was further enhanced with neoadjuvant chemoradiotherapy. After adjustment on propensity score and confounding factors, for all patients and subset analysis of squamous cell and adenocarcinoma, neoadjuvant therapy had no significant effect upon survival or recurrence (overall, loco-regional, distant or mixed) compared to surgery alone. There were no significant differences between neoadjuvant chemotherapy and chemoradiotherapy in short- or long-term outcomes.
CONCLUSION: The results of this study suggest that a surgery alone treatment approach should be recommended as the primary treatment approach for cT2N0 oesophageal cancer despite 50\% of patients having nodal disease at the time of surgery.},
	language = {eng},
	journal = {Eur J Cancer},
	author = {Markar, Sheraz R. and Gronnier, Caroline and Pasquer, Arnaud and Duhamel, Alain and Beal, Hélène and Théreaux, Jérémie and Gagnière, Johan and Lebreton, Gil and Brigand, Cécile and Meunier, Bernard and Collet, Denis and Mariette, Christophe and {FREGAT working group – FRENCH – AFC}},
	month = mar,
	year = {2016},
	pmid = {26808298},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Risk Factors, Time Factors, Chemotherapy, Adjuvant, Chi-Square Distribution, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Esophageal Squamous Cell Carcinoma, Incidence, Lymphatic Metastasis, Logistic Models, Surgery, cT2N0M0, Europe, Neoadjuvant treatment, Propensity Score, Review, Survival},
	pages = {59--68},
}

@article{mellow1443,
	title = {Endoscopic laser therapy for malignancies affecting the esophagus and gastroesophageal junction. {Analysis} of technical and functional efficacy},
	volume = {145},
	issn = {0003-9926},
	abstract = {Thirty consecutive patients with far-advanced cancer affecting the esophagus and gastroesophageal junction underwent palliative endoscopic neodymium-YAG laser therapy. No patients were excluded from treatment, regardless of age, extent of disease, or performance status. Sessions were performed every other day and concluded when an endoscope could be easily passed beyond the previously obstructed area. Treatment was completed in 3.3 sessions (seven days). Luminal patency was achieved in 97\%, but did not always equate with functional success. Seventy percent (21 patients) were able to ingest all necessary calories and leave hospital for home (functional success). Reasons for discrepancy between technical success and functional success included radiation-induced pharyngeal dysphagia, anorexia, painful tumor load and debility, and treatment complications. Endoscopic laser therapy of far-advanced esophageal or gastroesophageal junction carcinoma was almost always technically feasible, with relatively low morbidity. While technical success could not always be equated with functional success, therapy was "completely" functionally successful in 70\% of patients with far-advanced disease. Poor performance status at accession correlated best with poor functional outcome.},
	language = {eng},
	number = {8},
	journal = {Arch Intern Med},
	author = {Mellow, M. H. and Pinkas, H.},
	month = aug,
	year = {1985},
	pmid = {4026476},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagogastric Junction, Deglutition Disorders, Endoscopy, Anorexia, Hematemesis, Laser Therapy, Melanoma, Tracheoesophageal Fistula},
	pages = {1443--1446},
}

@article{xuAnalysisDefinitiveChemoradiotherapy2018,
	title = {Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on {CT} in a single institutional retrospective study: {A} propensity score matching analysis},
	volume = {13},
	issn = {1748-717X},
	shorttitle = {Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on {CT} in a single institutional retrospective study},
	doi = {10.1186/s13014-018-1145-4},
	abstract = {BACKGROUND: The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear. METHOD: From January 2009 to December 2015, a survival analysis was performed to retrospectively identify the prognostic value of SCLN metastasis on survival on 751 patients with EC treated with definitive chemo-radiotherapy (dCRT). RESULTS: The median follow-up duration for living patients was 56.6 months. The median overall survival (OS) for all patients was 16.6 months. Patients with SCLN metastasis had a much poorer prognosis for OS (χ2 = 17.342, P {\textless} 0.001), distant metastasis-free survival (DMFS) (χ2 = 24.793, P {\textless} 0.001) and progression-free survival (PFS) (χ2 = 25.802, P {\textless} 0.001) than those without SCLN metastasis. The same results were found after propensity score matching. Nonetheless, the prognosis of patients with cervical or upper thoracic EC metastasis in SCLN was better than those of patients with middle or lower thoracic EC metastasis in SCLN for OS (χ2 = 4.516, P = 0.038), DMFS (χ2 = 8.326, P = 0.004) and PFS (χ2 = 6.255, P = 0.012). Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for PFS. Gender, age, middle or lower thoracic EC with SCLN metastasis, tumor diameter, tumor length, and number of lymph nodes were prognostic factors for DMFS. According to the multivariate analysis, only middle or lower thoracic EC with SCLN metastasis and number of lymph nodes were independent prognostic factors for DMFS and PFS. CONCLUSION: For patients with cervical or upper thoracic EC, metastasis in SCLN should be considered to be regional lymph nodes and treated with curative intent if the total number of lymph nodes is limited. However, for patients with middle or lower thoracic EC, metastasis should be considered to be a higher level N stage or M1 stage, and it is thus necessary to provide consolidation chemotherapy after dCRT.},
	language = {English},
	number = {1},
	journal = {Radiat Oncol},
	author = {Xu, Hong-Yao and Wu, Sheng-Xi and Luo, He-San and Chen, Chu-Yun and Lin, Lian-Xing and Huang, He-Cheng},
	month = oct,
	year = {2018},
	pmid = {30326912},
	note = {tex.pmcid: PMC6192107},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Esophageal Neoplasms, Chemoradiotherapy, Esophageal cancer, Lymphatic Metastasis, Lymph Nodes, Carcinoma, Clavicle, Definitive chemo-radiotherapy, Squamous Cell, Supra-clavicular lymph node, Tomography, X-Ray Computed},
	pages = {200},
	file = {Xu et al. - 2018 - Analysis of definitive chemo-radiotherapy for esop:C\:\\Users\\jcsal\\Zotero\\storage\\XMX7K26T\\Xu et al. - 2018 - Analysis of definitive chemo-radiotherapy for esop.pdf:application/pdf},
}

@article{wangSurvivalNeoadjuvantChemoradiotherapy2019,
	title = {Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma},
	volume = {106},
	issn = {1365-2168},
	doi = {10.1002/bjs.11004},
	abstract = {BACKGROUND: Whether there is a difference in survival after neoadjuvant chemoradiotherapy plus surgery (CRT-S) compared with definitive chemoradiotherapy (dCRT) in patients with locally advanced oesophageal squamous cell carcinoma (SCC) remains controversial. METHODS: Patients with SCC who underwent curative treatment from 2008 to 2014 were identified from the Taiwan Cancer Registry. Propensity score matching was undertaken to balance pretreatment clinical variables. Overall survival was compared between patients undergoing CRT-S or dCRT. Univariable and multivariable analyses were performed to identify prognostic factors for overall survival. RESULTS: A total of 5832 patients with clinical stage II and III oesophageal SCC receiving CRT-S (1754) or dCRT (4078) were included. After propensity score matching, each group included 1661 patients. The 3-year overall survival rate for patients treated with CRT-S was 41⋅1 per cent compared with 17⋅9 per cent for those who had dCRT (P {\textless} 0⋅001). In multivariable analysis, treatment modality was an independent prognostic factor in the overall cohort before propensity score matching: hazard ratio 0⋅45 (95 per cent c.i. 0⋅40 to 0⋅51) for CRT-S versus dCRT (P {\textless} 0⋅001). In separate analyses of patients with clinical stage II and those with stage III disease, CRT-S was associated with significantly better overall survival than dCRT. CONCLUSION: Neoadjuvant chemoradiotherapy and oesophagectomy is associated with better overall survival than dCRT in patients with stage II and III oesophageal SCC.},
	language = {English},
	number = {3},
	journal = {Br J Surg},
	author = {Wang, B.-Y. and Wu, S.-C. and Chen, H.-C. and Hung, W.-H. and Lin, C.-H. and Huang, C.-L. and Chen, H.-S.},
	month = feb,
	year = {2019},
	pmid = {30395362},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Survival Rate, Cohort Studies, Adult, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma, Propensity Score, Taiwan},
	pages = {255--262},
}

@article{noordmanImpactSurgicalApproach2018,
	title = {Impact of {Surgical} {Approach} on {Long}-{Term} {Survival} in {Esophageal} {Adenocarcinoma} {Patients} {With} or {Without} {Neoadjuvant} {Chemoradiotherapy}},
	volume = {267},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000002240},
	abstract = {OBJECTIVE: To compare overall survival in patients with esophageal adenocarcinoma who underwent transhiatal esophagectomy (THE) with limited lymphadenectomy or transthoracic esophagectomy (TTE) with extended lymphadenectomy with or without neoadjuvant chemoradiotherapy (nCRT). BACKGROUND: The application of neoadjuvant therapy might change the association between the extent of lymphadenectomy and survival in patients with esophageal adenocarcinoma. This may influence the choice of surgical approach in patients treated with nCRT. METHODS: Patients with potentially curable subcarinal esophageal adenocarcinoma treated with surgery alone or nCRT followed by surgery in 7 centers were included. The effect of surgical approach on overall survival, differentiated by the addition or omission of nCRT, was analyzed using a multivariable Cox regression model that included well-known prognostic factors and factors that might have influenced the choice of surgical approach. RESULTS: In total, 701 patients were included, of whom 318 had TTE with extended lymphadenectomy and 383 had THE with limited lymphadenectomy. TTE had differential effects on survival (P for interaction = 0.02), with a more favorable prognostic effect in patients who were treated with surgery alone [hazard ratio (HR) = 0.77, 95\% confidence interval (CI) 0.58-1.03]. This association was statistically significant in a subgroup of patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 0.62, 95\% CI 0.43-0.90). The favorable prognostic effect of TTE over THE was absent in the nCRT and surgery group (HR = 1.16, 95\% CI 0.80-1.66) and in the subgroup of nCRT patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 1.00, 95\% CI 0.61-1.68). CONCLUSIONS: Compared to surgery alone, the addition of nCRT may reduce the need for TTE with extended lymphadenectomy to improve long-term survival in patients with esophageal adenocarcinoma.},
	language = {English},
	number = {5},
	journal = {Ann Surg},
	author = {Noordman, Bo Jan and van Klaveren, David and van Berge Henegouwen, Mark I. and Wijnhoven, Bas P. L. and Gisbertz, Suzanne S. and Lagarde, Sjoerd M. and van der Gaast, Ate and Hulshof, Maarten C. C. M. and Biermann, Katharina and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {also on behalf of the CROSS-study group}},
	month = may,
	year = {2018},
	pmid = {28350565},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Time Factors, Survival Rate, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Netherlands, Ultrasonography, Positron-Emission Tomography, Adjuvant},
	pages = {892--897},
}

@article{kalffLongTermSurvivalMinimally2020,
	title = {Long-{Term} {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Nationwide} {Propensity}-{Score} {Matched} {Analysis}},
	volume = {Publish Ahead of Print},
	issn = {1528-1140},
	shorttitle = {Long-{Term} {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000004708},
	abstract = {OBJECTIVES: This study aimed to compare long-term survival following minimally invasive esophagectomy (MIE) versus open esophagectomy (OE) for esophageal cancer using a nationwide propensity-score matched cohort. SUMMARY BACKGROUND DATA: MIE provides lower postoperative morbidity and mortality, and similar short-term oncological quality compared to OE. METHODS: Data was acquired from the Dutch Upper Gastrointestinal Cancer Audit. Patients undergoing minimally invasive or open, transthoracic or transhiatal esophagectomy for primary esophageal cancer between 2011-2015 were included. A propensity-score matching analysis for MIE versus OE was performed separately for transthoracic and transhiatal esophagectomies. RESULTS: A total of 1036 transthoracic MIE and OE patients, and 582 transhiatal MIE and OE patients were matched. Long-term survival was comparable for MIE and OE for both transthoracic and transhiatal procedures (5-year overall survival: transthoracic MIE 49.2\% vs. OE 51.1\%, p 0.695; transhiatal MIE 48.4\% vs. OE 50.7\%, p 0.832). For both procedures, MIE yielded more lymph nodes (transthoracic median 21 vs. 18, p {\textless} 0.001; transhiatal 15 vs. 13, p 0.007). Post-operative morbidity was comparable after transthoracic MIE and OE (60.8\% vs. 64.9\%, p 0.177), with a reduced length of stay after transthoracic MIE (median 12 vs. 15 days, p {\textless} 0.001). After transhiatal MIE, more postoperative complications (64.9\% vs. 56.4\%, p 0.034) were observed, without subsequent difference in length of stay. CONCLUSION: Long-term survival after minimally invasive esophagectomy was equivalent to open in both propensity-score matched cohorts of patients undergoing transthoracic or transhiatal esophageal resections. Transhiatal minimally invasive esophagectomy was accompanied with more post-operative morbidity. Both transthoracic and transhiatal minimally invasive esophagectomy resulted in a more extended lymphadenectomy.},
	language = {English},
	journal = {Ann Surg},
	author = {Kalff, Marianne C. and Fransen, Laura F. C. and de Groot, Eline M. and Gisbertz, Suzanne S. and Nieuwenhuijzen, Grard A. P. and Ruurda, Jelle P. and Verhoeven, Rob H. A. and Luyer, Misha D. P. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and {Dutch Upper Gastrointestinal Cancer Audit group}},
	month = dec,
	year = {2020},
	pmid = {33378310},
}

@article{noordmanDetectionResidualDisease2018,
	title = {Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer ({preSANO}): {A} prospective multicentre, diagnostic cohort study},
	volume = {19},
	issn = {1474-5488},
	shorttitle = {Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer ({preSANO})},
	doi = {10.1016/S1470-2045(18)30201-8},
	abstract = {BACKGROUND: After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have a pathological complete response of the primary tumour before surgery. Thus, the necessity of standard oesophagectomy after neoadjuvant chemoradiotherapy should be reconsidered for patients who respond sufficiently to neoadjuvant treatment. In this study, we aimed to establish the accuracy of detection of residual disease after neoadjuvant chemoradiotherapy with different diagnostic approaches, and the optimal combination of diagnostic techniques for clinical response evaluations. METHODS: The preSANO trial was a prospective, multicentre, diagnostic cohort study at six centres in the Netherlands. Eligible patients were aged 18 years or older, had histologically proven, resectable, squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric junction, and were eligible for potential curative therapy with neoadjuvant chemoradiotherapy (five weekly cycles of carboplatin [area under the curve 2 mg/mL per min] plus paclitaxel [50 mg/m2 of body-surface area] combined with 41⋅4 Gy radiotherapy in 23 fractions) followed by oesophagectomy. 4-6 weeks after completion of neoadjuvant chemoradiotherapy, patients had oesophagogastroduodenoscopy with biopsies and endoscopic ultrasonography with measurement of maximum tumour thickness. Patients with histologically proven locoregional residual disease or no-pass during endoscopy and without distant metastases underwent immediate surgical resection. In the remaining patients a second clinical response evaluation was done (PET-CT, oesophagogastroduodenoscopy with biopsies, endoscopic ultrasonography with measurement of maximum tumour thickness, and fine-needle aspiration of suspicious lymph nodes), followed by surgery 12-14 weeks after completion of neoadjuvant chemoradiotherapy. The primary endpoint was the correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens, as shown by the proportion of tumour regression grade (TRG) 3 or 4 ({\textgreater}10\% residual carcinoma in the resection specimen) residual tumours that was missed during clinical response evaluations. This study was registered with the Netherlands Trial Register (NTR4834), and has been completed. FINDINGS: Between July 22, 2013, and Dec 28, 2016, 219 patients were included, 207 of whom were included in the analyses. Eight of 26 TRG3 or TRG4 tumours (31\% [95\% CI 17-50]) were missed by endoscopy with regular biopsies and fine-needle aspiration. Four of 41 TRG3 or TRG4 tumours (10\% [95\% CI 4-23]) were missed with bite-on-bite biopsies and fine-needle aspiration. Endoscopic ultrasonography with maximum tumour thickness measurement missed TRG3 or TRG4 residual tumours in 11 of 39 patients (28\% [95\% CI 17-44]). PET-CT missed six of 41 TRG3 or TRG4 tumours (15\% [95\% CI 7-28]). PET-CT detected interval distant histologically proven metastases in 18 (9\%) of 190 patients (one squamous cell carcinoma, 17 adenocarcinomas). INTERPRETATION: After neoadjuvant chemoradiotherapy for oesophageal cancer, clinical response evaluation with endoscopic ultrasonography, bite-on-bite biopsies, and fine-needle aspiration of suspicious lymph nodes was adequate for detection of locoregional residual disease, with PET-CT for detection of interval metastases. Active surveillance with this combination of diagnostic modalities is now being assessed in a phase 3 randomised controlled trial (SANO trial; Netherlands Trial Register NTR6803). FUNDING: Dutch Cancer Society.},
	language = {English},
	number = {7},
	journal = {Lancet Oncol},
	author = {Noordman, Bo Jan and Spaander, Manon C. W. and Valkema, Roelf and Wijnhoven, Bas P. L. and van Berge Henegouwen, Mark I. and Shapiro, Joël and Biermann, Katharina and van der Gaast, Ate and van Hillegersberg, Richard and Hulshof, Maarten C. C. M. and Krishnadath, Kausilia K. and Lagarde, Sjoerd M. and Nieuwenhuijzen, Grard A. P. and Oostenbrug, Liekele E. and Siersema, Peter D. and Schoon, Erik J. and Sosef, Meindert N. and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {SANO study group}},
	month = jul,
	year = {2018},
	pmid = {29861116},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prospective Studies, Risk Assessment, Survival Rate, Prognosis, Cohort Studies, Neoplasm Invasiveness, Disease-Free Survival, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Endosonography, Area Under Curve, Biopsy, Fine-Needle, Neoplasm, Residual},
	pages = {965--974},
}

@article{jordanNutritionalTherapyPatients2018,
	title = {Nutritional {Therapy} for {Patients} with {Esophageal} {Cancer}},
	volume = {70},
	issn = {1532-7914},
	doi = {10.1080/01635581.2017.1374417},
	abstract = {Malnutrition develops in 79\% patients with esophageal cancer. Thus, these patients represent a group of cancer patients, which is the most nutritionally compromised. Dysphagia and more than 10\% loss of body weight are already present at the time of diagnosis. Treatments for esophageal cancer contribute significantly to the development of malnutrition. This paper describes the nutritional treatment of patients and nutritional strategies in patients with dysphagia and other nutritional problems that accompany the treatment of patients with esophageal cancer. Here are shown the types and methods of nutritional support, which are suitable for this group of patients. Nutritional support of patients with esophageal cancer is performed as a parallel therapeutic route.},
	language = {English},
	number = {1},
	journal = {Nutr Cancer},
	author = {Jordan, Taja and Mastnak, Denis Mlakar and Palamar, Nizra and Kozjek, Nada Rotovnik},
	month = jan,
	year = {2018},
	pmid = {29016197},
	keywords = {Body Composition, Humans, Nutrition Assessment, Esophageal Neoplasms, Esophagectomy, Deglutition Disorders, Enteral Nutrition, Nutritional Status, Dietary Supplements, Nutritional Support, Parenteral Nutrition},
	pages = {23--29},
}

@article{honmaClinicalOutcomesResectable2017,
	title = {Clinical {Outcomes} of {Resectable} {Esophageal} {Cancer} with {Supraclavicular} {Lymph} {Node} {Metastases} {Treated} with {Curative} {Intent}},
	volume = {37},
	issn = {1791-7530},
	doi = {10.21873/anticanres.11748},
	abstract = {BACKGROUND: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. PATIENTS AND METHODS: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. RESULTS: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. CONCLUSION: Over 30\% of patients with resectable M1LYM treated with curative intent achieved long-term survival.},
	language = {English},
	number = {7},
	journal = {Anticancer Res},
	author = {Honma, Yoshitaka and Hokamura, Nobukazu and Nagashima, Kengo and Sudo, Kazuki and Shoji, Hirokazu and Iwasa, Satoru and Takashima, Atsuo and Kato, Ken and Hamaguchi, Tetsuya and Boku, Narikazu and Umezawa, Rei and Ito, Yoshinori and Itami, Jun and Koyanagi, Kazuo and Igaki, Hiroyasu and Tachimori, Yuji},
	month = jul,
	year = {2017},
	pmid = {28668869},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Adult, Fluorouracil, Cisplatin, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Esophageal cancer, Lymphatic Metastasis, Lymph Nodes, 80 and over, Antimetabolites, Antineoplastic, chemoradiotherapy, supraclavicular lymph node metastases, surgery},
	pages = {3741--3749},
	file = {Honma et al. - 2017 - Clinical Outcomes of Resectable Esophageal Cancer:C\:\\Users\\jcsal\\Zotero\\storage\\WRQXFW6P\\Honma et al. - 2017 - Clinical Outcomes of Resectable Esophageal Cancer .pdf:application/pdf},
}

@article{yuen,
	title = {Long-term pharyngeal dysphagia after esophagectomy for esophageal cancer-an investigation using videofluoroscopic swallow studies},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30085000},
	doi = {10.1093/dote/doy068},
	journal = {Dis Esophagus},
	author = {Yuen, M. T. Y. and Tsang, R. K. and Wong, I. Y. H. and Chan, D. K. K. and Chan, F. S. Y. and Law, S. Y. K.},
	year = {2018},
	note = {Type: Journal Article},
}

@article{yoshida346,
	title = {Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer},
	volume = {45},
	issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24997754},
	doi = {10.1007/s00595-014-0958-5},
	number = {3},
	journal = {Surg Today},
	author = {Yoshida, N. and Baba, Y. and Watanabe, M. and Ida, S. and Ishimoto, T. and Karashima, R. and Iwagami, S. and Imamura, Y. and Sakamoto, Y. and Miyamoto, Y. and Baba, H.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {346--54},
}

@article{yi-frazier51,
	title = {A {Person}-{Focused} {Analysis} of {Resilience} {Resources} and {Coping} in {Diabetes} {Patients}},
	volume = {26},
	issn = {1532-2998 (Electronic) 1532-3005 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20526415},
	number = {1},
	journal = {Stress Health},
	author = {Yi-Frazier, J. P. and Smith, R. E. and Vitaliano, P. P. and Yi, J. C. and Mai, S. and Hillman, M. and Weinger, K.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {51--60},
}

@article{yibulayin304,
	title = {Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis},
	volume = {14},
	issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27927246},
	doi = {10.1186/s12957-016-1062-7},
	number = {1},
	journal = {World J Surg Oncol},
	author = {Yibulayin, W. and Abulizi, S. and Lv, H. and Sun, W.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {304},
}

@article{webster79,
	title = {The {Functional} {Assessment} of {Chronic} {Illness} {Therapy} ({FACIT}) {Measurement} {System}: properties, applications, and interpretation},
	volume = {1},
	issn = {1477-7525 (Electronic) 1477-7525 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/14678568},
	doi = {10.1186/1477-7525-1-79},
	journal = {Health Qual Life Outcomes},
	author = {Webster, K. and Cella, D. and Yost, K.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {79},
}

@article{weiss304,
	title = {Validation of patient and nurse short forms of the {Readiness} for {Hospital} {Discharge} {Scale} and their relationship to return to the hospital},
	volume = {49},
	issn = {1475-6773 (Electronic) 0017-9124 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23855675},
	doi = {10.1111/1475-6773.12092},
	number = {1},
	journal = {Health Serv Res},
	author = {Weiss, M. E. and Costa, L. L. and Yakusheva, O. and Bobay, K. L.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {304--17},
}

@article{weeks321,
	title = {Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial},
	volume = {287},
	issn = {0098-7484 (Print) 0098-7484 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11790211},
	number = {3},
	journal = {JAMA},
	author = {Weeks, J. C. and Nelson, H. and Gelber, S. and Sargent, D. and Schroeder, G. and Clinical Outcomes of Surgical Therapy Study, Group},
	year = {2002},
	note = {Type: Journal Article},
	pages = {321--8},
}

@article{watanabe160,
	title = {Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer},
	volume = {15},
	issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29951987},
	doi = {10.1007/s10388-018-0617-9},
	number = {3},
	journal = {Esophagus},
	author = {Watanabe, M. and Okamura, A. and Toihata, T. and Yamashita, K. and Yuda, M. and Hayami, M. and Fukudome, I. and Imamura, Y. and Mine, S.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {160--164},
}

@article{wang2053,
	title = {Validation and application of a module of the {M}. {D}. {Anderson} {Symptom} {Inventory} for measuring multiple symptoms in patients with gastrointestinal cancer (the {MDASI}-{GI})},
	volume = {116},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20166216},
	doi = {10.1002/cncr.24920},
	number = {8},
	journal = {Cancer},
	author = {Wang, X. S. and Williams, L. A. and Eng, C. and Mendoza, T. R. and Shah, N. A. and Kirkendoll, K. J. and Shah, P. K. and Trask, P. C. and Palos, G. R. and Cleeland, C. S.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {2053--63},
}

@article{watson421,
	title = {Jejunostomy at the time of esophagectomy is associated with improved short-term perioperative outcomes: analysis of the {NSQIP} database},
	volume = {11},
	issn = {2078-6891 (Print) 2078-6891 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32399282},
	doi = {10.21037/jgo.2020.02.06},
	number = {2},
	journal = {J Gastrointest Oncol},
	author = {Watson, M. and Trufan, S. and Benbow, J. H. and Gower, N. L. and Hill, J. and Salo, J. C.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {421--430},
}

@article{walston1173,
	title = {Frailty and the older man},
	volume = {83},
	issn = {0025-7125 (Print) 0025-7125 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10503059},
	number = {5},
	journal = {Med Clin North Am},
	author = {Walston, J. and Fried, L. P.},
	year = {1999},
	note = {Type: Journal Article},
	pages = {1173--94},
}

@article{wagnild165,
	title = {Development and psychometric evaluation of the {Resilience} {Scale}},
	volume = {1},
	issn = {1061-3749 (Print) 1061-3749 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7850498},
	number = {2},
	journal = {J Nurs Meas},
	author = {Wagnild, G. M. and Young, H. M.},
	year = {1993},
	note = {Type: Journal Article},
	pages = {165--78},
}

@incollection{walvekar,
	edition = {2nd edition},
	title = {Complications of {Percutaneous} {Gastrostomy}},
	booktitle = {Complications in {Head} and {Neck} {Surgery} ({Second} {Edition})},
	publisher = {Elsevier B.V.},
	author = {Walvekar, Rohan R. and Ferris, Robert L.},
	editor = {Eisele, David W. and Smith, Richard V.},
	year = {2009},
	doi = {10.1016/B978-1-4160-4220-4.X5001-9},
	note = {Type: Book Section},
}

@article{vondobelne53,
	title = {Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer},
	volume = {6},
	issn = {1879-8519 (Electronic) 1879-8500 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26725962},
	doi = {10.1016/j.prro.2015.10.015},
	number = {3},
	journal = {Pract Radiat Oncol},
	author = {von Dobeln, G. A. and Nilsson, M. and Adell, G. and Johnsen, G. and Hatlevoll, I. and Tsai, J. and Lundell, L. and Lund, M. and Lind, P.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e53--e59},
}

@article{vanveer600,
	title = {Validation of a new approach for mortality risk assessment in oesophagectomy for cancer based on age- and gender-corrected body mass index},
	volume = {48},
	issn = {1873-734X (Electronic) 1010-7940 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25564215},
	doi = {10.1093/ejcts/ezu503},
	number = {4},
	journal = {Eur J Cardiothorac Surg},
	author = {Van Veer, H. and Moons, J. and Darling, G. and Lerut, T. and Coosemans, W. and Waddell, T. and De Leyn, P. and Nafteux, P.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {600--7},
}

@article{vanheijl23,
	title = {Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer},
	volume = {17},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19830496},
	doi = {10.1245/s10434-009-0731-y},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {van Heijl, M. and Sprangers, M. A. and de Boer, A. G. and Lagarde, S. M. and Reitsma, H. B. and Busch, O. R. and Tilanus, H. W. and van Lanschot, J. J. and van Berge Henegouwen, M. I.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {23--30},
}

@article{vanblarigan218,
	title = {Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors ({Smart} {Pace}): a pilot randomized controlled trial},
	volume = {19},
	issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30866859},
	doi = {10.1186/s12885-019-5427-5},
	number = {1},
	journal = {BMC Cancer},
	author = {Van Blarigan, E. L. and Chan, H. and Van Loon, K. and Kenfield, S. A. and Chan, J. M. and Mitchell, E. and Zhang, L. and Paciorek, A. and Joseph, G. and Laffan, A. and Atreya, C. E. and Fukuoka, Y. and Miaskowski, C. and Meyerhardt, J. A. and Venook, A. P.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {218},
}

@article{tisdale301,
	title = {Amiodarone for prevention of atrial fibrillation following esophagectomy},
	volume = {158},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30853230},
	doi = {10.1016/j.jtcvs.2019.01.095},
	number = {1},
	journal = {J Thorac Cardiovasc Surg},
	author = {Tisdale, J. E. and Jaynes, H. A. and Watson, M. R. and Corya, A. L. and Shen, C. and Kesler, K. A.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {301--310 e1},
}

@article{teoh1,
	title = {Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial},
	volume = {253},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21233603},
	doi = {10.1097/SLA.0b013e3181fcd991},
	number = {1},
	journal = {Ann Surg},
	author = {Teoh, A. Y. and Yan Chiu, P. W. and Wong, T. C. and Liu, S. Y. and Hung Wong, S. K. and Ng, E. K.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {1--5},
}

@article{then55,
	title = {Esophageal {Cancer}: {An} {Updated} {Surveillance} {Epidemiology} and {End} {Results} {Database} {Analysis}},
	volume = {11},
	issn = {1920-454X (Electronic) 1920-4531 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32284773},
	doi = {10.14740/wjon1254},
	number = {2},
	journal = {World J Oncol},
	author = {Then, E. O. and Lopez, M. and Saleem, S. and Gayam, V. and Sunkara, T. and Culliford, A. and Gaduputi, V.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {55--64},
}

@article{tevis505,
	title = {Postdischarge complications are an important predictor of postoperative readmissions},
	volume = {208},
	issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25150195},
	doi = {10.1016/j.amjsurg.2014.05.013},
	number = {4},
	journal = {Am J Surg},
	author = {Tevis, S. E. and Kohlnhofer, B. M. and Weber, S. M. and Kennedy, G. D.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {505--10},
}

@article{tatematsu47,
	title = {Association between physical activity and postoperative complications after esophagectomy for cancer: a prospective observational study},
	volume = {14},
	issn = {2476-762X (Electronic) 1513-7368 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23534776},
	doi = {10.7314/apjcp.2013.14.1.47},
	number = {1},
	journal = {Asian Pac J Cancer Prev},
	author = {Tatematsu, N. and Park, M. and Tanaka, E. and Sakai, Y. and Tsuboyama, T.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {47--51},
}

@article{tamura556,
	title = {Tongue thickness relates to nutritional status in the elderly},
	volume = {27},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22538556},
	doi = {10.1007/s00455-012-9407-z},
	number = {4},
	journal = {Dysphagia},
	author = {Tamura, F. and Kikutani, T. and Tohara, T. and Yoshida, M. and Yaegaki, K.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {556--61},
}

@article{taketa300,
	title = {Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation},
	volume = {83},
	issn = {1423-0232 (Electronic) 0030-2414 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22964903},
	doi = {10.1159/000341353},
	number = {5},
	journal = {Oncology},
	author = {Taketa, T. and Correa, A. M. and Suzuki, A. and Blum, M. A. and Chien, P. and Lee, J. H. and Welsh, J. and Lin, S. H. and Maru, D. M. and Erasmus, J. J. and Bhutani, M. S. and Weston, B. and Rice, D. C. and Vaporciyan, A. A. and Hofstetter, W. L. and Swisher, S. G. and Ajani, J. A.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {300--4},
}

@article{taioli377,
	title = {Quality of {Life} after {Open} or {Minimally} {Invasive} {Esophagectomy} in {Patients} {With} {Esophageal} {Cancer}-{A} {Systematic} {Review}},
	volume = {29},
	issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28939239},
	doi = {10.1053/j.semtcvs.2017.08.013},
	number = {3},
	journal = {Semin Thorac Cardiovasc Surg},
	author = {Taioli, E. and Schwartz, R. M. and Lieberman-Cribbin, W. and Moskowitz, G. and van Gerwen, M. and Flores, R.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {377--390},
}

@article{stein383,
	title = {Was {This} {Readmission} {Preventable}? {Qualitative} {Study} of {Patient} and {Provider} {Perceptions} of {Readmissions}},
	volume = {109},
	issn = {1541-8243 (Electronic) 0038-4348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27255098},
	doi = {10.14423/SMJ.0000000000000465},
	number = {6},
	journal = {South Med J},
	author = {Stein, J. and Ossman, P. and Viera, A. and Moore, C. and Brubaker, B. A. and French, J. and Liles, E. A.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {383--9},
}

@article{sun852,
	title = {Wireless {Monitoring} {Program} of {Patient}-{Centered} {Outcomes} and {Recovery} {Before} and {After} {Major} {Abdominal} {Cancer} {Surgery}},
	volume = {152},
	issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28593266},
	doi = {10.1001/jamasurg.2017.1519},
	number = {9},
	journal = {JAMA Surg},
	author = {Sun, V. and Dumitra, S. and Ruel, N. and Lee, B. and Melstrom, L. and Melstrom, K. and Woo, Y. and Sentovich, S. and Singh, G. and Fong, Y.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {852--859},
}

@article{stewart199,
	title = {A systematic review of resilience in the physically ill},
	volume = {52},
	issn = {1545-7206 (Electronic) 0033-3182 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21565591},
	doi = {10.1016/j.psym.2011.01.036},
	number = {3},
	journal = {Psychosomatics},
	author = {Stewart, D. E. and Yuen, T.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {199--209},
}

@article{steffens510,
	title = {Is preoperative physical activity level of patients undergoing cancer surgery associated with postoperative outcomes? {A} systematic review and meta-analysis},
	volume = {45},
	issn = {1532-2157 (Electronic) 0748-7983 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30910052},
	doi = {10.1016/j.ejso.2018.10.063},
	number = {4},
	journal = {Eur J Surg Oncol},
	author = {Steffens, D. and Beckenkamp, P. R. and Young, J. and Solomon, M. and da Silva, T. M. and Hancock, M. J.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {510--518},
}

@article{splaingard637,
	title = {Aspiration in rehabilitation patients: videofluoroscopy vs bedside clinical assessment},
	volume = {69},
	issn = {0003-9993 (Print) 0003-9993 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/3408337},
	number = {8},
	journal = {Arch Phys Med Rehabil},
	author = {Splaingard, M. L. and Hutchins, B. and Sulton, L. D. and Chaudhuri, G.},
	year = {1988},
	note = {Type: Journal Article},
	pages = {637--40},
}

@article{smithe74373,
	title = {Skill set or mind set? {Associations} between health literacy, patient activation and health},
	volume = {8},
	issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24023942},
	doi = {10.1371/journal.pone.0074373},
	number = {9},
	journal = {PLoS One},
	author = {Smith, S. G. and Curtis, L. M. and Wardle, J. and von Wagner, C. and Wolf, M. S.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {e74373},
}

@article{simonsen58,
	title = {Sarcopenia and {Postoperative} {Complication} {Risk} in {Gastrointestinal} {Surgical} {Oncology}: {A} {Meta}-analysis},
	volume = {268},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29373365},
	doi = {10.1097/SLA.0000000000002679},
	number = {1},
	journal = {Ann Surg},
	author = {Simonsen, C. and de Heer, P. and Bjerre, E. D. and Suetta, C. and Hojman, P. and Pedersen, B. K. and Svendsen, L. B. and Christensen, J. F.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {58--69},
}

@article{siegel7,
	title = {Cancer statistics, 2020},
	volume = {70},
	issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31912902},
	doi = {10.3322/caac.21590},
	number = {1},
	journal = {CA Cancer J Clin},
	author = {Siegel, R. L. and Miller, K. D. and Jemal, A.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {7--30},
}

@article{shaker1314,
	title = {Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal {UES} opening},
	volume = {122},
	issn = {0016-5085 (Print) 0016-5085 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11984518},
	number = {5},
	journal = {Gastroenterology},
	author = {Shaker, R. and Easterling, C. and Kern, M. and Nitschke, T. and Massey, B. and Daniels, S. and Grande, B. and Kazandjian, M. and Dikeman, K.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {1314--21},
}

@article{shewale1114,
	title = {Impact of a {Fast}-track {Esophagectomy} {Protocol} on {Esophageal} {Cancer} {Patient} {Outcomes} and {Hospital} {Charges}},
	volume = {261},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25243545},
	doi = {10.1097/SLA.0000000000000971},
	number = {6},
	journal = {Ann Surg},
	author = {Shewale, J. B. and Correa, A. M. and Baker, C. M. and Villafane-Ferriol, N. and Hofstetter, W. L. and Jordan, V. S. and Kehlet, H. and Lewis, K. M. and Mehran, R. J. and Summers, B. L. and Schaub, D. and Wilks, S. A. and Swisher, S. G. and University of Texas, M. D. Anderson Esophageal Cancer Collaborative Group},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1114--23},
}

@article{shapiro807,
	title = {Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer},
	volume = {260},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25379852},
	doi = {10.1097/SLA.0000000000000966},
	number = {5},
	journal = {Ann Surg},
	author = {Shapiro, J. and van Hagen, P. and Lingsma, H. F. and Wijnhoven, B. P. and Biermann, K. and ten Kate, F. J. and Steyerberg, E. W. and van der Gaast, A. and van Lanschot, J. J. and Group, Cross Study},
	year = {2014},
	note = {Type: Journal Article},
	pages = {807--13; discussion 813--4},
}

@article{schmidt814,
	title = {Defining {Benchmarks} for {Transthoracic} {Esophagectomy}: {A} {Multicenter} {Analysis} of {Total} {Minimally} {Invasive} {Esophagectomy} in {Low} {Risk} {Patients}},
	volume = {266},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28796646},
	doi = {10.1097/SLA.0000000000002445},
	number = {5},
	journal = {Ann Surg},
	author = {Schmidt, H. M. and Gisbertz, S. S. and Moons, J. and Rouvelas, I. and Kauppi, J. and Brown, A. and Asti, E. and Luyer, M. and Lagarde, S. M. and Berlth, F. and Philippron, A. and Bruns, C. and Holscher, A. and Schneider, P. M. and Raptis, D. A. and van Berge Henegouwen, M. I. and Nafteux, P. and Nilsson, M. and Rasanen, J. and Palazzo, F. and Rosato, E. and Mercer, S. and Bonavina, L. and Nieuwenhuijzen, G. and Wijnhoven, B. P. L. and Schroder, W. and Pattyn, P. and Grimminger, P. P. and Gutschow, C. A.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {814--821},
}

@article{seder1646,
	title = {The {Society} of {Thoracic} {Surgeons} {General} {Thoracic} {Surgery} {Database} {Update} on {Outcomes} and {Quality}},
	volume = {101},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27041451},
	doi = {10.1016/j.athoracsur.2016.02.099},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {Seder, C. W. and Wright, C. D. and Chang, A. C. and Han, J. M. and McDonald, D. and Kozower, B. D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1646--54},
}

@article{scarpa156,
	title = {Sleep disturbances and quality of life in postoperative management after esophagectomy for esophageal cancer},
	volume = {12},
	issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24886219},
	doi = {10.1186/1477-7819-12-156},
	journal = {World J Surg Oncol},
	author = {Scarpa, M. and Pinto, E. and Saadeh, L. M. and Parotto, M. and Da Roit, A. and Pizzolato, E. and Alfieri, R. and Cagol, M. and Saraceni, E. and Baratto, F. and Castoro, C.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {156},
}

@article{saxton1223,
	title = {Preoperative frailty and quality of life as predictors of postoperative complications},
	volume = {253},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21412145},
	doi = {10.1097/SLA.0b013e318214bce7},
	number = {6},
	journal = {Ann Surg},
	author = {Saxton, A. and Velanovich, V.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {1223--9},
}

@article{sato1008,
	title = {Impact of preoperative hand grip strength on morbidity following gastric cancer surgery},
	volume = {19},
	issn = {1436-3305 (Electronic) 1436-3291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26466832},
	doi = {10.1007/s10120-015-0554-4},
	number = {3},
	journal = {Gastric Cancer},
	author = {Sato, T. and Aoyama, T. and Hayashi, T. and Segami, K. and Kawabe, T. and Fujikawa, H. and Yamada, T. and Yamamoto, N. and Oshima, T. and Rino, Y. and Masuda, M. and Ogata, T. and Cho, H. and Yoshikawa, T.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1008--15},
}

@article{salo188,
	title = {{ASO} {Author} {Reflections}: {Quality} {Improvement} in {Minimally} {Invasive} {Esophagectomy}},
	volume = {26},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30478633},
	doi = {10.1245/s10434-018-7079-0},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {188--189},
}

@article{sakai241,
	title = {Tongue {Strength} is {Associated} with {Grip} {Strength} and {Nutritional} {Status} in {Older} {Adult} {Inpatients} of a {Rehabilitation} {Hospital}},
	volume = {32},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27687521},
	doi = {10.1007/s00455-016-9751-5},
	number = {2},
	journal = {Dysphagia},
	author = {Sakai, K. and Nakayama, E. and Tohara, H. and Maeda, T. and Sugimoto, M. and Takehisa, T. and Takehisa, Y. and Ueda, K.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {241--249},
}

@article{rockwood17,
	title = {Frailty defined by deficit accumulation and geriatric medicine defined by frailty},
	volume = {27},
	issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21093719},
	doi = {10.1016/j.cger.2010.08.008},
	number = {1},
	journal = {Clin Geriatr Med},
	author = {Rockwood, K. and Mitnitski, A.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {17--26},
}

@article{rutten630,
	title = {Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer},
	volume = {8},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28513088},
	doi = {10.1002/jcsm.12180},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Rutten, I. J. G. and Ubachs, J. and Kruitwagen, Rfpm and Beets-Tan, R. G. H. and Olde Damink, S. W. M. and Van Gorp, T.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {630--638},
}

@article{rosenberg337,
	title = {Sarcopenia: origins and clinical relevance},
	volume = {27},
	issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21824550},
	doi = {10.1016/j.cger.2011.03.003},
	number = {3},
	journal = {Clin Geriatr Med},
	author = {Rosenberg, I. H.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {337--9},
}

@article{rosenbek93,
	title = {A penetration-aspiration scale},
	volume = {11},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8721066},
	number = {2},
	journal = {Dysphagia},
	author = {Rosenbek, J. C. and Robbins, J. A. and Roecker, E. B. and Coyle, J. L. and Wood, J. L.},
	year = {1996},
	note = {Type: Journal Article},
	pages = {93--8},
}

@article{rice317,
	title = {{T2N0M0} esophageal cancer},
	volume = {133},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17258554},
	doi = {10.1016/j.jtcvs.2006.09.023},
	number = {2},
	journal = {J Thorac Cardiovasc Surg},
	author = {Rice, T. W. and Mason, D. P. and Murthy, S. C. and Zuccaro, G., Jr. and Adelstein, D. J. and Rybicki, L. A. and Blackstone, E. H.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {317--24},
}

@article{rice1953,
	title = {Posterior {Intercostal} {Nerve} {Block} {With} {Liposomal} {Bupivacaine}: {An} {Alternative} to {Thoracic} {Epidural} {Analgesia}},
	volume = {99},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25912739},
	doi = {10.1016/j.athoracsur.2015.02.074},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Rice, D. C. and Cata, J. P. and Mena, G. E. and Rodriguez-Restrepo, A. and Correa, A. M. and Mehran, R. J.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1953--60},
}

@article{reichert11856,
	title = {Ivor {Lewis} esophagectomy patients are particularly vulnerable to respiratory impairment - a comparison to major lung resection},
	volume = {9},
	issn = {2045-2322 (Electronic) 2045-2322 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31413282},
	doi = {10.1038/s41598-019-48234-w},
	number = {1},
	journal = {Sci Rep},
	author = {Reichert, M. and Schistek, M. and Uhle, F. and Koch, C. and Bodner, J. and Hecker, M. and Horbelt, R. and Grau, V. and Padberg, W. and Weigand, M. A. and Hecker, A.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {11856},
}

@article{redelmeier1278,
	title = {Interpreting small differences in functional status: the {Six} {Minute} {Walk} test in chronic lung disease patients},
	volume = {155},
	issn = {1073-449X (Print) 1073-449X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9105067},
	doi = {10.1164/ajrccm.155.4.9105067},
	number = {4},
	journal = {Am J Respir Crit Care Med},
	author = {Redelmeier, D. A. and Bayoumi, A. M. and Goldstein, R. S. and Guyatt, G. H.},
	year = {1997},
	note = {Type: Journal Article},
	pages = {1278--82},
}

@article{raymond207,
	title = {Predictors of {Major} {Morbidity} or {Mortality} {After} {Resection} for {Esophageal} {Cancer}: {A} {Society} of {Thoracic} {Surgeons} {General} {Thoracic} {Surgery} {Database} {Risk} {Adjustment} {Model}},
	volume = {102},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27240449},
	doi = {10.1016/j.athoracsur.2016.04.055},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Raymond, D. P. and Seder, C. W. and Wright, C. D. and Magee, M. J. and Kosinski, A. S. and Cassivi, S. D. and Grogan, E. L. and Blackmon, S. H. and Allen, M. S. and Park, B. J. and Burfeind, W. R. and Chang, A. C. and DeCamp, M. M. and Wormuth, D. W. and Fernandez, F. G. and Kozower, B. D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {207--14},
}

@article{raber-durlacher433,
	title = {Swallowing dysfunction in cancer patients: {Dysphagia} {Section}, {Oral} {Care} {Study} {Group} {Multinational} {Association} of {Supportive} {Care} in {Cancer} {International} {Society} of {Oral} {Oncology}},
	volume = {20},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22205548},
	doi = {10.1007/s00520-011-1342-2},
	number = {3},
	journal = {Support Care Cancer},
	author = {Raber-Durlacher, J. E. and Brennan, M. T. and Verdonck-de Leeuw, I. M. and Gibson, R. J. and Eilers, J. G. and Waltimo, T. and Bots, C. P. and Michelet, M. and Sollecito, T. P. and Rouleau, T. S. and Sewnaik, A. and Bensadoun, R. J. and Fliedner, M. C. and Silverman, S., Jr. and Spijkervet, F. K.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {433--43},
}

@article{reddy559,
	title = {Timed {Stair} {Climbing} {Is} the {Single} {Strongest} {Predictor} of {Perioperative} {Complications} in {Patients} {Undergoing} {Abdominal} {Surgery}},
	volume = {222},
	issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26920993},
	doi = {10.1016/j.jamcollsurg.2016.01.010},
	number = {4},
	journal = {J Am Coll Surg},
	author = {Reddy, S. and Contreras, C. M. and Singletary, B. and Bradford, T. M. and Waldrop, M. G. and Mims, A. H. and Smedley, W. A. and Swords, J. A. and Wang, T. N. and Heslin, M. J.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {559--66},
}

@article{qin11,
	title = {Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? {A} meta-analysis},
	volume = {59},
	issn = {1743-9159 (Electronic) 1743-9159 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30261331},
	doi = {10.1016/j.ijsu.2018.09.013},
	journal = {Int J Surg},
	author = {Qin, Q. and Xu, H. and Liu, J. and Zhang, C. and Xu, L. and Di, X. and Zhang, X. and Sun, X.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {11--18},
}

@article{prado2920,
	title = {Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment},
	volume = {15},
	issn = {1078-0432 (Print) 1078-0432 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19351764},
	doi = {10.1158/1078-0432.CCR-08-2242},
	number = {8},
	journal = {Clin Cancer Res},
	author = {Prado, C. M. and Baracos, V. E. and McCargar, L. J. and Reiman, T. and Mourtzakis, M. and Tonkin, K. and Mackey, J. R. and Koski, S. and Pituskin, E. and Sawyer, M. B.},
	year = {2009},
	note = {Type: Journal Article},
	pages = {2920--6},
}

@article{porteous139,
	title = {A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomes},
	volume = {40},
	issn = {1532-8651 (Electronic) 1098-7339 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25658034},
	doi = {10.1097/AAP.0000000000000197},
	number = {2},
	journal = {Reg Anesth Pain Med},
	author = {Porteous, G. H. and Neal, J. M. and Slee, A. and Schmidt, H. and Low, D. E.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {139--49},
}

@article{persinger1632,
	title = {Consistency of the talk test for exercise prescription},
	volume = {36},
	issn = {0195-9131 (Print) 0195-9131 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15354048},
	number = {9},
	journal = {Med Sci Sports Exerc},
	author = {Persinger, R. and Foster, C. and Gibson, M. and Fater, D. C. and Porcari, J. P.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {1632--6},
}

@article{pope189,
	title = {Pre-operative assessment of cancer in the elderly ({PACE}): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery},
	volume = {15},
	issn = {0960-7404 (Print) 0960-7404 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17531743},
	doi = {10.1016/j.suronc.2007.04.009},
	number = {4},
	journal = {Surg Oncol},
	author = {Pope, D. and Ramesh, H. and Gennari, R. and Corsini, G. and Maffezzini, M. and Hoekstra, H. J. and Mobarak, D. and Sunouchi, K. and Stotter, A. and West, C. and Audisio, R. A.},
	year = {2006},
	note = {Type: Journal Article},
	pages = {189--97},
}

@article{phua488,
	title = {Patients with gastro-oesophageal reflux disease and cough have impaired laryngopharyngeal mechanosensitivity},
	volume = {60},
	issn = {0040-6376 (Print) 0040-6376 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15923249},
	doi = {10.1136/thx.2004.033894},
	number = {6},
	journal = {Thorax},
	author = {Phua, S. Y. and McGarvey, L. P. and Ngu, M. C. and Ing, A. J.},
	year = {2005},
	note = {Type: Journal Article},
	pages = {488--91},
}

@article{pennathurS2159,
	title = {Technique of minimally invasive {Ivor} {Lewis} esophagectomy},
	volume = {89},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20494002},
	doi = {10.1016/j.athoracsur.2010.03.069},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Pennathur, A. and Awais, O. and Luketich, J. D.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {S2159--62},
}

@article{park13,
	title = {Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients},
	volume = {24},
	issn = {1569-9285 (Electronic) 1569-9285 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27587471},
	doi = {10.1093/icvts/ivw274},
	number = {1},
	journal = {Interact Cardiovasc Thorac Surg},
	author = {Park, S. Y. and Yoon, J. K. and Lee, S. J. and Haam, S. and Jung, J.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {13--19},
}

@article{peng439,
	title = {Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis},
	volume = {13},
	issn = {1477-2574 (Electronic) 1365-182X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21689226},
	doi = {10.1111/j.1477-2574.2011.00301.x},
	number = {7},
	journal = {HPB (Oxford)},
	author = {Peng, P. D. and van Vledder, M. G. and Tsai, S. and de Jong, M. C. and Makary, M. and Ng, J. and Edil, B. H. and Wolfgang, C. L. and Schulick, R. D. and Choti, M. A. and Kamel, I. and Pawlik, T. M.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {439--46},
}

@article{participants156,
	title = {Shall we operate? {Preoperative} assessment in elderly cancer patients ({PACE}) can help. {A} {SIOG} surgical task force prospective study},
	volume = {65},
	issn = {1040-8428 (Print) 1040-8428 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18082416},
	doi = {10.1016/j.critrevonc.2007.11.001},
	number = {2},
	journal = {Crit Rev Oncol Hematol},
	author = {participants, Pace and Audisio, R. A. and Pope, D. and Ramesh, H. S. and Gennari, R. and van Leeuwen, B. L. and West, C. and Corsini, G. and Maffezzini, M. and Hoekstra, H. J. and Mobarak, D. and Bozzetti, F. and Colledan, M. and Wildiers, H. and Stotter, A. and Capewell, A. and Marshall, E.},
	year = {2008},
	note = {Type: Journal Article},
	pages = {156--63},
}

@article{palazzo1683,
	title = {Minimally invasive esophagectomy with extracorporeal gastric conduit creation–how {I} do it},
	volume = {17},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23835730},
	doi = {10.1007/s11605-013-2272-8},
	number = {9},
	journal = {J Gastrointest Surg},
	author = {Palazzo, F. and Evans, N. R., 3rd and Rosato, E. L.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {1683--8},
}

@article{palanivelu7,
	title = {Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position–experience of 130 patients},
	volume = {203},
	issn = {1072-7515 (Print) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16798482},
	doi = {10.1016/j.jamcollsurg.2006.03.016},
	number = {1},
	journal = {J Am Coll Surg},
	author = {Palanivelu, C. and Prakash, A. and Senthilkumar, R. and Senthilnathan, P. and Parthasarathi, R. and Rajan, P. S. and Venkatachlam, S.},
	year = {2006},
	note = {Type: Journal Article},
	pages = {7--16},
}

@article{okumura543,
	title = {Functional outcome assessment of swallowing ({FOAMS}) scoring and videofluoroscopic evaluation of perioperative swallowing rehabilitation in radical esophagectomy},
	volume = {46},
	issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26077288},
	doi = {10.1007/s00595-015-1203-6},
	number = {5},
	journal = {Surg Today},
	author = {Okumura, T. and Shimada, Y. and Watanabe, T. and Nakamichi, N. and Nagata, T. and Tsukada, K.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {543--51},
}

@article{nishigori678,
	title = {Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer},
	volume = {113},
	issn = {1096-9098 (Electronic) 0022-4790 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26936808},
	doi = {10.1002/jso.24214},
	number = {6},
	journal = {J Surg Oncol},
	author = {Nishigori, T. and Okabe, H. and Tanaka, E. and Tsunoda, S. and Hisamori, S. and Sakai, Y.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {678--84},
}

@incollection{oxenberg29,
	address = {London},
	title = {Prevention and {Management} of {Complications} from {Esophagectomy}},
	booktitle = {Esophageal {Cancer} and {Beyond}},
	publisher = {IntechOpen},
	author = {Oxenberg, Jacqueline},
	editor = {Chai, Jianyuan},
	year = {2018},
	note = {Type: Book Section},
	pages = {29--47},
}

@article{nguyen253,
	title = {Minimally invasive intrathoracic esophagogastric anastomosis: circular stapler technique with transoral placement of the anvil},
	volume = {22},
	issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21167461},
	doi = {10.1053/j.semtcvs.2010.10.012},
	number = {3},
	journal = {Semin Thorac Cardiovasc Surg},
	author = {Nguyen, N. T. and Nguyen, X. M. and Masoomi, H.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {253--5},
}

@article{nanson340,
	title = {Synchronous combined abdomino- thoraco-cervical (oesophagectomy)},
	volume = {45},
	issn = {0004-8682 (Print) 0004-8682 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1061553},
	number = {4},
	journal = {Aust N Z J Surg},
	author = {Nanson, E. M.},
	year = {1975},
	note = {Type: Journal Article},
	pages = {340--8},
}

@article{nagamatsu1064,
	title = {Preoperative evaluation of cardiopulmonary reserve with the use of expired gas analysis during exercise testing in patients with squamous cell carcinoma of the thoracic esophagus},
	volume = {121},
	issn = {0022-5223 (Print) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11385372},
	doi = {10.1067/mtc.2001.113596},
	number = {6},
	journal = {J Thorac Cardiovasc Surg},
	author = {Nagamatsu, Y. and Shima, I. and Yamana, H. and Fujita, H. and Shirouzu, K. and Ishitake, T.},
	year = {2001},
	note = {Type: Journal Article},
	pages = {1064--8},
}

@article{mulligan313,
	title = {Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit},
	volume = {30},
	issn = {0748-7983 (Print) 0748-7983 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15028315},
	doi = {10.1016/j.ejso.2003.11.009},
	number = {3},
	journal = {Eur J Surg Oncol},
	author = {Mulligan, E. D. and Dunne, B. and Griffin, M. and Keeling, N. and Reynolds, J. V.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {313--7},
}

@article{mourtzakis997,
	title = {A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care},
	volume = {33},
	issn = {1715-5312 (Print) 1715-5312 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18923576},
	doi = {10.1139/H08-075},
	number = {5},
	journal = {Appl Physiol Nutr Metab},
	author = {Mourtzakis, M. and Prado, C. M. and Lieffers, J. R. and Reiman, T. and McCargar, L. J. and Baracos, V. E.},
	year = {2008},
	note = {Type: Journal Article},
	keywords = {Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasms, Absorptiometry, Photon, Electric Impedance, Image Processing, Computer-Assisted, L3},
	pages = {997--1006},
}

@article{moyes125,
	title = {Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery},
	volume = {95},
	issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23484995},
	doi = {10.1308/003588413X13511609954897},
	number = {2},
	journal = {Ann R Coll Surg Engl},
	author = {Moyes, L. H. and McCaffer, C. J. and Carter, R. C. and Fullarton, G. M. and Mackay, C. K. and Forshaw, M. J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {125--30},
}

@article{motz,
	title = {Minimally {Invasive} {Ivor} {Lewis} {Esophagectomy} {Without} {Patient} {Repositioning}},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30623378},
	doi = {10.1007/s11605-018-4063-8},
	journal = {J Gastrointest Surg},
	author = {Motz, B. M. and Lorimer, P. D. and Boselli, D. and Symanowski, J. T. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
}

@article{mendoza1186,
	title = {The rapid assessment of fatigue severity in cancer patients: use of the {Brief} {Fatigue} {Inventory}},
	volume = {85},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10091805},
	number = {5},
	journal = {Cancer},
	author = {Mendoza, T. R. and Wang, X. S. and Cleeland, C. S. and Morrissey, M. and Johnson, B. A. and Wendt, J. K. and Huber, S. L.},
	year = {1999},
	note = {Type: Journal Article},
	pages = {1186--96},
}

@article{morley392,
	title = {Frailty consensus: a call to action},
	volume = {14},
	issn = {1538-9375 (Electronic) 1525-8610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23764209},
	doi = {10.1016/j.jamda.2013.03.022},
	number = {6},
	journal = {J Am Med Dir Assoc},
	author = {Morley, J. E. and Vellas, B. and van Kan, G. A. and Anker, S. D. and Bauer, J. M. and Bernabei, R. and Cesari, M. and Chumlea, W. C. and Doehner, W. and Evans, J. and Fried, L. P. and Guralnik, J. M. and Katz, P. R. and Malmstrom, T. K. and McCarter, R. J. and Gutierrez Robledo, L. M. and Rockwood, K. and von Haehling, S. and Vandewoude, M. F. and Walston, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {392--7},
}

@article{mitchell325,
	title = {Health literacy and 30-day postdischarge hospital utilization},
	volume = {17 Suppl 3},
	issn = {1087-0415 (Electronic) 1081-0730 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23030580},
	doi = {10.1080/10810730.2012.715233},
	journal = {J Health Commun},
	author = {Mitchell, S. E. and Sadikova, E. and Jack, B. W. and Paasche-Orlow, M. K.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {325--38},
}

@article{mehrane595,
	title = {Pain {Management} in an {Enhanced} {Recovery} {Pathway} {After} {Thoracic} {Surgical} {Procedures}},
	volume = {102},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27847094},
	doi = {10.1016/j.athoracsur.2016.05.050},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Mehran, R. J. and Martin, L. W. and Baker, C. M. and Mena, G. E. and Rice, D. C.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e595--e596},
}

@article{mattioli255,
	title = {Patient position for a synchronous cervicothoracoabdominal two-team esophagectomy},
	volume = {63},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8993287},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Mattioli, S. and D'Ovidio, F. and Di Simone, M. P. and Lazzari, A. and Paladini, R. and Begliomini, B.},
	year = {1997},
	note = {Type: Journal Article},
	pages = {255--7},
}

@article{martin-harris136,
	title = {Clinical utility of the modified barium swallow},
	volume = {15},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10839826},
	doi = {10.1007/s004550010015},
	number = {3},
	journal = {Dysphagia},
	author = {Martin-Harris, B. and Logemann, J. A. and McMahon, S. and Schleicher, M. and Sandidge, J.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {136--41},
}

@article{martin1,
	title = {The association of swallowing dysfunction and aspiration pneumonia},
	volume = {9},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8131418},
	doi = {10.1007/BF00262751},
	number = {1},
	journal = {Dysphagia},
	author = {Martin, B. J. and Corlew, M. M. and Wood, H. and Olson, D. and Golopol, L. A. and Wingo, M. and Kirmani, N.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {1--6},
}

@article{mariette152,
	title = {Hybrid {Minimally} {Invasive} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {380},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30625052},
	doi = {10.1056/NEJMoa1805101},
	number = {2},
	journal = {N Engl J Med},
	author = {Mariette, C. and Markar, S. R. and Dabakuyo-Yonli, T. S. and Meunier, B. and Pezet, D. and Collet, D. and D'Journo, X. B. and Brigand, C. and Perniceni, T. and Carrere, N. and Mabrut, J. Y. and Msika, S. and Peschaud, F. and Prudhomme, M. and Bonnetain, F. and Piessen, G. and Federation de Recherche en, Chirurgie and French Eso-Gastric Tumors Working, Group},
	year = {2019},
	note = {Type: Journal Article},
	pages = {152--162},
}

@article{markar250,
	title = {Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy},
	volume = {26},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22591068},
	doi = {10.1111/j.1442-2050.2012.01353.x},
	number = {3},
	journal = {Dis Esophagus},
	author = {Markar, S. R. and Karthikesalingam, A. and Thrumurthy, S. and Ho, A. and Muallem, G. and Low, D. E.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {250--62},
}

@article{mariette2416,
	title = {Surgery alone versus chemoradiotherapy followed by surgery for stage {I} and {II} esophageal cancer: final analysis of randomized controlled phase {III} trial {FFCD} 9901},
	volume = {32},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24982463},
	doi = {10.1200/JCO.2013.53.6532},
	number = {23},
	journal = {J Clin Oncol},
	author = {Mariette, C. and Dahan, L. and Mornex, F. and Maillard, E. and Thomas, P. A. and Meunier, B. and Boige, V. and Pezet, D. and Robb, W. B. and Le Brun-Ly, V. and Bosset, J. F. and Mabrut, J. Y. and Triboulet, J. P. and Bedenne, L. and Seitz, J. F.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {2416--22},
}

@article{makiura456,
	title = {Impact of {Sarcopenia} on {Unplanned} {Readmission} and {Survival} {After} {Esophagectomy} in {Patients} with {Esophageal} {Cancer}},
	volume = {25},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29214454},
	doi = {10.1245/s10434-017-6294-4},
	number = {2},
	journal = {Ann Surg Oncol},
	author = {Makiura, D. and Ono, R. and Inoue, J. and Fukuta, A. and Kashiwa, M. and Miura, Y. and Oshikiri, T. and Nakamura, T. and Kakeji, Y. and Sakai, Y.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {456--464},
}

@article{makiura430,
	title = {Preoperative sarcopenia is a predictor of postoperative pulmonary complications in esophageal cancer following esophagectomy: {A} retrospective cohort study},
	volume = {7},
	issn = {1879-4076 (Electronic) 1879-4068 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27452909},
	doi = {10.1016/j.jgo.2016.07.003},
	number = {6},
	journal = {J Geriatr Oncol},
	author = {Makiura, D. and Ono, R. and Inoue, J. and Kashiwa, M. and Oshikiri, T. and Nakamura, T. and Kakeji, Y. and Sakai, Y. and Miura, Y.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {430--436},
}

@article{maeda515,
	title = {Sarcopenia is an independent risk factor of dysphagia in hospitalized older people},
	volume = {16},
	issn = {1447-0594 (Electronic) 1447-0594 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25807861},
	doi = {10.1111/ggi.12486},
	number = {4},
	journal = {Geriatr Gerontol Int},
	author = {Maeda, K. and Akagi, J.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {515--21},
}

@article{lund16,
	title = {Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial},
	volume = {10},
	issn = {1748-717X (Electronic) 1748-717X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25582305},
	doi = {10.1186/s13014-014-0310-7},
	journal = {Radiat Oncol},
	author = {Lund, M. and Alexandersson von Dobeln, G. and Nilsson, M. and Winter, R. and Lundell, L. and Tsai, J. A. and Kalman, S.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {16},
}

@article{lorimer177,
	title = {Quality {Improvement} in {Minimally} {Invasive} {Esophagectomy}: {Outcome} {Improvement} {Through} {Data} {Review}},
	volume = {26},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30382434},
	doi = {10.1245/s10434-018-6938-z},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {Lorimer, P. D. and Motz, B. M. and Boselli, D. M. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {177--187},
}

@article{luketich95,
	title = {Outcomes after minimally invasive esophagectomy: review of over 1000 patients},
	volume = {256},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22668811},
	doi = {10.1097/SLA.0b013e3182590603},
	number = {1},
	journal = {Ann Surg},
	author = {Luketich, J. D. and Pennathur, A. and Awais, O. and Levy, R. M. and Keeley, S. and Shende, M. and Christie, N. A. and Weksler, B. and Landreneau, R. J. and Abbas, G. and Schuchert, M. J. and Nason, K. S.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {95--103},
}

@article{luketich486,
	title = {Minimally invasive esophagectomy: outcomes in 222 patients},
	volume = {238},
	issn = {0003-4932 (Print) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/14530720},
	doi = {10.1097/01.sla.0000089858.40725.68},
	number = {4},
	journal = {Ann Surg},
	author = {Luketich, J. D. and Alvelo-Rivera, M. and Buenaventura, P. O. and Christie, N. A. and McCaughan, J. S. and Litle, V. R. and Schauer, P. R. and Close, J. M. and Fernando, H. C.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {486--94; discussion 494--5},
}

@article{lin1107,
	title = {Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies},
	volume = {29},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26542065},
	doi = {10.1111/dote.12432},
	number = {8},
	journal = {Dis Esophagus},
	author = {Lin, G. and Han, S. Y. and Xu, Y. P. and Mao, W. M.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1107--1114},
}

@article{lakenman652,
	title = {Handgrip {Strength} {Is} {Associated} {With} {Treatment} {Modifications} {During} {Neoadjuvant} {Chemoradiation} in {Patients} {With} {Esophageal} {Cancer}},
	volume = {32},
	issn = {1941-2452 (Electronic) 0884-5336 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28459652},
	doi = {10.1177/0884533617700862},
	number = {5},
	journal = {Nutr Clin Pract},
	author = {Lakenman, P. and Ottens-Oussoren, K. and Witvliet-van Nierop, J. and van der Peet, D. and de van der Schueren, M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {652--657},
}

@article{laboratories111,
	title = {{ATS} statement: guidelines for the six-minute walk test},
	volume = {166},
	issn = {1073-449X (Print) 1073-449X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12091180},
	doi = {10.1164/ajrccm.166.1.at1102},
	number = {1},
	journal = {Am J Respir Crit Care Med},
	author = {Laboratories, A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function},
	year = {2002},
	note = {Type: Journal Article},
	pages = {111--7},
}

@article{kuwano328,
	title = {Gastric involvement of oesophageal squamous cell carcinoma},
	volume = {79},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1576500},
	number = {4},
	journal = {Br J Surg},
	author = {Kuwano, H. and Baba, K. and Ikebe, M. and Kitamura, K. and Adachi, Y. and Mori, M. and Sugimachi, K.},
	year = {1992},
	note = {Type: Journal Article},
	pages = {328--30},
}

@article{kukreja242,
	title = {Patient-{Reported} {Outcomes} {Are} {Associated} {With} {Enhanced} {Recovery} {Status} in {Patients} {With} {Bladder} {Cancer} {Undergoing} {Radical} {Cystectomy}},
	volume = {25},
	issn = {1553-3514 (Electronic) 1553-3506 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29557251},
	doi = {10.1177/1553350618764218},
	number = {3},
	journal = {Surg Innov},
	author = {Kukreja, J. B. and Shi, Q. and Chang, C. M. and Seif, M. A. and Sterling, B. M. and Chen, T. Y. and Creel, K. M. and Kamat, A. M. and Dinney, C. P. and Navai, N. and Shah, J. B. and Wang, X. S.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {242--250},
}

@article{koh480,
	title = {Functional assessment of the cervical esophagus after gastric transposition and cervical esophagogastrostomy},
	volume = {25},
	issn = {1010-7940 (Print) 1010-7940 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15037258},
	doi = {10.1016/j.ejcts.2003.12.034},
	number = {4},
	journal = {Eur J Cardiothorac Surg},
	author = {Koh, P. and Turnbull, G. and Attia, E. and LeBrun, P. and Casson, A. G.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {480--5},
}

@article{kim207,
	title = {Does the timing of esophagectomy after chemoradiation affect outcome?},
	volume = {93},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21962263},
	doi = {10.1016/j.athoracsur.2011.05.021},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Kim, J. Y. and Correa, A. M. and Vaporciyan, A. A. and Roth, J. A. and Mehran, R. J. and Walsh, G. L. and Rice, D. C. and Ajani, J. A. and Maru, D. M. and Bhutani, M. S. and Welsh, J. and Marom, E. M. and Swisher, S. G. and Hofstetter, W. L.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {207--12; discussion 212--3},
}

@article{khalil2013,
	title = {Operative {Intercostal} {Nerve} {Blocks} {With} {Long}-{Acting} {Bupivacaine} {Liposome} for {Pain} {Control} {After} {Thoracotomy}},
	volume = {100},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26507422},
	doi = {10.1016/j.athoracsur.2015.08.017},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Khalil, K. G. and Boutrous, M. L. and Irani, A. D. and Miller, C. C., 3rd and Pawelek, T. R. and Estrera, A. L. and Safi, H. J.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {2013--8},
}

@article{kelsen1979,
	title = {Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer},
	volume = {339},
	issn = {0028-4793 (Print) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9869669},
	doi = {10.1056/NEJM199812313392704},
	number = {27},
	journal = {N Engl J Med},
	author = {Kelsen, D. P. and Ginsberg, R. and Pajak, T. F. and Sheahan, D. G. and Gunderson, L. and Mortimer, J. and Estes, N. and Haller, D. G. and Ajani, J. and Kocha, W. and Minsky, B. D. and Roth, J. A.},
	year = {1998},
	note = {Type: Journal Article},
	pages = {1979--84},
}

@article{kawata,
	title = {Multidisciplinary team management for prevention of pneumonia and long-term weight loss after esophagectomy: a single-center retrospective study},
	issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32026048},
	doi = {10.1007/s10388-020-00721-0},
	journal = {Esophagus},
	author = {Kawata, S. and Hiramatsu, Y. and Shirai, Y. and Watanabe, K. and Nagafusa, T. and Matsumoto, T. and Kikuchi, H. and Kamiya, K. and Takeuchi, H.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{kaya707,
	title = {Patients' readiness for discharge: {Predictors} and effects on unplanned readmissions, emergency department visits and death},
	volume = {26},
	issn = {1365-2834 (Electronic) 0966-0429 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29573007},
	doi = {10.1111/jonm.12605},
	number = {6},
	journal = {J Nurs Manag},
	author = {Kaya, S. and Sain Guven, G. and Aydan, S. and Kar, A. and Teles, M. and Yildiz, A. and Koca, G. S. and Kartal, N. and Korku, C. and Urek, D. and Demir, I. B. and Toka, O.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {707--716},
}

@article{kato4249,
	title = {Videofluoroscopic evaluation in oropharyngeal swallowing after radical esophagectomy with lymphadenectomy for esophageal cancer},
	volume = {27},
	issn = {0250-7005 (Print) 0250-7005 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18214027},
	number = {6C},
	journal = {Anticancer Res},
	author = {Kato, H. and Miyazaki, T. and Sakai, M. and Sano, A. and Tanaka, N. and Kimura, H. and Inose, T. and Faried, A. and Saito, K. and Sohda, M. and Nakajima, M. and Fukai, Y. and Masuda, N. and Fukuchi, M. and Manda, R. and Ojima, H. and Tsukada, K. and Kuwano, H.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {4249--54},
}

@article{jones245,
	title = {Patient-{Reported} {Outcomes} {Measurement} {Information} {System} ({PROMIS}) {Use} in {Surgical} {Care}: {A} {Scoping} {Study}},
	volume = {224},
	issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27965131},
	doi = {10.1016/j.jamcollsurg.2016.11.015},
	number = {3},
	journal = {J Am Coll Surg},
	author = {Jones, R. S. and Stukenborg, G. J.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {245--254 e1},
}

@article{jones327,
	title = {Transitional care interventions and hospital readmissions in surgical populations: a systematic review},
	volume = {212},
	issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27353404},
	doi = {10.1016/j.amjsurg.2016.04.004},
	number = {2},
	journal = {Am J Surg},
	author = {Jones, C. E. and Hollis, R. H. and Wahl, T. S. and Oriel, B. S. and Itani, K. M. and Morris, M. S. and Hawn, M. T.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {327--35},
}

@article{kaneoka,
	title = {Presentation of oropharyngeal dysphagia and rehabilitative intervention following esophagectomy: a systematic review},
	volume = {31},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29788321},
	doi = {10.1093/dote/doy050},
	number = {8},
	journal = {Dis Esophagus},
	author = {Kaneoka, A. and Yang, S. and Inokuchi, H. and Ueha, R. and Yamashita, H. and Nito, T. and Seto, Y. and Haga, N.},
	year = {2018},
	note = {Type: Journal Article},
}

@article{jonesO20,
	title = {Simple psoas cross-sectional area measurement is a quick and easy method to assess sarcopenia and predicts major surgical complications},
	volume = {17},
	issn = {1463-1318 (Electronic) 1462-8910 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25328119},
	doi = {10.1111/codi.12805},
	number = {1},
	journal = {Colorectal Dis},
	author = {Jones, K. I. and Doleman, B. and Scott, S. and Lund, J. N. and Williams, J. P.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {O20--6},
}

@article{jack1313,
	title = {The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery},
	volume = {40},
	issn = {1532-2157 (Electronic) 0748-7983 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24731268},
	doi = {10.1016/j.ejso.2014.03.010},
	number = {10},
	journal = {Eur J Surg Oncol},
	author = {Jack, S. and West, M. A. and Raw, D. and Marwood, S. and Ambler, G. and Cope, T. M. and Shrotri, M. and Sturgess, R. P. and Calverley, P. M. and Ottensmeier, C. H. and Grocott, M. P.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {1313--20},
}

@article{irving370,
	title = {{NIH} {ImageJ} and {Slice}-{O}-{Matic} computed tomography imaging software to quantify soft tissue},
	volume = {15},
	issn = {1930-7381 (Print) 1930-7381 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17299110},
	doi = {10.1038/oby.2007.573},
	number = {2},
	journal = {Obesity (Silver Spring)},
	author = {Irving, B. A. and Weltman, J. Y. and Brock, D. W. and Davis, C. K. and Gaesser, G. A. and Weltman, A.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {370--6},
}

@article{iqbal,
	title = {Cost {Effectiveness} of a {Novel} {Attempt} to {Reduce} {Readmission} after {Ileostomy} {Creation}},
	volume = {21},
	issn = {1938-3797 (Electronic) 1086-8089 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28144122},
	doi = {10.4293/JSLS.2016.00082},
	number = {1},
	journal = {JSLS},
	author = {Iqbal, A. and Raza, A. and Huang, E. and Goldstein, L. and Hughes, S. J. and Tan, S. A.},
	year = {2017},
	note = {Type: Journal Article},
}

@book{zotero-296,
	url = {https://www.wcrf.org/dietandcancer/cancer-trends/oesophageal-cancer-statistics},
	month = jun,
	year = {2020},
	note = {Type: Web Page},
}

@article{inoue34,
	title = {Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomy},
	volume = {8},
	issn = {2052-1847 (Print) 2052-1847 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27822378},
	doi = {10.1186/s13102-016-0060-y},
	journal = {BMC Sports Sci Med Rehabil},
	author = {Inoue, T. and Ito, S. and Ando, M. and Nagaya, M. and Aso, H. and Mizuno, Y. and Hattori, K. and Nakajima, H. and Nishida, Y. and Niwa, Y. and Kodera, Y. and Koike, M. and Hasegawa, Y.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {34},
}

@article{inoue68,
	title = {Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer},
	volume = {26},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22409435},
	doi = {10.1111/j.1442-2050.2012.01336.x},
	number = {1},
	journal = {Dis Esophagus},
	author = {Inoue, J. and Ono, R. and Makiura, D. and Kashiwa-Motoyama, M. and Miura, Y. and Usami, M. and Nakamura, T. and Imanishi, T. and Kuroda, D.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {68--74},
}

@article{hutcheson1127,
	title = {Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it},
	volume = {139},
	issn = {2168-619X (Electronic) 2168-6181 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24051544},
	doi = {10.1001/jamaoto.2013.4715},
	number = {11},
	journal = {JAMA Otolaryngol Head Neck Surg},
	author = {Hutcheson, K. A. and Bhayani, M. K. and Beadle, B. M. and Gold, K. A. and Shinn, E. H. and Lai, S. Y. and Lewin, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {1127--34},
}

@article{hutcheson62,
	title = {Dynamic {Imaging} {Grade} of {Swallowing} {Toxicity} ({DIGEST}): {Scale} development and validation},
	volume = {123},
	issn = {1097-0142 (Electronic) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27564246},
	doi = {10.1002/cncr.30283},
	number = {1},
	journal = {Cancer},
	author = {Hutcheson, K. A. and Barrow, M. P. and Barringer, D. A. and Knott, J. K. and Lin, H. Y. and Weber, R. S. and Fuller, C. D. and Lai, S. Y. and Alvarez, C. P. and Raut, J. and Lazarus, C. L. and May, A. and Patterson, J. and Roe, J. W. and Starmer, H. M. and Lewin, J. S.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {62--70},
}

@article{howard-anderson1870,
	title = {Readmissions in the era of patient engagement},
	volume = {174},
	issn = {2168-6114 (Electronic) 2168-6106 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25264930},
	doi = {10.1001/jamainternmed.2014.4782},
	number = {11},
	journal = {JAMA Intern Med},
	author = {Howard-Anderson, J. and Lonowski, S. and Vangala, S. and Tseng, C. H. and Busuttil, A. and Afsar-Manesh, N.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {1870--2},
}

@article{hibbard1918,
	title = {Development and testing of a short form of the patient activation measure},
	volume = {40},
	issn = {0017-9124 (Print) 0017-9124 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16336556},
	doi = {10.1111/j.1475-6773.2005.00438.x},
	number = {6 Pt 1},
	journal = {Health Serv Res},
	author = {Hibbard, J. H. and Mahoney, E. R. and Stockard, J. and Tusler, M.},
	year = {2005},
	note = {Type: Journal Article},
	pages = {1918--30},
}

@article{humbert347,
	title = {Swallowing intentional off-state in aging and {Alzheimer}'s disease: preliminary study},
	volume = {26},
	issn = {1875-8908 (Electronic) 1387-2877 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21654061},
	doi = {10.3233/JAD-2011-110380},
	number = {2},
	journal = {J Alzheimers Dis},
	author = {Humbert, I. A. and McLaren, D. G. and Malandraki, G. and Johnson, S. C. and Robbins, J.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {347--54},
}

@article{hibbard207,
	title = {What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs},
	volume = {32},
	issn = {1544-5208 (Electronic) 0278-2715 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23381511},
	doi = {10.1377/hlthaff.2012.1061},
	number = {2},
	journal = {Health Aff (Millwood)},
	author = {Hibbard, J. H. and Greene, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {207--14},
}

@article{hayes95,
	title = {Comparison of conventional {Lewis}-{Tanner} two-stage oesophagectomy with the synchronous two-team approach},
	volume = {82},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7881969},
	number = {1},
	journal = {Br J Surg},
	author = {Hayes, N. and Shaw, I. H. and Raimes, S. A. and Griffin, S. M.},
	year = {1995},
	note = {Type: Journal Article},
	pages = {95--7},
}

@article{harris377,
	title = {Research electronic data capture ({REDCap})–a metadata-driven methodology and workflow process for providing translational research informatics support},
	volume = {42},
	issn = {1532-0480 (Electronic) 1532-0464 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18929686},
	doi = {10.1016/j.jbi.2008.08.010},
	number = {2},
	journal = {J Biomed Inform},
	author = {Harris, P. A. and Taylor, R. and Thielke, R. and Payne, J. and Gonzalez, N. and Conde, J. G.},
	year = {2009},
	note = {Type: Journal Article},
	pages = {377--81},
}

@article{hardiman1302,
	title = {Patient autonomy-centered self-care checklist reduces hospital readmissions after ileostomy creation},
	volume = {160},
	issn = {1532-7361 (Electronic) 0039-6060 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27320065},
	doi = {10.1016/j.surg.2016.05.007},
	number = {5},
	journal = {Surgery},
	author = {Hardiman, K. M. and Reames, C. D. and McLeod, M. C. and Regenbogen, S. E.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1302--1308},
}

@article{harter2525,
	title = {Nutritional and functional factors as prognostic of surgical cancer patients},
	volume = {25},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28303380},
	doi = {10.1007/s00520-017-3661-4},
	number = {8},
	journal = {Support Care Cancer},
	author = {Harter, J. and Orlandi, S. P. and Gonzalez, M. C.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {2525--2530},
}

@article{haisleye162743,
	title = {Association of {Intervals} {Between} {Neoadjuvant} {Chemoradiation} and {Surgical} {Resection} {With} {Pathologic} {Complete} {Response} and {Survival} in {Patients} {With} {Esophageal} {Cancer}},
	volume = {151},
	issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27627765},
	doi = {10.1001/jamasurg.2016.2743},
	number = {11},
	journal = {JAMA Surg},
	author = {Haisley, K. R. and Laird, A. E. and Nabavizadeh, N. and Gatter, K. M. and Holland, J. M. and Vaccaro, G. M. and Thomas, C. R., Jr. and Schipper, P. H. and Hunter, J. G. and Dolan, J. P.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e162743},
}

@article{gurtner1620,
	title = {Two-team synchronous oesophagectomy},
	volume = {81},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7827888},
	number = {11},
	journal = {Br J Surg},
	author = {Gurtner, G. C. and Robertson, C. S. and Chung, S. C. and Li, A. K.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {1620--2},
}

@article{guinan1569,
	title = {Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance},
	volume = {26},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29197960},
	doi = {10.1007/s00520-017-3993-0},
	number = {5},
	journal = {Support Care Cancer},
	author = {Guinan, E. M. and Doyle, S. L. and Bennett, A. E. and O'Neill, L. and Gannon, J. and Elliott, J. A. and O'Sullivan, J. and Reynolds, J. V. and Hussey, J.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {1569--1576},
}

@article{hanna521,
	title = {Minimally invasive esophagectomy in the community hospital setting},
	volume = {20},
	issn = {1558-5042 (Electronic) 1055-3207 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21640919},
	doi = {10.1016/j.soc.2011.01.009},
	number = {3},
	journal = {Surg Oncol Clin N Am},
	author = {Hanna, E. M. and Norton, H. J. and Reames, M. K. and Salo, J. C.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {521--30, ix},
}

@article{guralnikM221,
	title = {Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery},
	volume = {55},
	issn = {1079-5006 (Print) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10811152},
	number = {4},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Guralnik, J. M. and Ferrucci, L. and Pieper, C. F. and Leveille, S. G. and Markides, K. S. and Ostir, G. V. and Studenski, S. and Berkman, L. F. and Wallace, R. B.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {M221--31},
}

@article{gemmill173,
	title = {Systematic review of enhanced recovery after gastro-oesophageal cancer surgery},
	volume = {97},
	issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26263799},
	doi = {10.1308/003588414X14055925061630},
	number = {3},
	journal = {Ann R Coll Surg Engl},
	author = {Gemmill, E. H. and Humes, D. J. and Catton, J. A.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {173--9},
}

@article{fromer92,
	title = {Integrated medical processes: redesigning transitions of care},
	volume = {42},
	issn = {2154-8331 (Print) 2154-8331 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25502133},
	doi = {10.3810/hp.2014.10.1146},
	number = {4},
	journal = {Hosp Pract (1995)},
	author = {Fromer, L. and Pollack, C.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {92--8},
}

@article{fried255,
	title = {Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care},
	volume = {59},
	issn = {1079-5006 (Print) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15031310},
	number = {3},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Fried, L. P. and Ferrucci, L. and Darer, J. and Williamson, J. D. and Anderson, G.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {255--63},
}

@article{forshaw294,
	title = {Is cardiopulmonary exercise testing a useful test before esophagectomy?},
	volume = {85},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18154826},
	doi = {10.1016/j.athoracsur.2007.05.062},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Forshaw, M. J. and Strauss, D. C. and Davies, A. R. and Wilson, D. and Lams, B. and Pearce, A. and Botha, A. J. and Mason, R. C.},
	year = {2008},
	note = {Type: Journal Article},
	pages = {294--9},
}

@article{fish379,
	title = {Readmission {After} {Ileostomy} {Creation}: {Retrospective} {Review} of a {Common} and {Significant} {Event}},
	volume = {265},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28059966},
	doi = {10.1097/SLA.0000000000001683},
	number = {2},
	journal = {Ann Surg},
	author = {Fish, D. R. and Mancuso, C. A. and Garcia-Aguilar, J. E. and Lee, S. W. and Nash, G. M. and Sonoda, T. and Charlson, M. E. and Temple, L. K.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {379--387},
}

@article{fiorelli,
	title = {Ultrasound-{Guided} {Erector} {Spinae} {Plane} {Block} {Versus} {Intercostal} {Nerve} {Block} for {Post}-{Minithoracotomy} {Acute} {Pain} {Management}: {A} {Randomized} {Controlled} {Trial}},
	issn = {1532-8422 (Electronic) 1053-0770 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32144056},
	doi = {10.1053/j.jvca.2020.01.026},
	journal = {J Cardiothorac Vasc Anesth},
	author = {Fiorelli, S. and Leopizzi, G. and Menna, C. and Teodonio, L. and Ibrahim, M. and Rendina, E. A. and Ricci, A. and De Blasi, R. A. and Rocco, M. and Massullo, D.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{findlay413,
	title = {Enhanced recovery for esophagectomy: a systematic review and evidence-based guidelines},
	volume = {259},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24253135},
	doi = {10.1097/SLA.0000000000000349},
	number = {3},
	journal = {Ann Surg},
	author = {Findlay, J. M. and Gillies, R. S. and Millo, J. and Sgromo, B. and Marshall, R. E. and Maynard, N. D.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {413--31},
}

@article{fernando1144,
	title = {The {Society} of {Thoracic} {Surgeons} practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary},
	volume = {92},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21871327},
	doi = {10.1016/j.athoracsur.2011.06.104},
	number = {3},
	journal = {Ann Thorac Surg},
	author = {Fernando, H. C. and Jaklitsch, M. T. and Walsh, G. L. and Tisdale, J. E. and Bridges, C. D. and Mitchell, J. D. and Shrager, J. B.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {1144--52},
}

@article{feeney529a,
	title = {A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease},
	volume = {14},
	issn = {0954-691X (Print) 0954-691X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11984151},
	doi = {10.1097/00042737-200205000-00010},
	number = {5},
	journal = {Eur J Gastroenterol Hepatol},
	author = {Feeney, M. A. and Murphy, F. and Clegg, A. J. and Trebble, T. M. and Sharer, N. M. and Snook, J. A.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {529--34},
}

@article{ferguson661,
	title = {Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer},
	volume = {123},
	issn = {0022-5223 (Print) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11986593},
	doi = {10.1067/mtc.2002.120350},
	number = {4},
	journal = {J Thorac Cardiovasc Surg},
	author = {Ferguson, M. K. and Durkin, A. E.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {661--9},
}

@article{feeney489,
	title = {Preoperative physical activity levels and postoperative pulmonary complications post-esophagectomy},
	volume = {24},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21309920},
	doi = {10.1111/j.1442-2050.2010.01171.x},
	number = {7},
	journal = {Dis Esophagus},
	author = {Feeney, C. and Reynolds, J. V. and Hussey, J.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {489--94},
}

@article{feeney529,
	title = {Assessment of physical fitness for esophageal surgery, and targeting interventions to optimize outcomes},
	volume = {23},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20459443},
	doi = {10.1111/j.1442-2050.2010.01058.x},
	number = {7},
	journal = {Dis Esophagus},
	author = {Feeney, C. and Hussey, J. and Carey, M. and Reynolds, J. V.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {529--39},
}

@article{fagundes613,
	title = {Symptom recovery after thoracic surgery: {Measuring} patient-reported outcomes with the {MD} {Anderson} {Symptom} {Inventory}},
	volume = {150},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26088408},
	doi = {10.1016/j.jtcvs.2015.05.057},
	number = {3},
	journal = {J Thorac Cardiovasc Surg},
	author = {Fagundes, C. P. and Shi, Q. and Vaporciyan, A. A. and Rice, D. C. and Popat, K. U. and Cleeland, C. S. and Wang, X. S.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {613--9 e2},
}

@article{easterling989,
	title = {Pharyngeal dysphagia in postesophagectomy patients: correlation with deglutitive biomechanics},
	volume = {69},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10800780},
	number = {4},
	journal = {Ann Thorac Surg},
	author = {Easterling, C. S. and Bousamra, M., 2nd and Lang, I. M. and Kern, M. K. and Nitschke, T. and Bardan, E. and Shaker, R.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {989--92},
}

@article{fearon489,
	title = {Definition and classification of cancer cachexia: an international consensus},
	volume = {12},
	issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21296615},
	doi = {10.1016/S1470-2045(10)70218-7},
	number = {5},
	journal = {Lancet Oncol},
	author = {Fearon, K. and Strasser, F. and Anker, S. D. and Bosaeus, I. and Bruera, E. and Fainsinger, R. L. and Jatoi, A. and Loprinzi, C. and MacDonald, N. and Mantovani, G. and Davis, M. and Muscaritoli, M. and Ottery, F. and Radbruch, L. and Ravasco, P. and Walsh, D. and Wilcock, A. and Kaasa, S. and Baracos, V. E.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {489--95},
}

@article{ebadi1053,
	title = {Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis},
	volume = {9},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30269421},
	doi = {10.1002/jcsm.12349},
	number = {6},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Ebadi, M. and Wang, C. W. and Lai, J. C. and Dasarathy, S. and Kappus, M. R. and Dunn, M. A. and Carey, E. J. and Montano-Loza, A. J. and From the Fitness, Life Enhancement and Exercise in Liver Transplantation, Consortium},
	year = {2018},
	note = {Type: Journal Article},
	pages = {1053--1062},
}

@article{dutta164,
	title = {Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder},
	volume = {168},
	issn = {0022-5347 (Print) 0022-5347 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12050514},
	number = {1},
	journal = {J Urol},
	author = {Dutta, S. C. and Chang, S. C. and Coffey, C. S. and Smith, J. A., Jr. and Jack, G. and Cookson, M. S.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {164--7},
}

@article{dronkers67,
	title = {The association of pre-operative physical fitness and physical activity with outcome after scheduled major abdominal surgery},
	volume = {68},
	issn = {1365-2044 (Electronic) 0003-2409 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23121372},
	doi = {10.1111/anae.12066},
	number = {1},
	journal = {Anaesthesia},
	author = {Dronkers, J. J. and Chorus, A. M. and van Meeteren, N. L. and Hopman-Rock, M.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {67--73},
}

@incollection{dimitriosschizas,
	title = {Esophageal {Abnormalities}},
	url = {https://www.intechopen.com/books/esophageal-abnormalities/nutritional-management-of-esophageal-cancer-patients},
	booktitle = {Nutritional {Management} of {Esophageal} {Cancer} {Patients}},
	author = {Dimitrios Schizas, Irene Lidoriki, Demetrios Moris and Liakakos, Theodore},
	editor = {Chai, Jianyuan},
	year = {2017},
	note = {Type: Book Section},
}

@article{dieterich365,
	title = {Postoperative {Complications} {Predict} 30-{Day} {Readmission} in {Geriatric} {General} {Surgery} {Patients}},
	volume = {83},
	issn = {1555-9823 (Electronic) 0003-1348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28424131},
	number = {4},
	journal = {Am Surg},
	author = {Dieterich, J. D. and Divino, C. M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {365--370},
}

@article{deng,
	title = {Sarcopenia: an unneglectable nutritional status in oncological esophagectomy},
	volume = {32},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30496370},
	doi = {10.1093/dote/doy108},
	number = {3},
	journal = {Dis Esophagus},
	author = {Deng, H. Y. and Hou, L. and Zha, P.},
	year = {2019},
	note = {Type: Journal Article},
}

@article{denga,
	title = {Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis},
	volume = {32},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30496385},
	doi = {10.1093/dote/doy115},
	number = {3},
	journal = {Dis Esophagus},
	author = {Deng, H. Y. and Zha, P. and Peng, L. and Hou, L. and Huang, K. L. and Li, X. Y.},
	year = {2019},
	note = {Type: Journal Article},
}

@article{delmonico769,
	title = {Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women},
	volume = {55},
	issn = {0002-8614 (Print) 0002-8614 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17493199},
	doi = {10.1111/j.1532-5415.2007.01140.x},
	number = {5},
	journal = {J Am Geriatr Soc},
	author = {Delmonico, M. J. and Harris, T. B. and Lee, J. S. and Visser, M. and Nevitt, M. and Kritchevsky, S. B. and Tylavsky, F. A. and Newman, A. B. and Health, Aging and Body Composition, Study},
	year = {2007},
	note = {Type: Journal Article},
	pages = {769--74},
}

@incollection{dejaeger,
	title = {Presbyphagia},
	url = {https://www.intechopen.com/books/seminars-in-dysphagia/presbyphagia},
	booktitle = {Seminars in {Dysphagia}},
	publisher = {IntechOpen},
	author = {Dejaeger, Marian and Liesenborghs, Claudia and Dejaeger, Eddy},
	editor = {Speyer, Renee and Bogaardt, Hans},
	year = {2015},
	doi = {10.5772/60780},
	note = {Type: Book Section},
}

@article{davis391,
	title = {Rapid estimate of adult literacy in medicine: a shortened screening instrument},
	volume = {25},
	issn = {0742-3225 (Print) 0742-3225 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8349060},
	number = {6},
	journal = {Fam Med},
	author = {Davis, T. C. and Long, S. W. and Jackson, R. H. and Mayeaux, E. J. and George, R. B. and Murphy, P. W. and Crouch, M. A.},
	year = {1993},
	note = {Type: Journal Article},
	pages = {391--5},
}

@article{deftereose035824,
	title = {Nutritional {Outcomes} of patients {Undergoing} {Resection} for upper {gastroIntestinal} cancer in {AuStralian} {Hospitals} ({NOURISH}): protocol for a multicentre point prevalence study},
	volume = {10},
	issn = {2044-6055 (Electronic) 2044-6055 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32385064},
	doi = {10.1136/bmjopen-2019-035824},
	number = {5},
	journal = {BMJ Open},
	author = {Deftereos, I. and Yeung, J. M. C. and Carter, V. M. and Isenring, E. and Kiss, N. K. and Group, Nourish Point Prevalence Study},
	year = {2020},
	note = {Type: Journal Article},
	pages = {e035824},
}

@article{day1023,
	title = {Patient-{Reported} {Outcomes} {Accurately} {Measure} the {Value} of an {Enhanced} {Recovery} {Program} in {Liver} {Surgery}},
	volume = {221},
	issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26611799},
	doi = {10.1016/j.jamcollsurg.2015.09.011},
	number = {6},
	journal = {J Am Coll Surg},
	author = {Day, R. W. and Cleeland, C. S. and Wang, X. S. and Fielder, S. and Calhoun, J. and Conrad, C. and Vauthey, J. N. and Gottumukkala, V. and Aloia, T. A.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1023--30 e1--2},
}

@article{daly315,
	title = {Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer},
	volume = {9},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29318756},
	doi = {10.1002/jcsm.12267},
	number = {2},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Daly, L. E. and Ni Bhuachalla, E. B. and Power, D. G. and Cushen, S. J. and James, K. and Ryan, A. M.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {315--325},
}

@article{cuschieri7,
	title = {Endoscopic oesophagectomy through a right thoracoscopic approach},
	volume = {37},
	issn = {0035-8835 (Print) 0035-8835 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1573620},
	number = {1},
	journal = {J R Coll Surg Edinb},
	author = {Cuschieri, A. and Shimi, S. and Banting, S.},
	year = {1992},
	note = {Type: Journal Article},
	pages = {7--11},
}

@article{furlong107,
	title = {Targeting therapy for esophageal cancer in patients aged 70 and over},
	volume = {4},
	issn = {1879-4076},
	doi = {10.1016/j.jgo.2012.12.006},
	abstract = {BACKGROUND: While cancer is a disease of the elderly, these patients are under-represented in randomized trials. Esophageal cancer-management in the elderly is challenging because of the morbidity and mortality associated with surgery.
OBJECTIVES: We examined a strategy of neo-adjuvant chemo-radiotherapy (naCRT), followed by surgery or surveillance, in selected patients with cancer aged 70 and older.
METHODS: A prospectively-accrued database identified 56 consecutive patients over a 90-month period, who were aged 70years and over, presented with esophageal carcinoma and were treated with neo-adjuvant CRT (naCRT)±surgery.
RESULTS: Of 129 eligible patients, 66 (51\%) received palliative measures, while 63 (49\%) had curative intervention, namely 7 had surgery and 56 had naCRT±surgery. Of these 56 patients, 33 (59\%) had adenocarcinoma (AC) and 23 (41\%) had squamous cell carcinoma (SCC). Twenty-five (45\%) had a complete clinical response (cCR), of which 6 had immediate resection; 4 (67\%) had a complete pathological response (pCR); 19 patients with a cCR declined or were unfit for surgery and underwent surveillance; of these, 3 had interval esophagectomy; 16 were not offered or declined resection. Eight (50\%) have survived ≥3years. Mean overall survival was 28months for the entire cohort; 47months for cCRs; 61months for patients undergoing primary resection, 46months for cCRs who did not undergo resection and 29months for those undergoing interval resection for recurrent disease. In cCRs, surgery did not provide a survival advantage (p=0.861).
CONCLUSION: cCR yields an overall 3-year survival of 50\% without operation. As 45\% of patients have a cCR to naCRT, obligatory resection in high-risk cCR patients makes little sense. With the option for salvage esophagectomy in re-emergent disease, this selective strategy is an attractive alternative for elderly patients with cancer.},
	language = {eng},
	number = {2},
	journal = {J Geriatr Oncol},
	author = {Furlong, Heidi and Bass, Gary and Breathnach, Oscar and O'Neill, Brian and Leen, Eamonn and Walsh, Thomas N.},
	month = apr,
	year = {2013},
	pmid = {24071535},
	keywords = {Humans, Aged, Female, Male, Neoadjuvant Therapy, Follow-Up Studies, Kaplan-Meier Estimate, Palliative Care, Cohort Studies, Aged, 80 and over, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Watchful Waiting, Lymphatic Metastasis, dCRT},
	pages = {107--113},
}

@article{suzuki347,
	title = {Localized gastric cancer treated with chemoradation without surgery: {UTMD} {Anderson} {Cancer} {Center} experience},
	volume = {82},
	issn = {1423-0232},
	shorttitle = {Localized gastric cancer treated with chemoradation without surgery},
	doi = {10.1159/000338318},
	abstract = {BACKGROUND: In patients with localized gastric cancer (LGC) who are unfit for surgery, decline surgery, or have unresectable cancer, chemoradiotherapy may provide palliation; however, data in the literature are sparse.
METHODS: We identified 66 LGC patients who had definitive chemoradiation but no surgery. All patients had baseline and postchemoradiation staging including an endoscopic biopsy. Multiple statistical methods were used to analyze outcomes.
RESULTS: Most patients were men and most had stage III or IV cancer. Five patients were surgery eligible but declined to have surgery. The median follow-up time was 33.9 months (95\% CI 18.3-49.6). The median survival time (MST) for 66 patients was only 14.5 months (95\% CI 10.8-19.7) and the median relapse-free survival (RFS) was 5.03 months (95\% CI 4.67-6.40). The estimated overall survival (OS) and RFS rates at 3 years were 22.6\% (95\% CI 13.7-37.3) and 7.7\% (95\% CI 3.2-18.6), respectively. Twenty-three (35\%) patients who achieved a clinical complete response (cCR; negative postchemoradiation biopsy and no progression by imaging) fared better than those who achieved less than cCR ({\textless}cCR) [cCR: MST 30.7 months (95\% CI 20.4-NA); {\textless}cCR: MST 10.6 months (95\% CI 8.43-14.9); p {\textless} 001]. In multivariate analysis, cCR was the only independent prognosticator for OS [hazard ratio (HR) = 0.32, p {\textless} 0.0012] and RFS (HR = 0.12, p {\textless} 0.0001).
CONCLUSION: Our data demonstrate that in the absence of surgery, outcomes with definitive chemoradiation are only modest. A third of the patients achieved cCR and had a longer OS and RFS than those who achieved {\textless}cCR.},
	language = {eng},
	number = {6},
	journal = {Oncology},
	author = {Suzuki, Akihiro and Xiao, Lianchun and Taketa, Takashi and Blum, Mariela A. and Matamoros, Aurelio and Chien, Pamela L. and Mansfield, Paul F. and Fournier, Keith F. and Weston, Brian and Lee, Jeffrey H. and Bhutani, Manoop S. and Estrella, Jeannelyn S. and Delclos, Marc E. and Krishnan, Sunil and Das, Prajnan and Ajani, Jaffer A.},
	year = {2012},
	pmid = {22677933},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Disease Progression, Survival Rate, Prognosis, Stomach Neoplasms, Disease-Free Survival, Chemoradiotherapy, dCRT},
	pages = {347--351},
}

@article{malik1,
	title = {Metabolic tumor volume provides complementary prognostic information to {EUS} staging in esophageal and junctional cancer},
	volume = {30},
	issn = {1442-2050},
	doi = {10.1111/dote.12505},
	abstract = {To determine the correlation between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) derived esophageal tumor parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV)] and endoscopic ultrasound (EUS) derived tumor parameters (T stage, N stage) and their prognostic implications. 150 consecutive patients with cancer of the esophagus or esophagogastric junction underwent staging PET-CT and staging EUS. PET-CT derived SUVmax and MTV of the primary tumor was recorded. EUS evaluated T and N stage. Relationships between parameters were investigated using the Mann-Whitney U tests, survival analysis performed using Kaplan-Meier and independent prognostic factors determined using Cox regression multivariate analysis. A significant difference in MTV was noted between EUS T1/T2 tumors (median 6.7 cm3) and EUS T3/T4 tumors (median 35.7 cm3; P {\textless} 0.0001). An MTV of {\textless}23.4 cm3 (P = 0.0001), SUVmax {\textless} 4.1 (P = 0014), EUS T stage (P {\textless} 0.0001), EUS N stage (P {\textless} 0.0001), and clinical stage (P {\textless} 0.0001) were all significantly associated with survival, with MTV {\textless}23.4 cm3 (P = 0.004), EUS T stage (P = 0.01), and EUS N stage (P = 0.01) significant in multivariate analysis. MTV, a volumetric parameter of PET-CT, has more prognostic importance than SUVmax and provides valuable prognostic information in esophageal and junctional cancer, along with EUS T and N stage. MTV provides complementary information to EUS and should be included in the staging of esophageal and junctional cancer.},
	language = {eng},
	number = {3},
	journal = {Dis Esophagus},
	author = {Malik, Vinod and Johnston, Ciaran and O'Toole, Dermot and Lucey, Julie and O'Farrell, Naoimh and Claxton, Zieta and Reynolds, John V.},
	month = feb,
	year = {2017},
	pmid = {27862622},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Proportional Hazards Models, Prospective Studies, Prognosis, Aged, 80 and over, Adult, Statistics, Nonparametric, Young Adult, Esophageal Neoplasms, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals, Esophagogastric Junction, Esophagoscopy, esophageal cancer, endoscopic ultrasound, Endosonography, PET, 18F-FDG PET-CT, Regression Analysis, staging, Tumor Burden},
	pages = {1--8},
}

@article{ripley226,
	title = {Pretreatment {Dysphagia} in {Esophageal} {Cancer} {Patients} {May} {Eliminate} the {Need} for {Staging} by {Endoscopic} {Ultrasonography}},
	volume = {101},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2015.06.062},
	abstract = {BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancer patients with dysphagia.
METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage.
RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77\% (88 of 114) received neoadjuvant therapy, 18\% (20 of 114) did not, and 5\% (6 of 114) pursued treatment elsewhere. In total, 70\% (80 of 114) underwent esophagectomy; of these, 54\% (61 of 114) had dysphagia and 46\% (53 of 114) did not. Dysphagia scores were 66\% (40 of 61) grade 1, 25\% (15 of 61) grade 2, and 10\% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89\% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53\% (28 of 53) had T3-4 disease by EUS (p {\textless} 0.001).
CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50\% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.},
	language = {eng},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Ripley, R. Taylor and Sarkaria, Inderpal S. and Grosser, Rachel and Sima, Camelia S. and Bains, Manjit S. and Jones, David R. and Adusumilli, Prasad S. and Huang, James and Finley, David J. and Rusch, Valerie W. and Rizk, Nabil P.},
	month = jan,
	year = {2016},
	pmid = {26603024},
	pmcid = {PMC4765728},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Prospective Studies, Esophageal Neoplasms, Endosonography, Dysphonia, Unnecessary Procedures},
	pages = {226--230},
	file = {Accepted Version:C\:\\Users\\jcsal\\Zotero\\storage\\MY6K9FC9\\Ripley et al. - 2016 - Pretreatment Dysphagia in Esophageal Cancer Patien.pdf:application/pdf},
}

@article{chirieac1347,
	title = {Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation},
	volume = {103},
	issn = {0008-543X},
	doi = {10.1002/cncr.20916},
	abstract = {BACKGROUND: In patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether survival was better predicted by pretherapy clinical stage or by posttherapy pathologic stage.
METHODS: The authors studied 235 consecutive patients with pretherapy clinical Stage II, III, or IVA (according to American Joint Committee on Cancer criteria) carcinoma of the esophagus or esophagogastric junction who were treated with chemoradiation followed by esophagectomy. Posttherapy cancer status was classified using pathologic stage and semiquantitative assessment of residual carcinoma. Clinicopathologic features, residual carcinoma status, and pretherapy and posttherapy stage were compared with disease-free and overall survival.
RESULTS: Posttherapy pathologic stage was Stage 0 in 29\% of patients, Stage I in 11\% of patients, Stage II in 34\% of patients, Stage III in 20\% of patients, and Stage IV in 6\% of patients. Cancer downstaging occurred in 56\% of patients. In univariate analysis, disease-free and overall survival were predicted by posttherapy pathologic stage (both with P {\textless} 0.001), margin status (P = 0.002 and P = 0.01, respectively), extent of residual carcinoma (both with P {\textless} 0.001), and downstaging (both with P = 0.001), but not by age, gender, type of cancer, pretherapy clinical stage, or preoperative regimen. However, in multivariate analysis, disease-free and overall survival were independently predicted by posttherapy pathologic stage (both with P = 0.02). Extent of residual carcinoma was a marginally significant predictor of overall survival (P = 0.04).
CONCLUSIONS: Posttherapy pathologic stage was the best available predictor of outcome for patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent chemoradiation therapy followed by esophagectomy. The findings in the current study supported the concept of downstaging by preoperative therapy.},
	language = {eng},
	number = {7},
	journal = {Cancer},
	author = {Chirieac, Lucian R. and Swisher, Stephen G. and Ajani, Jaffer A. and Komaki, Ritsuko R. and Correa, Arlene M. and Morris, Jeffrey S. and Roth, Jack A. and Rashid, Asif and Hamilton, Stanley R. and Wu, Tsung-Teh},
	month = apr,
	year = {2005},
	pmid = {15719440},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Survival Rate, Prognosis, Chemotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Radiotherapy, Adjuvant, Carcinoma, naCRT},
	pages = {1347--1355},
}

@article{taketa95,
	title = {Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation},
	volume = {85},
	issn = {1423-0232},
	doi = {10.1159/000351999},
	abstract = {BACKGROUND: Trimodality therapy (TMT; chemoradiation plus surgery) has level-1 evidence for survival advantage for TMT-eligible esophagogastric cancer patients. Some patients, however, decline surgery after preoperative chemoradiation. The question of which patient should have esophagectomy and which one should not is unlikely to be answered by a prospective comparison; therefore, we matched the clinical covariates of several patients who had surgery with those who declined surgery (DS).
METHODS: Between 2002 and 2011, we identified 623 patients in our databases. Of 623 patients, 244 patients had TMT and 61 TMT-eligible patients were in the DS group. Using the propensity-score method, we matched 16 covariates between 36 DS patients and 36 TMT patients.
RESULTS: Baseline characteristics between the two groups were balanced (p = NS). The median overall survival times were: 57.9 months (95\% CI: 27.7 to not applicable, NA) for the DS group and 50.8 months (95\% CI: 30.7 to NA) for the TMT group (p = 0.28). The median relapse-free survival times were: 18.5 (95\% CI: 11.5-30.4) for the DS group and 26.5 months (95\% CI: 15.5-NA) for the TMT group (p = 0.45). Eleven (31\%) of 36 patients in the DS group had salvage surgery.
CONCLUSIONS: Our results are intriguing but skewed by the patients who had salvage surgery in the DS group. Until highly reliable predictive models are developed for esophageal preservation, TMT must be encouraged for all TMT-eligible gastroesophageal cancer patients.},
	language = {eng},
	number = {2},
	journal = {Oncology},
	author = {Taketa, Takashi and Xiao, Lianchun and Sudo, Kazuki and Suzuki, Akihiro and Wadhwa, Roopma and Blum, Mariela A. and Lee, Jeffrey H. and Weston, Brian and Bhutani, Manoop S. and Skinner, Heath and Komaki, Ritsuko and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	year = {2013},
	pmid = {23860252},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Retrospective Studies, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Preoperative Period, Treatment Refusal},
	pages = {95--99},
}

@article{bonvalot1366,
	title = {Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma ({EORTC}-62092: {STRASS}): a multicentre, open-label, randomised, phase 3 trial},
	volume = {21},
	issn = {1474-5488},
	shorttitle = {Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma ({EORTC}-62092},
	doi = {10.1016/S1470-2045(20)30446-0},
	abstract = {BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival.
METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50·4 Gy (in 28 daily fractions of 1·8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018.
FINDINGS: Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43·1 months (IQR 28·8-59·2). 128 (96\%) patients from the surgery alone group had surgery, and 119 (89\%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4·5 years (95\% CI 3·9 to not estimable) in the radiotherapy plus surgery group and 5·0 years (3·4 to not estimable) in the surgery only group (hazard ratio 1·01, 95\% CI 0·71-1·44; log rank p=0·95). The most common grade 3-4 adverse events were lymphopenia (98 [77\%] of 127 patients in the radiotherapy plus surgery group vs one [1\%] of 128 patients in the surgery alone group), anaemia (15 [12\%] vs ten [8\%]), and hypoalbuminaemia (15 [12\%] vs five [4\%]). Serious adverse events were reported in 30 (24\%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10\%) of 128 patients in the surgery alone group. One (1\%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events.
INTERPRETATION: Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma.
FUNDING: European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.},
	language = {eng},
	number = {10},
	journal = {Lancet Oncol},
	author = {Bonvalot, Sylvie and Gronchi, Alessandro and Le Péchoux, Cécile and Swallow, Carol J. and Strauss, Dirk and Meeus, Pierre and van Coevorden, Frits and Stoldt, Stephan and Stoeckle, Eberhard and Rutkowski, Piotr and Rastrelli, Marco and Raut, Chandrajit P. and Hompes, Daphne and De Paoli, Antonino and Sangalli, Claudia and Honoré, Charles and Chung, Peter and Miah, Aisha and Blay, Jean Yves and Fiore, Marco and Stelmes, Jean-Jacques and Dei Tos, Angelo P. and Baldini, Elizabeth H. and Litière, Saskia and Marreaud, Sandrine and Gelderblom, Hans and Haas, Rick L.},
	month = oct,
	year = {2020},
	pmid = {32941794},
	keywords = {Aged, Disease-Free Survival, Europe, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, North America, PreopRT, Radiotherapy, Adjuvant, Radiotherapy, Conformal, Retroperitoneal Neoplasms, Sarcoma, Treatment Outcome},
	pages = {1366--1377},
}

@article{cardona1257,
	title = {The {STRASS} trial: an important step in the right direction},
	volume = {21},
	issn = {1474-5488},
	shorttitle = {The {STRASS} trial},
	doi = {10.1016/S1470-2045(20)30429-0},
	language = {eng},
	number = {10},
	journal = {Lancet Oncol},
	author = {Cardona, Kenneth},
	month = oct,
	year = {2020},
	pmid = {32941793},
	keywords = {Connective Tissue Diseases, Humans, PreopRT, Retroperitoneal Neoplasms, Sarcoma, Soft Tissue Neoplasms},
	pages = {1257--1258},
}
